Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA single cell type specificity" "RNA single cell type distribution" "RNA single cell type specificity score" "RNA single cell type specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "CCD Protein" "CCD Transcript" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - GAMG [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - hTERT-RPE1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - JURKAT [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - OE19 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - SuSa [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" "Single Cell Type RNA - Alveolar cells type 1 [NX]" "Single Cell Type RNA - Alveolar cells type 2 [NX]" "Single Cell Type RNA - B-cells [NX]" "Single Cell Type RNA - Basal glandular cells [NX]" "Single Cell Type RNA - Basal keratinocytes [NX]" "Single Cell Type RNA - Bipolar cells [NX]" "Single Cell Type RNA - Cardiomyocytes [NX]" "Single Cell Type RNA - Cholangiocytes [NX]" "Single Cell Type RNA - Ciliated cells [NX]" "Single Cell Type RNA - Club cells [NX]" "Single Cell Type RNA - Collecting duct cells [NX]" "Single Cell Type RNA - Cone photoreceptor cells [NX]" "Single Cell Type RNA - Cytotrophoblasts [NX]" "Single Cell Type RNA - Distal tubular cells [NX]" "Single Cell Type RNA - Ductal cells [NX]" "Single Cell Type RNA - Early spermatids [NX]" "Single Cell Type RNA - Endothelial cells [NX]" "Single Cell Type RNA - Enterocytes [NX]" "Single Cell Type RNA - Erythroid cells [NX]" "Single Cell Type RNA - Exocrine glandular cells [NX]" "Single Cell Type RNA - Extravillous trophoblasts [NX]" "Single Cell Type RNA - Fibroblasts [NX]" "Single Cell Type RNA - Glandular cells [NX]" "Single Cell Type RNA - granulocytes [NX]" "Single Cell Type RNA - Hepatocytes [NX]" "Single Cell Type RNA - Hofbauer cells [NX]" "Single Cell Type RNA - Horizontal cells [NX]" "Single Cell Type RNA - Intestinal endocrine cells [NX]" "Single Cell Type RNA - Ito cells [NX]" "Single Cell Type RNA - Kupffer cells [NX]" "Single Cell Type RNA - Late spermatids [NX]" "Single Cell Type RNA - Leydig cells [NX]" "Single Cell Type RNA - Macrophages [NX]" "Single Cell Type RNA - Melanocytes [NX]" "Single Cell Type RNA - monocytes [NX]" "Single Cell Type RNA - Mucus-secreting cells [NX]" "Single Cell Type RNA - Muller glia cells [NX]" "Single Cell Type RNA - Pancreatic endocrine cells [NX]" "Single Cell Type RNA - Paneth cells [NX]" "Single Cell Type RNA - Peritubular cells [NX]" "Single Cell Type RNA - Proximal tubular cells [NX]" "Single Cell Type RNA - Rod photoreceptor cells [NX]" "Single Cell Type RNA - Sertoli cells [NX]" "Single Cell Type RNA - Smooth muscle cells [NX]" "Single Cell Type RNA - Spermatocytes [NX]" "Single Cell Type RNA - Spermatogonia [NX]" "Single Cell Type RNA - Suprabasal keratinocytes [NX]" "Single Cell Type RNA - Syncytiotrophoblasts [NX]" "Single Cell Type RNA - T-cells [NX]" "Single Cell Type RNA - Undifferentiated cells [NX]" "Single Cell Type RNA - Urothelial cells [NX]" ABCA1 "ABC1, HDLDT1, TGD" ENSG00000165029 "ATP binding cassette subfamily A member 1" O95477 9 104781002-104928237 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism, Transport" Translocase "Atherosclerosis, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Alveolar cells type 1: 98.3;Hepatocytes: 162.2;Kupffer cells: 103.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "eosinophil: 11.6;neutrophil: 10.6" "Lineage enriched" "Detected in many" 6 "granulocytes: 11.6" "Cell line enhanced" "Detected in many" "HSkMC: 17.0;U-87 MG: 39.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA057283, CAB069889" Approved Approved Nucleoplasm,Vesicles NA NA "Nucleoplasm, Vesicles" "CAB069889: AB_10002789, HPA057283: AB_2683396" "unprognostic (1.58e-2)" "unprognostic (2.54e-1)" "unprognostic (1.46e-1)" "unprognostic (2.80e-1)" "unprognostic (7.47e-3)" "unprognostic (1.85e-1)" "unprognostic (9.22e-2)" "unprognostic (9.80e-2)" "unprognostic (2.04e-1)" "unprognostic (7.28e-3)" "unprognostic (2.14e-1)" "unprognostic (4.78e-2)" "unprognostic (1.04e-2)" "unprognostic (2.00e-3)" "unprognostic (2.51e-2)" "unprognostic (6.71e-2)" "unprognostic (2.57e-1)" 25.7 38.1 6.3 9.8 13.1 15.8 23.0 2.3 8.5 8.2 14.8 8.0 6.5 4.4 7.8 9.6 7.0 7.9 13.6 10.7 7.5 3.7 7.1 33.3 12.7 29.4 18.9 2.3 8.7 5.4 1.8 3.3 20.1 10.2 9.4 9.4 7.7 6.3 8.7 21.3 12.1 8.1 25.2 16.1 12.8 7.3 8.8 8.0 16.9 5.8 2.2 5.0 16.4 20.0 1.8 0.2 11.6 1.5 0.1 0.6 0.1 0.0 2.7 2.2 0.0 6.5 2.5 2.0 2.8 10.9 0.9 1.0 0.4 0.4 3.8 3.1 2.8 10.7 0.0 1.2 0.1 0.8 0.0 0.0 0.4 0.9 9.5 11.8 0.0 6.7 17.0 0.7 11.1 0.2 10.6 1.0 0.3 0.0 9.8 0.2 0.3 2.3 5.2 3.1 0.5 0.8 0.0 0.0 0.2 1.8 1.8 0.3 0.1 2.9 0.5 0.6 4.5 0.0 1.9 1.0 3.0 0.2 3.9 3.1 3.8 1.8 2.3 39.0 0.0 0.0 2.2 0.8 11.6 0.2 1.0 0.2 1.2 0.3 0.0 0.2 1.8 0.6 0.0 10.6 0.1 1.5 0.1 0.1 0.1 6.3 13.1 2.3 4.0 7.5 3.7 18.9 2.3 10.2 8.0 98.3 9.4 5.1 4.8 26.4 11.9 7.8 12.7 2.7 9.1 10.4 45.2 21.2 0.0 3.8 1.5 9.3 3.2 0.0 1.4 4.6 28.8 3.1 46.1 162.2 63.2 0.0 8.7 25.2 103.3 0.7 28.7 31.4 25.3 2.8 2.4 0.1 4.9 3.5 26.5 17.0 5.5 45.3 16.4 1.2 0.7 16.9 7.4 4.4 2.3 8.9 ABCC1 "GS-X, MRP, MRP1" ENSG00000103222 "ATP binding cassette subfamily C member 1" P33527 16 15949577-16143074 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" Transport "Hydrolase, Translocase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 7.5;eosinophil: 3.1;T-reg: 2.1" "Group enriched" "Detected in many" 7 "granulocytes: 7.5;T-cells: 2.1" "Cell line enhanced" "Detected in many" "EFO-21: 39.0" "Low region specificity" "Detected in all" "HPA002380, HPA076011" Uncertain Supported "Plasma membrane,Cell Junctions" NA NA "Plasma membrane" "Cell Junctions" "HPA002380: AB_1844432, HPA076011: " "unprognostic (9.97e-2)" "unprognostic (2.06e-1)" "unprognostic (2.05e-2)" "unprognostic (2.94e-1)" "unprognostic (4.89e-2)" "unprognostic (1.15e-1)" "prognostic unfavorable (5.42e-5)" "unprognostic (3.42e-1)" "unprognostic (3.31e-1)" "unprognostic (4.07e-2)" "unprognostic (9.78e-3)" "unprognostic (7.19e-2)" "prognostic unfavorable (1.55e-6)" "unprognostic (1.84e-1)" "unprognostic (1.15e-1)" "unprognostic (1.43e-2)" "unprognostic (1.80e-2)" 8.9 8.2 2.4 8.3 3.1 8.4 9.6 4.4 5.0 8.3 10.7 2.6 15.5 3.5 10.5 12.7 14.7 5.6 9.6 8.0 2.1 2.4 4.5 1.6 10.9 12.2 3.0 2.1 6.8 5.8 18.4 4.2 5.2 4.1 9.6 4.1 12.0 16.9 10.9 20.8 6.6 8.2 16.4 4.0 9.2 10.9 15.1 2.3 26.8 15.7 12.6 15.6 15.3 11.8 0.7 0.5 7.5 0.5 0.4 2.1 0.2 2.3 24.7 0.1 6.5 5.7 3.5 1.3 7.3 8.9 6.3 6.6 3.9 17.8 6.7 39.0 14.0 5.9 6.7 2.0 7.1 4.8 11.8 2.3 8.3 14.4 14.3 17.1 3.0 21.5 7.5 4.8 1.8 1.0 5.4 6.9 12.9 8.4 3.4 1.9 4.6 5.3 2.8 3.9 3.3 3.6 18.9 3.7 3.3 2.3 8.3 3.6 5.9 9.2 10.0 2.4 6.6 3.5 1.6 0.7 0.4 1.5 5.2 5.8 6.4 3.2 2.3 3.3 3.1 0.7 7.5 0.1 3.1 0.6 0.4 0.6 0.7 0.5 0.6 0.5 0.3 0.6 0.6 0.0 0.4 0.5 0.3 2.1 0.2 2.4 3.1 4.4 5.0 2.1 2.4 3.0 2.1 4.1 2.3 23.8 6.4 10.4 6.8 7.8 3.1 5.3 5.1 2.7 12.5 5.2 21.6 0.6 3.3 8.7 7.2 6.2 1.1 0.0 5.5 2.2 3.3 13.8 20.9 0.2 7.2 4.8 17.9 8.6 15.5 11.0 6.9 10.2 3.3 6.4 7.2 1.2 8.5 3.5 6.3 1.4 8.3 0.0 3.1 2.4 5.9 4.4 0.5 9.6 3.1 8.4 ABCC2 "CMOAT, cMRP, DJS, MRP2" ENSG00000023839 "ATP binding cassette subfamily C member 2" Q92887 10 99782732-99852192 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" Transport Translocase "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 28.4;kidney: 25.6;liver: 74.3" "Cell type enriched" "Detected in some" 6 "Hepatocytes: 52.9" "Cancer enhanced" "Detected in many" "liver cancer: 24.0" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 4.1" "Lineage enriched" "Detected in single" 6 "granulocytes: 4.1" "Group enriched" "Detected in some" 5 "A549: 60.2;Hep G2: 60.0" "Not detected" "Not detected" "Not detected" "Not detected" HPA071145 Enhanced NA NA "HPA071145: " "unprognostic (1.49e-3)" "unprognostic (5.92e-2)" "unprognostic (1.59e-1)" "unprognostic (3.67e-1)" "unprognostic (1.93e-2)" "unprognostic (2.33e-1)" "unprognostic (2.51e-1)" "unprognostic (7.15e-3)" "unprognostic (5.68e-2)" "unprognostic (2.01e-1)" "unprognostic (4.30e-1)" "unprognostic (1.40e-3)" "prognostic unfavorable (1.93e-5)" "unprognostic (1.31e-1)" "unprognostic (3.22e-2)" "unprognostic (2.95e-1)" "unprognostic (1.26e-2)" 0.8 0.3 0.1 0.1 0.1 0.1 1.1 0.3 0.1 0.2 13.4 0.1 0.1 16.1 0.3 0.5 0.2 0.4 13.7 0.2 0.1 0.1 25.6 74.3 0.3 0.1 0.1 0.1 0.2 0.6 0.0 0.1 1.2 0.1 0.3 0.0 0.1 0.3 0.1 0.6 0.6 28.4 0.1 0.2 0.8 0.4 0.4 0.1 0.1 0.3 0.4 0.1 0.7 0.3 0.3 0.7 4.1 0.2 0.1 0.5 0.0 0.0 60.2 0.9 3.0 4.6 3.5 1.0 0.1 0.3 0.1 0.2 12.9 0.1 0.1 0.1 0.2 0.1 0.3 0.1 0.1 0.2 0.1 0.1 0.0 0.2 60.0 0.1 0.0 0.2 0.6 4.1 0.4 0.4 0.1 0.1 0.1 0.0 0.1 0.0 0.2 0.0 0.4 0.1 11.2 0.0 0.1 0.0 0.1 0.4 0.0 0.0 0.0 0.1 0.9 7.4 0.1 0.0 0.1 0.1 0.1 0.2 0.3 0.1 0.2 0.0 0.0 4.9 1.0 0.3 4.1 0.2 0.3 0.3 0.0 0.4 0.2 0.3 0.1 0.3 0.3 0.3 0.1 1.3 0.1 0.1 0.7 0.5 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.8 0.1 0.0 0.2 0.4 2.5 4.0 0.0 0.0 0.0 0.2 0.0 0.0 1.6 0.0 0.0 0.0 0.3 0.0 0.0 0.2 1.1 52.9 0.2 0.0 0.0 0.6 1.3 0.2 0.3 0.0 5.0 0.0 0.0 0.2 0.1 0.0 0.0 9.1 1.4 0.0 0.4 0.7 0.3 0.0 1.4 0.0 0.0 0.0 ABCC8 "ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2" ENSG00000006071 "ATP binding cassette subfamily C member 8" Q09428 11 17392498-17476879 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" Transport Receptor "Diabetes mellitus, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 28.0;pancreas: 25.5;pituitary gland: 26.6" "Group enriched" "Detected in some" 8 "Bipolar cells: 39.2;Intestinal endocrine cells: 21.0" "Cancer enriched" "Detected in some" 9 "pancreatic cancer: 16.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "A549: 4.7;AN3-CA: 3.8;SCLC-21H: 6.7" "Low region specificity" "Detected in all" "CAB011451, HPA042318" Approved Approved "Nucleoli,Golgi apparatus,Cytosol" No NA Nucleoli "Golgi apparatus, Cytosol" "CAB011451: , HPA042318: AB_2677947" "unprognostic (4.30e-2)" "unprognostic (1.02e-1)" "unprognostic (5.09e-2)" "unprognostic (4.73e-2)" "unprognostic (9.48e-3)" "unprognostic (2.23e-1)" "unprognostic (4.46e-3)" "unprognostic (2.53e-3)" "unprognostic (6.04e-2)" "unprognostic (2.34e-2)" "unprognostic (8.72e-3)" "unprognostic (1.13e-1)" "unprognostic (2.22e-2)" "unprognostic (1.96e-2)" "unprognostic (6.88e-5)" "unprognostic (2.72e-2)" "unprognostic (1.85e-1)" 1.3 6.7 4.4 0.8 6.1 0.9 4.0 28.0 12.3 3.0 1.3 2.6 7.7 1.9 3.1 3.7 0.8 1.2 0.9 2.9 5.1 4.8 1.0 0.8 2.9 0.8 3.6 7.2 0.9 25.5 1.0 26.6 1.6 8.5 2.8 1.3 0.7 0.9 8.5 2.3 1.1 1.5 1.3 4.0 0.9 3.5 1.1 2.3 0.0 6.2 0.0 0.8 0.7 0.8 0.1 0.0 0.5 0.0 0.1 0.2 0.0 0.0 4.7 0.1 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 6.7 0.9 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.5 0.1 0.0 0.0 0.0 0.0 4.4 6.1 28.0 12.3 5.1 4.8 3.6 7.2 8.5 2.3 0.0 0.0 0.0 0.0 0.0 39.2 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 1.1 0.0 0.0 0.1 0.0 21.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.7 0.0 0.0 0.0 1.2 0.0 1.6 0.0 0.2 0.1 0.0 0.0 0.0 0.1 ABCC9 "CMD1O, SUR2" ENSG00000069431 "ATP binding cassette subfamily C member 9" O60706 12 21797401-21942529 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" Transport Receptor "Atrial fibrillation, Cardiomyopathy, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 12 "Alveolar cells type 2: 47.6;Hepatocytes: 84.7;Sertoli cells: 129.4;Smooth muscle cells: 47.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 17.6;BJ hTERT+: 10.1;CACO-2: 16.0;HSkMC: 21.0;U-138 MG: 17.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007279 Uncertain Approved Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "HPA007279: AB_1844435" "unprognostic (4.82e-2)" "unprognostic (3.62e-2)" "unprognostic (5.51e-4)" "unprognostic (1.09e-1)" "unprognostic (1.09e-1)" "unprognostic (8.30e-2)" "unprognostic (3.17e-2)" "unprognostic (1.50e-2)" "unprognostic (2.47e-2)" "unprognostic (8.72e-2)" "unprognostic (2.51e-2)" "unprognostic (3.57e-1)" "prognostic unfavorable (1.85e-5)" "unprognostic (2.66e-2)" "unprognostic (1.21e-2)" "unprognostic (3.10e-3)" "unprognostic (8.22e-5)" 21.6 4.7 5.5 2.6 5.4 1.2 25.8 1.5 8.6 12.4 6.8 4.8 5.1 3.0 15.3 6.3 9.1 9.5 9.6 26.2 5.7 2.6 5.6 31.1 6.2 2.7 2.9 4.2 11.8 5.8 1.7 2.7 2.8 5.5 7.0 1.6 10.8 4.8 8.4 33.2 3.3 4.1 17.1 4.9 3.5 9.1 3.4 4.2 0.1 6.3 14.5 1.2 9.5 8.4 1.6 0.9 1.8 0.8 0.5 0.9 0.0 0.6 0.1 7.5 0.2 17.6 8.0 0.2 4.1 10.1 4.5 2.3 16.0 0.7 0.3 0.8 0.4 0.5 0.2 0.0 0.0 4.7 0.2 0.1 0.3 0.5 0.2 0.0 0.3 0.4 21.0 0.0 4.5 1.7 0.3 0.0 0.3 0.2 0.9 0.2 0.9 0.2 0.2 1.0 0.8 0.4 0.3 0.2 0.2 0.0 0.8 0.3 1.2 0.2 0.4 0.1 1.2 0.8 0.2 0.2 17.5 1.3 1.5 5.3 0.8 0.8 0.3 4.3 0.2 0.3 0.9 0.5 0.4 0.9 0.4 0.6 0.7 0.7 0.7 0.2 1.6 0.6 0.8 1.8 0.5 0.8 0.9 0.4 0.0 5.5 5.4 1.5 8.6 5.7 2.6 2.9 4.2 5.5 4.2 32.8 47.6 0.0 1.0 3.1 0.4 27.8 0.0 36.1 39.8 0.0 0.0 0.2 0.0 0.0 0.2 4.9 0.0 0.0 0.2 0.1 10.6 0.4 22.1 84.7 0.1 1.6 0.0 11.1 3.3 0.0 0.3 2.1 10.1 0.0 0.0 13.1 0.1 0.0 0.4 0.0 1.1 129.4 47.2 0.5 0.7 1.9 0.2 0.0 0.0 1.4 ADORA1 RDC7 ENSG00000163485 "Adenosine A1 receptor" P30542 1 203090654-203167405 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 38.7" "Group enriched" "Detected in some" 4 "granulocytes: 23.0;Muller glia cells: 40.0" "Cancer enhanced" "Detected in many" "glioma: 24.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "CACO-2: 19.7;MCF7: 11.9;RH-30: 32.7;RPTEC TERT1: 15.9;SK-BR-3: 17.7;U-138 MG: 10.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044383 Supported "Plasma membrane" NA NA "Plasma membrane" "HPA044383: AB_2678921" "unprognostic (3.93e-3)" "unprognostic (8.16e-2)" "unprognostic (6.16e-2)" "unprognostic (2.38e-3)" "unprognostic (2.25e-2)" "unprognostic (2.34e-1)" "unprognostic (4.64e-2)" "unprognostic (4.17e-2)" "unprognostic (3.04e-1)" "unprognostic (4.80e-3)" "unprognostic (1.42e-1)" "unprognostic (2.98e-1)" "unprognostic (2.96e-3)" "unprognostic (1.54e-1)" "unprognostic (1.27e-1)" "unprognostic (4.13e-2)" "unprognostic (5.76e-4)" 4.5 1.0 19.7 2.6 21.7 0.8 6.1 9.7 38.7 1.1 1.6 27.4 0.0 2.0 2.0 1.6 1.6 2.0 1.8 13.8 19.8 12.1 4.2 1.0 2.8 1.4 22.8 13.4 0.8 15.5 15.5 0.9 8.9 25.0 1.2 1.6 1.8 8.9 1.3 2.0 1.9 1.8 1.3 20.7 7.4 1.6 16.3 15.9 0.0 3.2 0.0 1.4 3.4 0.3 0.0 0.6 0.0 0.1 0.0 0.0 0.1 0.1 1.4 0.3 0.1 0.1 0.8 0.1 1.0 1.5 0.4 0.2 19.7 0.3 0.0 4.5 3.6 2.4 0.0 0.3 0.0 0.1 0.0 0.5 0.0 0.2 0.0 0.3 0.0 0.0 0.4 0.0 0.4 0.0 3.2 0.0 3.2 0.0 0.0 3.1 11.9 0.0 0.0 5.1 0.0 0.0 0.0 32.7 1.0 15.9 0.0 0.3 0.4 2.1 17.7 0.2 1.9 1.0 0.4 0.0 10.6 5.4 0.0 5.7 0.0 0.1 0.0 5.3 0.0 0.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 19.7 21.7 9.7 25.7 19.8 12.1 22.8 13.4 25.0 15.9 0.0 0.0 0.0 0.0 0.0 0.5 2.5 5.1 0.0 0.0 3.5 0.0 0.0 0.0 7.2 0.1 0.0 0.0 0.0 3.0 1.0 0.7 0.0 23.0 0.0 0.9 0.0 0.0 0.0 1.3 0.0 0.0 0.4 1.7 0.0 0.0 40.0 0.5 0.0 0.7 1.0 0.7 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 ADORA2A "ADORA2, RDC8" ENSG00000128271 "Adenosine A2a receptor" P29274 22 24417879-24442360 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 22.8;bone marrow: 28.1;brain: 43.9;lymphoid tissue: 59.0" "Cell type enriched" "Detected in single" 25 "monocytes: 19.0" "Not detected" "Not detected" "Region enriched" "Detected in all" 8 "basal ganglia: 43.9" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 15.4;Karpas-707: 21.2;RPMI-8226: 15.0;SK-BR-3: 30.4;U-266/70: 21.2;U-266/84: 27.7;U-698: 21.7" "Region enriched" "Detected in some" 10 "basal ganglia: 357.5" "Region enriched" "Detected in single" 92 "basal ganglia: 166.0" "CAB001943, HPA065566, HPA075997" Enhanced Supported NA NA "CAB001943: , HPA065566: , HPA075997: AB_2732298" "unprognostic (7.30e-2)" "unprognostic (2.42e-2)" "unprognostic (3.30e-2)" "unprognostic (2.04e-1)" "unprognostic (7.44e-2)" "unprognostic (1.88e-3)" "unprognostic (9.85e-2)" "unprognostic (3.63e-1)" "unprognostic (2.88e-2)" "unprognostic (4.57e-3)" "unprognostic (2.15e-3)" "unprognostic (1.87e-3)" "unprognostic (6.81e-4)" "unprognostic (1.50e-1)" "unprognostic (9.78e-3)" "unprognostic (1.30e-1)" "unprognostic (7.10e-3)" 1.0 2.4 1.9 10.4 43.9 28.1 1.5 3.4 3.8 0.8 2.0 1.7 0.3 5.4 1.4 1.4 1.0 0.9 2.4 3.5 2.4 1.8 3.5 4.3 5.1 14.8 2.6 1.6 1.2 0.8 0.0 2.1 1.4 2.3 1.6 0.8 3.3 2.7 1.5 1.2 0.9 2.6 0.7 1.3 7.5 2.8 2.0 5.7 59.0 1.3 0.9 8.6 3.8 1.3 17.7 1.1 13.7 9.0 2.2 22.8 11.2 0.2 0.3 0.4 0.1 0.2 0.1 0.4 0.2 9.5 0.5 1.0 1.7 0.1 15.4 1.0 0.3 1.0 0.3 0.9 0.0 0.0 1.8 2.7 0.2 0.0 2.2 0.2 0.3 7.7 0.1 0.0 2.9 0.0 0.2 3.4 2.2 0.1 21.2 0.0 0.2 5.3 1.6 0.6 2.0 0.0 0.2 0.7 15.0 0.0 0.1 1.5 8.9 0.4 30.4 0.1 0.4 0.4 1.5 0.2 0.9 1.5 0.2 0.1 21.2 27.7 21.7 4.8 5.2 0.1 3.0 0.8 4.8 8.6 2.6 20.1 9.6 16.1 16.9 1.1 17.7 22.8 18.3 13.7 2.2 9.0 1.1 21.4 11.2 1.9 43.9 3.4 3.8 2.4 1.8 2.6 1.6 2.3 5.7 0.0 0.3 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ADRB1 ADRB1R ENSG00000043591 "Adrenoceptor beta 1" P08588 10 114044056-114046908 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 48.0;placenta: 41.7" "Cell type enhanced" "Detected in many" 12 "Cardiomyocytes: 80.0;Cytotrophoblasts: 56.3;Sertoli cells: 51.8;Syncytiotrophoblasts: 32.2" "Cancer enriched" "Detected in many" 10 "prostate cancer: 12.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "myeloid DC: 1.9" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HDLM-2: 10.2;PC-3: 4.0;THP-1: 6.9;TIME: 8.9;U-937: 5.2" "Group enriched" "Detected in many" 4 "amygdala: 10.0;basal ganglia: 7.3;cerebral cortex: 17.1;hippocampal formation: 11.3;thalamus: 6.9" "Low region specificity" "Detected in many" HPA067972 Enhanced NA NA "HPA067972: AB_2685936" "unprognostic (1.45e-3)" "unprognostic (1.18e-3)" "unprognostic (1.44e-1)" "unprognostic (4.92e-2)" "unprognostic (3.22e-1)" "unprognostic (8.88e-2)" "unprognostic (9.28e-2)" "unprognostic (3.52e-2)" "unprognostic (1.51e-1)" "unprognostic (1.96e-2)" "unprognostic (2.77e-4)" "unprognostic (1.33e-1)" "unprognostic (7.80e-3)" "unprognostic (1.53e-1)" "unprognostic (1.85e-1)" "unprognostic (1.59e-2)" "unprognostic (1.44e-1)" 4.3 1.0 6.9 1.1 14.0 1.3 5.9 1.0 10.7 0.8 3.1 0.8 0.0 1.8 0.9 0.9 1.9 0.8 0.9 48.0 5.6 2.4 1.7 2.5 18.3 0.9 3.5 4.4 0.8 2.4 0.9 1.2 41.7 2.6 6.5 1.6 4.5 10.7 0.8 3.1 0.9 2.3 0.9 1.3 1.7 1.4 1.0 2.5 0.0 1.0 0.0 1.1 1.1 0.4 1.4 1.9 0.1 1.3 0.0 0.5 0.1 2.1 1.3 0.2 1.3 0.0 0.0 0.3 0.1 0.1 0.2 0.2 0.5 1.6 0.3 0.4 0.0 0.6 0.4 0.1 0.1 0.3 10.2 0.6 0.4 0.2 0.2 0.0 0.4 0.7 0.0 1.1 0.0 2.1 0.2 0.3 1.6 0.1 0.1 0.2 1.2 1.6 1.4 0.5 0.3 4.0 0.3 0.4 0.1 0.0 1.7 0.2 0.4 0.0 0.8 0.1 0.5 0.3 6.9 8.9 0.3 0.1 0.2 0.2 0.0 0.1 0.5 0.0 5.2 0.2 0.0 1.3 0.0 0.5 0.9 0.0 0.6 0.1 0.3 1.9 1.4 0.0 0.4 0.1 0.0 0.1 0.2 0.0 0.1 6.9 14.0 1.0 10.7 5.6 2.4 3.5 4.4 2.6 2.5 17.9 8.5 0.0 4.2 0.9 4.7 80.0 5.1 12.0 13.6 0.0 0.0 56.3 1.7 0.0 0.1 0.7 0.0 0.0 0.2 2.1 3.7 7.1 0.0 0.2 3.9 12.7 0.0 0.6 2.4 0.0 0.0 0.6 1.7 0.0 3.1 0.7 0.1 0.3 0.4 0.0 1.2 51.8 0.8 0.5 0.0 0.0 32.2 1.5 0.4 3.1 ADRB2 "ADRB2R, ADRBR, B2AR, BAR" ENSG00000169252 "Adrenoceptor beta 2" P07550 5 148825245-148828687 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 34.6" "Group enriched" "Detected in many" 4 "Alveolar cells type 1: 104.2;Basal keratinocytes: 344.2;granulocytes: 116.5;Suprabasal keratinocytes: 214.5" "Low cancer specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTCEpi: 24.5;hTERT-HME1: 25.4;PC-3: 10.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003431, HPA075322" Uncertain Uncertain Cytosol NA NA Cytosol "HPA003431: AB_1845333, HPA075322: " "unprognostic (2.28e-2)" "unprognostic (1.50e-1)" "unprognostic (1.21e-1)" "unprognostic (1.17e-2)" "unprognostic (1.69e-1)" "unprognostic (1.17e-1)" "unprognostic (9.35e-3)" "unprognostic (5.54e-2)" "unprognostic (2.34e-1)" "unprognostic (9.85e-2)" "unprognostic (3.17e-2)" "unprognostic (2.23e-1)" "prognostic favorable (3.15e-9)" "unprognostic (1.55e-2)" "unprognostic (1.46e-1)" "unprognostic (1.49e-1)" "unprognostic (7.65e-2)" 11.7 0.2 0.7 0.9 0.4 4.6 13.8 0.0 0.3 6.1 0.9 0.3 0.9 0.2 6.4 1.4 1.1 2.8 0.7 0.3 0.2 6.0 8.5 1.1 0.9 0.0 0.0 0.5 0.0 4.0 3.8 0.7 3.3 0.1 4.4 15.9 1.3 1.2 1.0 3.7 2.9 0.0 0.5 2.0 2.3 5.4 4.8 6.1 14.0 10.8 7.3 34.6 9.6 7.6 0.0 0.0 0.0 0.3 0.0 0.0 1.5 4.4 2.0 2.3 0.0 3.3 0.0 2.1 0.4 7.4 6.8 0.0 9.2 2.3 0.0 0.2 0.0 1.6 0.0 0.2 0.0 3.8 0.0 24.5 0.6 25.4 1.7 0.9 0.0 0.0 2.9 5.3 0.0 0.0 4.2 0.1 0.0 10.5 2.2 1.4 4.3 1.1 1.9 0.0 0.0 1.8 0.2 0.6 0.9 0.0 2.3 4.1 0.0 1.8 2.5 1.1 0.7 0.0 0.1 0.0 5.0 0.8 3.5 4.7 14.0 34.6 7.8 25.7 4.8 8.2 20.9 5.3 3.0 1.4 12.9 7.6 7.3 10.8 6.1 0.4 9.6 104.2 33.5 11.1 31.2 344.2 0.2 12.4 0.0 8.1 33.0 0.0 0.0 0.3 0.0 1.4 0.2 17.5 0.0 0.0 0.2 0.2 6.1 16.2 116.5 11.9 14.7 0.0 2.9 6.7 12.7 0.4 0.0 16.5 28.7 1.0 1.4 3.5 5.3 0.0 0.0 0.0 4.8 0.0 3.6 0.0 0.0 214.5 0.5 35.5 0.8 48.5 AGTR1 "AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R" ENSG00000144891 "Angiotensin II receptor type 1" P30556 3 148697784-148743008 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 29.6;placenta: 44.9" "Group enriched" "Detected in many" 5 "Leydig cells: 134.3;Sertoli cells: 142.3" "Group enriched" "Detected in many" 8 "breast cancer: 9.6;liver cancer: 9.8;prostate cancer: 6.8;renal cancer: 2.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 64.4;ASC TERT1: 9.0;BJ hTERT+ SV40 Large T+: 12.3;HBF TERT88: 19.4;HSkMC: 11.7" "Low region specificity" "Detected in many" HPA003596 Enhanced Uncertain Vesicles NA NA Vesicles "HPA003596: AB_1845163" "unprognostic (2.19e-1)" "unprognostic (1.17e-1)" "unprognostic (8.78e-2)" "unprognostic (2.48e-4)" "unprognostic (5.28e-3)" "unprognostic (1.55e-1)" "unprognostic (3.46e-1)" "unprognostic (1.28e-2)" "unprognostic (3.26e-2)" "unprognostic (3.08e-2)" "unprognostic (9.25e-3)" "unprognostic (4.11e-2)" "unprognostic (4.79e-2)" "unprognostic (3.21e-3)" "unprognostic (1.46e-1)" "unprognostic (2.54e-1)" "unprognostic (5.41e-3)" 18.8 11.6 0.0 0.1 0.0 0.0 10.8 0.0 0.0 0.8 5.5 0.0 0.6 0.5 0.5 2.2 1.6 3.1 0.0 0.1 5.7 29.6 2.6 0.0 0.9 0.8 0.6 0.6 0.8 44.9 1.3 1.0 1.0 1.0 2.9 4.4 0.7 1.1 0.0 2.3 1.7 0.2 4.1 0.0 4.2 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.0 64.4 9.0 0.0 0.0 1.3 12.3 7.1 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 19.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.7 0.0 1.1 0.6 0.3 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.2 3.1 0.0 5.7 5.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.8 0.2 0.0 0.0 6.6 0.2 13.7 1.2 0.0 26.8 0.6 0.0 22.7 29.4 0.8 0.2 134.3 0.0 1.7 0.0 0.0 4.5 0.8 0.0 7.1 0.0 0.0 142.3 15.5 0.0 0.4 1.5 0.2 0.0 0.0 0.0 ANO1 "DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A" ENSG00000131620 "Anoctamin 1" Q5XXA6 11 70078302-70189528 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Developmental protein, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "ductus deferens: 142.4;epididymis: 38.5;salivary gland: 122.9;seminal vesicle: 93.6" "Cell type enhanced" "Detected in many" 12 "Early spermatids: 56.2;Hepatocytes: 117.3;Late spermatids: 50.1;Sertoli cells: 45.3;Smooth muscle cells: 42.3;Suprabasal keratinocytes: 40.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "A-431: 32.9;CAPAN-2: 50.5;HaCaT: 61.6;OE19: 43.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA032148, HPA057356" Enhanced Supported "Nucleoplasm,Plasma membrane" NA NA "Plasma membrane" Nucleoplasm "HPA032148: AB_2674180, HPA057356: AB_2732610" "unprognostic (2.73e-1)" "unprognostic (7.91e-2)" "unprognostic (3.66e-2)" "prognostic favorable (4.58e-6)" "unprognostic (1.90e-1)" "prognostic unfavorable (7.28e-5)" "unprognostic (1.16e-3)" "prognostic unfavorable (2.40e-4)" "unprognostic (2.13e-2)" "unprognostic (3.51e-1)" "prognostic unfavorable (1.70e-4)" "unprognostic (1.21e-1)" "prognostic unfavorable (4.09e-6)" "unprognostic (1.56e-1)" "unprognostic (1.06e-1)" "unprognostic (8.85e-3)" "unprognostic (1.81e-1)" 6.9 0.4 1.1 2.1 1.1 0.0 17.2 1.6 1.4 9.7 5.3 1.1 142.4 0.2 14.2 38.5 3.6 11.7 10.6 6.9 1.1 0.2 2.6 24.4 4.4 1.5 1.0 1.0 3.9 4.5 0.5 2.0 6.2 1.5 7.2 1.7 1.7 122.9 93.6 3.4 19.1 1.8 5.7 1.0 1.1 9.5 7.6 0.9 1.1 8.9 8.1 3.8 4.5 5.9 0.0 0.0 0.0 0.0 0.0 0.3 0.0 32.9 1.3 0.0 1.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 50.5 0.0 0.6 0.0 0.0 61.6 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.2 43.3 4.8 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.0 10.5 0.2 0.3 3.9 0.1 0.1 0.0 0.3 0.0 0.8 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 1.1 1.6 1.4 1.1 0.2 1.0 1.0 1.5 0.9 0.0 0.0 0.0 18.1 15.8 0.0 2.8 25.5 0.0 1.2 0.0 0.0 1.1 0.0 2.9 56.2 2.2 0.0 0.0 0.0 0.6 3.5 9.1 4.6 117.3 0.2 0.0 0.0 4.9 1.6 50.1 1.7 0.9 5.0 0.0 11.4 1.0 0.6 0.0 1.4 0.4 0.3 45.3 42.3 1.4 1.5 40.8 3.4 0.0 0.2 17.8 ANXA1 "ANX1, LPC1" ENSG00000135046 "Annexin A1" P04083 9 73151757-73170393 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters" "Adaptive immunity, Immunity, Inflammatory response, Innate immunity" "Phospholipase A2 inhibitor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 432.6;tongue: 235.4" "Cell type enhanced" "Detected in many" 10 "granulocytes: 2387.0;Syncytiotrophoblasts: 5914.0;Urothelial cells: 4139.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA011271, HPA011272, CAB013023, CAB035987, CAB058693" Enhanced Enhanced "Nucleoplasm,Plasma membrane,Cytosol" "Secreted to blood" NA Yes 77000000 "Plasma membrane, Cytosol" Nucleoplasm "CAB013023: AB_2533983, CAB035987: , CAB058693: AB_2665585, HPA011271: AB_1844883, HPA011272: AB_1844884" "unprognostic (2.53e-2)" "unprognostic (1.31e-1)" "unprognostic (9.08e-2)" "prognostic favorable (5.71e-5)" "unprognostic (1.53e-2)" "unprognostic (4.28e-2)" "unprognostic (1.82e-2)" "unprognostic (1.30e-2)" "unprognostic (1.30e-1)" "unprognostic (1.14e-1)" "unprognostic (2.54e-3)" "unprognostic (1.47e-1)" "unprognostic (9.82e-3)" "unprognostic (1.13e-1)" "unprognostic (8.55e-2)" "prognostic favorable (4.57e-5)" "prognostic unfavorable (6.19e-6)" 52.7 3.5 2.7 11.5 3.3 81.4 45.9 0.9 2.5 61.5 8.5 3.6 5.5 2.4 6.9 11.2 432.6 11.9 14.9 8.9 3.2 2.5 9.1 2.1 37.3 7.6 4.3 1.9 11.7 2.4 0.5 6.3 149.5 13.5 12.9 4.4 6.4 93.0 7.2 7.9 11.6 6.4 12.3 6.5 5.9 5.9 5.6 3.1 3.9 21.7 235.4 153.3 18.0 83.1 0.7 98.9 146.2 79.1 27.3 52.5 102.8 66.2 104.7 4.7 4.9 66.8 63.6 0.3 114.8 71.8 47.5 32.2 3.0 59.9 0.1 38.0 100.1 105.0 81.6 10.1 69.5 37.7 37.5 0.7 5.1 31.1 0.1 53.3 11.0 2.5 36.6 57.6 48.0 94.4 44.0 67.3 6.0 21.0 2.8 58.5 0.2 19.5 6.0 5.9 26.5 42.6 0.0 26.7 0.2 106.8 14.0 0.0 0.0 39.5 1.0 26.5 65.5 0.2 1.7 83.1 55.7 35.1 76.5 58.9 0.4 0.1 0.2 128.7 10.3 83.8 146.2 79.1 141.1 52.2 21.5 52.5 0.7 47.0 45.9 98.9 0.2 13.7 25.4 8.6 27.3 19.3 3.5 8.3 102.8 2.7 3.3 0.9 2.5 3.2 2.5 4.3 1.9 13.5 3.1 541.9 512.9 7.3 2232.0 752.1 0.0 11.9 17.8 1060.0 889.5 59.3 0.0 1215.0 0.0 156.6 6.3 398.1 0.8 0.0 20.0 1352.9 735.1 1709.3 2387.0 2.5 570.9 0.0 5.1 113.5 449.6 2.3 206.0 1058.5 291.8 475.3 1.8 0.2 431.7 0.0 8.9 3.1 0.0 64.7 275.6 0.7 2.9 522.6 5914.0 282.4 0.5 4139.3 APP AD1 ENSG00000142192 "Amyloid beta precursor protein" P05067 21 25880550-26171128 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Cell adhesion, Endocytosis, Notch signaling pathway" "Heparin-binding, Protease inhibitor, Serine protease inhibitor" "Alzheimer disease, Amyloidosis, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "plasmacytoid DC: 24.0" "Lineage enriched" "Detected in many" 6 "dendritic cells: 24.0" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000157, HPA001462" Enhanced Approved "Golgi apparatus,Vesicles" NA NA 15000000 "Golgi apparatus" Vesicles "CAB000157: AB_323833, HPA001462: AB_1078185" "unprognostic (3.30e-1)" "unprognostic (1.02e-2)" "unprognostic (1.90e-1)" "unprognostic (1.24e-1)" "unprognostic (1.92e-1)" "unprognostic (3.69e-3)" "unprognostic (2.54e-1)" "unprognostic (8.22e-2)" "unprognostic (1.28e-1)" "unprognostic (9.45e-2)" "unprognostic (4.28e-2)" "unprognostic (5.35e-2)" "prognostic favorable (2.79e-6)" "unprognostic (3.77e-2)" "unprognostic (2.46e-1)" "unprognostic (5.23e-2)" "unprognostic (2.08e-3)" 44.8 92.5 89.9 26.3 109.3 21.2 79.9 64.5 139.1 51.7 63.4 86.9 72.0 39.7 52.2 57.2 33.0 57.6 63.4 69.1 104.6 97.7 102.2 54.5 50.2 12.9 97.4 95.8 58.9 57.1 36.4 34.1 79.7 83.2 49.2 59.6 48.9 47.2 66.6 17.2 38.2 34.9 69.3 109.0 26.3 37.9 32.2 67.5 13.9 85.0 21.5 16.7 52.5 58.4 1.5 24.0 0.9 3.9 0.3 1.5 1.8 31.2 40.4 44.3 36.9 60.4 75.0 47.9 63.4 84.6 32.2 37.9 23.2 76.7 0.0 73.9 49.6 42.0 21.4 27.0 74.5 27.3 1.1 21.8 0.0 24.4 16.3 59.0 29.6 1.6 67.5 82.4 37.7 69.3 133.1 144.0 13.0 0.0 3.2 50.5 35.0 0.5 0.3 34.8 51.2 36.1 19.4 42.7 26.0 109.0 22.0 22.6 33.0 68.0 44.8 31.8 63.1 39.6 32.3 153.9 71.7 30.4 26.1 29.9 19.6 0.2 0.3 58.3 0.1 68.8 0.4 3.9 0.0 0.1 1.2 0.2 0.5 1.4 0.5 3.4 1.5 1.5 0.4 0.9 0.3 0.9 24.0 0.3 1.8 89.9 109.3 64.5 124.6 104.6 97.7 97.4 95.8 83.2 67.5 101.3 43.6 31.5 195.4 161.4 26.5 130.8 282.8 120.5 119.4 476.3 27.5 341.9 48.0 308.0 33.6 371.9 139.3 0.0 158.2 112.6 202.6 156.7 8.1 105.8 67.9 79.4 156.1 527.9 77.8 43.7 224.6 45.9 153.5 92.8 307.0 330.4 178.5 181.4 279.0 124.0 22.1 116.4 133.6 37.0 87.7 92.8 461.7 25.5 256.5 110.0 ATP1A1 ENSG00000163399 "ATPase Na+/K+ transporting subunit alpha 1" P05023 1 116372668-116410261 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" Translocase "Cancer-related genes, Charcot-Marie-Tooth disease, Epilepsy, FDA approved drug targets, Mental retardation, Neurodegeneration, Neuropathy, Primary hypomagnesemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 195.4;parathyroid gland: 194.4" "Cell type enhanced" "Detected in all" 5 "Enterocytes: 917.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-MEL-30: 254.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018702, CAB069993" Enhanced NA NA 380000 "CAB018702: AB_626713, CAB069993: AB_2060979" "unprognostic (6.18e-2)" "unprognostic (2.18e-1)" "unprognostic (6.91e-2)" "unprognostic (1.42e-2)" "unprognostic (6.80e-2)" "unprognostic (2.15e-1)" "prognostic unfavorable (1.42e-4)" "unprognostic (1.80e-1)" "unprognostic (1.21e-2)" "unprognostic (6.32e-2)" "unprognostic (1.61e-2)" "unprognostic (1.65e-1)" "prognostic favorable (8.98e-8)" "unprognostic (4.75e-2)" "unprognostic (1.17e-1)" "unprognostic (3.11e-2)" "prognostic unfavorable (4.01e-4)" 17.4 25.6 22.4 16.2 40.3 10.5 26.9 74.2 67.4 17.8 121.9 14.2 56.1 92.3 13.1 38.3 34.9 17.7 65.8 41.1 26.1 18.7 162.7 34.6 35.1 9.6 19.2 27.6 17.4 78.6 194.4 25.0 19.2 34.1 22.1 65.7 24.1 84.4 53.7 19.0 40.5 195.4 17.7 20.7 13.7 25.0 17.0 13.9 9.1 101.2 13.7 16.2 14.2 23.1 10.3 22.0 6.4 29.7 10.4 30.2 17.2 33.7 12.4 12.9 6.5 26.0 25.3 66.6 20.2 40.3 24.9 35.4 49.8 24.2 26.7 28.6 23.9 25.3 44.1 25.5 42.6 36.3 9.8 28.3 15.5 23.5 42.0 19.9 38.9 21.9 28.1 71.5 29.0 38.3 35.2 30.5 16.3 25.6 25.8 22.0 67.0 15.7 14.1 30.4 53.6 25.0 15.2 30.3 23.6 90.1 34.8 12.7 11.2 31.4 59.6 254.2 33.2 15.7 22.6 26.9 14.2 19.9 36.7 40.9 12.5 9.7 20.5 43.6 22.5 83.4 6.4 13.3 6.1 23.2 20.9 24.8 10.3 26.4 24.9 22.0 5.3 30.2 22.0 1.6 10.4 29.7 11.1 20.3 17.2 22.4 40.3 74.2 67.4 26.1 18.7 19.2 27.6 34.1 13.9 256.1 246.7 58.7 265.3 245.9 76.0 62.7 540.1 113.8 203.6 731.0 375.0 70.1 316.7 432.8 25.0 117.9 917.6 93.5 278.3 130.8 110.9 297.5 43.8 66.4 114.8 96.9 169.4 90.9 77.6 11.5 109.0 130.5 197.4 47.7 304.0 513.0 192.4 264.8 94.7 289.6 141.6 32.3 179.2 17.9 27.5 235.0 56.5 95.6 365.5 236.0 ATP2C1 "ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1" ENSG00000017260 "ATPase secretory pathway Ca2+ transporting 1" P98194 3 130850595-131016712 "Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" Translocase "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010207, HPA035116, HPA069684" Supported Supported "Golgi apparatus" NA NA 28000 "Golgi apparatus" "CAB010207: AB_2061744, HPA035116: AB_10673106, HPA069684: AB_2686169" "unprognostic (1.52e-1)" "unprognostic (1.37e-1)" "unprognostic (2.74e-2)" "unprognostic (1.08e-1)" "unprognostic (2.99e-1)" "unprognostic (1.32e-2)" "prognostic unfavorable (5.06e-6)" "unprognostic (7.66e-2)" "unprognostic (6.52e-2)" "unprognostic (2.45e-1)" "prognostic unfavorable (1.52e-4)" "unprognostic (8.44e-2)" "prognostic favorable (1.55e-4)" "unprognostic (2.19e-1)" "unprognostic (1.95e-1)" "unprognostic (3.73e-2)" "unprognostic (3.06e-1)" 18.6 22.9 29.6 14.5 29.4 20.4 36.8 24.5 34.6 22.2 21.6 23.0 14.3 14.4 19.3 18.0 16.9 23.4 16.8 19.2 31.6 32.3 28.0 17.1 30.7 16.0 31.8 25.4 18.5 14.6 47.6 31.0 19.6 26.7 54.0 22.4 18.1 20.3 16.6 16.1 21.3 16.0 19.2 44.6 11.1 18.7 16.0 25.6 20.5 21.7 15.5 15.4 19.3 29.6 4.7 7.6 21.6 7.0 8.7 7.2 4.9 36.6 14.4 14.5 13.9 40.6 32.9 15.6 40.1 53.5 20.2 25.5 23.4 30.3 13.3 27.9 37.9 28.1 43.7 27.2 22.1 29.6 28.7 9.8 35.4 15.3 10.8 25.9 14.1 43.2 25.8 22.3 21.2 24.1 36.9 21.3 16.9 10.2 24.3 24.8 16.3 13.8 11.3 16.4 20.0 15.7 10.0 14.4 20.9 37.2 24.7 22.4 13.4 34.5 10.8 20.2 21.6 16.0 11.6 29.1 21.5 12.0 27.6 18.4 15.7 19.0 19.7 22.2 10.6 17.9 21.6 7.0 12.1 6.3 6.0 5.9 4.7 6.2 5.6 7.6 2.9 4.3 4.3 3.5 8.7 7.0 6.6 7.2 4.9 29.6 29.4 24.5 34.6 31.6 32.3 31.8 25.4 26.7 25.6 35.7 45.2 11.3 32.9 34.9 26.4 27.0 40.8 24.1 23.9 43.6 19.6 13.5 5.0 32.7 12.6 25.1 15.9 0.0 33.1 24.1 29.4 68.4 27.7 24.6 26.6 77.9 34.2 22.7 18.3 14.0 15.0 28.6 20.3 19.8 31.3 22.6 44.4 25.9 13.8 18.6 33.2 6.5 24.2 15.2 14.9 46.2 14.8 13.8 29.3 33.5 ATP4A ATP6A ENSG00000105675 "ATPase H+/K+ transporting alpha subunit" P20648 19 35550043-35563658 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Hydrogen ion transport, Ion transport, Potassium transport, Transport" Translocase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 24 "stomach 1: 120.1" "Group enriched" "Detected in some" 4 "Early spermatids: 7.3;Late spermatids: 15.2" "Cancer enriched" "Detected in single" 21 "stomach cancer: 5.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "THP-1: 1.2;U-138 MG: 1.5" "Low region specificity" "Detected in single" "Low region specificity" "Detected in some" "HPA039154, HPA076684" Enhanced NA NA 790000 "HPA039154: AB_10672772, HPA076684: " "unprognostic (3.54e-2)" "unprognostic (6.98e-3)" "unprognostic (2.77e-2)" "unprognostic (1.43e-1)" "unprognostic (5.84e-3)" "unprognostic (4.96e-2)" "unprognostic (1.02e-1)" "unprognostic (1.50e-1)" "unprognostic (9.68e-2)" "unprognostic (1.47e-3)" "unprognostic (3.90e-3)" "unprognostic (3.92e-2)" "unprognostic (4.86e-2)" "unprognostic (1.23e-1)" "unprognostic (2.18e-1)" 0.1 0.2 0.1 0.1 0.6 0.0 0.1 0.1 0.6 0.1 0.1 3.4 0.1 0.0 0.1 0.1 4.9 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 2.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 2.1 0.1 0.1 120.1 0.1 0.1 0.7 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 1.2 0.0 1.5 0.3 0.0 0.0 0.4 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.1 0.6 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.2 0.6 0.0 0.0 1.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.9 2.6 0.0 0.0 0.0 0.0 0.0 ATP4B ATP6B ENSG00000186009 "ATPase H+/K+ transporting beta subunit" P51164 13 113648804-113658186 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Cell adhesion, Hydrogen ion transport, Ion transport, Potassium transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 24 "stomach 1: 156.3" "Cell type enriched" "Detected in single" 6 "Distal tubular cells: 1.7" "Cancer enriched" "Detected in some" 12 "stomach cancer: 8.9" "Region enriched" "Detected in single" 9 "cerebral cortex: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "REH: 3.9;RPMI-8226: 1.6;SCLC-21H: 2.6" "Not detected" "Not detected" "Not detected" "Not detected" "HPA045400, HPA052649" Enhanced NA NA "HPA045400: AB_2679314, HPA052649: AB_2681900" "unprognostic (9.92e-2)" "unprognostic (2.19e-1)" "unprognostic (2.66e-1)" "unprognostic (4.86e-1)" "unprognostic (6.43e-3)" "unprognostic (7.81e-3)" "unprognostic (1.95e-1)" "unprognostic (3.22e-1)" "unprognostic (6.50e-2)" "unprognostic (6.65e-4)" "unprognostic (2.25e-1)" "unprognostic (2.78e-1)" "unprognostic (3.78e-2)" 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 1.0 0.1 0.1 2.0 0.1 0.0 0.1 0.1 1.5 1.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 6.5 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 156.3 0.1 0.1 0.6 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.0 0.2 0.1 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 3.9 0.0 1.6 0.0 0.0 2.6 0.9 0.2 0.7 0.0 0.0 0.1 0.8 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 1.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ATP6V1B2 "ATP6B2, HO57, VATB, Vma2, VPP3" ENSG00000147416 "ATPase H+ transporting V1 subunit B2" P21281 8 20197367-20226819 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters" "Hydrogen ion transport, Ion transport, Transport" Hydrolase "Deafness, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 116.0" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "classical monocyte: 69.7;eosinophil: 47.6;intermediate monocyte: 62.5;myeloid DC: 34.5;neutrophil: 116.0;non-classical monocyte: 54.1" "Group enriched" "Detected in all" 10 "dendritic cells: 34.5;granulocytes: 116.0;monocytes: 69.7" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008147 Enhanced Supported Vesicles NA NA 240000 Vesicles "HPA008147: AB_1845195" "unprognostic (1.90e-1)" "unprognostic (7.24e-3)" "unprognostic (3.62e-2)" "unprognostic (2.57e-1)" "unprognostic (2.84e-2)" "unprognostic (5.59e-3)" "unprognostic (1.76e-2)" "unprognostic (3.78e-2)" "unprognostic (4.68e-2)" "unprognostic (4.23e-3)" "unprognostic (1.29e-2)" "unprognostic (1.34e-1)" "prognostic favorable (8.41e-4)" "unprognostic (2.41e-1)" "unprognostic (2.09e-2)" "unprognostic (2.47e-2)" "unprognostic (5.25e-2)" 17.1 29.9 31.7 25.8 45.0 14.4 13.2 39.2 72.9 12.2 13.9 15.9 5.5 16.2 10.6 12.2 15.3 10.3 14.8 13.9 33.8 47.8 53.9 18.0 22.8 17.5 46.9 47.1 10.9 12.2 18.8 23.6 18.5 64.2 11.0 16.5 17.3 12.8 10.9 18.2 18.2 21.1 15.0 19.2 20.9 10.7 24.0 12.7 10.3 12.7 9.3 17.5 14.3 12.4 4.9 34.5 116.0 69.7 4.8 7.1 51.1 10.8 18.2 22.7 7.4 31.0 19.2 20.4 24.5 15.7 31.6 32.7 20.5 6.4 19.3 10.0 23.3 32.2 9.3 17.9 16.3 33.7 8.1 12.0 13.4 8.2 15.7 36.4 9.5 28.0 17.1 14.9 19.6 18.1 34.9 19.7 25.8 19.9 18.7 33.7 6.1 27.8 11.3 16.8 16.0 8.0 11.5 29.2 10.0 29.2 17.2 17.6 25.4 11.8 16.0 77.9 19.6 20.9 17.5 20.8 15.9 12.2 26.2 19.5 7.6 10.2 22.7 22.0 22.8 40.3 15.9 69.7 47.6 5.7 62.5 6.2 4.9 5.9 6.1 34.5 4.3 6.1 6.0 116.0 4.8 54.1 8.4 7.1 51.1 31.7 45.0 39.2 69.0 33.8 47.8 46.9 47.1 64.2 12.7 23.8 20.2 30.3 24.8 51.5 100.1 14.0 12.7 12.0 11.4 27.9 96.2 100.2 68.0 38.5 22.5 24.8 23.6 46.7 33.2 46.1 30.0 15.5 21.9 30.6 167.3 179.6 71.4 28.3 171.7 15.9 18.1 165.7 99.5 87.4 19.6 39.2 37.2 20.4 26.5 193.9 117.5 12.9 37.6 83.9 46.7 62.6 104.2 27.7 20.0 18.2 ATP6V1C1 "ATP6C, ATP6D, VATC, Vma5" ENSG00000155097 "ATPase H+ transporting V1 subunit C1" P21283 8 103021063-103073051 "FDA approved drug targets, Predicted intracellular proteins, Transporters" "Hydrogen ion transport, Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023943, HPA057297" Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA023943: AB_1845197, HPA057297: AB_2683402" "unprognostic (5.73e-3)" "unprognostic (3.30e-1)" "unprognostic (1.09e-2)" "unprognostic (1.93e-2)" "unprognostic (1.52e-2)" "unprognostic (3.35e-2)" "prognostic unfavorable (8.82e-4)" "unprognostic (3.29e-2)" "unprognostic (3.87e-1)" "unprognostic (5.62e-2)" "unprognostic (1.19e-1)" "unprognostic (5.59e-2)" "unprognostic (3.98e-2)" "unprognostic (1.23e-1)" "unprognostic (3.85e-1)" "unprognostic (3.88e-1)" "unprognostic (2.83e-1)" 17.1 23.1 25.1 16.8 36.7 6.5 15.7 26.2 58.8 13.6 11.1 11.4 7.6 12.1 14.1 10.9 10.6 12.2 13.7 19.0 28.5 28.0 35.0 18.1 12.9 15.9 23.2 33.3 14.4 12.9 21.3 29.2 20.2 45.1 13.2 13.7 11.5 10.4 12.2 11.7 8.5 12.8 14.5 15.0 14.3 12.1 13.0 12.5 10.7 26.9 8.4 15.6 15.5 10.7 10.6 16.3 27.9 24.3 10.0 12.5 10.8 29.1 17.5 9.3 6.9 24.4 15.8 11.5 21.9 21.8 24.6 29.1 12.9 29.6 18.8 25.1 17.4 39.3 11.8 18.3 17.0 35.2 12.3 14.1 18.3 13.3 15.3 26.0 9.8 22.1 15.1 22.2 33.0 15.9 14.8 18.5 12.2 23.3 15.4 27.3 13.2 18.3 7.2 8.1 26.5 17.0 10.6 16.4 14.2 27.5 21.0 11.9 10.2 12.3 11.7 38.3 17.3 24.5 11.6 22.0 14.3 14.5 31.7 15.3 20.2 7.3 17.9 27.7 20.4 13.8 8.4 17.4 20.6 9.1 24.3 10.2 10.6 7.7 8.9 16.3 10.2 9.0 9.7 27.9 10.0 22.1 8.8 12.5 10.8 25.1 36.7 26.2 58.8 28.5 28.0 23.2 33.3 45.1 12.5 29.8 23.7 18.1 27.2 31.0 29.7 39.1 12.7 41.5 18.2 29.6 15.7 32.6 54.7 34.3 128.0 23.1 13.6 23.3 27.3 30.1 23.0 29.4 23.1 15.3 87.3 35.0 15.0 18.4 45.4 117.5 22.5 45.4 18.6 26.2 12.6 31.4 26.9 14.4 17.3 112.2 20.4 19.4 32.5 10.5 20.2 28.7 62.6 17.5 13.4 25.0 AVPR1B AVPR3 ENSG00000198049 "Arginine vasopressin receptor 1B" P47901 1 206109692-206117699 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 23 "pituitary gland: 52.8" "Not detected" "Not detected" "Cancer enhanced" "Detected in some" "renal cancer: 1.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "EFO-21: 1.0;NTERA-2: 1.0;PC-3: 3.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA075404 Enhanced NA NA "HPA075404: AB_2732291" "unprognostic (4.87e-2)" "unprognostic (1.44e-1)" "unprognostic (4.82e-1)" "unprognostic (2.82e-1)" "unprognostic (2.87e-1)" "unprognostic (1.08e-2)" "unprognostic (3.33e-1)" "unprognostic (2.96e-2)" "unprognostic (6.23e-2)" "unprognostic (7.65e-2)" "unprognostic (1.86e-1)" "unprognostic (6.66e-3)" 0.0 0.0 0.2 0.2 0.2 0.0 0.0 0.6 0.5 0.1 1.3 0.0 0.0 1.0 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.6 0.0 0.0 0.1 0.0 0.0 0.0 2.1 0.0 52.8 0.1 0.1 0.2 0.8 0.0 0.0 0.4 0.0 0.0 1.0 0.1 0.0 0.0 2.2 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.5 1.0 0.0 3.6 0.0 0.0 0.2 0.0 0.3 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.6 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 AVPR2 "DIR, DIR3, V2R" ENSG00000126895 "Arginine vasopressin receptor 2" P30518 X 153902531-153907166 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Diabetes insipidus, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 8.9" "Cell type enriched" "Detected in some" 8 "Collecting duct cells: 47.1" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in some" 26 "intermediate monocyte: 6.2;non-classical monocyte: 5.3" "Lineage enriched" "Detected in single" 28 "monocytes: 6.2" "Cell line enhanced" "Detected in some" "EFO-21: 5.7;SCLC-21H: 6.6;U-266/84: 6.0;U-698: 6.3" "Not detected" "Not detected" "Region enriched" "Detected in single" 18 "cerebellum: 7.9" NA NA "unprognostic (3.05e-2)" "unprognostic (5.62e-2)" "unprognostic (1.99e-4)" "unprognostic (2.50e-4)" "unprognostic (2.76e-1)" "unprognostic (7.10e-6)" "unprognostic (3.80e-3)" "unprognostic (1.17e-1)" "unprognostic (2.20e-1)" "unprognostic (2.56e-2)" "unprognostic (4.21e-2)" "unprognostic (1.91e-1)" "unprognostic (1.33e-1)" "unprognostic (1.08e-2)" "unprognostic (1.87e-1)" "unprognostic (4.38e-1)" "unprognostic (9.83e-2)" 8.9 0.1 0.0 0.1 0.0 0.9 7.1 1.2 0.0 2.1 1.5 0.7 2.7 0.0 0.8 2.6 1.4 6.3 0.0 0.0 4.7 0.0 1.9 1.1 0.0 0.1 0.6 0.2 0.0 0.1 1.1 0.0 1.2 0.8 4.3 2.2 1.3 1.0 0.0 0.0 1.2 0.0 1.9 0.2 1.8 2.1 0.0 0.2 0.0 6.2 0.0 0.0 0.2 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.4 2.8 5.7 0.0 0.9 0.0 0.0 0.0 0.0 1.9 0.2 2.2 0.9 0.0 0.1 2.8 2.2 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 2.7 0.0 0.1 1.4 1.6 0.2 0.0 0.1 2.5 1.1 2.5 0.1 0.0 6.6 1.2 0.1 0.0 0.1 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.2 1.1 6.0 6.3 0.0 1.6 0.1 0.0 0.1 0.0 0.0 6.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.2 3.0 2.2 0.0 0.0 0.9 0.0 1.4 0.0 1.4 0.0 47.1 0.0 0.0 0.0 0.0 0.1 5.8 0.0 0.0 0.0 0.0 0.2 0.0 1.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.1 0.0 0.0 0.0 0.1 CACNA1A "APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6" ENSG00000141837 "Calcium voltage-gated channel subunit alpha1 A" O00555 19 13206442-13633025 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "brain: 77.9" "Group enriched" "Detected in many" 8 "Bipolar cells: 68.3;Horizontal cells: 235.2;Intestinal endocrine cells: 205.4" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in all" 4 "cerebellum: 77.9" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 5 "SCLC-21H: 31.2;U-87 MG: 17.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA064258, HPA068138, HPA071902" Enhanced Supported Uncertain "Endoplasmic reticulum" NA NA "Endoplasmic reticulum" "HPA064258: AB_2685229, HPA068138: , HPA071902: " "unprognostic (1.09e-1)" "unprognostic (3.73e-3)" "unprognostic (2.27e-1)" "unprognostic (2.78e-4)" "unprognostic (4.00e-2)" "unprognostic (2.29e-3)" "unprognostic (5.47e-2)" "unprognostic (3.13e-1)" "unprognostic (2.86e-1)" "unprognostic (1.14e-2)" "prognostic favorable (4.32e-4)" "unprognostic (5.31e-3)" "unprognostic (5.03e-6)" "unprognostic (6.29e-2)" "unprognostic (1.59e-1)" "unprognostic (2.61e-2)" "unprognostic (6.25e-2)" 2.2 5.3 7.6 1.0 12.2 0.7 0.9 77.9 19.7 0.8 1.5 1.8 0.0 3.9 1.2 2.8 0.7 2.2 0.8 1.1 5.7 5.1 0.7 0.5 0.7 1.3 3.9 7.3 1.1 3.0 0.7 1.5 0.6 7.2 0.8 1.7 1.2 0.9 0.8 1.3 0.7 2.8 0.9 3.3 1.3 7.7 1.9 2.8 0.0 0.7 0.0 1.0 0.8 0.3 2.8 0.8 1.9 1.1 0.8 0.8 0.4 0.0 0.1 0.0 3.9 0.1 0.3 0.0 1.6 1.6 0.2 0.0 0.0 0.0 0.1 0.0 0.1 3.4 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 2.1 0.0 1.3 0.0 0.0 0.0 0.0 0.0 4.6 0.1 0.0 0.0 0.1 0.9 0.0 0.2 0.4 0.0 0.1 0.0 0.1 31.2 0.0 0.0 0.0 0.2 0.1 0.0 1.2 0.1 0.1 0.7 0.1 0.0 0.0 0.0 0.0 17.6 0.0 0.4 1.9 0.4 0.7 0.5 0.5 0.8 2.8 0.5 0.3 0.4 1.7 0.6 0.7 1.6 0.8 1.1 0.8 0.6 0.4 7.6 12.2 77.9 17.4 5.7 5.1 3.9 7.3 7.2 2.8 6.0 2.7 1.3 1.4 0.6 68.3 2.2 0.0 6.7 2.3 1.8 15.7 0.0 0.0 0.6 22.1 4.2 0.0 0.0 0.3 0.1 2.1 0.8 1.1 0.0 0.5 235.2 205.4 1.8 1.3 17.9 1.1 2.1 0.0 1.0 1.1 2.9 1.9 0.0 0.4 2.0 6.2 0.0 4.2 4.1 5.1 0.1 0.2 4.3 0.8 0.9 CACNA1C "CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS" ENSG00000151067 "Calcium voltage-gated channel subunit alpha1 C" Q13936 12 1970786-2697950 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Host-virus interaction, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Brugada syndrome, Disease mutation, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 32.5" "Cell type enriched" "Detected in many" 4 "Horizontal cells: 284.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 4.2" "Group enriched" "Detected in many" 19 "NK-cells: 4.2;T-cells: 1.2" "Cell line enriched" "Detected in some" 17 "HDLM-2: 47.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039796, CAB079031" Enhanced Approved NA NA "CAB079031: , HPA039796: AB_10673019" "unprognostic (1.76e-1)" "unprognostic (1.19e-1)" "unprognostic (6.29e-2)" "unprognostic (9.35e-2)" "unprognostic (3.71e-2)" "unprognostic (1.60e-2)" "unprognostic (4.68e-2)" "unprognostic (7.99e-2)" "unprognostic (3.07e-2)" "unprognostic (1.03e-5)" "unprognostic (1.93e-2)" "unprognostic (1.01e-1)" "unprognostic (4.02e-7)" "unprognostic (8.85e-2)" "unprognostic (3.60e-2)" "unprognostic (6.90e-2)" "unprognostic (3.39e-2)" 3.8 2.5 8.6 6.0 7.7 1.4 2.4 7.1 11.7 11.2 26.5 1.3 7.4 2.4 29.7 4.5 5.2 4.3 7.1 32.5 5.5 4.0 2.7 1.4 4.7 2.0 2.4 6.6 2.7 3.2 1.5 8.1 5.1 3.9 7.9 3.8 6.5 2.4 8.1 2.3 1.7 5.2 28.8 1.9 3.5 7.2 11.3 1.7 0.0 2.0 1.1 1.7 12.6 5.4 0.0 0.1 0.0 0.1 4.2 1.2 0.2 0.0 0.0 0.0 0.0 1.6 1.1 0.1 1.7 2.0 1.1 0.8 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.5 47.6 0.4 0.6 0.0 0.0 1.2 0.0 0.0 2.7 0.0 0.6 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.6 0.0 0.0 0.0 2.7 0.3 2.6 0.0 0.0 0.0 0.0 2.2 0.1 0.6 0.0 0.0 0.0 0.6 0.0 1.2 0.0 0.5 0.7 0.0 0.0 0.9 0.7 0.0 4.2 0.1 0.1 0.4 0.2 8.6 7.7 7.1 11.7 5.5 4.0 2.4 6.6 3.9 1.7 0.0 0.0 0.0 1.2 0.6 15.3 42.8 0.0 0.0 0.0 0.0 2.0 0.1 0.0 0.0 27.5 2.9 0.0 0.0 0.0 0.2 2.5 1.4 0.0 0.0 0.2 284.4 35.2 2.5 0.0 64.7 0.9 0.0 0.0 0.0 0.6 6.1 0.3 0.2 3.9 0.0 1.2 12.9 17.5 2.6 5.8 0.1 0.1 0.0 0.4 2.4 CACNA1D "CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2" ENSG00000157388 "Calcium voltage-gated channel subunit alpha1 D" Q01668 3 53328963-53813733 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Cancer-related genes, Deafness, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 9 "Alveolar cells type 2: 45.9;Cone photoreceptor cells: 33.4;Intestinal endocrine cells: 57.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 9 "basophil: 7.2" "Lineage enriched" "Detected in single" 20 "granulocytes: 7.2" "Cell line enhanced" "Detected in some" "HMC-1: 14.4;RPMI-8226: 33.6;SK-BR-3: 6.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA020215 Uncertain Approved "Nuclear membrane" NA NA "Nuclear membrane" "HPA020215: AB_1845860" "unprognostic (5.85e-2)" "unprognostic (4.90e-3)" "unprognostic (5.09e-2)" "unprognostic (2.24e-2)" "unprognostic (7.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.92e-1)" "unprognostic (2.32e-2)" "unprognostic (2.95e-1)" "unprognostic (4.42e-2)" "unprognostic (3.90e-3)" "unprognostic (1.53e-1)" "prognostic favorable (8.34e-8)" "unprognostic (1.14e-1)" "unprognostic (3.05e-2)" "unprognostic (8.09e-3)" "unprognostic (6.70e-3)" 0.6 13.4 10.0 0.8 12.6 1.4 3.6 12.2 16.5 11.2 2.8 3.7 0.1 3.3 6.8 13.2 1.2 14.9 6.2 1.8 5.3 3.5 4.2 3.0 9.0 0.5 2.5 9.6 1.2 5.3 3.0 13.6 1.4 8.7 5.7 3.1 10.1 1.1 3.5 0.6 1.5 4.2 1.7 2.2 4.4 1.8 3.0 1.6 0.0 5.2 0.0 0.6 2.3 0.6 0.1 0.3 7.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 0.0 1.6 1.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 14.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.2 0.5 0.0 0.0 0.1 33.6 0.3 2.2 3.1 1.3 0.2 6.3 0.7 0.0 1.8 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 7.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 10.0 12.6 12.2 16.5 5.3 3.5 2.5 9.6 8.7 1.6 3.0 45.9 0.0 0.6 0.8 23.0 1.2 12.7 14.7 14.8 1.8 33.4 0.6 0.0 5.5 3.6 0.5 3.3 0.0 2.0 0.1 1.0 2.6 11.6 2.4 0.2 7.9 57.1 0.0 1.0 4.9 4.0 0.3 5.0 0.0 2.7 2.5 2.6 3.5 25.5 1.6 13.0 0.0 2.8 1.1 2.5 0.9 0.2 1.3 4.5 0.6 CACNA1F "AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2" ENSG00000102001 "Calcium voltage-gated channel subunit alpha1 F" O60840 X 49205063-49233371 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Sensory transduction, Transport, Vision" "Calcium channel, Ion channel, Voltage-gated channel" "Cone-rod dystrophy, Congenital stationary night blindness, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "retina: 55.8" "Group enriched" "Detected in some" 15 "Bipolar cells: 66.5;Cone photoreceptor cells: 125.7;Rod photoreceptor cells: 91.4" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 4.6" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "MCF7: 2.8;U-266/70: 4.6" "Not detected" "Not detected" "Not detected" "Not detected" HPA068379 Enhanced NA NA "HPA068379: AB_2732782" "unprognostic (1.20e-3)" "unprognostic (8.62e-2)" "unprognostic (4.25e-3)" "unprognostic (1.56e-2)" "unprognostic (8.46e-2)" "unprognostic (1.84e-1)" "unprognostic (1.23e-2)" "unprognostic (1.76e-1)" "unprognostic (1.23e-1)" "unprognostic (9.04e-2)" "unprognostic (7.36e-2)" "unprognostic (1.59e-1)" "unprognostic (6.08e-7)" "unprognostic (8.03e-2)" "unprognostic (1.09e-1)" "unprognostic (4.65e-2)" "unprognostic (3.77e-3)" 0.7 0.8 1.8 0.7 1.5 4.0 1.8 5.3 2.0 0.7 1.0 0.7 0.7 1.9 0.7 2.7 0.7 1.0 0.7 0.7 0.8 0.6 0.7 0.7 1.4 2.7 0.7 0.7 0.7 1.4 0.0 0.7 0.7 0.7 0.7 1.5 55.8 1.2 0.9 0.7 2.4 3.7 0.7 0.7 1.8 1.0 0.7 0.7 0.7 1.2 0.7 0.9 0.7 0.7 1.4 4.6 2.0 0.9 0.5 1.0 0.2 0.2 2.5 0.2 0.0 0.6 0.0 2.5 0.4 0.2 0.0 0.0 0.1 0.9 1.4 0.5 0.5 0.0 0.1 0.4 0.0 0.0 0.1 0.0 0.7 0.0 0.5 0.6 0.1 0.8 0.6 0.0 0.4 0.0 0.2 0.8 0.8 1.0 0.3 0.0 2.8 1.3 1.5 1.1 1.9 0.0 0.1 0.0 0.5 0.4 1.5 0.6 0.0 0.0 0.1 0.0 0.9 0.9 1.5 1.0 0.2 0.3 0.3 0.1 4.6 1.6 0.1 0.8 0.4 0.0 0.9 0.7 0.6 0.6 0.5 0.5 0.7 0.8 0.4 0.8 1.4 0.5 1.0 2.0 0.5 0.9 4.6 0.7 0.2 1.8 1.5 5.3 2.0 0.8 0.6 0.7 0.7 0.7 0.7 0.0 0.3 0.0 0.1 0.0 66.5 1.2 0.0 0.0 0.0 1.8 125.7 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.2 6.4 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 1.3 5.5 0.0 0.0 0.4 0.0 91.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.1 CACNA1H Cav3.2 ENSG00000196557 "Calcium voltage-gated channel subunit alpha1 H" O95180 16 1153121-1221772 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 49.5" "Cell type enhanced" "Detected in many" 8 "Bipolar cells: 16.2;Late spermatids: 13.2;Peritubular cells: 24.4;Sertoli cells: 25.8;Smooth muscle cells: 16.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 10.9;AN3-CA: 15.7;MCF7: 28.9;OE19: 9.6;T-47d: 8.6" "Low region specificity" "Detected in many" HPA039125 Approved Approved Nucleoplasm,Vesicles NA NA "Nucleoplasm, Vesicles" "HPA039125: AB_10795578" "unprognostic (1.66e-3)" "unprognostic (2.10e-1)" "unprognostic (4.07e-2)" "unprognostic (1.21e-3)" "unprognostic (1.37e-2)" "unprognostic (2.15e-1)" "unprognostic (4.39e-2)" "unprognostic (2.38e-2)" "unprognostic (1.06e-1)" "unprognostic (3.30e-2)" "prognostic favorable (3.12e-5)" "unprognostic (1.66e-2)" "prognostic unfavorable (1.78e-5)" "unprognostic (1.93e-2)" "unprognostic (4.65e-2)" "unprognostic (1.70e-2)" "unprognostic (5.55e-2)" 5.0 6.8 5.1 4.2 12.0 0.3 3.3 0.3 4.3 17.5 28.1 1.6 10.2 5.4 25.7 5.9 16.3 11.7 26.0 2.2 2.5 2.1 4.7 5.5 3.5 0.7 1.0 2.8 31.8 2.1 6.6 14.8 1.9 2.0 21.0 2.2 4.2 1.7 24.9 2.9 4.8 8.5 49.5 1.1 0.5 9.7 11.7 2.1 0.0 5.2 1.4 0.5 34.6 20.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 10.9 1.9 15.7 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 6.4 0.0 0.0 6.5 1.9 0.0 2.8 0.2 0.0 0.0 0.0 0.0 0.0 1.9 2.9 0.0 0.0 28.9 0.0 0.0 5.9 9.6 2.2 0.0 0.0 0.1 2.9 0.0 0.0 0.0 0.0 0.0 0.5 0.7 8.6 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 12.0 0.3 4.3 2.5 2.1 1.0 2.8 2.0 2.1 0.0 0.0 0.0 0.0 1.3 16.2 1.8 2.5 0.0 0.0 0.0 0.0 0.0 0.0 3.1 5.0 1.2 0.0 0.0 0.0 0.0 0.2 3.3 4.6 8.1 0.1 0.0 10.4 0.6 0.0 13.2 7.8 0.0 0.0 0.0 0.3 0.8 0.7 0.0 24.4 0.8 1.0 25.8 16.5 1.8 4.5 3.0 0.0 0.0 0.0 0.5 CACNA1S "CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5" ENSG00000081248 "Calcium voltage-gated channel subunit alpha1 S" Q13698 1 201039512-201112566 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "skeletal muscle: 83.1" "Cell type enhanced" "Detected in some" 21 "Cardiomyocytes: 1.4;Cone photoreceptor cells: 5.9;Early spermatids: 1.4;Late spermatids: 3.3;Rod photoreceptor cells: 1.2" "Cancer enhanced" "Detected in single" "head and neck cancer: 0.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 20 "BEWO: 5.5;HSkMC: 7.1" "Low region specificity" "Detected in single" "Region enriched" "Detected in single" 13 "olfactory region: 5.3" "CAB009507, HPA048892, HPA056815" Enhanced NA NA "CAB009507: AB_2069576, HPA048892: AB_2680548, HPA056815: AB_2683242" "unprognostic (2.14e-2)" "unprognostic (1.38e-1)" "unprognostic (1.12e-2)" "unprognostic (1.09e-1)" "unprognostic (3.52e-3)" "unprognostic (4.53e-2)" "unprognostic (2.84e-1)" "unprognostic (2.23e-1)" "unprognostic (2.53e-2)" "unprognostic (1.51e-1)" "unprognostic (4.72e-3)" "unprognostic (1.12e-1)" "unprognostic (5.28e-2)" "unprognostic (7.36e-2)" "unprognostic (1.57e-1)" 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.9 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.4 0.6 0.0 83.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 10.6 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.4 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 5.9 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 CACNA2D1 "CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3" ENSG00000153956 "Calcium voltage-gated channel auxiliary subunit alpha2delta 1" P54289 7 81946444-82443798 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 59.0" "Cell type enhanced" "Detected in many" 11 "Cardiomyocytes: 89.3;Early spermatids: 53.8;Intestinal endocrine cells: 37.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "hTERT-RPE1: 49.0;HUVEC TERT2: 20.6;SH-SY5Y: 23.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008213, HPA008621" Enhanced "Intracellular and membrane" NA NA 310000000 "HPA008213: AB_1233654, HPA008621: AB_1845863" "unprognostic (5.07e-3)" "unprognostic (2.21e-1)" "unprognostic (4.27e-3)" "unprognostic (2.92e-2)" "unprognostic (2.27e-1)" "unprognostic (1.39e-1)" "unprognostic (1.70e-1)" "unprognostic (3.22e-1)" "unprognostic (3.76e-1)" "unprognostic (2.05e-1)" "unprognostic (6.24e-3)" "unprognostic (2.23e-2)" "prognostic unfavorable (1.16e-4)" "unprognostic (4.28e-3)" "unprognostic (2.13e-1)" "unprognostic (9.18e-2)" "unprognostic (1.03e-4)" 9.9 13.4 15.7 4.2 18.1 0.7 4.3 8.8 20.8 5.7 11.3 7.3 1.0 5.0 7.1 2.9 5.4 4.1 6.3 25.8 12.7 14.9 8.0 1.8 3.6 2.2 6.3 15.6 7.8 2.0 1.9 8.3 4.2 8.6 12.8 5.3 1.9 3.3 6.6 59.0 4.7 3.5 13.0 5.6 4.3 5.5 3.7 8.0 0.0 16.9 14.6 3.3 6.8 7.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 4.0 0.0 7.1 9.0 0.0 8.7 5.6 4.3 4.3 0.0 1.3 0.0 0.0 7.5 5.4 0.0 4.2 0.0 5.7 0.0 5.6 0.2 5.6 0.0 4.6 1.9 0.0 5.3 0.0 15.1 0.0 49.0 20.6 0.0 0.0 0.0 9.7 0.0 0.0 0.0 4.7 0.0 1.8 0.8 0.8 0.0 0.3 0.3 8.0 23.9 1.7 0.0 0.0 4.4 0.0 0.0 14.7 7.7 5.8 7.6 0.0 0.0 0.0 0.0 6.5 0.0 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.7 18.1 8.8 20.8 12.7 14.9 6.3 15.6 8.6 8.0 0.0 1.7 0.0 4.0 5.0 30.7 89.3 0.0 1.4 2.3 7.0 17.7 0.0 0.0 0.0 53.8 9.0 0.0 0.0 0.0 0.0 11.0 11.4 24.3 0.0 0.2 23.8 37.2 1.3 0.0 25.0 9.5 0.4 1.7 1.0 0.2 5.8 0.6 0.0 5.6 9.9 6.0 6.5 17.6 1.0 2.3 5.6 0.1 0.0 0.0 1.4 CACNA2D2 KIAA0558 ENSG00000007402 "Calcium voltage-gated channel auxiliary subunit alpha2delta 2" Q9NY47 3 50362799-50504244 "FDA approved drug targets, Predicted intracellular proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "lung: 86.1" "Group enriched" "Detected in many" 6 "Alveolar cells type 1: 71.5;Alveolar cells type 2: 145.9" "Cancer enhanced" "Detected in many" "testis cancer: 20.4" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in some" 8 "SH-SY5Y: 66.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA034771, HPA071829" Enhanced Approved Vesicles NA NA 1000000 Vesicles "HPA034771: AB_10603555, HPA071829: AB_2686454" "unprognostic (2.06e-1)" "unprognostic (2.37e-1)" "unprognostic (1.72e-2)" "prognostic unfavorable (7.62e-5)" "unprognostic (6.59e-2)" "unprognostic (6.37e-2)" "unprognostic (6.91e-2)" "unprognostic (6.57e-3)" "unprognostic (4.39e-2)" "unprognostic (1.17e-1)" "prognostic favorable (1.21e-4)" "unprognostic (2.71e-2)" "unprognostic (1.57e-4)" "unprognostic (3.03e-1)" "unprognostic (4.14e-2)" "unprognostic (3.55e-1)" "unprognostic (4.22e-2)" 1.0 0.9 1.6 1.3 11.1 1.1 1.4 14.9 6.5 1.1 1.7 0.9 0.6 1.4 1.7 1.2 0.9 1.1 0.9 7.6 1.7 9.1 1.6 0.5 86.1 1.3 3.9 3.2 2.2 4.0 3.8 6.0 1.9 6.1 3.0 2.0 6.1 1.5 1.4 1.7 2.6 1.7 1.4 1.4 1.5 4.1 5.8 2.5 0.2 2.3 0.1 0.7 0.7 0.7 1.8 0.3 0.7 0.1 2.3 3.6 1.1 0.0 0.0 1.0 2.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 8.5 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.3 0.0 0.0 2.7 0.0 0.2 0.0 0.0 0.2 0.0 0.0 6.4 66.5 0.2 0.1 0.0 2.0 0.5 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.4 2.2 0.0 2.7 1.8 2.6 2.0 0.0 1.3 3.6 2.2 0.0 2.3 0.1 0.3 3.2 1.1 1.6 11.1 14.9 6.5 1.7 9.1 3.9 3.2 6.1 2.5 71.5 145.9 0.0 0.3 1.3 7.2 3.0 0.0 4.0 4.5 1.8 19.6 0.0 0.0 0.0 0.5 0.3 0.0 0.0 0.0 0.0 1.1 0.7 19.7 0.0 0.1 0.0 1.2 0.6 0.0 2.3 0.3 0.0 0.0 0.0 3.5 4.0 0.6 0.0 1.8 0.4 10.0 12.9 0.8 1.6 11.1 0.5 0.2 1.0 0.4 0.3 CACNB2 "CACNLB2, MYSB" ENSG00000165995 "Calcium voltage-gated channel auxiliary subunit beta 2" Q08289 10 18140677-18543557 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Brugada syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 15 "Bipolar cells: 30.8;Cone photoreceptor cells: 102.1;Intestinal endocrine cells: 35.6;Rod photoreceptor cells: 76.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HAP1: 10.7;HSkMC: 13.5;SCLC-21H: 5.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035326 Enhanced NA NA "HPA035326: AB_10669903" "unprognostic (3.03e-3)" "unprognostic (3.04e-1)" "unprognostic (1.49e-2)" "unprognostic (1.16e-1)" "unprognostic (4.58e-3)" "unprognostic (4.67e-4)" "unprognostic (8.03e-2)" "unprognostic (3.76e-2)" "unprognostic (8.10e-2)" "unprognostic (1.70e-1)" "unprognostic (7.78e-4)" "unprognostic (1.40e-1)" "prognostic favorable (3.56e-5)" "unprognostic (3.48e-2)" "unprognostic (5.72e-2)" "unprognostic (1.03e-1)" "unprognostic (8.16e-2)" 2.7 15.6 10.5 4.2 16.4 2.1 2.8 27.0 25.8 7.0 11.6 1.9 7.4 3.4 9.6 5.8 9.7 7.8 4.6 15.8 8.8 9.7 4.6 4.0 2.7 1.8 4.3 11.8 18.1 8.6 2.7 16.9 1.3 9.2 9.7 8.7 10.0 7.1 18.0 2.1 5.6 9.4 31.1 2.4 1.7 6.5 2.0 3.2 0.1 2.5 0.0 1.0 13.4 12.8 1.9 0.8 4.0 0.7 1.0 3.7 0.2 0.2 1.4 1.0 0.7 0.7 0.5 0.6 0.4 0.0 0.1 0.4 0.6 0.6 1.1 0.3 0.3 0.5 0.9 10.7 0.0 0.0 0.4 3.3 1.0 1.8 2.0 2.8 0.8 1.9 13.5 0.0 0.0 0.0 0.4 0.0 1.8 1.1 2.2 0.0 0.8 1.1 1.3 3.8 0.0 0.1 0.9 1.0 1.0 0.0 1.1 5.4 1.6 0.1 0.1 0.5 1.2 0.2 1.1 0.2 0.8 2.4 0.4 0.7 2.5 2.4 2.2 0.3 1.5 0.5 4.0 0.5 0.6 1.0 0.7 1.4 1.3 1.1 0.5 0.1 1.9 1.8 2.6 0.7 1.0 0.7 0.8 3.7 0.2 10.5 16.4 27.0 18.3 8.8 9.7 4.3 11.8 9.2 3.2 0.0 1.1 0.0 1.1 3.0 30.8 16.2 0.0 0.0 0.0 0.0 102.1 0.2 1.7 0.3 0.7 0.3 3.8 0.0 0.2 0.0 1.3 2.0 0.0 0.9 0.1 7.9 35.6 0.0 0.0 0.6 0.9 0.5 1.7 0.0 6.9 14.8 0.3 3.1 4.2 0.0 76.6 6.5 9.2 0.1 0.0 3.6 0.2 0.0 5.2 0.7 CACNB3 CACNLB3 ENSG00000167535 "Calcium voltage-gated channel auxiliary subunit beta 3" P54284 12 48813794-48828941 "FDA approved drug targets, Predicted intracellular proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 42.9" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 4.7" "Lineage enriched" "Detected in single" 9 "T-cells: 4.7" "Cell line enhanced" "Detected in many" "U-937: 44.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA059515 Approved "Golgi apparatus,Vesicles" NA NA "Golgi apparatus, Vesicles" "HPA059515: AB_2684047" "unprognostic (1.77e-2)" "unprognostic (4.84e-2)" "unprognostic (2.16e-3)" "unprognostic (2.12e-2)" "unprognostic (8.76e-2)" "unprognostic (2.68e-1)" "unprognostic (2.06e-1)" "unprognostic (3.60e-2)" "unprognostic (3.27e-2)" "unprognostic (2.24e-1)" "unprognostic (5.67e-3)" "unprognostic (1.04e-1)" "unprognostic (5.44e-3)" "unprognostic (6.31e-3)" "unprognostic (6.58e-2)" "unprognostic (1.98e-1)" "unprognostic (2.78e-3)" 3.8 3.7 27.4 2.9 22.4 1.2 4.2 18.5 42.9 11.9 9.1 1.5 3.0 3.8 22.6 8.1 11.6 16.1 6.7 2.6 16.4 12.2 3.9 1.3 6.1 1.7 10.0 14.5 24.1 2.1 2.8 4.2 5.3 4.4 5.7 7.8 3.4 4.5 9.1 2.1 7.8 5.8 20.4 2.4 2.2 4.7 4.7 2.3 4.6 6.1 3.4 3.6 7.5 6.9 0.2 0.5 0.0 0.3 0.0 4.7 0.5 6.6 5.3 8.9 18.2 10.9 7.7 5.4 6.8 14.5 10.2 6.0 1.7 5.5 0.8 9.0 11.5 1.7 7.1 8.1 7.5 3.8 7.8 2.4 3.5 4.3 0.2 4.3 0.6 3.9 4.9 4.5 4.2 2.1 28.4 11.6 7.4 0.4 2.8 6.5 16.6 8.3 0.9 5.5 6.9 4.5 9.5 2.0 2.6 7.4 12.6 12.7 12.5 2.1 15.2 5.0 7.5 10.4 2.9 11.0 6.5 9.2 3.1 3.7 3.3 1.3 0.2 5.4 44.2 2.0 0.0 0.3 0.0 0.9 0.1 0.4 0.2 1.8 1.8 0.5 0.0 0.4 0.2 0.0 0.0 0.0 0.4 4.7 0.5 27.4 22.4 18.5 42.9 16.4 12.2 10.0 14.5 4.4 2.3 3.0 7.0 0.0 3.1 2.6 1.0 2.4 0.0 2.7 2.3 1.8 3.9 0.5 1.7 8.6 0.7 3.1 8.4 0.0 3.7 9.3 6.6 2.8 1.1 0.0 1.5 0.0 9.8 3.1 0.6 1.8 12.4 2.3 1.7 5.4 9.1 0.9 8.5 5.8 10.3 0.6 1.0 0.0 10.8 0.5 5.9 4.4 0.9 4.4 11.7 1.4 CACNB4 EJM4 ENSG00000182389 "Calcium voltage-gated channel auxiliary subunit beta 4" O00305 2 151832768-152099475 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 35.7" "Cell type enhanced" "Detected in many" 10 "Alveolar cells type 2: 38.2;Glandular cells: 25.1;Horizontal cells: 19.1" "Low cancer specificity" "Detected in single" "Group enriched" "Detected in all" 4 "basal ganglia: 28.0;cerebellum: 35.7;cerebral cortex: 21.7;olfactory region: 10.9;pons and medulla: 9.8" "Cell type enriched" "Detected in some" 5 "neutrophil: 7.0" "Lineage enriched" "Detected in many" 5 "granulocytes: 7.0" "Cell line enriched" "Detected in some" 4 "HMC-1: 21.2" HPA015601 Approved NA NA "HPA015601: AB_1845873" "unprognostic (2.92e-1)" "unprognostic (1.98e-1)" "unprognostic (1.80e-1)" "unprognostic (1.29e-1)" "unprognostic (1.14e-1)" "unprognostic (1.49e-2)" "unprognostic (3.70e-1)" "unprognostic (9.42e-4)" "unprognostic (1.23e-1)" "unprognostic (1.98e-1)" "unprognostic (1.05e-3)" "unprognostic (2.02e-1)" "unprognostic (1.55e-2)" "unprognostic (7.26e-3)" "unprognostic (3.93e-2)" "unprognostic (9.55e-3)" "unprognostic (2.45e-1)" 1.6 1.7 5.2 1.3 28.0 1.7 3.2 35.7 28.0 1.4 1.2 2.6 0.0 1.2 1.4 1.7 3.1 1.1 2.1 1.1 4.5 4.4 2.8 0.9 3.9 1.1 4.3 10.9 1.3 1.2 1.0 3.8 2.1 9.8 3.9 1.4 0.9 2.1 3.9 0.8 11.7 1.1 4.2 3.0 1.2 1.6 4.1 3.4 0.0 3.1 0.0 2.2 3.5 0.8 0.4 1.3 7.0 0.6 0.2 0.1 0.1 0.0 0.0 0.7 0.7 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.9 0.0 2.0 0.0 0.1 0.3 3.3 0.0 0.2 4.1 0.0 0.2 21.2 0.2 0.1 0.4 0.0 1.6 0.0 0.8 0.0 0.5 0.2 0.0 0.2 0.3 0.5 0.1 0.6 1.8 0.2 0.6 1.2 0.6 1.4 0.8 0.0 0.0 0.0 0.1 3.4 0.9 0.0 1.9 2.2 0.7 0.4 0.4 0.0 0.0 0.5 4.9 0.1 1.2 0.6 0.0 0.1 0.0 0.1 0.1 0.0 0.0 1.3 0.4 0.1 0.1 7.0 0.2 0.0 1.3 0.0 0.1 5.2 28.0 35.7 21.7 4.5 4.4 4.3 10.9 9.8 3.4 11.9 38.2 0.8 10.5 11.0 3.1 0.9 0.0 1.4 5.7 3.5 3.9 0.1 3.3 0.3 0.8 0.6 0.0 0.0 1.3 0.0 3.9 25.1 0.0 0.0 2.6 19.1 0.0 0.6 0.8 1.7 3.1 2.4 1.7 0.0 0.0 1.9 1.2 0.0 4.2 0.6 3.3 0.0 0.7 0.5 0.0 7.2 0.0 0.7 0.0 12.2 CACNG1 CACNLG ENSG00000108878 "Calcium voltage-gated channel auxiliary subunit gamma 1" Q06432 17 67044590-67056797 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "skeletal muscle: 126.7" "Not detected" "Not detected" "Cancer enhanced" "Detected in some" "head and neck cancer: 1.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "HSkMC: 8.3;SH-SY5Y: 2.6" "Region enriched" "Detected in single" 6 "basal ganglia: 3.0" "Not detected" "Not detected" NA NA "unprognostic (1.76e-1)" "unprognostic (9.83e-3)" "unprognostic (1.75e-5)" "unprognostic (2.60e-1)" "unprognostic (6.72e-3)" "unprognostic (2.85e-1)" "unprognostic (1.44e-2)" "unprognostic (4.84e-3)" "unprognostic (1.07e-1)" "unprognostic (4.20e-2)" "unprognostic (1.60e-1)" "unprognostic (2.31e-1)" "unprognostic (3.03e-1)" "unprognostic (1.94e-1)" 5.7 0.4 0.3 0.0 0.6 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 5.3 1.6 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.9 0.0 126.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.7 25.0 1.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 8.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 2.6 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.6 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CAMLG "CAML, GET2" ENSG00000164615 "Calcium modulating ligand" P49069 5 134738501-134752160 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Host-virus interaction" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 5 "Early spermatids: 658.5;Late spermatids: 1206.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA052636, HPA056472" Approved Approved Nucleoplasm,Nucleoli,Vesicles NA NA Vesicles "Nucleoplasm, Nucleoli" "HPA052636: AB_2681893, HPA056472: AB_2683143" "unprognostic (9.23e-2)" "unprognostic (8.54e-2)" "unprognostic (2.95e-1)" "unprognostic (2.21e-1)" "unprognostic (1.07e-1)" "unprognostic (1.07e-2)" "unprognostic (3.68e-2)" "unprognostic (5.41e-3)" "unprognostic (3.07e-1)" "unprognostic (8.54e-2)" "unprognostic (5.34e-3)" "unprognostic (4.58e-2)" "prognostic unfavorable (1.09e-5)" "unprognostic (3.26e-2)" "unprognostic (1.43e-2)" "unprognostic (2.19e-1)" "unprognostic (3.16e-1)" 24.2 29.0 37.6 14.3 32.4 22.7 29.3 28.2 39.3 33.3 32.7 15.5 20.2 26.1 31.7 45.2 21.4 23.0 21.8 22.3 32.4 38.3 20.1 19.7 18.9 18.4 36.2 22.7 53.0 25.7 14.8 21.9 14.0 22.4 27.5 14.3 21.7 15.9 26.2 32.5 19.7 22.2 30.4 26.0 15.1 17.7 36.6 14.0 21.1 21.6 18.5 19.3 40.3 20.0 25.0 16.1 32.1 23.3 16.6 28.6 17.4 9.6 7.5 12.8 23.8 28.5 44.2 5.8 13.7 19.9 10.2 19.4 13.7 14.7 39.3 20.1 9.5 15.9 12.5 10.5 16.7 14.6 18.3 19.5 10.4 13.6 11.1 21.0 5.5 33.0 35.8 18.2 12.6 21.7 33.9 19.3 17.4 6.6 18.3 15.2 10.7 14.5 23.3 6.6 12.0 7.6 16.4 17.0 15.1 17.5 9.4 19.0 13.3 9.8 6.3 32.7 17.2 17.3 11.5 18.4 10.0 6.2 15.2 12.4 17.2 18.6 15.0 16.8 17.4 5.4 32.1 15.2 32.1 18.3 17.3 24.6 25.0 26.4 22.9 16.1 22.4 27.8 26.8 27.6 16.6 23.3 14.7 28.6 17.4 37.6 32.4 28.2 39.3 32.4 38.3 36.2 22.7 22.4 14.0 35.7 31.3 84.3 104.0 148.5 76.2 38.6 76.5 32.1 48.9 40.1 23.6 43.8 77.9 53.1 658.5 74.5 44.2 0.0 78.9 53.3 107.2 105.7 119.1 66.0 62.6 52.4 60.0 81.6 102.8 1206.3 155.6 92.2 91.1 124.4 64.9 79.0 61.6 59.6 124.5 149.1 63.7 97.0 161.7 114.4 74.5 176.2 61.2 108.0 83.2 90.1 CASR "FHH, GPRC2A, HHC, HHC1, NSHPT" ENSG00000036828 "Calcium sensing receptor" P41180 3 122183683-122291629 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "parathyroid gland: 155.3" "Group enriched" "Detected in some" 5 "Alveolar cells type 1: 23.8;Alveolar cells type 2: 13.2;Cholangiocytes: 33.1;Ciliated cells: 28.1;Club cells: 10.3;Distal tubular cells: 11.6;Intestinal endocrine cells: 11.1" "Cancer enriched" "Detected in some" 7 "pancreatic cancer: 5.5" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "RPTEC TERT1: 4.0" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA039686, HPA050335" Enhanced NA NA "HPA039686: AB_10673536, HPA050335: AB_2681092" "unprognostic (1.97e-2)" "unprognostic (7.40e-2)" "unprognostic (8.20e-4)" "unprognostic (3.15e-1)" "unprognostic (8.55e-4)" "unprognostic (1.58e-1)" "unprognostic (7.32e-2)" "unprognostic (7.67e-2)" "unprognostic (1.62e-1)" "unprognostic (1.48e-1)" "unprognostic (1.91e-5)" "unprognostic (2.72e-1)" "unprognostic (2.26e-1)" "unprognostic (1.24e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.8 0.4 0.0 0.1 0.0 0.0 0.0 0.0 21.0 0.0 0.1 0.2 18.1 0.5 0.0 0.0 0.1 0.0 0.6 12.1 155.3 0.6 0.0 0.2 0.0 0.0 0.6 0.5 0.0 0.0 0.0 0.6 0.3 0.2 0.2 0.5 0.3 0.0 0.1 1.6 0.0 0.1 0.7 0.0 1.4 0.5 1.1 0.3 0.8 1.1 0.2 0.6 1.3 0.7 1.1 0.3 0.3 0.7 0.7 0.0 0.0 0.1 0.6 0.9 1.1 0.9 0.4 0.8 0.5 0.2 0.2 0.3 0.8 0.1 1.4 1.1 1.1 0.0 0.7 0.8 0.4 0.4 0.5 0.2 0.5 0.2 1.1 0.6 2.0 0.3 0.7 0.5 0.9 1.4 0.8 0.7 0.6 0.5 0.6 4.0 1.5 0.6 0.8 0.9 0.5 0.3 1.7 1.0 0.3 1.3 1.0 1.9 1.0 0.3 1.7 1.1 0.5 0.7 0.6 1.0 1.0 0.3 0.1 0.9 0.2 0.9 0.7 0.9 0.9 0.1 1.4 0.7 0.6 1.1 0.8 0.2 0.5 1.1 0.2 0.0 0.0 0.0 0.6 0.1 0.2 0.1 0.0 0.2 0.0 23.8 13.2 0.0 0.0 0.0 0.0 0.8 33.1 28.1 10.3 3.5 0.0 0.0 11.6 3.7 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.1 0.0 0.1 0.0 11.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.9 0.0 0.4 0.2 1.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 CFTR "ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR" ENSG00000001626 "Cystic fibrosis transmembrane conductance regulator" P13569 7 117465784-117715971 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Isomerase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "pancreas: 103.0" "Cell type enriched" "Detected in many" 5 "Ductal cells: 325.5" "Cancer enhanced" "Detected in many" "colorectal cancer: 23.9;pancreatic cancer: 28.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 22 "CACO-2: 12.8;MOLT-4: 48.1;U-266/70: 26.3" "Low region specificity" "Detected in some" "Region enriched" "Detected in single" 5 "olfactory region: 6.3" "CAB001951, HPA021939, HPA079652" Enhanced NA NA "CAB001951: , HPA021939: AB_1846578, HPA079652: " "unprognostic (6.38e-3)" "unprognostic (9.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.44e-2)" "unprognostic (8.74e-2)" "unprognostic (8.57e-2)" "prognostic unfavorable (9.44e-4)" "unprognostic (3.20e-3)" "unprognostic (1.13e-1)" "unprognostic (8.89e-2)" "unprognostic (1.55e-2)" "unprognostic (2.14e-2)" "unprognostic (4.78e-3)" "unprognostic (1.24e-1)" "unprognostic (2.58e-1)" "unprognostic (9.08e-2)" "unprognostic (6.64e-2)" 0.4 0.2 0.4 10.5 0.4 0.0 0.3 0.3 0.3 2.5 19.8 0.1 0.8 10.5 0.6 2.1 0.4 0.4 15.8 0.3 0.4 0.3 1.1 1.4 5.7 0.1 0.5 0.1 0.3 103.0 0.0 0.3 0.1 0.1 1.5 12.5 0.1 22.4 0.1 0.3 1.1 24.2 0.3 0.7 0.3 0.6 0.9 0.1 0.1 0.3 0.2 0.3 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.8 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 48.1 0.0 0.8 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 26.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.3 0.3 0.4 0.3 0.5 0.1 0.1 0.1 6.0 48.7 0.0 1.7 0.0 0.4 1.2 43.3 9.4 23.9 0.0 0.0 0.0 0.0 325.5 2.9 0.0 19.4 0.0 3.7 0.0 0.1 3.6 1.1 0.2 0.0 0.0 6.9 0.0 0.0 1.6 0.3 0.0 0.0 11.8 11.5 0.6 21.5 37.7 0.0 0.0 0.0 0.0 0.3 1.8 0.4 0.0 0.0 0.0 64.4 3.9 CHRNA4 "BFNC, EBN, EBN1" ENSG00000101204 "Cholinergic receptor nicotinic alpha 4 subunit" P43681 20 63343223-63378401 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 16.4;liver: 38.8;parathyroid gland: 21.6" "Cell type enriched" "Detected in some" 5 "Horizontal cells: 131.9" "Cancer enhanced" "Detected in some" "liver cancer: 1.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "U-2 OS: 7.6" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "midbrain: 22.6;pons and medulla: 19.3;thalamus: 29.6" CAB034064 Uncertain NA NA "CAB034064: AB_2080535" "unprognostic (3.40e-1)" "unprognostic (1.71e-1)" "unprognostic (2.87e-2)" "unprognostic (3.98e-1)" "unprognostic (8.03e-2)" "unprognostic (1.75e-1)" "unprognostic (1.22e-1)" "unprognostic (1.74e-1)" "unprognostic (2.10e-3)" "unprognostic (5.72e-4)" "unprognostic (9.02e-3)" "unprognostic (9.79e-4)" "unprognostic (6.77e-2)" "unprognostic (1.08e-1)" "unprognostic (3.81e-2)" 0.6 0.8 5.2 0.6 8.7 0.6 0.6 3.1 14.5 0.6 0.6 11.0 0.0 0.6 0.6 0.6 0.6 2.0 0.6 0.6 5.1 6.8 2.1 38.8 0.7 0.6 11.3 8.2 0.7 0.6 21.6 1.0 0.6 16.4 1.3 0.6 5.7 0.6 0.6 0.6 0.6 0.6 0.6 3.9 4.8 0.6 1.9 3.9 0.0 1.2 0.0 0.6 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 8.7 3.1 14.5 5.1 6.8 11.3 8.2 16.4 3.9 0.0 0.0 0.0 0.0 0.0 20.2 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.2 0.0 131.9 0.0 0.0 1.0 1.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 2.8 2.3 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 CHRNA7 ENSG00000175344 "Cholinergic receptor nicotinic alpha 7 subunit" P36544 15 31923438-32173018 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 27.2" "Cell type enhanced" "Detected in some" 14 "Cholangiocytes: 5.1;Enterocytes: 7.1;Horizontal cells: 15.9;Spermatogonia: 7.9" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "AN3-CA: 6.3;RT4: 12.2;SH-SY5Y: 6.9;SK-BR-3: 13.5;U-2 OS: 11.1" "Low region specificity" "Detected in all" "HPA029422, CAB033624" Enhanced NA NA "CAB033624: AB_784835, HPA029422: AB_10600863" "unprognostic (3.43e-2)" "unprognostic (8.44e-2)" "unprognostic (2.02e-1)" "unprognostic (4.61e-4)" "unprognostic (6.19e-2)" "unprognostic (1.31e-1)" "unprognostic (2.14e-2)" "unprognostic (5.08e-2)" "unprognostic (1.63e-1)" "unprognostic (4.31e-2)" "unprognostic (3.22e-1)" "unprognostic (1.05e-1)" "unprognostic (2.40e-2)" "unprognostic (4.36e-3)" "unprognostic (5.44e-2)" "unprognostic (7.41e-3)" "unprognostic (2.43e-1)" 0.8 12.9 4.4 1.5 3.4 2.3 2.0 0.9 8.4 1.1 12.2 1.0 1.1 7.9 1.4 0.8 0.8 0.7 4.6 1.2 2.5 5.6 0.9 0.4 1.2 2.0 3.8 2.7 2.9 4.9 1.8 2.0 0.4 11.8 2.2 4.0 11.7 2.1 1.2 0.8 0.7 27.2 0.9 3.1 5.2 11.2 5.1 0.6 0.1 4.3 0.9 1.4 3.1 2.0 0.3 1.2 3.1 1.1 1.8 0.7 0.4 0.0 1.4 2.3 6.3 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.4 0.0 2.9 0.0 0.0 0.0 1.8 0.4 0.0 1.9 0.0 0.3 0.6 0.0 0.0 0.1 0.0 0.1 0.1 2.5 0.0 0.2 0.0 0.2 0.0 0.2 1.1 3.5 0.0 0.0 3.8 0.2 0.2 12.2 0.5 6.9 0.2 13.5 0.0 0.7 0.0 0.0 0.7 0.0 11.1 0.2 0.0 0.0 0.0 0.3 0.0 0.3 0.0 1.5 1.1 3.1 0.7 0.4 0.2 0.3 0.4 0.1 1.2 0.2 0.2 0.3 0.7 1.8 0.6 0.7 0.5 0.4 4.4 3.4 0.9 8.4 2.5 5.6 3.8 2.7 11.8 0.6 0.0 0.0 0.0 2.2 0.2 1.7 1.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.2 7.1 0.0 2.2 0.0 0.0 0.5 1.1 0.0 0.1 15.9 2.9 0.0 0.0 0.0 0.0 0.2 0.0 0.0 3.6 0.0 1.5 1.1 0.0 0.0 0.0 0.0 0.4 0.2 7.9 0.0 0.0 0.0 1.5 0.9 CHRNB2 ENSG00000160716 "Cholinergic receptor nicotinic beta 2 subunit" P17787 1 154567781-154580026 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 28.4" "Cell type enhanced" "Detected in some" 22 "Bipolar cells: 12.2;Cone photoreceptor cells: 13.7;Horizontal cells: 39.7;Late spermatids: 8.0;Rod photoreceptor cells: 7.6" "Cancer enhanced" "Detected in some" "glioma: 1.9" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "neutrophil: 1.2" "Lineage enhanced" "Detected in single" "granulocytes: 1.2" "Group enriched" "Detected in some" 6 "SCLC-21H: 20.7;SH-SY5Y: 20.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (1.13e-1)" "unprognostic (6.33e-2)" "unprognostic (8.15e-3)" "unprognostic (3.32e-1)" "unprognostic (4.37e-3)" "unprognostic (2.25e-1)" "unprognostic (3.51e-1)" "unprognostic (1.28e-1)" "unprognostic (3.65e-2)" "unprognostic (2.37e-1)" "unprognostic (1.24e-3)" "unprognostic (1.83e-1)" "unprognostic (4.36e-1)" "unprognostic (2.32e-1)" "unprognostic (1.45e-1)" "unprognostic (5.65e-2)" "unprognostic (1.84e-1)" 0.9 3.2 7.8 1.2 16.4 1.0 1.8 8.1 28.4 0.9 1.1 1.6 0.0 1.4 1.0 0.9 1.1 1.0 0.9 0.9 9.4 8.9 0.9 0.9 0.9 0.9 7.9 9.8 1.0 2.1 0.9 3.3 0.9 15.4 0.9 1.2 3.1 1.0 0.9 0.9 1.3 1.2 1.1 1.4 0.9 1.6 2.0 1.7 0.0 0.9 0.0 0.9 0.9 0.0 0.0 0.0 1.2 0.0 0.0 0.3 0.0 0.0 0.5 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 20.7 20.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 7.8 16.4 8.1 22.1 9.4 8.9 7.9 9.8 15.4 1.7 0.0 0.0 0.0 0.0 0.1 12.2 1.6 0.0 0.0 0.0 0.0 13.7 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 39.7 3.5 0.0 0.0 8.0 0.0 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.0 7.6 0.0 0.0 0.9 0.3 0.3 0.0 0.0 0.0 0.0 CLCN2 "ClC-2, CLC2, EJM6" ENSG00000114859 "Chloride voltage-gated channel 2" P51788 3 184346185-184361651 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 21.0;intestine: 20.2" "Cell type enhanced" "Detected in many" 13 "Cholangiocytes: 10.2;Enterocytes: 30.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009397, HPA014545, HPA024108" Approved Approved Cytosol NA NA Cytosol "CAB009397: AB_2079256, HPA014545: AB_1846881, HPA024108: AB_1846883" "unprognostic (1.13e-1)" "unprognostic (4.01e-2)" "unprognostic (6.48e-2)" "unprognostic (5.11e-3)" "unprognostic (1.15e-1)" "unprognostic (2.53e-2)" "prognostic unfavorable (4.67e-8)" "unprognostic (1.72e-2)" "unprognostic (2.26e-1)" "unprognostic (1.23e-1)" "unprognostic (2.10e-1)" "unprognostic (2.50e-3)" "unprognostic (1.19e-1)" "unprognostic (4.40e-2)" "unprognostic (5.88e-2)" "unprognostic (4.60e-2)" "unprognostic (1.35e-1)" 1.6 5.4 4.9 2.6 8.3 1.3 1.6 8.8 6.3 2.8 20.2 16.9 5.1 11.6 4.5 5.0 1.7 2.8 21.0 1.5 6.3 3.1 3.7 1.8 1.3 1.0 15.3 4.1 6.1 5.9 4.4 4.0 1.5 8.9 2.6 14.0 15.6 3.7 9.0 1.2 2.2 11.8 2.4 10.8 1.6 2.7 11.9 9.8 0.1 3.2 1.3 1.3 2.2 2.2 0.0 0.0 0.0 0.4 0.0 0.1 0.0 8.0 2.8 2.3 6.2 2.1 1.8 5.4 2.9 1.6 2.9 1.8 15.1 2.7 2.8 8.0 1.4 7.5 14.0 3.3 3.1 0.9 2.5 4.0 2.5 5.8 6.4 1.3 1.0 2.5 3.4 2.5 2.5 2.9 1.3 2.7 3.0 1.0 1.4 1.0 4.4 0.8 1.3 3.5 6.7 4.4 5.0 2.2 9.6 3.5 6.1 3.9 2.3 3.0 10.5 4.7 1.6 8.5 1.1 1.3 1.5 4.4 7.1 7.0 3.8 4.8 1.7 2.6 4.8 6.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 8.3 8.8 6.3 6.3 3.1 15.3 4.1 8.9 9.8 3.0 2.6 0.0 0.7 0.9 2.2 1.1 10.2 4.0 1.2 0.0 0.0 0.9 0.0 3.5 2.4 0.5 30.8 0.0 1.8 0.4 1.0 0.6 1.1 0.4 0.5 1.6 2.9 1.8 0.0 1.3 4.9 0.4 0.0 1.0 3.6 1.8 1.8 7.8 4.6 2.2 2.6 0.0 0.8 3.3 1.6 0.4 1.3 0.0 6.5 0.3 CNR1 "CANN6, CB-R, CB1, CB1A, CB1K5, CNR" ENSG00000118432 "Cannabinoid receptor 1" P21554 6 88139864-88166359 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 30.5" "Cell type enriched" "Detected in some" 14 "Sertoli cells: 97.0" "Cancer enriched" "Detected in many" 13 "glioma: 12.5" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "memory B-cell: 2.9;naive B-cell: 2.1" "Lineage enriched" "Detected in single" 6 "B-cells: 2.9" "Group enriched" "Detected in some" 7 "ASC diff: 40.3;HSkMC: 26.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042256, HPA069945" Enhanced Supported Supported "Plasma membrane,Actin filaments" NA NA "Plasma membrane" "Actin filaments" "HPA042256: AB_2677917, HPA069945: " "unprognostic (1.28e-1)" "unprognostic (7.04e-2)" "unprognostic (4.61e-2)" "unprognostic (4.08e-3)" "unprognostic (1.21e-1)" "unprognostic (1.07e-3)" "unprognostic (1.37e-1)" "unprognostic (2.07e-2)" "unprognostic (2.49e-1)" "unprognostic (1.16e-2)" "unprognostic (2.74e-2)" "unprognostic (2.68e-1)" "unprognostic (1.70e-1)" "unprognostic (5.59e-3)" "unprognostic (2.68e-3)" "unprognostic (5.88e-2)" "unprognostic (7.00e-2)" 19.4 6.4 18.0 5.2 15.8 1.5 14.9 13.8 30.5 3.9 5.5 0.8 0.8 2.3 3.1 4.7 3.7 5.5 3.6 1.4 17.6 7.7 0.9 0.7 6.4 6.5 2.3 14.7 4.1 1.8 1.3 18.3 5.2 4.2 1.5 5.1 0.0 4.3 4.0 1.7 2.4 4.2 5.8 3.2 2.3 2.3 2.7 2.8 0.0 2.6 0.0 9.9 2.7 3.1 2.9 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 40.3 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.1 0.9 1.4 0.0 2.6 0.0 0.0 26.6 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.2 0.0 3.3 0.0 0.8 0.0 0.0 0.0 0.0 0.1 0.0 0.6 2.3 0.0 0.0 0.0 0.0 0.0 0.7 3.3 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 2.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 18.0 15.8 13.8 21.4 17.6 7.7 2.3 14.7 4.2 2.8 0.0 7.2 2.7 0.4 0.6 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.6 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 97.0 2.3 0.0 0.1 0.1 0.1 0.0 0.0 0.7 CNR2 CB2 ENSG00000188822 "Cannabinoid receptor 2" P34972 1 23870526-23913362 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Inflammatory response" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "blood: 19.2;lymphoid tissue: 31.1" "Cell type enhanced" "Detected in some" 17 "Alveolar cells type 2: 4.6;B-cells: 16.4;T-cells: 5.7" "Cancer enriched" "Detected in single" 6 "testis cancer: 2.5" "Not detected" "Not detected" "Group enriched" "Detected in many" 7 "basophil: 19.2;eosinophil: 16.2;memory B-cell: 14.9;naive B-cell: 15.1;NK-cell: 8.7" "Group enriched" "Detected in many" 7 "B-cells: 15.1;granulocytes: 19.2;NK-cells: 8.7" "Cell line enhanced" "Detected in some" "Daudi: 5.0;HEL: 4.2;HMC-1: 19.4;U-698: 13.0" "Not detected" "Not detected" "Not detected" "Not detected" CAB009719 Uncertain NA NA "CAB009719: AB_2082784" "unprognostic (9.45e-4)" "unprognostic (5.40e-3)" "unprognostic (8.50e-3)" "unprognostic (8.19e-3)" "unprognostic (3.55e-3)" "unprognostic (9.34e-6)" "unprognostic (5.58e-3)" "unprognostic (6.96e-3)" "unprognostic (1.74e-1)" "unprognostic (7.87e-2)" "unprognostic (1.53e-1)" "unprognostic (4.93e-2)" "unprognostic (1.04e-3)" "unprognostic (3.67e-1)" "unprognostic (1.80e-1)" "unprognostic (3.75e-2)" "unprognostic (4.91e-2)" 0.3 0.2 0.2 18.5 0.2 1.8 0.2 0.2 0.2 0.2 0.4 0.0 0.0 0.1 0.2 0.1 1.8 0.2 0.3 0.3 0.2 0.2 0.4 0.3 0.6 27.7 0.2 0.0 0.2 0.2 0.0 0.2 0.0 0.0 0.4 0.3 0.3 3.1 0.0 1.8 0.2 5.5 0.0 0.2 29.7 0.4 0.4 0.0 3.0 0.6 0.6 31.1 1.5 0.3 15.1 0.8 19.2 0.1 8.7 2.0 0.9 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.2 0.1 0.0 0.0 0.0 19.4 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 13.0 0.0 0.1 0.0 19.2 0.1 16.2 1.7 0.0 2.0 14.9 0.1 1.5 0.2 15.1 0.1 0.9 0.6 8.7 0.1 0.8 0.1 0.9 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.0 0.0 3.0 4.6 16.4 0.7 0.6 0.7 0.3 0.0 1.4 3.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.9 0.3 3.5 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.1 2.5 0.0 0.0 0.8 0.0 0.3 0.3 0.2 0.3 0.2 5.7 0.0 0.6 CPT1A "CPT1, CPT1-L, L-CPT1" ENSG00000110090 "Carnitine palmitoyltransferase 1A" P50416 11 68754620-68844410 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Fatty acid metabolism, Lipid metabolism, Transport" "Acyltransferase, Transferase" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008835 Supported Supported Mitochondria NA NA 790000 Mitochondria "HPA008835: AB_1078563" "prognostic unfavorable (3.84e-4)" "unprognostic (1.38e-3)" "unprognostic (3.04e-3)" "unprognostic (2.46e-2)" "unprognostic (1.45e-1)" "unprognostic (7.25e-2)" "unprognostic (2.17e-1)" "unprognostic (4.99e-2)" "unprognostic (2.72e-1)" "unprognostic (1.47e-2)" "unprognostic (2.92e-2)" "unprognostic (2.34e-1)" "prognostic favorable (2.67e-7)" "unprognostic (9.76e-2)" "unprognostic (1.06e-1)" "unprognostic (1.49e-1)" "unprognostic (2.46e-3)" 18.0 18.3 9.9 9.9 12.1 15.8 24.4 7.0 10.3 12.8 31.9 8.2 14.1 33.7 17.0 7.2 11.2 12.8 14.7 14.6 12.0 6.6 30.6 62.0 13.1 10.1 10.5 8.6 17.0 24.4 16.9 13.8 8.7 10.8 15.6 22.0 19.7 12.9 11.4 6.9 10.3 33.4 16.9 8.7 18.9 16.8 10.4 9.0 17.9 13.2 7.5 7.6 11.3 30.2 2.5 11.9 10.6 8.6 5.7 8.8 2.5 8.1 14.5 2.1 14.2 9.3 8.4 0.6 6.5 5.4 5.2 1.0 0.5 27.6 0.0 24.2 17.2 18.2 26.9 18.4 3.9 1.5 13.0 1.8 20.1 15.8 6.7 13.9 11.6 24.3 8.7 1.9 10.4 6.3 7.1 18.3 8.1 2.1 16.5 4.7 23.4 9.4 20.6 0.2 42.2 15.4 26.5 0.3 35.6 12.2 20.4 0.2 9.3 18.0 34.9 5.7 1.4 31.1 11.3 18.4 11.3 0.2 22.6 9.4 12.9 16.4 8.3 11.9 8.6 12.3 9.2 7.8 10.6 8.8 8.6 5.1 2.3 5.5 5.3 5.0 2.5 3.4 7.0 3.8 5.7 7.2 11.9 2.9 2.5 9.9 12.1 7.0 10.3 12.0 6.6 10.5 8.6 10.8 9.0 35.7 36.9 11.5 7.7 8.4 4.9 22.1 28.1 32.1 22.7 22.7 60.9 12.9 16.6 11.2 9.2 25.4 82.1 0.0 8.1 4.1 13.9 7.4 27.8 79.0 14.6 1.6 15.5 37.4 42.3 15.7 8.9 13.5 0.0 11.8 44.9 12.9 9.7 40.3 30.1 9.4 41.0 38.8 16.0 12.1 8.8 6.8 6.5 16.6 59.0 6.4 CRHR1 "CRF-R, CRF1, CRHR" ENSG00000120088 "Corticotropin releasing hormone receptor 1" P34998 17 45784280-45835828 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "brain: 23.2;pituitary gland: 16.5" "Group enriched" "Detected in some" 13 "Early spermatids: 37.9;Late spermatids: 37.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "RT4: 8.1;SH-SY5Y: 5.0" CAB025251 Enhanced "Intracellular and membrane" NA NA "CAB025251: " "unprognostic (4.59e-2)" "unprognostic (1.43e-2)" "unprognostic (2.59e-7)" "unprognostic (1.76e-1)" "unprognostic (2.71e-1)" "unprognostic (3.94e-2)" "unprognostic (2.48e-1)" "unprognostic (4.55e-4)" "unprognostic (1.65e-2)" "unprognostic (2.21e-1)" "unprognostic (3.33e-4)" "unprognostic (2.07e-5)" "unprognostic (3.26e-1)" "unprognostic (1.49e-1)" "unprognostic (1.59e-1)" 0.8 0.6 14.7 0.5 5.1 0.5 1.5 23.2 11.5 1.4 0.6 1.1 0.0 0.8 2.7 1.1 0.5 1.6 0.7 0.5 3.2 2.2 0.6 0.5 0.6 0.5 1.8 5.2 0.6 0.5 0.6 16.5 0.6 2.9 1.3 0.6 1.9 1.2 2.5 0.6 1.4 1.0 1.2 1.0 0.5 0.5 1.0 2.8 0.0 0.9 0.0 0.5 1.4 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.1 1.6 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.7 5.1 23.2 11.5 3.2 2.2 1.8 5.2 2.9 2.8 0.0 0.0 0.0 1.1 1.0 0.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 37.9 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 37.3 0.6 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.0 0.5 0.0 0.1 2.3 1.5 2.9 0.0 0.0 0.0 0.5 CXCR4 "CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R" ENSG00000121966 "C-X-C motif chemokine receptor 4" P61073 2 136114349-136118165 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 149.9;lymphoid tissue: 186.3" "Cell type enhanced" "Detected in many" 14 "B-cells: 772.9;Macrophages: 299.5;monocytes: 255.1;T-cells: 588.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 76.4;JURKAT: 43.5;Karpas-707: 41.0;MOLT-4: 69.2;REH: 36.7;U-266/70: 88.9;U-698: 89.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA "unprognostic (1.19e-1)" "unprognostic (1.46e-2)" "unprognostic (2.69e-1)" "unprognostic (5.97e-2)" "unprognostic (1.29e-2)" "unprognostic (1.12e-2)" "unprognostic (4.99e-2)" "unprognostic (9.25e-2)" "unprognostic (6.06e-2)" "prognostic favorable (2.05e-4)" "unprognostic (1.23e-1)" "unprognostic (2.66e-1)" "prognostic unfavorable (1.41e-7)" "prognostic unfavorable (5.67e-4)" "unprognostic (1.57e-1)" "unprognostic (3.47e-2)" "unprognostic (9.33e-2)" 15.4 26.5 3.0 39.1 3.4 149.9 9.7 0.8 2.1 7.7 8.7 6.8 1.5 1.6 8.3 3.8 16.4 9.1 12.0 5.4 4.1 4.7 8.2 7.1 29.3 94.5 6.5 1.3 6.3 3.1 0.7 8.1 7.8 6.1 6.8 7.0 10.0 10.6 2.2 3.2 2.3 57.8 3.8 22.9 82.4 8.0 7.2 3.4 186.3 9.2 4.6 97.5 50.0 6.6 47.3 16.8 37.8 7.2 4.0 32.0 11.9 0.1 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 76.4 0.2 0.0 0.0 0.0 0.2 0.0 0.0 3.8 0.9 4.6 12.1 0.0 0.0 10.5 8.3 0.0 0.0 0.0 0.0 0.0 7.3 43.5 0.1 41.0 0.0 0.2 69.2 9.4 1.2 5.9 0.4 36.7 8.5 13.3 0.6 0.0 4.2 3.5 0.0 0.2 0.0 0.4 0.0 20.7 1.0 0.0 0.2 0.0 0.0 88.9 15.0 89.4 0.0 17.4 0.0 17.9 7.2 29.6 22.9 3.8 18.7 30.1 21.1 21.7 6.6 47.3 32.0 30.1 37.8 4.0 2.1 16.8 18.9 11.9 3.0 3.4 0.8 2.1 4.1 4.7 6.5 1.3 6.1 3.4 14.9 64.2 772.9 4.0 36.5 4.4 3.6 2.5 4.0 6.8 3.5 0.0 1.4 11.6 3.6 0.9 19.0 0.0 46.7 0.8 2.2 30.2 4.8 11.6 5.5 168.4 0.0 1.7 22.7 175.5 1.7 1.4 299.5 108.0 255.1 0.1 1.0 1.6 0.0 2.5 2.1 0.6 45.3 16.3 0.5 5.5 31.1 5.3 588.4 0.4 3.2 CYSLTR1 "CysLT(1), CysLT1, CYSLT1R" ENSG00000173198 "Cysteinyl leukotriene receptor 1" Q9Y271 X 78271464-78327691 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 33.9;esophagus: 24.6" "Cell type enhanced" "Detected in many" 7 "Alveolar cells type 1: 62.5;Alveolar cells type 2: 54.8;Ciliated cells: 65.6;Club cells: 67.1;granulocytes: 76.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "eosinophil: 33.9" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HL-60: 11.6;Karpas-707: 7.5;NB-4: 16.2;RPMI-8226: 24.7;THP-1: 15.2;U-937: 16.8" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA010546 Approved NA NA "HPA010546: AB_1078268" "unprognostic (9.48e-2)" "unprognostic (6.01e-5)" "unprognostic (4.72e-3)" "unprognostic (3.04e-1)" "unprognostic (6.30e-2)" "unprognostic (2.80e-3)" "unprognostic (2.52e-1)" "unprognostic (8.19e-2)" "unprognostic (1.19e-1)" "unprognostic (2.53e-2)" "unprognostic (4.55e-1)" "unprognostic (2.43e-1)" "unprognostic (4.41e-4)" "unprognostic (5.82e-2)" "unprognostic (3.56e-2)" "unprognostic (9.87e-2)" "unprognostic (8.94e-2)" 7.3 2.0 1.7 7.8 1.7 2.8 5.4 0.8 2.2 3.0 3.3 1.7 2.9 2.2 2.3 4.4 24.6 2.3 5.6 3.1 2.3 1.9 4.8 2.7 6.9 19.5 3.8 0.8 1.7 2.0 1.7 1.5 3.3 2.9 3.7 4.8 3.1 5.4 0.8 1.7 3.1 7.1 4.2 5.1 22.8 5.2 2.3 4.0 4.7 4.5 4.8 11.3 9.8 3.5 8.1 7.4 33.9 11.9 4.1 3.7 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 11.6 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.0 0.0 0.0 16.2 0.0 0.0 0.0 3.3 0.0 24.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 15.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 16.8 0.0 5.8 6.3 33.9 0.0 10.9 0.0 8.1 2.4 0.1 4.8 5.8 3.7 0.0 18.4 4.1 11.9 7.4 0.5 2.8 1.7 1.7 0.8 2.2 2.3 1.9 3.8 0.8 2.9 4.0 62.5 54.8 40.4 3.9 3.3 2.9 0.6 0.0 65.6 67.1 0.0 5.9 0.3 0.0 0.1 0.0 9.0 0.0 0.0 0.2 0.2 1.4 1.2 76.2 0.0 23.3 0.0 0.0 3.7 30.2 0.0 0.6 32.2 6.8 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.6 0.0 1.4 0.0 0.2 3.1 0.7 17.5 0.5 1.4 DRD2 ENSG00000149295 "Dopamine receptor D2" P14416 11 113409615-113475691 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "adrenal gland: 17.3;brain: 52.0;pituitary gland: 51.6" "Cell type enriched" "Detected in some" 12 "Horizontal cells: 57.2" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in many" 5 "basal ganglia: 52.0" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 9 "SCLC-21H: 45.2" "Region enriched" "Detected in many" 10 "basal ganglia: 183.8" "Group enriched" "Detected in many" 8 "basal ganglia: 126.7;midbrain: 41.7" "HPA015139, HPA015691" Supported Supported NA NA "HPA015139: , HPA015691: AB_1847834" "unprognostic (8.49e-2)" "unprognostic (2.11e-1)" "unprognostic (1.69e-1)" "unprognostic (1.29e-4)" "unprognostic (2.32e-2)" "unprognostic (1.15e-1)" "unprognostic (1.97e-2)" "unprognostic (5.89e-2)" "unprognostic (4.40e-2)" "unprognostic (8.33e-4)" "unprognostic (1.10e-1)" "unprognostic (6.65e-3)" "unprognostic (2.29e-1)" "unprognostic (1.71e-1)" "unprognostic (4.82e-2)" "unprognostic (8.49e-3)" 0.6 17.3 0.9 0.5 52.0 0.2 2.1 0.2 3.3 1.3 0.6 1.5 0.0 0.3 2.3 0.4 0.9 2.1 0.6 0.5 0.3 4.1 0.3 0.2 0.6 0.2 9.9 0.2 0.3 0.4 0.3 51.6 0.2 2.4 1.5 0.9 3.9 5.1 1.7 1.7 0.3 0.5 3.2 0.2 0.2 0.5 1.6 9.5 0.0 0.2 0.0 0.3 0.3 0.3 0.0 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.1 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 0.8 0.0 0.6 0.0 0.0 0.0 0.0 0.0 1.5 0.2 0.0 0.0 0.5 0.0 0.0 0.0 4.8 0.0 0.0 0.0 45.2 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.9 52.0 0.2 3.3 0.3 4.1 9.9 0.2 2.4 9.5 0.0 0.0 0.0 0.0 0.0 4.9 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 57.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 DRD3 ENSG00000151577 "Dopamine receptor D3" P35462 3 114128652-114199407 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets, Schizophrenia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 2.0;brain: 8.3;testis: 4.2" "Group enriched" "Detected in some" 39 "Early spermatids: 5.5;Late spermatids: 12.5" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 2.0;T-reg: 1.4" "Lineage enriched" "Detected in single" 6 "T-cells: 2.0" "Cell line enhanced" "Detected in single" "HAP1: 1.0" "Region enriched" "Detected in some" 5 "basal ganglia: 7.5" "Region enriched" "Detected in many" 12 "basal ganglia: 25.2" NA NA "unprognostic (2.32e-1)" 0.0 0.0 0.0 0.1 8.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 4.2 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 2.0 0.6 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 1.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 ERBB4 "ALS19, HER4" ENSG00000178568 "Erb-b2 receptor tyrosine kinase 4" Q15303 2 211375717-212538841 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Lactation, Transcription, Transcription regulation" "Activator, Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "fallopian tube: 24.5" "Cell type enhanced" "Detected in many" 10 "Bipolar cells: 11.2;Cardiomyocytes: 15.3;Ciliated cells: 26.8;Club cells: 17.0;Collecting duct cells: 12.2;Muller glia cells: 12.4" "Cancer enhanced" "Detected in many" "breast cancer: 4.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 9.6;EFO-21: 7.2;HEK 293: 5.3;RPTEC TERT1: 7.8;SCLC-21H: 4.4;T-47d: 7.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000276, HPA012016, CAB025522" Enhanced NA NA 140000 "CAB000276: , CAB025522: , HPA012016: AB_1846541" "unprognostic (1.48e-1)" "unprognostic (3.28e-1)" "unprognostic (4.31e-3)" "unprognostic (1.76e-3)" "unprognostic (3.59e-1)" "unprognostic (2.75e-1)" "unprognostic (2.88e-1)" "unprognostic (9.56e-2)" "unprognostic (2.07e-1)" "unprognostic (4.67e-3)" "unprognostic (1.07e-1)" "unprognostic (3.61e-1)" "unprognostic (7.14e-3)" "unprognostic (1.49e-3)" "unprognostic (1.41e-1)" "unprognostic (1.14e-1)" "unprognostic (4.11e-2)" 1.6 1.9 15.1 1.2 15.0 1.0 13.4 18.6 14.1 7.8 1.1 7.6 8.8 1.1 1.5 1.2 1.3 24.5 1.2 7.0 14.3 6.5 11.9 1.1 2.9 1.2 7.8 10.7 1.3 2.4 10.8 5.1 1.3 8.8 1.7 1.1 2.0 9.7 18.1 3.8 1.8 1.2 1.1 7.3 1.2 1.5 7.6 12.0 0.0 4.5 1.1 1.2 1.4 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 9.6 0.2 0.0 0.0 0.0 0.0 0.3 0.5 0.1 0.0 0.0 0.0 7.2 1.0 0.0 0.4 0.2 0.0 0.0 0.1 5.3 0.0 1.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 2.8 0.0 0.0 0.5 0.0 7.8 0.4 4.4 0.2 0.0 0.1 0.1 0.1 7.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.1 15.0 18.6 14.1 14.3 6.5 7.8 10.7 8.8 12.0 0.0 9.3 0.0 0.8 0.6 11.2 15.3 0.0 26.8 17.0 12.2 0.0 0.0 5.0 0.4 4.1 0.1 0.0 0.0 0.4 0.1 0.2 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.3 1.7 0.0 3.3 0.0 0.0 12.4 0.0 0.0 0.4 0.0 1.4 6.5 3.1 1.9 1.5 1.1 0.0 0.0 0.0 1.0 FGF2 FGFB ENSG00000138685 "Fibroblast growth factor 2" P09038 4 122826708-122898236 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins, Transporters" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 5 "Fibroblasts: 12.4;Smooth muscle cells: 15.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "BJ: 57.4;BJ hTERT+: 33.7;fHDF/TERT166: 62.3;hTERT-HME1: 34.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000125, HPA065502" Enhanced Supported "Nucleoplasm,Nuclear bodies" "Secreted in other tissues" NA NA 92500 "Nucleoplasm, Nuclear bodies" "CAB000125: , HPA065502: " "unprognostic (1.53e-2)" "unprognostic (3.12e-1)" "unprognostic (1.08e-1)" "unprognostic (7.42e-2)" "unprognostic (2.10e-1)" "unprognostic (3.33e-1)" "unprognostic (6.98e-2)" "unprognostic (1.25e-1)" "unprognostic (2.82e-1)" "unprognostic (1.79e-1)" "prognostic unfavorable (9.85e-4)" "unprognostic (3.37e-1)" "unprognostic (4.61e-3)" "unprognostic (2.36e-1)" "unprognostic (1.81e-1)" "unprognostic (4.45e-2)" "unprognostic (3.45e-3)" 28.1 3.8 19.4 6.9 21.3 0.7 12.1 6.5 15.3 10.2 14.2 10.3 1.9 2.6 17.9 6.3 6.4 10.1 9.4 5.6 17.1 11.0 5.5 2.9 8.3 2.5 9.9 10.7 16.8 2.4 10.1 4.0 8.1 18.6 10.3 5.6 7.5 4.6 11.9 2.0 2.3 4.1 16.2 17.3 1.9 7.6 3.0 12.3 0.0 3.1 3.8 2.7 7.5 14.5 0.8 0.8 0.5 0.5 0.3 1.0 0.0 1.2 3.1 1.8 6.9 4.4 7.4 0.0 57.4 33.7 24.1 14.0 0.0 0.1 0.0 6.7 62.3 19.0 0.2 1.8 0.1 24.3 4.5 0.8 0.0 6.5 0.0 13.0 0.3 0.0 3.9 0.4 23.8 34.4 12.1 2.6 0.0 1.7 1.9 6.2 0.0 0.0 0.0 5.2 0.0 1.4 0.0 0.9 0.0 7.6 0.0 1.0 0.9 11.1 0.0 0.4 10.8 0.0 0.1 2.4 20.0 3.9 7.4 4.9 3.4 3.6 0.0 5.7 0.0 2.1 0.5 0.5 0.4 0.3 0.4 0.2 0.4 0.5 0.4 0.2 0.8 0.7 1.0 0.4 0.3 0.4 0.8 0.7 0.0 19.4 21.3 6.5 15.3 17.1 11.0 9.9 10.7 18.6 12.3 6.0 0.0 0.0 1.5 1.4 3.5 3.9 0.0 0.0 2.3 7.0 0.0 1.8 3.3 6.9 8.7 5.8 0.0 0.0 0.8 0.0 12.4 5.2 0.0 0.4 0.4 0.0 1.7 7.4 0.0 2.5 9.2 0.9 5.0 1.0 0.0 8.4 6.7 0.0 7.8 0.4 1.8 0.0 15.5 3.1 0.2 1.1 4.0 0.0 0.0 0.3 FGFR1 "BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM" ENSG00000077782 "Fibroblast growth factor receptor 1" P11362 8 38411138-38468834 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Transcription, Transcription regulation" "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Leydig cells: 177.8;Muller glia cells: 106.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AN3-CA: 111.2;BJ hTERT+: 50.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033614, HPA056402" Approved NA NA 120000000 "CAB033614: AB_783377, HPA056402: AB_2683118" "unprognostic (9.53e-2)" "unprognostic (7.33e-2)" "unprognostic (2.44e-1)" "unprognostic (1.35e-2)" "unprognostic (4.23e-3)" "unprognostic (7.02e-2)" "unprognostic (6.59e-2)" "unprognostic (2.77e-1)" "unprognostic (1.81e-1)" "unprognostic (3.99e-2)" "unprognostic (7.97e-3)" "unprognostic (4.59e-2)" "unprognostic (7.69e-2)" "unprognostic (6.87e-3)" "unprognostic (5.60e-2)" "unprognostic (4.59e-3)" "unprognostic (1.05e-3)" 41.1 8.6 12.5 14.5 12.2 7.2 39.5 45.0 10.5 36.0 31.5 10.1 11.6 5.5 29.3 20.6 22.9 29.4 32.4 31.7 12.8 10.1 11.8 5.4 18.6 9.7 11.4 14.3 42.0 51.2 11.5 22.3 28.4 20.0 28.2 10.8 35.8 14.0 31.6 12.0 12.9 14.4 52.4 15.6 4.5 16.4 16.4 8.5 11.3 12.6 13.0 9.8 39.6 41.2 1.6 0.7 1.8 1.1 0.8 5.7 0.7 2.4 9.4 41.1 111.2 25.5 18.2 27.1 25.3 50.7 17.6 18.4 6.1 1.4 0.3 7.0 24.2 22.6 0.0 19.4 1.2 20.4 6.6 4.3 0.0 1.6 6.0 14.4 5.9 0.1 16.5 0.1 14.3 2.9 9.5 16.9 1.4 2.3 0.1 8.3 2.9 17.4 2.0 28.9 0.3 3.9 16.0 4.3 0.0 8.5 0.0 1.6 3.6 4.5 0.2 1.0 21.5 2.3 1.1 10.6 11.5 6.4 31.8 6.0 0.4 0.8 0.0 13.6 0.3 6.0 1.4 1.1 0.4 5.7 0.3 3.9 0.7 2.7 3.7 0.1 1.6 1.5 4.1 1.8 0.8 0.5 0.7 2.2 0.7 12.5 12.2 45.0 10.5 12.8 10.1 11.4 14.3 20.0 8.5 3.0 12.0 0.0 68.4 27.9 1.3 48.2 17.8 1.4 9.1 8.7 3.9 6.5 0.0 23.4 14.2 57.3 0.0 0.0 56.3 69.1 85.6 80.3 8.1 0.9 19.7 20.6 24.0 47.3 3.2 9.3 177.8 7.5 32.1 2.8 0.0 106.2 29.8 0.0 93.7 8.0 2.4 12.9 68.0 1.4 11.3 17.2 8.7 6.4 0.4 8.4 FGFR4 "CD334, JTK2" ENSG00000160867 "Fibroblast growth factor receptor 4" P22455 5 177086886-177098144 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 33.6;kidney: 37.7;liver: 45.3" "Cell type enhanced" "Detected in many" 11 "Cholangiocytes: 50.9;Hepatocytes: 23.7;Proximal tubular cells: 19.5;Sertoli cells: 19.4;Undifferentiated cells: 33.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "neutrophil: 3.0" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in many" 4 "CACO-2: 43.0;Hep G2: 43.0;RH-30: 69.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB005196, HPA027273, HPA027369, HPA028251" Approved "Intracellular and membrane" NA NA 4300000 "CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221" "unprognostic (1.96e-1)" "unprognostic (2.10e-2)" "unprognostic (1.12e-1)" "unprognostic (9.06e-3)" "unprognostic (2.87e-1)" "unprognostic (1.95e-2)" "unprognostic (7.85e-3)" "unprognostic (9.19e-2)" "unprognostic (4.25e-1)" "unprognostic (4.46e-2)" "unprognostic (1.16e-1)" "unprognostic (3.48e-2)" "unprognostic (1.78e-1)" "unprognostic (1.71e-3)" "unprognostic (2.41e-1)" "unprognostic (5.75e-2)" "unprognostic (4.68e-2)" 0.5 5.7 0.7 14.3 0.6 0.1 1.6 2.6 0.5 2.8 10.4 0.9 0.7 13.5 0.9 4.8 1.6 1.7 33.6 0.7 0.8 0.3 37.7 45.3 25.3 2.5 0.7 1.0 13.6 26.0 0.0 0.7 1.3 0.8 4.0 3.7 2.0 1.6 0.3 4.3 0.5 17.3 1.6 0.8 11.2 5.4 2.9 0.4 0.3 0.8 2.3 0.7 1.9 3.6 1.1 0.9 3.0 1.1 0.4 0.4 0.0 0.7 12.1 0.2 2.9 0.0 0.0 5.9 0.0 0.0 0.0 0.0 43.0 1.6 1.3 5.6 0.0 0.6 0.6 2.4 0.4 0.0 0.7 2.8 0.1 0.6 43.0 1.3 0.1 1.0 0.2 0.0 2.1 0.0 0.0 0.0 0.8 4.0 0.1 0.9 9.8 0.0 0.8 7.3 7.6 1.0 1.9 69.1 7.2 5.8 0.1 0.4 0.7 0.4 3.1 1.4 1.6 2.9 0.6 0.2 0.0 5.8 0.0 0.1 0.4 0.4 0.7 0.0 0.2 0.5 1.5 1.1 0.4 0.4 0.3 0.3 1.1 0.4 0.0 0.1 0.6 0.4 0.4 3.0 0.4 0.3 0.9 0.2 0.0 0.7 0.6 2.6 0.5 0.8 0.3 0.7 1.0 0.8 0.4 0.0 0.0 0.8 0.6 0.6 0.4 0.8 50.9 0.0 0.0 3.5 0.0 1.1 3.3 8.4 0.1 0.1 10.6 0.0 4.4 3.2 1.7 0.3 0.0 23.7 0.3 0.0 4.1 2.5 0.8 0.0 0.6 0.0 0.0 1.0 5.2 0.9 3.6 2.9 1.4 19.5 0.1 19.4 0.5 1.6 12.8 0.4 7.3 0.0 33.6 0.6 FKBP1A "FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE" ENSG00000088832 "FK506 binding protein 1A" P62942 20 1368978-1393172 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Isomerase, Rotamase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Group enriched" "Detected in all" 4 "dendritic cells: 63.6;granulocytes: 88.4;monocytes: 94.3" "Cell line enhanced" "Detected in all" "HUVEC TERT2: 152.2;TIME: 176.4" "CAB004639, HPA051798" Uncertain NA NA 16000000 "CAB004639: AB_425434, HPA051798: AB_2681615" "unprognostic (4.09e-2)" "unprognostic (2.29e-1)" "unprognostic (5.22e-3)" "unprognostic (1.28e-2)" "unprognostic (2.66e-1)" "unprognostic (7.18e-3)" "prognostic unfavorable (3.44e-7)" "unprognostic (7.05e-3)" "unprognostic (2.76e-1)" "unprognostic (8.81e-2)" "unprognostic (5.12e-3)" "unprognostic (6.65e-2)" "prognostic unfavorable (6.69e-5)" "unprognostic (1.97e-2)" "unprognostic (2.06e-1)" "unprognostic (1.21e-1)" "unprognostic (1.47e-1)" 106.0 42.4 67.3 55.0 114.8 44.4 63.5 15.8 55.8 33.2 39.7 22.1 33.8 32.7 45.5 45.9 42.7 33.8 32.0 36.4 51.7 30.6 41.9 41.7 59.2 84.1 26.0 36.5 41.7 57.7 20.6 21.7 65.0 22.5 34.4 49.4 21.4 30.8 40.6 38.9 31.5 37.1 56.0 23.3 68.0 33.0 21.1 28.4 47.4 62.2 39.7 48.3 48.1 37.0 13.3 63.6 88.4 94.3 14.5 18.6 84.3 71.4 19.8 15.8 22.8 53.5 67.2 20.8 45.4 30.8 36.4 33.8 19.8 27.8 29.3 14.6 42.3 52.9 32.9 20.4 83.1 47.9 8.4 22.1 30.0 9.3 37.6 32.9 34.8 16.7 39.0 26.5 33.7 34.8 42.5 152.2 33.0 27.4 15.1 42.8 8.9 34.0 48.0 33.9 25.3 38.8 29.2 27.6 35.4 47.0 18.1 26.3 19.9 22.4 45.3 75.2 22.1 17.7 29.7 176.4 135.4 22.7 28.8 33.5 7.5 16.3 30.6 23.3 35.4 29.9 23.9 79.4 88.4 11.5 94.3 10.2 12.8 13.9 13.2 63.6 13.3 14.8 14.2 77.9 14.5 90.3 31.6 18.6 84.3 67.3 114.8 15.8 55.8 51.7 30.6 26.0 36.5 22.5 28.4 80.4 70.6 192.2 178.9 233.8 16.6 52.9 173.3 66.9 58.0 164.0 0.0 249.8 202.2 393.2 31.1 486.6 196.8 23.3 297.3 496.2 197.8 189.6 142.9 99.4 651.5 33.4 317.5 445.0 487.0 41.0 185.2 363.6 229.5 390.5 244.5 40.1 382.3 768.7 153.1 245.7 11.0 135.8 189.1 153.9 133.6 261.7 193.6 124.6 263.1 202.2 FSHR "FSHRO, LGR1, ODG1" ENSG00000170820 "Follicle stimulating hormone receptor" P23945 2 48962157-49154537 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "gallbladder: 5.3;ovary: 6.5;testis: 16.3" "Group enriched" "Detected in some" 24 "Early spermatids: 1.6;Late spermatids: 4.9" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "basal ganglia: 1.5;cerebral cortex: 2.9" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 11 "SuSa: 3.6" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Intracellular and membrane" NA NA "unprognostic (5.94e-2)" "unprognostic (4.06e-3)" "unprognostic (5.78e-2)" 0.1 0.1 0.1 0.0 1.5 0.1 0.1 0.1 2.9 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.3 5.3 1.0 0.1 0.4 0.3 0.1 0.1 0.0 0.1 0.1 6.5 0.1 0.0 0.1 0.0 0.5 0.1 0.0 0.3 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 16.3 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.1 0.0 0.0 0.3 0.0 3.6 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 1.5 0.1 2.9 0.1 0.4 0.1 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 FXYD2 "ATP1G1, HOMG2, MGC12372" ENSG00000137731 "FXYD domain containing ion transport regulator 2" P54710 11 117800844-117828698 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" "Disease mutation, FDA approved drug targets, Primary hypomagnesemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "kidney: 258.1;pancreas: 68.9;salivary gland: 91.7" "Group enriched" "Detected in many" 5 "Cholangiocytes: 1434.4;Distal tubular cells: 2501.8;Proximal tubular cells: 3101.2" "Cancer enriched" "Detected in some" 8 "renal cancer: 49.9" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "memory CD8 T-cell: 14.1" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 25 "MOLT-4: 141.0;RPTEC TERT1: 323.5" "Low region specificity" "Detected in many" "Not detected" "Not detected" "HPA064218, HPA068838" Supported Approved Mitochondria NA NA 26000 Mitochondria "HPA064218: AB_2685214, HPA068838: AB_2686047" "unprognostic (4.11e-4)" "unprognostic (1.14e-2)" "unprognostic (1.63e-1)" "unprognostic (1.36e-3)" "unprognostic (1.09e-3)" "unprognostic (2.30e-2)" "unprognostic (3.65e-2)" "unprognostic (4.62e-1)" "unprognostic (4.01e-2)" "unprognostic (4.91e-2)" "unprognostic (1.24e-2)" "unprognostic (2.64e-1)" "prognostic favorable (3.23e-9)" "unprognostic (3.22e-3)" "unprognostic (4.38e-2)" "unprognostic (4.62e-1)" "unprognostic (3.00e-2)" 0.3 0.2 0.2 0.2 0.1 0.0 0.7 0.2 0.2 0.2 0.2 0.1 0.0 0.0 0.3 2.8 0.3 0.3 54.7 0.2 0.1 0.2 258.1 2.2 0.2 0.6 0.1 0.0 0.4 68.9 0.0 0.3 0.6 0.1 0.3 0.0 0.1 91.7 0.1 0.1 0.2 0.3 0.1 0.1 0.4 0.2 0.2 0.0 9.5 0.2 0.3 0.4 0.2 0.6 0.4 3.2 0.0 1.1 8.4 14.1 2.0 0.0 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 9.2 0.0 0.0 0.0 0.0 141.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 323.5 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 1.0 0.0 1.1 0.2 1.8 14.1 0.2 0.4 5.1 4.1 0.0 8.4 0.0 3.2 1.6 2.0 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.0 0.1 0.0 0.0 1.1 0.0 0.0 1.0 0.1 0.8 1434.4 0.0 0.0 413.5 0.0 0.1 2501.8 465.3 14.4 1.3 0.0 0.0 8.3 0.1 1.1 0.1 0.0 2.4 2.9 0.0 14.6 5.5 4.3 15.4 8.6 2.6 0.0 14.4 0.0 0.5 33.3 0.0 7.1 3101.2 3.5 6.5 3.9 0.4 0.2 0.6 0.2 0.0 0.0 0.0 GABBR2 "GABABR2, GPR51, GPRC3B, HG20" ENSG00000136928 "Gamma-aminobutyric acid type B receptor subunit 2" O75899 9 98288082-98709197 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "brain: 52.7" "Group enriched" "Detected in some" 11 "Bipolar cells: 87.5;Early spermatids: 83.9;Late spermatids: 26.5" "Group enriched" "Detected in many" 10 "glioma: 7.2;thyroid cancer: 11.6;urothelial cancer: 3.9" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "BJ: 11.1;fHDF/TERT166: 5.5;HUVEC TERT2: 23.0;U-138 MG: 9.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013820, HPA031684, CAB079065" Enhanced Approved NA NA "CAB079065: , HPA013820: AB_1849364, HPA031684: AB_2673993" "unprognostic (2.00e-1)" "unprognostic (7.56e-2)" "unprognostic (3.75e-1)" "unprognostic (3.09e-5)" "unprognostic (2.52e-1)" "unprognostic (1.16e-1)" "unprognostic (2.81e-2)" "unprognostic (1.42e-1)" "unprognostic (2.66e-1)" "unprognostic (4.43e-2)" "unprognostic (1.43e-2)" "unprognostic (2.06e-1)" "unprognostic (1.76e-2)" "unprognostic (3.52e-2)" "unprognostic (1.91e-1)" "unprognostic (2.68e-2)" "unprognostic (3.45e-2)" 0.9 4.4 13.6 1.0 14.6 0.8 0.9 19.7 52.7 0.8 0.9 2.1 0.0 0.8 1.1 1.1 0.9 0.8 0.9 0.9 14.6 11.1 0.9 0.9 1.0 0.9 7.6 17.6 0.8 0.8 0.9 0.3 0.9 10.3 0.9 0.8 0.6 0.9 0.9 3.2 0.9 0.8 1.0 2.2 0.9 1.0 1.3 0.2 0.0 2.3 0.0 1.1 1.5 0.1 0.7 0.7 1.7 1.1 1.7 1.0 0.4 0.0 0.0 0.0 0.0 0.1 0.1 1.0 11.1 2.2 2.4 4.3 0.0 0.1 0.0 0.7 5.5 0.5 0.0 0.1 0.2 0.8 0.0 0.4 0.0 0.0 0.0 1.1 0.0 0.0 0.3 0.0 0.8 0.2 0.0 23.0 0.0 0.2 0.1 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.6 3.1 0.0 0.0 2.8 0.0 0.0 0.0 0.1 1.0 9.0 0.6 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.2 1.7 0.4 0.8 0.6 0.7 1.0 0.7 0.7 0.7 0.4 0.6 0.8 0.9 1.2 1.7 1.1 0.7 1.0 0.4 13.6 14.6 19.7 35.0 14.6 11.1 7.6 17.6 10.3 0.2 0.0 0.0 0.0 0.0 0.1 87.5 1.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 83.9 0.0 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 26.5 0.3 0.0 1.7 0.0 0.0 1.9 0.0 0.0 0.0 0.0 5.8 0.0 0.5 0.6 0.7 0.1 0.3 0.0 0.0 0.0 GABRA1 EJM5 ENSG00000022355 "Gamma-aminobutyric acid type A receptor alpha1 subunit" P14867 5 161847063-161899981 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 22 "brain: 58.6" "Cell type enriched" "Detected in some" 24 "Bipolar cells: 209.5" "Cancer enriched" "Detected in single" 5 "glioma: 1.1" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEL: 3.7;SCLC-21H: 1.1;U-2 OS: 1.6;U-87 MG: 2.3;WM-115: 1.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022502, HPA029363, HPA055746" Enhanced Supported Approved "Nucleoplasm,Plasma membrane" NA NA "Plasma membrane" Nucleoplasm "CAB022502: , HPA029363: , HPA055746: AB_2682904" "unprognostic (2.58e-2)" "unprognostic (4.78e-3)" "unprognostic (1.84e-1)" "unprognostic (3.31e-1)" "unprognostic (2.43e-1)" 1.0 2.6 8.5 1.0 21.9 1.0 1.0 35.2 58.6 1.0 1.0 1.8 0.0 1.1 1.0 1.0 1.0 1.0 1.0 1.0 10.5 8.8 1.0 1.0 1.0 1.0 6.7 22.0 1.0 1.0 1.0 0.1 1.0 7.4 1.2 1.0 0.2 1.0 1.1 1.0 1.0 1.0 1.0 1.3 1.1 1.5 1.1 0.0 0.0 1.0 0.0 1.3 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 3.7 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.1 0.0 0.1 0.0 0.0 2.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.5 21.9 35.2 49.8 10.5 8.8 6.7 22.0 7.4 0.0 0.0 0.0 0.0 0.0 0.0 209.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 7.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 8.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GABRA2 ENSG00000151834 "Gamma-aminobutyric acid type A receptor alpha2 subunit" P47869 4 46248427-46475230 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 52.6" "Group enriched" "Detected in some" 4 "Collecting duct cells: 38.4;Enterocytes: 16.9;Intestinal endocrine cells: 30.6" "Cancer enhanced" "Detected in some" "glioma: 0.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 1.0" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "U-2 OS: 9.6;U-87 MG: 4.5;WM-115: 5.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029363, CAB079061" Supported Uncertain "Nucleoplasm,Plasma membrane" "Intracellular and membrane" NA NA "Plasma membrane" Nucleoplasm "CAB079061: , HPA029363: " "unprognostic (2.03e-2)" "unprognostic (2.77e-1)" "unprognostic (2.45e-4)" "unprognostic (6.87e-3)" "unprognostic (2.65e-1)" "unprognostic (2.08e-1)" "unprognostic (1.01e-1)" "unprognostic (4.09e-1)" "unprognostic (6.90e-3)" "unprognostic (8.83e-2)" "unprognostic (2.22e-5)" "unprognostic (1.75e-1)" "unprognostic (1.15e-1)" "unprognostic (2.67e-1)" "unprognostic (3.04e-2)" 2.2 1.3 38.5 1.4 34.4 1.2 1.9 10.4 52.6 1.7 4.5 4.9 0.0 2.0 1.4 11.7 1.7 1.0 1.6 1.0 38.9 7.7 8.8 1.4 1.0 1.4 3.7 31.0 1.9 1.0 0.9 0.6 1.5 10.5 1.0 3.5 0.0 1.2 1.9 1.0 1.3 7.7 1.3 6.9 2.3 1.6 1.5 7.1 0.0 1.1 0.0 1.4 1.2 0.8 0.2 0.3 1.0 0.1 0.1 0.1 0.0 0.5 0.5 0.1 0.6 0.0 0.0 0.5 0.3 0.0 0.0 0.0 2.1 0.6 0.2 0.5 0.0 0.1 0.8 0.0 0.0 0.2 0.5 0.5 0.1 0.7 0.3 0.8 0.1 0.2 0.0 0.0 0.2 0.2 0.0 0.0 0.2 0.8 0.2 0.0 0.4 0.0 0.3 0.9 1.8 0.1 0.0 0.6 0.4 0.1 0.6 0.2 0.0 0.1 0.3 0.0 0.6 0.4 0.4 0.1 0.5 9.6 0.5 0.1 0.8 1.2 0.2 4.5 0.4 5.1 1.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.9 0.1 0.1 0.3 0.0 0.0 38.5 34.4 10.4 31.4 38.9 7.7 3.7 31.0 10.5 7.1 0.0 0.0 0.0 0.0 0.1 1.5 0.4 0.0 0.0 0.0 38.4 3.9 0.0 3.3 0.0 6.4 0.2 16.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 30.6 0.0 0.0 6.9 0.6 0.0 1.7 0.0 1.9 0.3 0.0 0.9 0.0 0.0 1.1 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.6 0.0 GABRA3 ENSG00000011677 "Gamma-aminobutyric acid type A receptor alpha3 subunit" P34903 X 152166234-152451358 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 30.1" "Cell type enriched" "Detected in some" 4 "Hofbauer cells: 12.1" "Cancer enriched" "Detected in many" 7 "testis cancer: 16.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 1.5" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "GAMG: 9.1;HMC-1: 7.7;Karpas-707: 13.0;PC-3: 7.6;U-266/70: 7.0;U-266/84: 11.6;U-87 MG: 7.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000839, HPA029363" Approved Supported Uncertain "Nucleoplasm,Plasma membrane" NA NA "Plasma membrane" Nucleoplasm "HPA000839: AB_1078929, HPA029363: " "unprognostic (9.63e-3)" "unprognostic (2.04e-1)" "unprognostic (2.02e-1)" "unprognostic (1.18e-2)" "unprognostic (7.07e-2)" "unprognostic (5.42e-2)" "unprognostic (2.34e-6)" "unprognostic (1.24e-1)" "unprognostic (2.70e-1)" "unprognostic (2.39e-2)" "unprognostic (2.63e-2)" "unprognostic (1.73e-1)" "unprognostic (7.29e-6)" "unprognostic (7.42e-3)" "unprognostic (6.20e-2)" "unprognostic (8.13e-2)" 0.7 0.7 7.7 0.6 15.2 0.7 0.7 1.3 30.1 2.2 0.8 3.3 0.0 0.8 1.2 0.8 1.3 0.7 0.7 0.7 10.9 15.9 0.7 0.7 0.7 0.7 4.7 10.5 0.6 0.7 0.6 0.9 5.2 6.2 0.8 0.8 0.4 0.7 1.8 0.8 1.1 0.9 0.8 2.1 0.7 0.7 1.8 1.1 0.0 0.7 0.0 0.9 1.8 0.4 0.0 0.1 1.5 0.3 0.3 0.2 0.0 0.0 0.8 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.0 0.0 0.0 0.0 7.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 13.0 0.0 0.0 0.0 0.0 2.4 5.5 7.6 0.0 0.0 0.0 0.0 0.0 0.2 4.7 0.0 4.8 0.4 0.3 0.1 1.2 0.0 4.9 6.5 0.3 1.4 7.0 11.6 0.0 7.7 0.0 4.9 1.5 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.3 0.3 0.1 0.2 0.0 7.7 15.2 1.3 28.4 10.9 15.9 4.7 10.5 6.2 1.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.0 3.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 12.1 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.9 0.0 1.6 0.0 0.0 0.3 GABRB2 ENSG00000145864 "Gamma-aminobutyric acid type A receptor beta2 subunit" P47870 5 161288429-161549044 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 48.7" "Cell type enhanced" "Detected in some" 17 "Bipolar cells: 17.4;Cone photoreceptor cells: 25.5;Rod photoreceptor cells: 9.0" "Cancer enriched" "Detected in some" 20 "thyroid cancer: 10.2" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 10 "SCLC-21H: 23.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001964, HPA067632" Enhanced NA NA "CAB001964: , HPA067632: AB_2685874" "unprognostic (5.46e-2)" "unprognostic (1.03e-1)" "unprognostic (3.29e-1)" "unprognostic (2.26e-6)" "unprognostic (2.33e-2)" "unprognostic (6.65e-2)" "unprognostic (3.58e-2)" "unprognostic (1.82e-1)" "unprognostic (1.01e-2)" "unprognostic (1.22e-1)" "unprognostic (5.19e-3)" "unprognostic (2.24e-4)" "unprognostic (1.22e-1)" "unprognostic (1.33e-2)" "unprognostic (1.58e-1)" "unprognostic (7.18e-3)" "unprognostic (1.04e-2)" 1.2 3.6 7.7 0.8 19.2 0.7 0.9 48.7 45.4 1.3 1.5 0.9 0.0 2.0 0.9 5.8 0.8 1.2 0.8 0.9 8.1 4.6 2.8 0.7 1.8 0.8 3.7 16.3 0.9 0.9 0.8 0.5 1.0 4.3 0.9 2.2 0.1 1.3 1.5 0.8 0.8 1.4 0.9 1.1 3.4 1.2 1.5 1.8 0.0 1.3 0.0 0.8 0.8 0.3 0.4 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.0 1.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 23.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.2 0.1 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 7.7 19.2 48.7 34.1 8.1 4.6 3.7 16.3 4.3 1.8 0.0 0.0 0.0 0.0 0.2 17.4 1.6 0.0 0.0 0.0 0.0 25.5 0.0 5.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.1 0.0 1.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.9 1.4 0.0 0.0 0.4 2.6 9.0 0.0 0.4 2.7 1.5 0.4 0.0 0.0 3.0 0.0 GABRB3 ENSG00000166206 "Gamma-aminobutyric acid type A receptor beta3 subunit" P28472 15 26543546-26939539 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 48.6" "Cell type enhanced" "Detected in many" 16 "Bipolar cells: 136.2;Cone photoreceptor cells: 37.3;Horizontal cells: 71.5;Rod photoreceptor cells: 48.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 32.3;HAP1: 13.3;NTERA-2: 23.2;OE19: 10.0;SCLC-21H: 21.5;U-2 OS: 8.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (1.72e-1)" "unprognostic (4.91e-2)" "unprognostic (3.20e-2)" "unprognostic (4.25e-2)" "unprognostic (1.66e-1)" "unprognostic (7.07e-2)" "unprognostic (1.00e-1)" "unprognostic (8.87e-2)" "unprognostic (1.02e-1)" "unprognostic (2.44e-1)" "unprognostic (1.44e-2)" "unprognostic (3.62e-1)" "unprognostic (3.56e-3)" "unprognostic (2.99e-2)" "unprognostic (1.49e-1)" "unprognostic (3.33e-2)" "unprognostic (4.05e-1)" 1.2 6.2 16.8 1.1 22.6 0.7 1.5 12.7 48.6 3.0 1.8 1.6 0.1 1.4 2.4 1.6 1.9 3.0 13.9 7.4 14.3 11.7 7.8 1.5 1.5 0.7 4.6 13.7 2.5 5.2 1.2 12.2 0.7 3.7 5.7 1.6 3.2 1.2 1.9 0.7 1.3 1.2 2.0 2.5 1.2 6.0 4.4 3.4 0.0 9.1 0.0 0.9 1.3 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 32.3 5.1 0.0 0.0 0.0 1.2 0.5 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 13.3 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 2.6 1.6 0.0 0.0 0.0 0.0 0.0 7.0 0.9 0.0 0.0 0.0 2.2 0.0 23.2 10.0 1.6 0.0 0.0 0.0 2.3 0.0 21.5 8.1 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 8.9 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 16.8 22.6 12.7 25.7 14.3 11.7 4.6 13.7 3.7 3.4 11.9 2.2 0.0 1.0 0.0 136.2 8.9 17.8 18.7 2.3 5.2 37.3 0.4 0.0 3.3 9.0 1.3 0.5 0.0 0.4 0.0 0.2 3.6 0.0 0.5 0.0 71.5 9.9 1.3 0.0 4.9 1.7 0.0 0.0 0.0 1.8 6.7 1.4 0.0 3.2 6.3 48.7 0.0 0.9 5.1 15.1 0.1 0.2 0.0 0.4 0.3 GABRG2 ENSG00000113327 "Gamma-aminobutyric acid type A receptor gamma2 subunit" P18507 5 162000057-162162977 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 47.1" "Cell type enriched" "Detected in some" 4 "Bipolar cells: 81.7" "Cancer enhanced" "Detected in single" "glioma: 1.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 7.3" "Group enriched" "Detected in many" 5 "B-cells: 2.9;granulocytes: 7.3;T-cells: 3.2" "Cell line enhanced" "Detected in many" "CACO-2: 10.6;RPMI-8226: 10.2;SuSa: 11.4;U-266/70: 17.8;U-266/84: 14.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB079060 Supported NA NA "CAB079060: " "unprognostic (2.88e-2)" "unprognostic (1.56e-2)" "unprognostic (6.31e-3)" "unprognostic (3.07e-3)" "unprognostic (1.52e-1)" 1.1 5.7 9.7 1.2 28.8 3.3 0.9 21.7 47.1 0.7 1.5 1.1 0.0 2.2 1.2 1.3 1.3 1.3 3.8 1.6 10.6 19.6 1.0 1.2 1.9 1.2 7.5 19.1 1.5 1.0 0.8 5.3 2.9 17.6 1.0 1.3 0.6 1.3 0.8 1.2 3.3 1.9 1.6 2.6 1.2 3.3 1.7 1.8 0.0 1.8 0.0 1.3 1.5 0.3 2.9 0.7 7.3 0.3 0.9 3.2 0.2 3.6 1.7 1.9 0.3 0.0 0.0 2.0 0.6 0.0 0.0 0.0 10.6 4.7 0.7 5.2 0.0 0.4 1.6 1.2 0.0 0.0 0.8 1.1 0.0 2.1 1.3 0.0 0.2 0.5 0.3 0.0 0.0 0.0 0.5 0.0 1.0 1.8 8.5 0.0 2.5 0.4 0.1 6.1 3.4 2.9 0.4 0.1 10.2 0.0 3.4 0.9 0.8 0.3 0.6 3.4 11.4 5.6 5.7 0.2 0.3 4.5 0.3 0.5 17.8 14.1 0.5 0.2 0.4 0.4 7.3 0.3 0.6 0.4 0.3 2.7 2.9 0.7 0.6 0.0 2.5 3.2 0.7 1.6 0.9 0.2 0.7 0.6 0.2 9.7 28.8 21.7 38.1 10.6 19.6 7.5 19.1 17.6 1.8 17.9 19.7 0.0 0.0 0.0 81.7 0.2 0.0 12.0 19.4 0.0 11.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.1 0.0 0.1 15.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.1 0.0 0.0 0.0 8.4 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 GABRR1 ENSG00000146276 "Gamma-aminobutyric acid type A receptor rho1 subunit" P24046 6 89177501-89231278 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "retina: 12.3;testis: 4.6" "Cell type enriched" "Detected in some" 11 "Bipolar cells: 53.4" "Not detected" "Not detected" "Region enriched" "Detected in single" 6 "amygdala: 2.2" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "NTERA-2: 3.3;OE19: 6.7;SuSa: 4.6" "Not detected" "Not detected" NA NA "unprognostic (5.75e-2)" "unprognostic (3.92e-2)" "unprognostic (1.12e-1)" "unprognostic (2.90e-2)" "unprognostic (5.78e-2)" "unprognostic (4.90e-2)" "unprognostic (8.32e-3)" "unprognostic (2.52e-3)" "unprognostic (1.74e-1)" "unprognostic (1.82e-1)" "unprognostic (1.43e-1)" "unprognostic (1.62e-5)" "unprognostic (1.18e-1)" "unprognostic (9.90e-2)" "unprognostic (2.12e-2)" "unprognostic (2.29e-1)" 0.4 0.0 2.2 0.1 0.1 0.0 0.2 0.3 0.1 0.2 0.3 0.1 0.1 0.1 0.1 0.2 1.0 0.1 0.1 0.1 0.1 0.2 0.4 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.2 1.0 0.3 0.2 0.1 12.3 0.2 0.1 0.7 0.6 0.7 0.1 0.1 0.1 0.0 4.6 0.1 0.1 0.1 0.1 0.2 0.6 0.2 0.0 0.1 0.2 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 3.3 6.7 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 4.6 0.0 1.0 0.0 0.1 0.2 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 2.2 0.1 0.3 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.2 53.4 0.3 0.0 0.0 0.0 0.0 3.9 0.3 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.4 0.0 3.8 0.0 0.3 0.0 0.2 0.0 0.2 0.0 0.0 0.1 GHRHR ENSG00000106128 "Growth hormone releasing hormone receptor" Q02643 7 30938669-30993254 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 36 "pituitary gland: 108.9" "Cell type enhanced" "Detected in single" 31 "Spermatogonia: 2.4" "Cancer enhanced" "Detected in single" "liver cancer: 0.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "SCLC-21H: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Intracellular and membrane" NA NA "unprognostic (8.32e-2)" "unprognostic (1.45e-1)" "unprognostic (9.30e-2)" "unprognostic (1.39e-1)" "unprognostic (7.23e-2)" "unprognostic (4.15e-1)" "unprognostic (2.28e-2)" "unprognostic (1.54e-1)" "unprognostic (1.20e-1)" "unprognostic (1.27e-1)" "unprognostic (1.43e-2)" "unprognostic (1.47e-1)" "unprognostic (5.87e-3)" 0.4 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.0 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 108.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.6 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.4 2.4 0.0 0.0 0.0 0.0 0.0 GLP1R GLP-1R ENSG00000112164 "Glucagon like peptide 1 receptor" P43220 6 39048798-39087743 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "pancreas: 19.0" "Cell type enhanced" "Detected in single" 37 "Cardiomyocytes: 2.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CAPAN-2: 1.6;HAP1: 1.3;HMC-1: 1.5;NTERA-2: 3.3;SCLC-21H: 8.1;SH-SY5Y: 1.8" "Group enriched" "Detected in some" 5 "basal ganglia: 16.1;hypothalamus: 4.8" "Low region specificity" "Detected in some" NA NA "unprognostic (4.06e-3)" "unprognostic (5.38e-6)" "unprognostic (1.80e-2)" "unprognostic (4.16e-2)" "unprognostic (4.98e-2)" "unprognostic (3.55e-1)" "unprognostic (2.11e-1)" "unprognostic (1.38e-1)" "unprognostic (9.76e-2)" "unprognostic (3.29e-1)" "unprognostic (1.73e-1)" "unprognostic (8.60e-3)" "unprognostic (2.47e-1)" "unprognostic (1.15e-2)" "unprognostic (1.42e-2)" 0.2 0.1 0.1 0.0 1.8 0.0 0.9 0.1 2.2 0.1 0.1 0.8 0.0 2.4 0.1 0.6 0.1 0.0 3.5 4.8 1.4 1.4 0.1 0.0 0.5 1.0 0.1 2.3 0.0 19.0 0.0 0.1 0.0 2.0 0.1 0.0 0.0 4.1 0.0 0.4 0.3 0.1 0.0 1.4 0.1 1.8 0.4 0.0 0.4 0.8 0.4 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.4 3.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 8.1 1.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 1.8 0.1 0.7 1.4 1.4 0.1 2.3 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GLRA1 STHE ENSG00000145888 "Glycine receptor alpha 1" P23415 5 151822513-151924842 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "brain: 31.7" "Cell type enhanced" "Detected in some" 26 "Basal glandular cells: 1.1;Bipolar cells: 4.9;Horizontal cells: 1.6" "Not detected" "Not detected" "Region enriched" "Detected in many" 10 "pons and medulla: 31.7" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "HeLa: 1.4" "Group enriched" "Detected in many" 4 "hypothalamus: 11.0;midbrain: 18.1;pons and medulla: 27.6" "Region enhanced" "Detected in all" "pons and medulla: 54.9" CAB079042 Supported NA NA "CAB079042: " "unprognostic (3.17e-1)" "unprognostic (2.47e-1)" "unprognostic (3.85e-7)" "unprognostic (8.24e-2)" "unprognostic (9.45e-3)" 0.3 3.2 1.2 0.1 0.7 0.2 0.1 3.2 0.9 0.1 0.2 0.0 0.0 0.5 0.1 0.1 0.1 0.1 0.1 0.3 0.1 2.7 0.2 0.1 0.1 0.1 2.7 0.0 0.1 2.2 0.1 0.1 0.2 31.7 0.1 0.1 1.6 0.1 0.1 0.6 0.1 0.1 0.1 12.6 0.1 0.1 0.2 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.7 3.2 0.9 0.1 2.7 2.7 0.0 31.7 0.0 0.0 0.0 0.0 1.1 0.1 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.6 GLRA2 GLR ENSG00000101958 "Glycine receptor alpha 2" P23416 X 14529298-14731812 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 14 "brain: 21.0;intestine: 11.1" "Cell type enhanced" "Detected in some" 16 "Cardiomyocytes: 1.2;Horizontal cells: 1.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 33 "AN3-CA: 20.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB070422 Approved NA NA "CAB070422: AB_11153055" "unprognostic (2.52e-1)" "unprognostic (3.13e-1)" "unprognostic (5.52e-2)" "unprognostic (1.90e-1)" "unprognostic (5.74e-2)" "unprognostic (1.81e-2)" "unprognostic (3.39e-1)" "unprognostic (5.82e-2)" "unprognostic (7.95e-3)" "unprognostic (1.13e-1)" "unprognostic (2.76e-1)" "unprognostic (6.69e-2)" 0.4 0.5 14.5 0.7 13.2 0.7 0.5 21.0 10.8 0.4 4.1 0.1 0.0 0.7 0.5 0.5 0.4 0.8 0.7 0.4 3.6 13.9 0.5 0.5 0.4 0.5 1.6 8.4 0.9 0.5 0.4 0.5 0.8 10.1 0.4 11.1 1.1 0.8 0.5 0.5 0.8 0.9 0.7 6.5 0.5 0.5 0.9 0.8 0.0 0.5 0.0 0.4 0.4 0.1 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 20.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.5 13.2 21.0 10.4 3.6 13.9 1.6 8.4 10.1 0.8 0.0 0.0 0.0 0.0 0.1 0.2 1.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.4 0.0 GLRA3 ENSG00000145451 "Glycine receptor alpha 3" O75311 4 174636914-174829314 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 15.2;breast: 6.1;pituitary gland: 12.5" "Group enriched" "Detected in some" 9 "Early spermatids: 18.4;Late spermatids: 13.2" "Cancer enhanced" "Detected in single" "breast cancer: 1.2" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "memory B-cell: 2.7" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 5 "HEL: 2.7;Karpas-707: 6.3;U-698: 2.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" NA NA "unprognostic (2.75e-3)" "unprognostic (3.14e-1)" "unprognostic (1.78e-2)" "unprognostic (1.36e-1)" "unprognostic (9.02e-2)" "unprognostic (3.82e-2)" "unprognostic (2.37e-1)" "unprognostic (1.22e-1)" "unprognostic (1.12e-2)" "unprognostic (4.26e-2)" "unprognostic (1.64e-5)" "unprognostic (4.61e-4)" "unprognostic (2.24e-1)" "unprognostic (1.15e-2)" 0.5 2.6 13.3 0.6 7.3 0.6 6.1 0.7 15.2 0.5 0.5 0.3 0.0 0.5 0.7 0.5 0.5 0.4 0.6 0.4 2.7 7.4 0.5 0.4 0.5 0.9 4.6 8.7 0.4 1.4 0.5 12.5 0.5 4.4 0.5 0.5 0.0 0.5 0.5 0.4 0.7 0.5 0.8 2.1 0.6 0.5 1.7 0.0 0.0 0.5 0.0 0.9 0.4 0.2 2.7 0.1 1.1 0.0 0.3 0.5 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 2.7 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.0 0.6 0.0 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.1 0.0 0.6 0.0 0.7 0.6 0.0 0.1 0.0 0.1 0.1 0.0 0.2 0.0 2.3 0.1 0.1 0.1 0.6 0.0 0.4 0.1 0.0 0.5 2.7 0.2 0.1 0.0 0.5 0.2 0.2 1.1 0.3 0.0 0.1 0.1 0.0 13.3 7.3 0.7 14.5 2.7 7.4 4.6 8.7 4.4 0.0 0.0 1.1 0.0 1.0 0.0 0.7 1.7 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 18.4 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.1 0.0 0.0 0.0 0.0 0.0 0.0 13.2 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.6 0.0 0.4 0.2 1.5 0.1 0.0 0.0 0.0 0.3 GLRB ENSG00000109738 "Glycine receptor beta" P48167 4 157076057-157172090 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 43.1;parathyroid gland: 37.0" "Cell type enhanced" "Detected in many" 7 "Cardiomyocytes: 12.6;Cholangiocytes: 7.6;Ciliated cells: 8.1;Muller glia cells: 11.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 18 "plasmacytoid DC: 1.7" "Lineage enriched" "Detected in single" 18 "dendritic cells: 1.7" "Cell line enhanced" "Detected in many" "AN3-CA: 17.5;hTERT-RPE1: 23.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA052363 Approved NA NA "HPA052363: AB_2681800" "unprognostic (7.36e-2)" "unprognostic (6.53e-2)" "unprognostic (1.44e-1)" "unprognostic (2.59e-3)" "unprognostic (5.65e-2)" "unprognostic (1.18e-1)" "unprognostic (9.47e-2)" "unprognostic (1.52e-1)" "unprognostic (1.19e-2)" "unprognostic (2.99e-2)" "unprognostic (6.81e-2)" "unprognostic (1.48e-1)" "prognostic favorable (4.89e-4)" "unprognostic (4.32e-3)" "unprognostic (1.85e-1)" "unprognostic (5.61e-2)" "unprognostic (1.66e-2)" 4.5 7.2 12.6 1.5 20.9 0.7 10.3 15.9 43.1 9.4 2.3 2.8 0.1 1.1 3.3 5.4 1.5 7.4 3.5 9.9 18.3 17.3 4.1 1.6 3.4 0.8 11.1 21.3 1.8 14.2 37.0 6.7 2.9 16.5 6.5 1.4 0.7 16.7 5.2 3.3 1.5 1.2 4.0 6.1 0.6 2.2 1.9 4.5 0.0 1.5 0.5 0.7 1.9 1.4 0.0 1.7 0.0 0.0 0.0 0.0 0.0 4.8 2.0 5.8 17.5 11.3 4.6 0.0 9.6 6.2 4.7 8.9 0.0 14.8 0.0 2.3 9.7 5.8 0.0 4.4 1.5 8.9 0.0 5.8 2.9 2.2 0.2 5.2 3.7 0.0 4.1 1.3 8.2 1.2 23.3 4.2 3.1 0.0 0.0 8.5 0.0 0.4 0.0 0.3 0.0 1.3 0.0 7.9 0.0 12.7 0.8 6.3 3.8 0.0 4.5 0.7 0.9 4.1 0.9 6.2 2.8 8.3 4.7 9.3 0.0 0.0 0.0 6.7 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 12.6 20.9 15.9 43.1 18.3 17.3 11.1 21.3 16.5 4.5 0.0 0.6 0.0 0.7 1.0 6.9 12.6 7.6 8.1 3.4 0.0 2.0 0.3 0.0 6.9 0.2 1.0 0.0 0.0 1.5 0.0 2.6 0.6 1.1 0.0 0.1 1.6 0.0 1.8 0.0 0.0 0.3 0.0 3.3 1.0 0.0 11.6 1.9 0.0 3.2 0.4 1.6 0.0 1.1 1.1 3.0 0.3 0.1 0.0 0.0 0.1 GNRHR "GRHR, LHRHR" ENSG00000109163 "Gonadotropin releasing hormone receptor" P30968 4 67739328-67754360 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets, Hypogonadotropic hypogonadism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "pituitary gland: 56.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "naive B-cell: 1.3" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "K-562: 3.0" "Not detected" "Not detected" HPA013424 Enhanced NA NA "HPA013424: AB_2668840" "unprognostic (2.77e-1)" "unprognostic (1.58e-1)" "unprognostic (4.05e-1)" "unprognostic (1.78e-1)" "unprognostic (4.65e-1)" "unprognostic (8.75e-3)" "unprognostic (3.09e-2)" "unprognostic (1.34e-1)" "unprognostic (1.90e-1)" "unprognostic (1.01e-1)" "unprognostic (6.84e-2)" "unprognostic (1.63e-1)" "unprognostic (9.03e-2)" "unprognostic (3.23e-2)" "unprognostic (9.67e-2)" "unprognostic (1.22e-3)" "unprognostic (3.99e-2)" 0.1 3.9 0.1 0.4 0.2 0.2 0.1 0.3 1.7 0.3 0.1 0.1 0.1 0.7 0.1 0.1 1.6 0.0 0.2 0.2 0.2 0.2 0.1 0.1 0.1 1.1 0.1 0.1 0.2 0.3 0.0 56.6 0.1 0.5 0.2 0.0 0.1 0.3 0.1 0.2 0.9 0.1 0.1 0.1 0.2 0.3 0.3 0.1 0.2 1.0 0.1 0.4 0.1 0.5 1.3 0.2 0.0 0.0 0.4 0.3 0.0 0.2 1.5 1.5 1.6 0.0 0.0 0.6 0.3 0.0 0.0 0.0 0.5 1.7 1.3 0.2 0.0 0.6 0.5 0.0 0.0 0.0 0.3 0.5 0.3 0.3 0.7 0.0 1.1 0.4 0.0 0.0 0.0 0.0 0.7 0.0 1.2 3.0 0.0 0.0 0.8 0.6 0.4 1.0 0.5 0.0 0.6 1.3 0.6 0.0 0.0 0.9 2.1 0.0 0.3 0.0 0.3 0.3 0.2 1.0 0.1 0.2 0.6 0.2 1.2 0.3 0.6 1.4 0.8 0.9 0.0 0.0 0.0 0.2 0.0 0.2 0.5 0.1 0.0 0.0 1.3 0.1 0.3 0.0 0.4 0.0 0.2 0.0 0.0 0.1 0.2 0.3 0.3 0.2 0.2 0.1 0.1 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GRIN1 "GluN1, NMDAR1" ENSG00000176884 "Glutamate ionotropic receptor NMDA type subunit 1" Q05586 9 137138390-137168762 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 38 "brain: 97.5" "Cell type enhanced" "Detected in some" 10 "Bipolar cells: 5.6;Cardiomyocytes: 2.4;monocytes: 3.6;Rod photoreceptor cells: 5.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "OE19: 2.6;REH: 3.1;RPMI-8226: 4.3;SCLC-21H: 10.0;SH-SY5Y: 6.9;T-47d: 2.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067773 Enhanced NA NA "HPA067773: " "unprognostic (3.58e-2)" "unprognostic (4.51e-1)" "unprognostic (2.68e-2)" "unprognostic (5.48e-4)" "unprognostic (5.20e-2)" "unprognostic (1.25e-1)" "unprognostic (2.34e-2)" "unprognostic (2.81e-2)" "unprognostic (6.46e-3)" "unprognostic (1.51e-1)" "unprognostic (1.69e-1)" "unprognostic (1.78e-1)" "unprognostic (1.21e-3)" "unprognostic (4.47e-2)" "unprognostic (1.44e-1)" "unprognostic (3.56e-3)" "unprognostic (4.72e-2)" 1.7 2.0 23.6 2.0 47.5 1.7 1.8 28.1 97.5 1.8 2.0 3.2 0.0 2.2 1.7 1.8 1.7 1.7 1.7 1.7 29.1 26.4 1.8 1.7 1.8 1.8 15.4 37.9 1.7 1.8 1.8 0.0 1.7 22.0 2.2 1.8 0.7 2.5 1.8 1.7 1.8 2.2 1.8 4.7 1.8 1.8 1.9 6.3 0.0 1.7 0.0 1.8 1.8 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.7 0.0 0.1 0.0 0.0 0.4 1.0 0.0 0.1 0.0 0.0 1.2 0.0 0.0 0.0 1.5 0.1 0.0 0.2 0.2 0.0 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.9 0.0 0.0 0.1 2.6 0.0 3.1 0.0 4.3 0.0 0.0 10.0 6.9 0.1 0.6 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 23.6 47.5 28.1 87.9 29.1 26.4 15.4 37.9 22.0 6.3 0.0 0.0 0.0 0.4 0.0 5.6 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.1 1.6 1.7 0.0 0.0 0.4 0.0 0.0 0.0 3.6 1.7 1.6 0.3 0.0 0.0 0.0 5.7 0.0 0.0 0.2 1.3 0.0 0.0 0.0 0.0 0.3 GRIN2A "GluN2A, NMDAR2A" ENSG00000183454 "Glutamate ionotropic receptor NMDA type subunit 2A" Q12879 16 9753404-10182754 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 25.2" "Cell type enhanced" "Detected in some" 9 "Cardiomyocytes: 14.9;Early spermatids: 13.4;Late spermatids: 13.0;Muller glia cells: 17.7;Rod photoreceptor cells: 12.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "fHDF/TERT166: 7.8;hTERT-RPE1: 3.4;RPMI-8226: 2.9;U-138 MG: 8.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB022725 Enhanced NA NA "CAB022725: " "unprognostic (6.43e-2)" "unprognostic (2.47e-1)" "unprognostic (5.97e-2)" "unprognostic (3.21e-2)" "unprognostic (3.13e-2)" "unprognostic (1.59e-2)" "unprognostic (1.62e-1)" "unprognostic (2.10e-1)" "unprognostic (2.08e-1)" "unprognostic (5.39e-2)" "unprognostic (1.47e-1)" "unprognostic (1.69e-1)" "unprognostic (3.75e-3)" "unprognostic (4.79e-3)" "unprognostic (2.05e-1)" "unprognostic (3.92e-3)" "unprognostic (3.33e-2)" 0.9 1.0 5.4 0.5 5.9 0.4 0.6 8.5 25.2 0.6 0.7 1.5 0.0 0.9 0.8 4.5 2.1 4.1 0.5 4.0 8.0 1.9 0.9 0.4 1.0 0.5 1.7 10.3 0.5 0.6 0.4 0.3 0.4 1.4 0.5 0.7 1.4 0.7 1.0 0.5 1.2 0.7 0.9 1.2 0.4 1.1 5.2 0.8 0.0 0.8 0.0 0.7 0.6 0.5 0.6 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 1.9 0.6 1.4 0.0 0.1 0.0 0.0 7.8 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.3 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 8.5 0.8 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 5.4 5.9 8.5 17.9 8.0 1.9 1.7 10.3 1.4 0.8 0.0 0.0 0.0 1.9 1.6 3.6 14.9 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.6 13.4 0.1 0.0 0.0 0.2 0.0 0.2 0.4 0.0 0.0 0.1 1.6 0.0 0.0 0.0 13.0 0.9 0.0 0.0 0.0 0.0 17.7 1.2 0.0 0.0 0.0 12.1 0.0 4.2 3.2 3.8 0.4 0.0 0.0 0.0 0.3 GRIN2C "GluN2C, NMDAR2C" ENSG00000161509 "Glutamate ionotropic receptor NMDA type subunit 2C" Q14957 17 74842023-74861504 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "brain: 43.6;heart muscle: 13.2;salivary gland: 14.2;thyroid gland: 12.4" "Cell type enhanced" "Detected in some" 13 "Cardiomyocytes: 15.9;Hofbauer cells: 9.4;Muller glia cells: 18.3" "Cancer enhanced" "Detected in some" "thyroid cancer: 2.3" "Region enriched" "Detected in many" 5 "cerebellum: 43.6" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.3" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "BEWO: 11.3;RPMI-8226: 4.0;SCLC-21H: 5.2" "Low region specificity" "Detected in all" "Region enriched" "Detected in some" 13 "cerebellum: 65.6" NA NA "unprognostic (7.21e-3)" "unprognostic (4.68e-2)" "unprognostic (9.38e-3)" "unprognostic (2.24e-5)" "unprognostic (3.42e-1)" "unprognostic (1.53e-2)" "unprognostic (1.84e-1)" "unprognostic (1.82e-2)" "unprognostic (1.78e-1)" "unprognostic (2.95e-2)" "unprognostic (3.31e-3)" "unprognostic (3.25e-1)" "unprognostic (1.14e-3)" "unprognostic (4.20e-2)" "unprognostic (1.49e-1)" "unprognostic (1.51e-2)" "unprognostic (1.14e-1)" 1.0 1.4 7.8 0.5 9.1 1.0 0.5 43.6 8.9 0.5 0.5 2.4 0.0 0.5 0.5 0.5 0.4 0.6 0.6 13.2 4.5 1.4 0.3 0.2 0.3 0.3 3.2 4.5 0.4 0.2 0.5 0.0 2.7 4.2 0.3 0.4 0.3 14.2 0.5 0.6 0.4 0.6 0.5 1.0 0.4 0.3 2.7 0.9 0.0 12.4 0.0 0.3 0.4 0.0 0.2 1.3 0.3 0.1 0.2 0.7 0.0 0.0 0.4 0.4 0.1 0.1 0.0 11.3 0.0 0.0 0.0 0.0 1.4 0.2 0.5 0.1 0.0 0.1 0.4 0.1 0.0 0.0 1.0 0.3 0.2 0.3 0.3 0.0 0.8 0.9 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.4 0.3 0.0 1.7 0.1 0.1 0.1 0.1 0.1 0.3 0.9 4.0 0.0 0.3 5.2 0.4 2.2 0.2 0.8 0.8 0.7 0.1 0.2 0.4 2.0 0.5 0.2 1.1 0.1 0.2 0.5 0.7 0.2 0.1 0.1 0.3 0.7 0.1 0.1 0.0 0.1 0.3 0.1 0.2 0.3 0.2 0.3 0.2 0.0 1.3 0.2 0.0 7.8 9.1 43.6 6.3 4.5 1.4 3.2 4.5 4.2 0.9 0.0 0.0 0.0 0.0 0.1 2.5 15.9 2.5 0.0 0.0 1.8 0.0 0.2 0.0 0.0 0.8 0.3 0.0 0.0 0.2 0.1 0.0 0.2 0.0 0.0 9.4 1.6 0.0 1.3 0.3 4.3 0.0 0.0 1.7 0.0 0.0 18.3 0.0 0.0 0.4 0.0 2.4 0.0 1.0 3.0 2.5 0.0 0.6 0.0 0.0 0.0 GUCY2C "GUC2C, STAR" ENSG00000070019 "Guanylate cyclase 2C" P25092 12 14612632-14696585 "Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters" "cGMP biosynthesis" "Lyase, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 19 "intestine: 85.1" "Cell type enhanced" "Detected in some" 21 "Enterocytes: 37.2;Intestinal endocrine cells: 169.6;Mucus-secreting cells: 61.9;Paneth cells: 99.3;Undifferentiated cells: 41.2" "Group enriched" "Detected in many" 5 "colorectal cancer: 23.9;stomach cancer: 9.1" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "memory B-cell: 4.3" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "AN3-CA: 3.7;BEWO: 2.2;CACO-2: 3.2;CAPAN-2: 4.6;SiHa: 4.2" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA037655, HPA073759" Uncertain Uncertain Vesicles NA NA Vesicles "HPA037655: AB_10672388, HPA073759: " "unprognostic (1.08e-1)" "unprognostic (2.12e-1)" "unprognostic (3.58e-2)" "unprognostic (2.11e-2)" "unprognostic (1.60e-2)" "unprognostic (5.67e-3)" "prognostic unfavorable (1.37e-5)" "unprognostic (9.14e-2)" "unprognostic (1.49e-2)" "unprognostic (2.95e-1)" "unprognostic (1.58e-1)" "unprognostic (5.40e-2)" "unprognostic (2.35e-4)" "unprognostic (8.02e-2)" "unprognostic (1.64e-1)" "unprognostic (1.33e-1)" "unprognostic (1.98e-1)" 0.2 0.1 0.2 3.4 0.2 0.0 0.2 0.2 0.2 0.2 38.8 0.2 0.2 28.0 0.3 0.2 0.4 0.2 0.3 0.4 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.5 0.0 0.2 0.2 0.2 0.2 17.5 0.2 0.5 0.2 0.2 1.0 85.1 0.3 0.2 0.2 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 4.3 0.7 2.7 1.7 0.0 0.0 0.6 1.1 0.1 0.0 3.7 0.0 0.0 2.2 0.2 0.0 0.0 0.0 3.2 4.6 0.7 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.7 0.0 0.4 0.4 0.0 0.0 0.0 0.0 0.5 0.1 0.6 0.0 0.6 4.2 0.3 0.0 1.1 0.4 0.1 0.0 0.0 0.0 0.9 0.1 1.3 0.8 1.3 0.0 0.0 0.1 0.0 1.7 0.0 0.0 0.5 0.0 4.3 0.0 0.0 0.7 2.3 0.0 0.0 2.7 0.0 0.0 0.7 0.0 0.6 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.0 0.0 1.5 0.0 0.5 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 37.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 169.6 0.0 0.8 0.0 0.0 0.0 0.0 0.0 61.9 0.0 0.3 99.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 41.2 0.0 HBA1 HBA-T3 ENSG00000206172 "Hemoglobin subunit alpha 1" P69905 16 176680-177522 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "bone marrow: 1020.7" "Cell type enriched" "Detected in many" 24 "Erythroid cells: 99681.0" "Cancer enhanced" "Detected in many" "glioma: 6.3" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 11.7;plasmacytoid DC: 7.4" "Group enriched" "Detected in many" 4 "dendritic cells: 7.4;granulocytes: 11.7" "Group enriched" "Detected in some" 37 "HEL: 248.9;K-562: 175.4" "CAB032534, HPA043780" Enhanced NA NA 17000000000 "CAB032534: AB_2294993, HPA043780: AB_2678667" "unprognostic (1.16e-1)" "unprognostic (1.45e-2)" "unprognostic (8.87e-2)" "unprognostic (9.78e-3)" "unprognostic (3.02e-1)" "unprognostic (1.44e-1)" "unprognostic (1.67e-1)" "unprognostic (1.35e-1)" "unprognostic (6.21e-3)" "unprognostic (1.92e-2)" "unprognostic (1.64e-1)" "unprognostic (1.02e-2)" "unprognostic (3.59e-2)" "unprognostic (3.79e-1)" "unprognostic (6.61e-2)" "unprognostic (2.67e-2)" "unprognostic (9.56e-2)" 12.6 8.8 7.1 5.0 6.6 1020.7 5.0 7.9 10.0 2.2 3.2 3.0 2.2 1.3 2.2 4.1 2.8 4.8 4.0 16.9 5.2 5.1 20.6 15.7 30.3 8.1 10.1 5.8 4.9 2.2 0.9 7.5 104.1 3.3 4.8 1.4 4.5 6.7 3.3 9.4 1.9 2.2 5.1 7.9 101.4 1.6 6.7 2.2 2.2 9.3 2.2 2.2 3.4 9.4 0.6 7.4 11.7 0.5 0.9 2.1 186.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.4 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 248.9 0.0 2.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 175.4 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.8 0.0 0.0 0.5 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 3.3 1.9 0.0 0.0 0.6 0.2 0.7 0.7 0.4 0.7 2.1 11.7 0.9 0.0 7.4 0.0 186.1 7.1 6.6 7.9 10.0 5.2 5.1 10.1 5.8 3.3 2.2 0.0 0.0 18.2 0.0 9.4 0.2 0.8 2.5 0.0 0.0 0.0 0.0 0.0 6.6 0.0 4.6 0.5 0.7 99681.0 0.0 0.0 0.0 0.1 0.0 30.9 0.0 0.0 1.2 17.2 53.0 11.2 0.0 0.0 4114.8 0.0 0.9 0.3 0.1 1.7 0.4 3.7 14.8 0.0 179.2 0.1 5.1 11.5 0.0 21.3 1.4 0.0 HBA2 HBA-T2 ENSG00000188536 "Hemoglobin subunit alpha 2" P69905 16 172876-173710 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 427.1;bone marrow: 1094.2" "Cell type enriched" "Detected in many" 20 "Erythroid cells: 168432.0" "Cancer enhanced" "Detected in all" "glioma: 59.7" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "eosinophil: 9.8;neutrophil: 33.6;plasmacytoid DC: 15.7" "Group enriched" "Detected in many" 8 "dendritic cells: 15.7;granulocytes: 33.6" "Group enriched" "Detected in some" 18 "HEL: 161.2;K-562: 43.2" "CAB038417, HPA043780" Enhanced NA NA 17000000000 "CAB038417: , HPA043780: AB_2678667" "unprognostic (1.57e-1)" "unprognostic (7.02e-2)" "unprognostic (2.59e-2)" "unprognostic (2.13e-1)" "unprognostic (3.59e-1)" "unprognostic (3.18e-1)" "unprognostic (3.39e-2)" "unprognostic (2.12e-1)" "unprognostic (4.99e-2)" "unprognostic (4.43e-1)" "unprognostic (1.09e-2)" "unprognostic (1.19e-2)" "unprognostic (1.72e-3)" "unprognostic (1.36e-1)" "unprognostic (2.11e-1)" "unprognostic (4.73e-2)" "unprognostic (8.92e-2)" 15.4 11.8 7.2 6.9 7.3 1094.2 7.6 4.1 4.1 4.1 4.1 4.1 4.1 1.1 4.1 4.1 4.1 7.7 5.8 19.5 5.8 6.2 24.3 17.7 38.4 4.1 11.2 4.1 4.1 4.1 0.5 8.9 128.7 4.1 4.1 1.3 4.1 9.2 5.6 17.7 0.9 4.1 4.1 9.3 98.3 1.9 4.1 4.1 4.1 12.5 4.1 4.1 4.1 20.1 1.4 15.7 33.6 0.9 1.5 3.0 427.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 161.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 43.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.7 0.0 0.1 1.6 1.3 0.1 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.9 9.8 3.0 0.0 0.1 1.4 0.3 0.2 1.4 0.8 0.8 2.6 33.6 1.5 0.0 15.7 0.0 427.1 7.2 7.3 4.1 4.1 5.8 6.2 11.2 4.1 4.1 4.1 3.0 1.0 72.9 0.1 39.4 1.2 4.0 12.7 4.0 1.2 0.0 0.0 0.0 46.4 0.0 2.6 9.0 1.0 168432.0 0.0 0.0 2.1 0.2 1.1 54.4 0.0 0.0 2.9 39.9 114.1 9.4 0.0 1.1 8337.5 0.0 1.3 1.3 0.0 3.7 0.0 12.3 41.0 0.0 364.9 0.2 6.6 39.0 0.0 20.8 0.7 0.0 HBB "beta-globin, CD113t-C" ENSG00000244734 "Hemoglobin subunit beta" P68871 11 5225464-5229395 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Hypotensive agent, Vasoactive" "Congenital dyserythropoietic anemia, Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 7 "bone marrow: 3646.7" "Cell type enriched" "Detected in many" 16 "Erythroid cells: 407904.6" "Cancer enhanced" "Detected in all" "glioma: 244.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 7 "neutrophil: 19.3;plasmacytoid DC: 9.9" "Group enriched" "Detected in many" 12 "dendritic cells: 9.9;granulocytes: 19.3" "Cell line enhanced" "Detected in some" "HEL: 5.5;SCLC-21H: 4.8;SH-SY5Y: 6.1;U-266/70: 22.3;U-266/84: 3.7" "CAB009526, HPA043234" Enhanced NA NA 15000000000 "CAB009526: AB_2143058, HPA043234: AB_2678378" "unprognostic (2.41e-1)" "unprognostic (8.55e-2)" "unprognostic (2.40e-1)" "unprognostic (4.40e-2)" "unprognostic (1.14e-1)" "unprognostic (3.22e-1)" "unprognostic (4.88e-2)" "unprognostic (7.46e-2)" "unprognostic (2.91e-2)" "unprognostic (1.76e-1)" "unprognostic (1.91e-1)" "unprognostic (8.11e-3)" "unprognostic (2.40e-2)" "unprognostic (5.81e-2)" "unprognostic (1.42e-1)" "unprognostic (8.87e-3)" "unprognostic (6.41e-2)" 32.7 20.0 20.9 10.1 21.0 3646.7 43.4 6.5 10.7 9.2 11.3 7.2 3.4 3.2 7.3 11.1 36.6 28.4 30.4 38.9 17.9 17.4 45.0 37.6 305.8 7.0 31.6 10.8 82.6 28.4 2.9 18.6 236.8 23.7 23.1 7.5 32.0 17.4 12.8 29.5 3.8 3.9 12.0 26.5 216.8 4.0 9.3 3.8 5.6 46.4 20.2 7.6 124.5 256.7 0.6 9.9 19.3 0.6 1.2 1.1 523.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 2.1 0.0 0.0 0.0 0.8 0.2 0.4 0.0 0.0 0.4 0.3 0.0 0.0 4.8 6.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 22.3 3.7 0.0 0.0 0.0 0.0 2.2 0.6 1.9 0.9 0.0 0.1 0.6 0.2 0.0 0.9 0.4 0.4 1.1 19.3 1.2 0.1 9.9 0.0 523.2 20.9 21.0 6.5 10.7 17.9 17.4 31.6 10.8 23.7 3.8 3.0 5.9 120.0 0.0 139.4 3.4 2.0 28.1 49.5 2.3 7.0 3.9 1.1 43.1 0.0 0.0 20.2 1.0 407904.6 0.0 2.3 16.4 0.0 0.0 226.1 6.6 3.2 3.5 92.1 289.2 0.0 0.0 2.3 25972.5 0.0 3.8 6.2 0.1 2.9 0.0 79.6 86.7 0.0 737.5 0.0 0.0 220.7 1.8 46.8 0.6 0.0 HMGCR ENSG00000113161 "3-hydroxy-3-methylglutaryl-CoA reductase" P04035 5 75336329-75362104 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cholesterol biosynthesis, Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Suprabasal keratinocytes: 80.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008338, CAB016797" Approved NA NA "CAB016797: , HPA008338: AB_10960401" "unprognostic (5.07e-2)" "unprognostic (1.65e-2)" "unprognostic (3.65e-3)" "unprognostic (1.02e-2)" "unprognostic (1.65e-3)" "unprognostic (1.02e-1)" "unprognostic (1.45e-1)" "unprognostic (4.41e-2)" "unprognostic (5.45e-2)" "unprognostic (1.90e-2)" "unprognostic (1.41e-1)" "unprognostic (3.99e-2)" "prognostic favorable (9.42e-6)" "unprognostic (2.44e-1)" "unprognostic (2.55e-2)" "unprognostic (3.64e-3)" "unprognostic (4.37e-2)" 5.6 28.9 12.4 8.7 31.1 12.1 16.4 14.4 36.3 13.9 23.0 10.9 7.1 18.9 9.0 14.4 35.0 6.5 8.2 4.0 21.8 16.5 12.1 53.5 12.1 7.0 9.8 19.4 15.2 8.4 16.2 11.4 9.2 29.6 12.4 19.7 7.8 12.4 4.5 3.4 36.1 19.0 6.8 17.0 7.9 14.6 14.0 8.8 13.9 12.5 23.2 12.4 6.2 18.1 4.3 12.5 23.2 11.0 9.5 6.5 5.1 15.3 6.0 61.4 21.1 13.0 25.2 15.4 4.4 12.4 9.0 20.1 22.6 37.8 13.7 16.1 7.1 58.9 19.4 31.9 51.8 9.6 4.6 11.7 10.5 9.1 17.5 19.2 8.7 7.7 16.3 30.5 31.5 15.6 4.5 7.2 19.7 11.2 21.0 14.2 10.0 16.0 8.8 26.2 3.9 4.5 11.3 18.4 19.6 37.1 35.8 21.3 9.7 9.7 10.1 8.8 22.1 10.0 22.9 8.4 4.9 7.3 5.2 7.5 6.7 8.5 18.9 7.1 17.1 10.1 6.7 11.0 6.3 6.1 6.9 5.1 4.3 4.6 6.4 12.5 4.2 4.5 6.2 23.2 9.5 7.4 3.9 6.5 5.1 12.4 31.1 14.4 36.3 21.8 16.5 9.8 19.4 29.6 8.8 17.9 33.4 7.5 8.5 36.9 20.9 5.7 12.7 32.1 22.7 26.2 17.7 16.3 3.3 12.1 38.1 7.6 33.8 0.0 18.8 21.6 10.5 13.9 24.2 22.5 11.5 38.1 41.2 9.8 19.3 19.5 8.6 12.3 15.1 2.8 50.6 10.3 11.9 20.1 5.6 6.3 13.1 12.9 8.2 21.0 14.0 80.0 39.0 8.7 20.2 17.3 HTR1B "5-HT1B, 5-HT1DB, HTR1D2, S12" ENSG00000135312 "5-hydroxytryptamine receptor 1B" P28222 6 77461753-77463773 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 11.8;placenta: 14.2;stomach 1: 10.2" "Not detected" "Not detected" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in many" "basal ganglia: 11.8" "Cell type enriched" "Detected in single" 17 "basophil: 1.6" "Lineage enriched" "Detected in single" 17 "granulocytes: 1.6" "Group enriched" "Detected in some" 15 "HUVEC TERT2: 41.8;TIME: 18.4" "Region enriched" "Detected in many" 4 "basal ganglia: 34.5" HPA028808 Enhanced Supported "Plasma membrane" NA NA "Plasma membrane" "HPA028808: AB_2672782" "unprognostic (3.86e-2)" "unprognostic (3.56e-1)" "unprognostic (7.68e-2)" "unprognostic (2.58e-1)" "unprognostic (1.88e-1)" "unprognostic (1.18e-2)" "unprognostic (2.67e-1)" "unprognostic (2.11e-1)" "unprognostic (8.96e-2)" "unprognostic (4.03e-1)" "unprognostic (1.77e-2)" "unprognostic (1.24e-1)" "unprognostic (1.10e-3)" "unprognostic (3.08e-2)" "unprognostic (2.81e-2)" "unprognostic (1.34e-1)" "unprognostic (1.02e-1)" 2.2 1.5 1.3 1.1 11.8 0.3 2.4 0.4 3.7 2.9 0.6 0.1 0.0 0.6 1.1 1.0 1.4 0.8 2.8 0.4 1.0 2.1 0.9 0.3 1.1 0.3 1.2 0.9 1.1 0.5 0.3 0.5 14.2 3.0 1.6 0.4 0.3 1.3 1.2 0.9 0.5 0.4 4.1 0.6 0.4 10.2 1.5 0.6 0.0 0.5 0.0 0.3 2.6 1.4 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 1.9 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.1 0.4 1.1 0.8 41.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 11.8 0.4 3.7 1.0 2.1 1.2 0.9 3.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HTR2B "5-HT(2B), 5-HT2B" ENSG00000135914 "5-hydroxytryptamine receptor 2B" P41595 2 231108230-231125118 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 26.0" "Cell type enhanced" "Detected in some" 14 "Cone photoreceptor cells: 3.9;Ito cells: 5.5;monocytes: 10.8;Peritubular cells: 4.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 12 "basophil: 3.8;T-reg: 2.9" "Group enriched" "Detected in many" 29 "granulocytes: 3.8;T-cells: 2.9" "Group enriched" "Detected in some" 4 "HHSteC: 7.0;HSkMC: 13.3;SK-MEL-30: 24.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA012867, HPA063658" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "HPA012867: AB_1856710, HPA063658: AB_2685079" "unprognostic (1.86e-1)" "unprognostic (3.55e-2)" "unprognostic (1.20e-3)" "unprognostic (1.45e-2)" "unprognostic (1.12e-1)" "unprognostic (1.16e-1)" "unprognostic (1.53e-2)" "unprognostic (1.00e-1)" "unprognostic (1.33e-2)" "unprognostic (1.15e-4)" "unprognostic (3.59e-1)" "unprognostic (2.17e-2)" "unprognostic (1.42e-3)" "unprognostic (7.44e-4)" "unprognostic (1.81e-1)" "unprognostic (1.17e-1)" "unprognostic (1.14e-2)" 2.3 17.9 0.2 5.8 0.3 0.7 4.1 0.3 0.6 17.8 7.3 0.2 1.7 1.0 14.9 9.5 5.7 1.9 0.8 4.6 0.3 0.3 5.6 2.5 1.8 0.5 0.3 0.4 4.3 0.3 0.3 0.4 26.0 0.9 2.6 1.5 1.8 0.5 1.0 0.2 0.2 6.3 12.8 0.3 0.4 5.2 3.3 0.3 2.4 6.8 1.0 0.4 4.9 0.8 0.0 0.1 3.8 0.0 0.0 2.9 0.0 0.1 0.2 0.0 0.1 0.4 3.6 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 7.0 0.1 0.3 13.3 0.0 0.0 0.0 0.0 2.5 1.1 0.1 0.0 0.0 0.1 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.1 0.0 0.1 24.4 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.8 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 2.9 0.0 0.2 0.3 0.3 0.6 0.3 0.3 0.3 0.4 0.9 0.3 0.0 0.0 0.0 0.0 0.1 0.5 0.3 0.0 2.7 0.0 0.0 3.9 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.6 0.1 0.3 0.0 0.0 0.9 2.6 1.6 0.0 5.5 1.2 0.0 0.6 0.0 0.0 10.8 0.0 0.0 0.1 0.0 4.9 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 HTR3A "5-HT3A, 5-HT3R, HTR3" ENSG00000166736 "5-hydroxytryptamine receptor 3A" P46098 11 113974881-113990313 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 11.1;lymphoid tissue: 12.0;salivary gland: 8.6" "Group enriched" "Detected in some" 11 "Ductal cells: 14.6;Exocrine glandular cells: 44.3;Pancreatic endocrine cells: 54.7" "Cancer enriched" "Detected in many" 7 "ovarian cancer: 15.2" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 13 "memory B-cell: 4.1;naive B-cell: 9.7;plasmacytoid DC: 11.1" "Group enriched" "Detected in many" 104 "B-cells: 9.7;dendritic cells: 11.1" "Cell line enhanced" "Detected in some" "CAPAN-2: 6.3;Daudi: 6.0;NTERA-2: 3.8;SCLC-21H: 20.0" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 15 "amygdala: 3.3;cerebral cortex: 4.0;hippocampal formation: 4.2" HPA069442 Supported NA NA "HPA069442: AB_2732132" "unprognostic (6.46e-3)" "prognostic favorable (6.26e-4)" "unprognostic (1.09e-1)" "prognostic unfavorable (1.26e-4)" "unprognostic (3.36e-3)" "unprognostic (8.36e-3)" "unprognostic (1.65e-5)" "unprognostic (1.46e-2)" "unprognostic (8.87e-2)" "unprognostic (6.21e-2)" "unprognostic (6.80e-3)" "unprognostic (3.00e-2)" "unprognostic (1.65e-2)" "unprognostic (8.72e-2)" "unprognostic (2.01e-1)" "unprognostic (3.79e-1)" "unprognostic (3.40e-2)" 0.3 0.5 2.2 4.4 3.9 0.0 0.3 0.3 0.9 0.3 2.5 0.3 0.3 1.0 0.3 0.3 0.8 0.0 0.3 0.3 2.1 0.0 0.3 0.3 0.3 9.7 0.3 0.3 0.3 3.7 0.0 0.3 0.3 0.3 0.3 0.6 0.3 8.6 0.3 0.3 0.6 2.0 1.0 0.3 3.0 0.9 0.3 0.3 0.7 0.3 0.3 12.0 0.3 0.3 9.7 11.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 6.0 0.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.7 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.6 9.7 0.0 0.0 0.0 0.0 0.0 11.1 0.0 0.2 2.2 3.9 0.3 0.9 2.1 0.0 0.3 0.3 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 14.6 0.0 0.0 0.0 0.0 44.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 54.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HTR3D ENSG00000186090 "5-hydroxytryptamine receptor 3D" Q70Z44 3 184031544-184039369 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "RPTEC TERT1: 1.8" "Low region specificity" "Detected in many" NA NA "unprognostic (3.08e-1)" 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.8 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 IFNAR1 "IFNAR, IFRC" ENSG00000142166 "Interferon alpha and beta receptor subunit 1" P17181 21 33324477-33359862 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Karpas-707: 50.8" "Low region specificity" "Detected in all" HPA029226 Approved NA NA 100000 "HPA029226: AB_2672954" "unprognostic (2.42e-3)" "unprognostic (2.95e-1)" "unprognostic (3.01e-1)" "unprognostic (1.15e-1)" "unprognostic (4.93e-2)" "unprognostic (2.22e-1)" "unprognostic (1.01e-1)" "unprognostic (3.02e-1)" "unprognostic (4.69e-2)" "unprognostic (1.28e-1)" "unprognostic (2.31e-2)" "unprognostic (2.38e-1)" "unprognostic (9.38e-3)" "unprognostic (5.93e-2)" "unprognostic (2.01e-1)" "unprognostic (8.45e-2)" "unprognostic (3.06e-2)" 27.2 16.4 18.5 16.8 18.7 14.8 15.9 18.1 22.9 14.2 16.8 15.1 10.0 12.3 15.7 10.9 15.8 13.5 16.2 14.5 16.9 15.8 17.5 56.4 16.6 15.0 19.7 13.8 16.6 18.3 30.6 17.9 23.2 18.3 14.7 12.2 12.1 17.6 12.6 17.3 10.6 15.8 13.7 22.2 29.8 18.8 10.3 16.7 26.9 21.4 9.1 13.1 18.7 18.1 20.5 17.8 64.5 23.1 7.3 12.1 10.7 13.3 12.2 5.2 5.9 17.2 17.5 6.0 14.4 15.5 6.7 6.8 13.1 15.3 10.3 11.7 9.9 8.4 8.0 4.9 8.5 7.1 11.7 9.8 15.4 11.8 7.7 7.3 11.3 11.0 14.5 7.5 11.0 6.6 8.8 12.7 11.8 17.6 50.8 10.9 11.1 8.4 4.6 5.6 8.9 7.8 8.3 18.3 17.6 7.3 17.6 6.2 5.6 14.5 10.3 9.2 3.6 15.9 8.3 20.2 13.4 7.3 17.6 8.0 33.9 46.6 11.9 18.0 16.0 14.3 18.9 16.8 9.7 8.0 19.7 7.5 18.5 10.6 9.0 11.3 20.5 12.1 9.4 64.5 7.3 23.1 17.8 12.0 10.7 18.5 18.7 18.1 22.9 16.9 15.8 19.7 13.8 18.3 16.7 101.3 37.9 45.4 49.1 40.6 49.3 32.2 25.5 61.6 71.7 41.8 27.5 23.5 18.3 64.6 10.8 66.9 25.8 23.3 78.0 78.5 32.8 57.7 37.1 71.7 60.0 55.6 25.8 50.3 69.5 7.7 30.2 70.9 35.4 83.0 28.9 32.2 57.6 24.6 29.0 21.4 25.6 19.4 33.4 26.3 12.1 39.3 16.8 29.3 26.0 69.1 IL1B "IL-1B, IL1-BETA, IL1F2" ENSG00000125538 "Interleukin 1 beta" P01584 2 112829751-112836903 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters" "Inflammatory response" "Cytokine, Mitogen, Pyrogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 62.3;lymphoid tissue: 35.4" "Cell type enriched" "Detected in many" 7 "Macrophages: 764.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in many" 5 "neutrophil: 34.4" "Lineage enriched" "Detected in many" 5 "granulocytes: 34.4" "Cell line enhanced" "Detected in some" "BJ hTERT+: 93.2;HBEC3-KT: 42.4;HMC-1: 34.6;hTEC/SVTERT24-B: 46.6;hTERT-RPE1: 40.3;U-87 MG: 85.2" "Low region specificity" "Detected in some" "Secreted to blood" NA NA 2330 "unprognostic (1.55e-3)" "prognostic unfavorable (1.31e-4)" "unprognostic (2.75e-2)" "unprognostic (5.71e-2)" "unprognostic (1.34e-1)" "unprognostic (7.12e-2)" "unprognostic (2.63e-2)" "unprognostic (1.61e-2)" "unprognostic (1.07e-1)" "unprognostic (3.63e-3)" "unprognostic (3.72e-2)" "unprognostic (5.57e-2)" "prognostic unfavorable (7.49e-5)" "unprognostic (1.29e-2)" "unprognostic (4.42e-2)" "unprognostic (5.09e-2)" "unprognostic (4.01e-2)" 19.6 3.3 4.2 20.4 15.3 62.3 0.8 1.1 10.8 1.6 3.2 12.7 0.2 1.2 3.0 1.5 3.5 3.4 7.5 3.7 19.0 3.6 1.7 4.0 17.3 5.0 5.9 0.3 3.4 2.4 2.4 3.0 10.3 24.9 2.6 2.6 1.0 2.2 0.8 0.4 0.9 3.7 3.5 29.7 35.4 20.9 1.6 5.8 0.8 1.1 13.5 14.0 10.4 1.2 0.0 6.9 34.4 7.0 0.0 0.0 1.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 93.2 0.4 1.0 0.0 0.0 0.0 2.6 0.0 1.6 2.1 0.0 42.4 5.8 0.0 0.0 4.1 0.0 0.0 0.3 0.0 34.6 0.1 1.3 46.6 15.7 40.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.1 3.5 0.1 0.0 0.0 0.0 5.6 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.4 0.0 2.2 0.0 0.1 0.0 0.0 0.0 0.0 85.2 1.9 3.2 0.5 4.2 1.5 0.0 7.0 0.0 0.0 0.0 0.0 6.9 0.0 0.0 0.0 34.4 0.0 2.7 0.0 0.0 1.0 4.2 15.3 1.1 10.8 19.0 3.6 5.9 0.3 24.9 5.8 8.9 45.3 1.4 4.6 27.4 0.0 4.3 0.0 13.4 7.9 1.8 0.0 1.2 0.0 12.2 0.1 2.2 0.3 0.0 0.5 2.1 9.9 2.3 39.4 0.0 109.6 0.0 0.0 1.3 54.0 0.0 0.0 764.6 21.9 0.0 2.2 0.0 3.6 6.2 0.0 0.5 0.2 0.0 4.3 0.0 0.2 17.8 3.7 2.2 0.0 4.6 IL1R1 "CD121A, D2S1473, IL1R, IL1RA" ENSG00000115594 "Interleukin 1 receptor type 1" P14778 2 102064544-102179874 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Inflammatory response" "Hydrolase, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Club cells: 93.3;Ito cells: 139.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 4.0" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 95.6;ASC TERT1: 42.7;HHSteC: 30.0;HSkMC: 117.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001237, HPA005823, CAB007779, HPA029560" Approved Approved "Nucleoplasm,Vesicles,Plasma membrane,Cytosol" "Secreted to blood" NA NA 1000000 "Nucleoplasm, Vesicles" "Plasma membrane, Cytosol" "CAB007779: AB_562073, HPA001237: , HPA005823: AB_2667445, HPA029560: AB_2673094" "unprognostic (6.16e-3)" "unprognostic (3.55e-2)" "unprognostic (3.33e-1)" "unprognostic (1.22e-1)" "unprognostic (4.26e-2)" "unprognostic (7.10e-2)" "unprognostic (2.01e-1)" "unprognostic (3.36e-2)" "unprognostic (1.44e-1)" "unprognostic (3.16e-1)" "unprognostic (4.26e-2)" "unprognostic (7.77e-2)" "prognostic unfavorable (6.92e-6)" "unprognostic (2.48e-2)" "unprognostic (6.95e-2)" "unprognostic (4.83e-2)" "unprognostic (7.73e-2)" 48.6 25.2 2.6 18.2 5.2 4.0 92.4 2.4 3.9 47.8 21.0 2.5 34.3 5.2 15.2 30.2 18.2 17.1 25.8 27.0 4.2 2.5 23.7 74.8 40.5 28.0 5.6 1.1 25.1 17.1 16.9 7.3 66.2 10.9 26.0 8.4 8.6 12.7 36.4 15.5 13.5 13.0 15.1 10.0 19.2 15.6 13.4 2.8 3.5 33.6 9.0 9.6 32.0 36.4 0.1 0.1 4.0 0.5 0.8 1.8 0.2 0.2 1.8 0.0 1.5 95.6 42.7 0.6 4.0 18.2 2.8 4.3 0.8 0.5 0.0 2.9 8.0 5.0 0.8 0.0 0.3 2.4 7.9 0.0 0.1 0.4 4.4 30.0 0.0 0.0 117.7 0.3 3.2 0.7 1.2 1.2 0.0 0.5 0.1 4.1 0.8 0.0 0.1 0.1 0.8 0.1 0.0 0.3 0.0 2.7 1.9 0.0 0.0 1.8 1.1 0.0 0.5 1.6 0.1 0.0 8.2 0.5 13.7 0.3 0.0 0.0 0.0 3.2 0.0 0.5 0.6 0.5 0.1 0.0 0.0 0.7 0.1 1.1 0.0 0.1 0.1 0.0 0.1 4.0 0.8 0.0 0.1 1.8 0.2 2.6 5.2 2.4 3.9 4.2 2.5 5.6 1.1 10.9 2.8 23.8 55.6 3.7 27.6 27.6 0.0 3.9 28.1 40.2 93.3 5.2 0.0 5.3 3.3 21.6 6.4 58.3 0.0 0.0 18.7 76.6 77.2 84.5 1.1 43.2 5.1 0.0 1.2 139.3 12.4 9.4 25.9 21.6 18.6 9.0 0.7 7.3 15.4 0.0 1.4 6.2 1.0 6.5 23.1 0.7 0.9 33.8 20.0 2.6 0.9 19.6 IL2RB "CD122, IL15RB" ENSG00000100385 "Interleukin 2 receptor subunit beta" P14784 22 37125838-37175054 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Host-virus interaction" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 51.6;lymphoid tissue: 35.0;placenta: 58.5" "Group enriched" "Detected in many" 8 "Extravillous trophoblasts: 80.1;T-cells: 97.0" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "gdT-cell: 14.7;NK-cell: 51.6" "Group enriched" "Detected in many" 32 "NK-cells: 51.6;T-cells: 14.7" "Cell line enriched" "Detected in some" 8 "HDLM-2: 106.6" "Region enriched" "Detected in single" 7 "basal ganglia: 1.6" "Low region specificity" "Detected in single" HPA062657 Enhanced NA NA "HPA062657: AB_2684822" "unprognostic (3.38e-3)" "unprognostic (1.21e-2)" "prognostic favorable (6.76e-4)" "prognostic favorable (3.18e-5)" "unprognostic (2.44e-2)" "unprognostic (9.69e-3)" "unprognostic (2.60e-1)" "unprognostic (5.22e-2)" "unprognostic (1.03e-3)" "unprognostic (5.37e-2)" "unprognostic (1.09e-1)" "unprognostic (2.74e-1)" "prognostic unfavorable (3.50e-7)" "unprognostic (4.63e-2)" "unprognostic (7.96e-2)" "unprognostic (3.94e-3)" "unprognostic (2.46e-2)" 2.2 1.0 0.8 20.5 0.8 12.3 1.6 0.6 0.7 1.3 5.5 0.6 1.4 1.8 4.3 2.8 2.6 1.8 5.8 3.7 0.7 0.8 1.9 6.0 7.4 20.8 0.8 0.2 1.5 1.0 0.0 1.1 58.5 0.7 3.5 1.8 2.9 3.7 2.1 0.9 4.0 7.3 0.6 1.1 35.0 2.3 1.1 0.2 21.0 2.1 1.8 28.7 4.0 1.5 0.3 0.0 1.0 0.1 51.6 14.7 7.9 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 0.0 0.0 0.0 106.6 0.1 0.2 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.8 0.7 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.2 0.0 0.0 2.8 0.0 0.1 7.7 13.2 0.0 0.1 0.0 0.1 1.0 0.0 0.1 14.7 0.1 8.1 0.1 3.3 8.2 0.0 0.3 1.1 4.3 0.3 51.6 0.1 0.0 6.8 7.9 0.8 0.8 0.6 0.7 0.7 0.8 0.8 0.2 0.7 0.2 3.0 11.6 1.5 0.8 2.9 0.0 1.1 0.0 1.4 1.2 1.8 0.0 0.4 0.0 0.0 1.7 0.0 0.0 0.0 0.2 80.1 1.1 0.1 9.3 1.0 2.1 0.0 0.0 8.6 1.6 0.9 0.3 0.5 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.4 1.0 97.0 0.0 0.0 ITGAV "CD51, MSK8, VNRA, VTNR" ENSG00000138448 "Integrin subunit alpha V" P06756 2 186590065-186680901 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 7.7" "Group enriched" "Detected in many" 4 "granulocytes: 7.7;monocytes: 2.3" "Cell line enhanced" "Detected in many" "RT4: 71.7;SuSa: 62.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002499, HPA004856" Supported Approved "Focal adhesion sites,Cytosol" NA NA 750000 "Focal adhesion sites, Cytosol" "CAB002499: AB_563594, HPA004856: AB_1846316" "unprognostic (4.03e-2)" "unprognostic (5.17e-3)" "unprognostic (1.22e-2)" "unprognostic (5.22e-2)" "unprognostic (1.33e-1)" "unprognostic (1.18e-1)" "prognostic unfavorable (2.08e-4)" "unprognostic (1.48e-2)" "unprognostic (6.95e-2)" "unprognostic (2.89e-1)" "prognostic unfavorable (5.07e-4)" "unprognostic (5.84e-2)" "unprognostic (2.67e-2)" "prognostic unfavorable (1.05e-6)" "unprognostic (2.61e-1)" "unprognostic (9.11e-2)" "unprognostic (8.07e-2)" 23.2 22.1 17.9 18.3 21.8 3.1 25.8 16.7 23.1 22.9 13.6 23.4 11.6 8.4 26.0 11.4 14.2 14.5 25.2 40.7 16.8 12.3 51.5 9.5 20.6 7.6 24.2 11.6 35.4 18.7 65.0 11.0 29.6 22.1 16.5 11.9 83.4 17.9 15.9 13.1 21.5 10.1 29.6 33.0 12.1 17.3 11.2 17.0 7.8 33.1 10.9 11.1 17.6 17.9 0.3 0.9 7.7 2.3 0.4 1.1 0.5 9.3 11.1 7.4 23.7 27.3 18.5 28.3 18.3 14.8 6.5 6.5 9.7 32.2 0.0 36.1 20.6 22.7 11.7 3.8 17.2 9.4 1.8 3.4 2.2 14.6 13.3 10.8 1.5 1.4 13.4 8.2 14.4 12.3 39.0 15.4 1.1 2.1 4.7 17.2 3.7 0.9 1.3 5.6 5.6 5.6 0.0 15.2 1.2 16.8 71.7 1.5 4.6 21.1 6.5 7.7 62.1 5.1 4.3 46.8 40.2 12.6 8.2 15.4 1.1 1.9 1.0 16.2 0.6 19.8 7.7 1.1 1.6 1.0 2.3 0.7 0.3 0.5 0.8 0.9 0.1 0.5 0.5 0.5 0.4 1.2 0.4 1.1 0.5 17.9 21.8 16.7 17.3 16.8 12.3 24.2 11.6 22.1 17.0 26.8 18.5 2.4 54.8 114.0 118.2 124.7 73.9 12.0 20.5 73.3 72.6 46.9 1.7 78.4 0.5 50.4 13.2 0.0 89.0 21.8 61.3 83.9 49.5 15.8 26.1 14.3 7.0 34.4 33.9 1.6 17.8 18.2 43.9 20.8 18.9 82.5 120.4 18.2 24.4 16.5 54.8 32.3 47.2 0.7 1.4 90.7 33.2 6.9 11.4 48.6 ITGB1 "CD29, FNRB, GPIIA, MDF2, MSK12" ENSG00000150093 "Integrin subunit beta 1" P05556 10 32900319-33005792 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Ductal cells: 1163.1;Pancreatic endocrine cells: 917.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "hTERT-RPE1: 196.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003434, HPA059297, HPA069003" Enhanced Supported "Endoplasmic reticulum,Plasma membrane,Focal adhesion sites" NA NA 540000000 "Plasma membrane, Focal adhesion sites" "Endoplasmic reticulum" "CAB003434: AB_303570, HPA059297: AB_2732634, HPA069003: AB_2732125" "unprognostic (3.07e-2)" "prognostic unfavorable (5.01e-4)" "unprognostic (8.67e-2)" "unprognostic (4.36e-1)" "unprognostic (1.20e-2)" "unprognostic (3.87e-2)" "unprognostic (1.60e-2)" "prognostic unfavorable (3.36e-6)" "unprognostic (3.22e-1)" "unprognostic (2.36e-3)" "unprognostic (3.68e-3)" "unprognostic (2.42e-1)" "unprognostic (1.02e-3)" "unprognostic (1.25e-2)" "unprognostic (2.23e-1)" "unprognostic (2.48e-1)" "unprognostic (3.08e-2)" 95.2 30.6 13.7 32.1 19.7 9.7 107.7 6.5 14.8 55.1 61.3 17.0 80.2 20.2 84.2 56.2 59.9 45.0 49.8 68.7 15.0 14.4 47.3 85.8 55.4 34.5 23.0 11.1 47.4 37.4 17.6 35.2 83.3 19.5 53.1 32.2 18.6 30.3 76.2 58.0 19.5 42.3 109.3 30.1 59.8 45.4 26.9 18.8 12.7 36.8 27.6 19.4 92.7 47.4 31.3 9.1 4.3 27.1 21.9 68.4 26.2 45.6 67.0 36.2 40.1 87.3 75.2 31.6 153.5 89.0 73.1 66.9 15.0 106.9 12.3 27.8 128.7 48.0 31.9 10.9 87.3 81.6 12.1 8.8 14.8 31.9 17.5 61.5 3.3 14.7 76.2 47.8 76.9 31.3 196.1 89.8 6.1 10.2 5.4 120.5 7.5 5.7 3.3 8.0 13.9 34.0 3.7 26.8 2.2 104.2 13.2 8.6 21.4 47.8 8.1 34.4 61.5 10.9 11.9 100.4 94.2 54.7 66.9 51.1 5.0 1.1 6.9 69.4 14.1 36.9 1.6 9.8 4.3 25.5 17.8 6.0 31.3 54.6 37.5 9.1 8.6 7.1 19.1 2.3 21.9 27.1 3.7 68.4 26.2 13.7 19.7 6.5 14.8 15.0 14.4 23.0 11.1 19.5 18.8 318.6 128.6 76.4 295.7 485.6 32.6 175.3 242.0 164.6 252.5 214.6 29.5 156.7 11.6 1163.1 4.3 314.7 83.6 70.0 355.7 460.3 265.1 177.2 86.6 221.3 161.3 36.5 185.6 387.9 152.7 9.7 235.6 174.3 325.6 83.0 81.4 76.8 917.0 113.2 565.7 64.3 45.2 627.3 497.4 10.0 63.7 149.1 183.8 106.6 98.8 257.2 KCNA2 "HK4, Kv1.2" ENSG00000177301 "Potassium voltage-gated channel subfamily A member 2" P16389 1 110519837-110631474 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 28.0" "Cell type enriched" "Detected in some" 5 "Muller glia cells: 24.2" "Cancer enhanced" "Detected in some" "glioma: 1.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 4.1" "Lineage enriched" "Detected in single" 8 "T-cells: 4.1" "Cell line enhanced" "Detected in some" "Karpas-707: 10.9;SCLC-21H: 2.8;U-2 OS: 2.4;U-266/70: 3.6;U-266/84: 5.4;WM-115: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB001976 Enhanced NA NA "CAB001976: " "unprognostic (1.84e-2)" "unprognostic (9.70e-3)" "unprognostic (1.97e-1)" "unprognostic (2.98e-1)" "unprognostic (7.17e-3)" "unprognostic (6.68e-3)" "unprognostic (5.05e-3)" "unprognostic (2.02e-1)" "unprognostic (1.29e-1)" "unprognostic (4.50e-3)" "unprognostic (3.08e-3)" "unprognostic (2.93e-4)" "unprognostic (2.15e-1)" "unprognostic (3.55e-1)" "unprognostic (6.41e-2)" "unprognostic (2.83e-1)" 3.2 1.4 7.1 2.2 13.1 0.8 1.2 17.2 28.0 1.2 1.6 3.1 0.0 1.4 1.0 1.3 1.7 1.1 1.6 1.6 7.2 6.1 0.9 0.9 1.0 1.9 7.2 14.5 1.1 1.9 0.8 1.4 0.7 21.1 1.8 2.0 1.4 1.8 2.4 2.1 1.6 1.6 1.6 2.8 1.3 1.3 2.5 3.8 0.3 5.3 0.0 3.5 1.4 0.5 0.5 0.0 0.0 0.0 0.0 4.1 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 10.9 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.5 0.0 1.4 0.0 0.0 2.8 0.0 0.0 0.0 1.2 0.6 0.0 0.0 0.0 0.1 2.4 0.0 0.0 3.6 5.4 0.2 0.1 0.0 2.9 0.0 0.0 0.0 0.4 0.0 0.3 0.5 1.8 1.3 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.0 4.1 0.1 7.1 13.1 17.2 26.3 7.2 6.1 7.2 14.5 21.1 3.8 0.0 0.0 0.0 0.0 0.0 3.7 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 24.2 0.0 0.0 4.9 0.0 2.9 0.0 0.5 0.0 1.4 0.0 0.0 0.0 0.0 0.0 KCNA3 "HLK3, HPCN3, Kv1.3, MK3" ENSG00000177272 "Potassium voltage-gated channel subfamily A member 3" P22001 1 110672465-110675033 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 59.4" "Cell type enhanced" "Detected in some" 12 "Alveolar cells type 2: 3.4;Melanocytes: 3.3;Sertoli cells: 6.5;T-cells: 8.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 7 "B-cells: 3.3;T-cells: 11.5" "Cell line enhanced" "Detected in some" "HDLM-2: 12.7;Karpas-707: 26.1;U-266/70: 18.9;U-266/84: 16.9" "Low region specificity" "Detected in all" HPA016625 Approved NA NA "HPA016625: AB_2669407" "unprognostic (2.17e-2)" "unprognostic (5.07e-3)" "unprognostic (3.92e-3)" "unprognostic (1.20e-2)" "unprognostic (2.35e-1)" "unprognostic (1.76e-5)" "unprognostic (1.70e-4)" "unprognostic (8.48e-2)" "unprognostic (1.49e-2)" "unprognostic (5.92e-4)" "unprognostic (1.81e-2)" "unprognostic (3.96e-2)" "unprognostic (1.39e-1)" "unprognostic (3.13e-2)" "unprognostic (2.99e-2)" "unprognostic (1.73e-1)" "unprognostic (1.40e-1)" 1.9 1.3 4.0 7.8 5.7 5.6 1.3 5.0 5.6 1.7 3.1 0.5 0.0 3.2 1.1 0.4 1.1 1.3 2.3 1.4 3.5 4.3 1.5 1.3 7.8 14.5 1.5 3.1 1.3 0.9 0.4 1.8 0.9 3.1 1.1 2.6 0.5 3.7 0.3 0.5 0.8 5.9 0.7 1.9 7.7 5.3 1.4 1.5 59.4 2.1 0.3 10.9 5.8 1.3 3.3 1.0 0.0 0.7 0.9 11.5 2.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.7 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 26.1 0.0 0.0 5.4 0.0 0.5 0.0 0.0 0.0 0.0 5.2 0.0 0.0 3.6 0.3 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.4 0.0 0.0 18.9 16.9 6.5 0.0 1.5 0.0 0.0 0.7 0.0 7.2 0.0 8.2 2.3 10.8 11.5 1.0 3.3 8.5 6.4 0.0 0.9 0.1 0.5 9.5 2.9 4.0 5.7 5.0 5.6 3.5 4.3 1.5 3.1 3.1 1.5 0.0 3.4 2.2 0.0 0.3 1.3 0.4 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 2.5 0.6 0.0 0.0 1.6 3.3 2.8 0.0 0.2 0.0 0.0 0.0 0.0 0.1 6.5 0.0 0.9 0.2 0.5 0.0 8.7 0.0 0.0 KCNA5 "HK2, HPCN1, Kv1.5" ENSG00000130037 "Potassium voltage-gated channel subfamily A member 5" P22460 12 5043989-5046788 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Atrial fibrillation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 33.0" "Cell type enriched" "Detected in some" 8 "Bipolar cells: 153.4" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 134 "plasmacytoid DC: 13.3" "Lineage enriched" "Detected in single" 134 "dendritic cells: 13.3" "Cell line enriched" "Detected in single" 12 "NTERA-2: 10.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA021516, CAB022562" Approved NA NA "CAB022562: , HPA021516: AB_2670732" "unprognostic (3.87e-1)" "unprognostic (9.91e-3)" "unprognostic (1.94e-1)" "unprognostic (3.23e-1)" "unprognostic (2.64e-1)" "unprognostic (7.06e-3)" "unprognostic (1.20e-1)" "unprognostic (4.61e-3)" "unprognostic (1.34e-1)" "unprognostic (2.14e-1)" "unprognostic (2.37e-2)" "unprognostic (5.08e-3)" "unprognostic (6.73e-4)" "unprognostic (1.92e-3)" "unprognostic (1.90e-1)" "unprognostic (2.86e-2)" "unprognostic (3.08e-2)" 3.4 1.4 1.9 0.9 8.6 0.7 1.2 0.4 2.3 1.6 3.3 7.2 0.0 1.1 1.7 2.6 7.6 2.1 2.3 33.0 3.5 5.8 1.9 0.8 2.3 0.9 2.3 2.2 3.2 2.4 0.6 7.5 3.4 8.8 3.7 1.3 7.2 0.9 2.0 5.3 0.6 1.1 3.0 3.9 1.2 3.3 0.8 4.9 0.0 1.1 3.4 1.2 4.5 3.4 0.0 13.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.3 0.0 0.0 1.9 8.6 0.4 2.3 3.5 5.8 2.3 2.2 8.8 4.9 0.0 0.0 0.0 0.0 0.8 153.4 8.6 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.1 0.0 0.4 0.0 3.4 12.9 19.1 0.0 0.0 0.3 0.1 0.0 0.0 0.0 KCNB1 Kv2.1 ENSG00000158445 "Potassium voltage-gated channel subfamily B member 1" Q14721 20 49293394-49484297 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Exocytosis, Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 25.9;retina: 22.4" "Group enriched" "Detected in some" 7 "Bipolar cells: 119.5;Cone photoreceptor cells: 200.3;Rod photoreceptor cells: 366.4" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "ASC diff: 3.6;CACO-2: 5.1;hTCEpi: 3.2;U-2 OS: 4.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB001979, HPA042434" Enhanced NA NA "CAB001979: , HPA042434: AB_2677996" "unprognostic (4.51e-1)" "unprognostic (1.72e-1)" "unprognostic (6.54e-3)" "unprognostic (4.87e-2)" "unprognostic (1.94e-1)" "unprognostic (1.82e-1)" "unprognostic (8.09e-2)" "unprognostic (6.22e-2)" "unprognostic (5.31e-1)" "unprognostic (8.32e-2)" "unprognostic (1.87e-3)" "unprognostic (1.37e-1)" "unprognostic (1.31e-2)" "unprognostic (2.07e-3)" "unprognostic (8.17e-2)" "unprognostic (9.35e-2)" "unprognostic (5.25e-4)" 16.9 3.6 11.4 1.3 14.6 0.8 2.4 8.1 25.9 2.3 5.1 1.8 0.7 1.2 6.8 2.3 3.9 9.0 1.9 1.9 6.6 5.3 1.3 3.5 1.2 0.8 3.3 12.5 1.2 1.2 0.9 2.5 1.0 2.5 4.8 1.9 22.4 1.7 6.5 6.2 1.1 1.8 9.6 1.2 1.2 3.9 1.5 2.4 0.0 1.0 0.1 0.8 4.0 0.9 0.4 0.3 1.2 0.2 0.3 0.7 0.0 0.0 0.1 0.8 0.0 3.6 0.3 0.1 0.0 0.4 0.4 0.0 5.1 0.0 0.0 0.0 0.1 1.3 0.1 0.0 0.1 0.3 0.1 0.2 0.0 0.1 0.0 0.0 2.6 0.0 0.6 3.2 0.0 0.1 0.2 0.0 0.0 0.0 1.9 1.2 0.3 0.0 2.4 0.1 0.0 0.9 0.0 1.0 0.0 0.0 0.0 2.3 1.9 1.6 2.3 0.0 0.0 1.7 0.0 0.0 2.2 4.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.3 0.2 0.0 0.1 0.1 0.3 0.2 0.0 0.4 0.7 0.2 1.2 0.3 0.1 0.3 0.1 0.0 11.4 14.6 8.1 25.9 6.6 5.3 3.3 12.5 2.5 2.4 0.0 2.1 0.0 0.1 0.7 119.5 1.2 2.5 5.3 1.2 0.0 200.3 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.4 0.1 3.5 4.7 0.1 17.5 0.0 0.0 0.0 0.4 4.0 0.1 0.0 0.0 0.0 26.9 0.1 0.0 32.5 0.0 366.4 0.0 3.4 0.2 0.3 0.3 0.1 0.0 0.0 0.0 KCNB2 Kv2.2 ENSG00000182674 "Potassium voltage-gated channel subfamily B member 2" Q92953 8 72537391-72938349 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 9.7;lymphoid tissue: 8.6;pituitary gland: 9.2" "Cell type enriched" "Detected in some" 15 "Cone photoreceptor cells: 249.4" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "HaCaT: 3.2;HDLM-2: 3.1;HEK 293: 7.6;SCLC-21H: 6.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA065970 Approved "Nucleoli,Plasma membrane,Midbody" Yes NA "Plasma membrane" "Nucleoli, Midbody" "HPA065970: AB_2685591" "unprognostic (9.87e-3)" "unprognostic (1.71e-1)" "unprognostic (7.57e-2)" "unprognostic (1.10e-3)" "unprognostic (1.22e-1)" "unprognostic (1.34e-1)" "unprognostic (1.44e-2)" "unprognostic (2.72e-1)" "unprognostic (6.93e-5)" "unprognostic (5.53e-3)" "unprognostic (3.30e-2)" "unprognostic (1.62e-1)" "unprognostic (3.35e-2)" "unprognostic (3.26e-1)" 0.8 1.9 3.8 0.6 5.3 0.4 0.7 0.3 9.7 0.5 0.7 0.0 0.0 1.2 0.4 0.4 1.1 2.1 0.5 0.4 7.1 3.1 0.5 0.4 0.6 0.5 0.9 7.8 0.4 2.4 0.4 9.2 0.5 3.2 0.7 0.7 4.2 0.5 0.5 0.4 0.4 1.6 0.5 1.6 8.6 2.4 1.7 0.4 0.9 0.4 0.0 0.9 0.6 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 3.1 7.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 5.3 0.3 9.7 7.1 3.1 0.9 7.8 3.2 0.4 0.0 0.0 0.0 0.0 0.0 12.9 0.2 0.0 0.0 0.0 1.8 249.4 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 17.1 0.0 0.0 5.0 1.1 0.0 0.0 0.0 0.0 0.7 0.2 0.0 0.4 0.0 2.4 0.0 0.0 0.4 0.7 0.0 0.0 0.0 0.0 0.0 KCNC1 Kv3.1 ENSG00000129159 "Potassium voltage-gated channel subfamily C member 1" P48547 11 17734774-17856804 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 12 "brain: 67.5" "Cell type enriched" "Detected in some" 4 "Bipolar cells: 36.6" "Cancer enhanced" "Detected in some" "glioma: 1.1" "Region enhanced" "Detected in all" "cerebellum: 67.5" "Cell type enhanced" "Detected in some" "basophil: 5.8" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "RH-30: 7.5;SCLC-21H: 7.1;SH-SY5Y: 4.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047634, HPA048249" Enhanced Approved "Nucleoplasm,Nuclear membrane,Vesicles,Cytosol" NA NA "Nucleoplasm, Nuclear membrane" "Vesicles, Cytosol" "HPA047634: AB_2680109, HPA048249: " "unprognostic (1.79e-2)" "unprognostic (2.68e-1)" "unprognostic (1.33e-1)" "unprognostic (4.09e-3)" "unprognostic (1.12e-1)" "unprognostic (8.02e-2)" "unprognostic (2.40e-1)" "unprognostic (1.27e-1)" "unprognostic (8.37e-2)" "unprognostic (2.14e-1)" "unprognostic (7.04e-5)" "unprognostic (5.89e-2)" "unprognostic (7.32e-4)" "unprognostic (1.29e-1)" "unprognostic (5.44e-2)" "unprognostic (1.05e-2)" "unprognostic (7.83e-2)" 0.7 2.3 8.2 1.0 10.0 2.9 0.9 67.5 33.3 3.0 1.0 1.0 0.0 1.4 1.5 0.6 1.1 0.9 1.3 0.6 5.6 4.9 0.9 1.1 1.0 1.2 3.3 12.6 1.1 0.9 0.6 1.4 0.7 19.5 1.2 0.8 0.7 1.2 0.7 1.7 1.8 1.2 0.8 1.9 1.0 1.3 2.9 2.0 0.0 1.5 0.0 0.8 2.4 0.5 1.7 0.8 5.8 0.8 0.7 1.1 0.3 0.4 0.1 3.1 1.2 0.5 0.0 0.1 0.0 0.0 0.1 0.0 0.2 1.0 0.0 0.2 0.0 0.9 1.1 1.8 0.0 0.3 0.3 2.1 0.6 3.0 0.2 0.4 0.5 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.8 0.5 1.4 0.0 0.5 0.5 1.2 1.5 0.0 0.0 0.8 7.5 0.9 0.0 0.4 7.1 4.4 0.4 0.5 0.0 0.4 0.6 0.5 0.1 0.2 2.3 0.3 0.3 0.5 0.6 1.0 0.5 0.3 1.0 5.8 0.7 1.1 1.1 0.7 0.7 0.7 0.9 0.5 0.2 1.7 0.7 0.8 3.8 0.7 0.8 0.8 0.4 0.3 8.2 10.0 67.5 33.3 5.6 4.9 3.3 12.6 19.5 2.0 0.0 0.0 0.0 0.0 0.0 36.6 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 7.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.6 7.5 0.0 0.0 8.4 0.3 0.0 0.0 1.0 0.0 1.5 0.2 0.0 0.0 0.1 7.4 0.0 0.4 5.4 4.5 0.0 0.0 0.0 0.0 0.0 KCNC3 "Kv3.3, SCA13" ENSG00000131398 "Potassium voltage-gated channel subfamily C member 3" Q14003 19 50311937-50333515 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 32.1;parathyroid gland: 31.1;thyroid gland: 23.9" "Cell type enhanced" "Detected in many" 11 "Bipolar cells: 9.8;Collecting duct cells: 19.2;Cone photoreceptor cells: 7.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.1" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "CACO-2: 8.9;CAPAN-2: 7.8;HDLM-2: 8.0;HMC-1: 21.4;K-562: 7.9;SK-BR-3: 14.5;T-47d: 13.8;U-2 OS: 9.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA018041 Approved NA NA "HPA018041: AB_1855579" "unprognostic (8.05e-2)" "unprognostic (2.34e-2)" "unprognostic (3.01e-4)" "unprognostic (4.41e-2)" "unprognostic (3.84e-2)" "unprognostic (1.91e-2)" "unprognostic (2.79e-2)" "unprognostic (1.12e-2)" "unprognostic (1.46e-1)" "unprognostic (1.59e-1)" "unprognostic (3.94e-3)" "unprognostic (2.10e-5)" "prognostic unfavorable (1.23e-4)" "unprognostic (1.68e-2)" "unprognostic (1.45e-1)" "unprognostic (2.85e-2)" "unprognostic (1.19e-1)" 1.4 2.2 7.2 5.4 9.4 1.4 2.3 32.1 31.2 3.1 1.1 3.4 3.0 1.8 4.5 5.8 1.1 12.8 1.4 1.7 6.9 4.2 10.6 2.5 4.5 4.7 4.0 6.6 0.6 3.7 31.1 9.7 2.4 15.6 2.4 1.4 3.0 2.3 15.1 1.2 2.1 1.8 1.7 3.8 6.5 2.1 2.4 2.9 1.1 23.9 0.0 3.4 1.8 1.0 0.4 1.1 0.0 0.8 0.0 0.0 0.0 0.0 0.4 0.0 1.5 0.0 0.0 4.2 0.0 0.0 0.0 0.0 8.9 7.8 0.7 1.0 0.0 0.5 1.2 0.2 0.0 0.0 8.0 1.8 0.0 0.0 1.7 0.0 0.0 21.4 0.1 0.0 0.0 0.0 0.0 0.1 0.3 7.9 0.0 0.0 2.8 0.1 0.0 1.1 0.9 3.3 0.0 0.1 0.0 0.5 0.2 0.0 1.4 1.7 14.5 0.0 0.2 13.8 2.2 0.2 0.0 9.5 0.0 0.0 0.1 0.1 0.5 0.3 1.8 0.0 0.0 0.4 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 7.2 9.4 32.1 31.2 6.9 4.2 4.0 6.6 15.6 2.9 0.0 0.3 0.0 0.8 0.7 9.8 2.6 0.0 1.4 1.2 19.2 7.9 1.9 0.0 1.2 0.3 0.0 0.0 0.0 1.2 0.7 0.2 1.1 0.0 1.5 2.8 1.6 4.1 0.6 5.3 0.0 0.6 2.3 0.0 2.8 0.0 0.7 0.2 0.0 0.0 2.3 6.3 0.0 1.0 0.9 1.1 0.5 1.9 0.0 0.0 0.9 KCND1 Kv4.1 ENSG00000102057 "Potassium voltage-gated channel subfamily D member 1" Q9NSA2 X 48961378-48971569 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 16.8" "Cell type enhanced" "Detected in some" 8 "Collecting duct cells: 1.8;Distal tubular cells: 1.7;Intestinal endocrine cells: 3.4;Leydig cells: 1.7;Peritubular cells: 3.5;Rod photoreceptor cells: 2.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 1.4" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HSkMC: 13.2;NB-4: 10.5;SuSa: 10.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000524, HPA001066" Supported Uncertain Nucleoplasm Yes No Nucleoplasm "HPA000524: AB_2666013, HPA001066: AB_1079662" "unprognostic (6.00e-2)" "unprognostic (2.58e-1)" "unprognostic (1.01e-4)" "unprognostic (2.19e-4)" "unprognostic (1.41e-1)" "unprognostic (3.79e-2)" "unprognostic (2.79e-1)" "unprognostic (8.13e-3)" "unprognostic (1.13e-2)" "unprognostic (2.41e-3)" "prognostic favorable (2.66e-6)" "unprognostic (2.61e-1)" "unprognostic (4.30e-11)" "unprognostic (3.13e-2)" "unprognostic (3.49e-1)" "unprognostic (7.64e-2)" "unprognostic (2.22e-3)" 4.9 2.4 4.2 3.4 4.7 6.0 2.2 16.8 7.8 5.1 2.2 6.3 1.9 2.0 5.0 3.8 1.4 7.4 6.3 2.9 6.9 2.5 2.5 1.8 3.0 3.1 3.1 3.5 4.6 1.4 1.8 3.0 2.5 10.4 3.3 2.1 2.6 1.2 6.0 0.7 1.6 2.6 6.6 6.5 4.2 2.5 3.0 2.7 1.1 2.3 0.5 3.6 3.0 3.0 0.6 1.3 1.4 0.1 0.0 0.8 0.1 0.4 1.9 0.8 4.7 6.4 5.1 1.6 1.0 4.0 2.8 1.9 1.2 0.6 1.6 3.4 3.1 0.8 0.6 0.8 0.4 2.7 2.6 3.1 1.4 1.9 0.1 2.4 0.4 2.9 13.2 1.8 5.2 0.6 4.7 0.9 2.2 1.1 3.6 2.0 3.5 0.4 10.5 2.5 0.3 0.7 1.3 0.9 1.5 3.1 1.5 0.5 2.1 0.9 0.0 2.1 10.2 2.0 1.5 2.4 0.6 2.6 0.6 0.2 2.9 3.8 3.8 1.7 3.7 2.1 0.0 0.1 0.0 0.5 0.0 0.3 0.6 0.2 0.8 0.0 0.1 0.2 0.0 1.4 0.0 0.0 1.3 0.0 0.1 4.2 4.7 16.8 7.8 6.9 2.5 3.1 3.5 10.4 2.7 0.0 1.4 0.0 0.0 0.7 0.2 0.4 0.0 0.0 0.0 1.8 0.0 0.0 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.1 0.0 3.4 0.6 0.8 0.0 1.7 0.0 0.0 0.0 0.2 0.3 0.1 0.0 3.5 0.0 2.8 0.0 0.4 0.2 0.0 0.0 0.1 0.0 0.0 0.1 KCND2 "KIAA1044, Kv4.2, RK5" ENSG00000184408 "Potassium voltage-gated channel subfamily D member 2" Q9NZV8 7 120273668-120750331 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 41.1" "Cell type enhanced" "Detected in some" 9 "Bipolar cells: 2.9;Cholangiocytes: 5.1;Ductal cells: 2.5;Leydig cells: 3.4;Spermatocytes: 4.2;Spermatogonia: 3.3" "Cancer enhanced" "Detected in many" "glioma: 6.2" "Region enhanced" "Detected in all" "cerebellum: 41.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC TERT1: 6.5;HSkMC: 4.1;NTERA-2: 3.2;RT4: 3.3;SCLC-21H: 16.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029068 Enhanced NA NA "HPA029068: AB_10601436" "unprognostic (4.22e-1)" "unprognostic (2.79e-4)" "unprognostic (3.79e-2)" "unprognostic (3.40e-1)" "unprognostic (1.23e-1)" "unprognostic (3.91e-2)" "unprognostic (4.98e-3)" "unprognostic (9.07e-3)" "unprognostic (1.03e-1)" "unprognostic (1.14e-1)" "unprognostic (9.77e-3)" "unprognostic (1.51e-1)" "unprognostic (4.51e-4)" "unprognostic (4.07e-5)" "unprognostic (2.71e-2)" "unprognostic (2.92e-2)" "unprognostic (1.83e-3)" 2.9 1.0 3.9 1.0 6.7 0.3 1.9 41.1 20.6 2.4 0.7 1.5 0.0 0.7 5.6 0.5 0.5 1.7 7.0 0.5 3.7 5.4 0.3 0.4 0.6 0.5 4.2 3.6 5.9 0.6 2.5 6.6 0.8 12.1 0.5 0.6 0.0 0.7 1.7 0.5 0.3 0.5 3.7 3.7 0.3 0.5 2.9 4.5 0.0 0.8 1.1 0.3 2.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.7 6.5 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.1 2.6 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.7 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.2 0.0 0.0 0.0 3.2 0.0 0.2 0.0 0.0 0.0 0.0 3.3 16.6 0.0 0.0 0.0 0.0 0.2 0.2 0.8 0.0 0.5 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 6.7 41.1 5.3 3.7 5.4 4.2 3.6 12.1 4.5 0.0 0.0 0.0 0.0 0.0 2.9 1.2 5.1 0.0 0.0 0.0 0.0 0.0 0.0 2.5 2.3 0.1 0.0 0.0 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 1.4 3.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.5 0.0 0.4 4.2 3.3 0.1 0.0 0.0 0.0 0.1 KCND3 "KSHIVB, Kv4.3, SCA19, SCA22" ENSG00000171385 "Potassium voltage-gated channel subfamily D member 3" Q9UK17 1 111770662-111989155 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Brugada syndrome, Disease mutation, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 25.9" "Cell type enhanced" "Detected in many" 6 "Bipolar cells: 38.5;Cardiomyocytes: 34.4;Early spermatids: 29.0;Horizontal cells: 28.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "OE19: 6.6;SCLC-21H: 15.9;U-2 OS: 2.4;WM-115: 3.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029452 Approved NA NA "HPA029452: AB_10602239" "unprognostic (1.11e-2)" "unprognostic (1.73e-3)" "unprognostic (1.71e-1)" "unprognostic (2.60e-2)" "unprognostic (1.37e-1)" "unprognostic (2.42e-1)" "unprognostic (1.41e-1)" "unprognostic (9.48e-2)" "unprognostic (1.15e-1)" "unprognostic (9.17e-2)" "unprognostic (1.86e-2)" "unprognostic (1.40e-1)" "unprognostic (7.44e-2)" "unprognostic (3.64e-1)" "unprognostic (1.23e-1)" "unprognostic (2.51e-3)" "unprognostic (6.64e-3)" 3.3 0.8 6.8 3.1 6.9 0.0 2.1 25.9 11.9 1.3 2.5 1.3 1.3 0.3 4.1 9.6 3.2 3.4 4.2 5.5 5.6 5.6 1.3 11.6 1.3 1.3 8.9 5.7 1.3 2.2 4.1 1.5 1.3 1.6 9.2 1.6 1.9 1.3 10.0 2.8 5.1 1.3 7.7 1.3 2.0 1.7 1.3 1.3 1.3 1.3 2.3 1.3 3.7 1.3 0.5 0.4 1.2 0.3 0.9 0.3 0.7 0.0 0.0 0.3 0.0 0.5 0.1 0.1 0.4 0.0 0.0 0.0 0.8 0.1 0.0 1.6 0.6 0.0 0.5 0.6 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.0 1.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.2 0.3 6.6 0.0 0.0 0.1 0.0 0.0 0.3 15.9 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.5 0.2 0.1 0.3 0.1 0.1 0.1 0.1 0.3 0.4 0.5 0.3 0.2 1.2 0.9 0.3 0.3 0.1 0.7 6.8 6.9 25.9 9.3 5.6 5.6 8.9 5.7 1.6 1.3 0.0 9.4 0.0 10.7 6.6 38.5 34.4 0.0 0.0 1.2 0.0 3.9 0.1 0.0 0.7 29.0 1.8 0.0 0.0 21.1 0.1 1.4 14.3 0.0 23.7 0.2 28.6 0.0 1.8 0.6 20.3 16.7 0.0 3.3 0.0 0.2 6.1 4.4 0.3 1.8 0.2 4.2 0.0 3.1 1.1 0.7 5.8 0.0 0.0 0.0 12.3 KCNH2 "erg1, HERG, Kv11.1, LQT2" ENSG00000055118 "Potassium voltage-gated channel subfamily H member 2" Q12809 7 150944961-150978315 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Deafness, Disease mutation, FDA approved drug targets, Long QT syndrome, Short QT syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 37.9" "Group enriched" "Detected in many" 5 "Bipolar cells: 199.1;Cardiomyocytes: 76.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "eosinophil: 2.0" "Lineage enriched" "Detected in single" 10 "granulocytes: 2.0" "Group enriched" "Detected in some" 7 "K-562: 59.8;NB-4: 29.8;SH-SY5Y: 25.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (2.22e-1)" "unprognostic (1.75e-2)" "unprognostic (1.06e-2)" "prognostic unfavorable (6.06e-5)" "unprognostic (9.79e-3)" "unprognostic (1.95e-2)" "unprognostic (3.40e-2)" "unprognostic (3.84e-2)" "unprognostic (3.53e-2)" "unprognostic (3.52e-1)" "prognostic favorable (5.61e-4)" "unprognostic (6.08e-2)" "unprognostic (2.26e-2)" "unprognostic (4.90e-2)" "unprognostic (2.83e-1)" "unprognostic (6.24e-2)" "unprognostic (3.02e-2)" 1.1 4.9 5.0 3.2 8.3 37.9 0.7 19.3 8.0 4.3 17.3 2.8 3.1 3.5 9.3 4.6 3.4 4.1 28.5 24.9 4.8 9.3 0.8 0.7 1.7 0.9 4.7 3.9 6.6 5.1 10.5 23.8 2.2 14.1 6.8 1.8 8.0 1.8 10.2 0.8 0.7 6.9 9.4 2.2 1.6 6.8 18.0 1.6 0.1 0.7 0.0 0.7 7.5 2.4 0.1 0.0 2.0 0.0 0.0 0.1 0.0 0.0 0.1 0.3 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.5 0.9 0.0 0.0 0.0 1.1 0.0 0.0 0.2 0.1 5.7 0.0 0.0 0.1 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 1.3 59.8 0.0 0.0 0.3 0.5 29.8 0.4 0.0 0.0 0.0 0.0 3.0 0.0 0.0 1.2 25.0 0.0 0.0 0.0 0.3 0.0 0.5 0.2 0.0 0.5 0.0 0.0 1.7 0.0 0.6 0.0 3.7 0.0 0.8 0.0 2.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 8.3 19.3 8.0 4.8 9.3 4.7 3.9 14.1 1.6 0.0 0.0 0.0 0.1 0.0 199.1 76.1 0.0 0.0 0.0 0.0 3.9 0.1 0.0 1.8 0.8 0.0 0.0 23.3 0.2 1.0 0.9 0.1 26.4 0.0 0.3 15.9 15.6 2.5 0.0 2.5 2.3 0.0 0.0 0.0 0.7 2.7 0.5 0.0 12.4 0.0 9.6 0.0 1.9 0.7 2.6 0.0 0.2 0.0 0.2 0.3 KCNJ1 "Kir1.1, ROMK1" ENSG00000151704 "Potassium voltage-gated channel subfamily J member 1" P48048 11 128836315-128867373 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Bartter syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 51 "kidney: 123.2" "Cell type enriched" "Detected in some" 5 "Distal tubular cells: 165.8" "Cancer enriched" "Detected in some" 7 "renal cancer: 3.4" "Region enriched" "Detected in single" 4 "basal ganglia: 2.3" "Cell type enhanced" "Detected in single" "memory B-cell: 1.3" "Low lineage specificity" "Detected in single" "Cell line enriched" "Detected in some" 40 "RPTEC TERT1: 51.8" "Not detected" "Not detected" "Not detected" "Not detected" HPA026962 Enhanced NA NA "HPA026962: AB_10601934" "unprognostic (1.75e-1)" "unprognostic (4.38e-2)" "unprognostic (1.14e-1)" "unprognostic (3.19e-1)" "unprognostic (7.55e-2)" "unprognostic (1.29e-1)" "unprognostic (3.01e-2)" "unprognostic (2.69e-1)" "unprognostic (1.46e-1)" "unprognostic (2.44e-2)" "unprognostic (6.47e-2)" "unprognostic (2.78e-1)" "unprognostic (6.05e-2)" "unprognostic (4.99e-2)" "unprognostic (1.61e-1)" "unprognostic (1.28e-1)" "unprognostic (7.81e-3)" 0.1 0.0 0.5 0.2 2.3 0.0 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.0 0.1 0.5 0.1 0.0 0.1 0.1 0.1 0.0 123.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 1.3 0.0 0.0 0.4 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 51.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.3 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.4 0.9 1.3 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 2.3 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.0 36.6 0.0 0.0 165.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 KCNJ11 "BIR, Kir6.2" ENSG00000187486 "Potassium voltage-gated channel subfamily J member 11" Q14654 11 17385859-17389331 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Diabetes mellitus, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "skeletal muscle: 63.1" "Cell type enhanced" "Detected in some" 17 "Cardiomyocytes: 11.3;Collecting duct cells: 5.2;Intestinal endocrine cells: 4.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "Daudi: 7.1;HEK 293: 13.5;MCF7: 10.8;SCLC-21H: 9.2" "Low region specificity" "Detected in all" HPA048891 Approved NA NA "HPA048891: AB_2680547" "unprognostic (1.95e-2)" "unprognostic (6.18e-3)" "unprognostic (7.79e-2)" "unprognostic (2.26e-1)" "unprognostic (1.77e-1)" "unprognostic (1.25e-1)" "unprognostic (4.81e-5)" "unprognostic (1.83e-3)" "unprognostic (5.45e-2)" "unprognostic (8.09e-3)" "unprognostic (3.72e-3)" "unprognostic (9.23e-3)" "prognostic favorable (1.56e-4)" "unprognostic (4.05e-2)" "unprognostic (2.10e-2)" "unprognostic (1.67e-1)" "unprognostic (4.75e-2)" 2.5 1.1 2.9 1.0 7.8 0.8 2.7 13.6 7.8 1.0 1.1 0.7 4.9 1.4 1.1 2.1 1.7 1.1 1.1 6.2 3.5 2.4 1.3 0.9 1.3 1.2 2.7 5.2 0.8 8.7 2.7 3.3 0.7 3.5 2.5 1.0 0.1 1.2 7.6 63.1 1.0 1.1 0.8 1.7 1.0 4.6 0.8 1.9 0.0 4.1 4.5 1.0 0.9 1.1 0.8 0.4 1.4 0.3 0.8 0.4 0.4 1.5 2.4 0.3 4.0 0.0 0.0 1.6 0.0 0.0 0.0 0.1 2.5 0.2 7.1 0.2 0.0 0.3 0.3 4.8 0.1 0.3 1.7 13.5 3.7 0.9 0.8 0.1 0.4 0.3 0.1 0.3 0.0 0.1 0.1 0.0 6.1 3.8 3.8 0.0 10.8 0.7 0.1 1.0 4.2 0.3 1.4 1.7 2.1 0.4 0.9 9.2 0.8 0.0 3.6 0.0 0.0 4.7 0.2 0.0 0.0 1.2 0.0 0.1 0.2 6.0 0.9 0.0 1.0 0.0 1.4 0.3 0.2 0.4 0.3 0.3 0.7 0.4 0.4 0.1 0.8 0.4 0.4 1.3 0.8 0.1 0.4 0.3 0.4 2.9 7.8 13.6 7.8 3.5 2.4 2.7 5.2 3.5 1.9 0.0 2.4 0.0 0.1 0.0 2.4 11.3 0.0 0.0 1.2 5.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 1.0 0.1 0.0 4.1 0.6 0.6 0.0 0.0 0.0 0.0 0.0 0.8 0.5 0.2 0.0 0.0 0.0 0.7 0.0 0.1 0.2 0.2 0.0 0.0 0.0 0.2 0.1 KCNJ8 Kir6.1 ENSG00000121361 "Potassium voltage-gated channel subfamily J member 8" Q15842 12 21764955-21775581 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 60.1;pancreas: 47.6" "Group enriched" "Detected in many" 5 "Sertoli cells: 194.1;Smooth muscle cells: 65.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 12 "eosinophil: 4.5" "Lineage enriched" "Detected in single" 45 "granulocytes: 4.5" "Cell line enhanced" "Detected in some" "CACO-2: 42.5;HSkMC: 8.6;SH-SY5Y: 14.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031066 Uncertain NA NA "HPA031066: AB_10602240" "unprognostic (8.12e-3)" "unprognostic (1.89e-1)" "prognostic unfavorable (9.29e-4)" "unprognostic (7.81e-2)" "unprognostic (8.71e-2)" "unprognostic (2.34e-1)" "unprognostic (3.15e-2)" "unprognostic (1.27e-1)" "unprognostic (1.36e-2)" "unprognostic (3.90e-2)" "unprognostic (3.66e-3)" "unprognostic (2.88e-2)" "prognostic unfavorable (1.62e-6)" "unprognostic (4.70e-3)" "unprognostic (9.61e-2)" "unprognostic (1.73e-2)" "unprognostic (3.54e-3)" 14.6 12.9 3.2 2.7 3.4 0.0 14.7 1.7 5.1 7.7 6.6 2.3 3.6 2.0 10.6 4.5 6.7 5.9 6.3 60.1 2.2 1.7 6.4 29.7 12.4 3.5 2.9 3.0 12.4 47.6 1.7 3.8 4.9 3.7 10.6 1.6 8.8 2.9 15.7 15.0 2.4 3.8 13.2 2.6 3.8 6.5 3.4 2.8 0.9 8.4 7.0 1.2 11.4 5.6 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.2 1.4 0.0 5.2 3.4 0.0 5.7 4.6 6.6 3.4 42.5 0.0 0.0 0.0 0.1 0.7 0.0 0.2 0.0 1.9 0.0 2.1 1.3 0.0 0.0 0.2 0.0 0.0 8.6 0.0 2.5 0.0 0.6 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.8 0.0 0.0 0.0 4.2 0.0 0.0 0.0 4.2 1.9 0.0 1.7 0.1 0.0 0.0 0.1 0.0 0.1 0.3 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 3.4 1.7 5.1 2.2 1.7 2.9 3.0 3.7 2.8 3.0 19.8 0.0 0.4 1.1 0.0 24.3 0.0 0.0 1.2 1.8 0.0 0.1 0.0 0.0 0.0 2.4 0.0 0.0 1.1 0.0 6.6 0.3 0.0 22.1 0.2 0.0 1.2 1.8 1.5 0.0 0.3 0.0 1.7 0.0 0.0 12.2 2.0 0.0 0.7 0.0 1.1 194.1 65.3 0.0 0.4 0.6 0.2 0.0 0.0 0.1 KCNK3 "K2p3.1, TASK, TASK-1" ENSG00000171303 "Potassium two pore domain channel subfamily K member 3" O14649 2 26692690-26733420 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 69.2" "Cell type enhanced" "Detected in many" 17 "Collecting duct cells: 97.7;Exocrine glandular cells: 82.2;Pancreatic endocrine cells: 31.4" "Cancer enhanced" "Detected in many" "renal cancer: 9.7" "Group enriched" "Detected in many" 4 "basal ganglia: 4.0;cerebellum: 4.7;cerebral cortex: 6.2;hypothalamus: 4.0;pons and medulla: 13.4" "Cell type enhanced" "Detected in some" "neutrophil: 2.5" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 4.7;EFO-21: 10.0;HeLa: 3.4;SCLC-21H: 23.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (4.16e-3)" "unprognostic (7.13e-2)" "unprognostic (1.04e-1)" "unprognostic (1.67e-4)" "unprognostic (2.08e-1)" "unprognostic (2.91e-1)" "unprognostic (5.01e-2)" "unprognostic (2.16e-1)" "unprognostic (3.31e-1)" "unprognostic (5.48e-2)" "unprognostic (3.77e-2)" "unprognostic (1.48e-2)" "prognostic unfavorable (2.37e-7)" "unprognostic (3.09e-2)" "unprognostic (7.45e-2)" "unprognostic (1.44e-2)" "unprognostic (9.24e-3)" 2.4 69.2 1.3 1.9 4.0 0.6 8.3 4.7 6.2 3.5 4.0 0.8 5.7 1.3 2.4 5.6 1.9 2.0 2.3 10.3 1.0 4.0 1.8 0.7 10.0 0.6 1.5 1.5 4.6 24.7 0.7 3.6 16.6 13.4 8.2 1.1 1.9 0.6 7.7 0.6 0.6 2.6 4.7 1.1 0.9 2.2 0.9 0.0 0.0 2.1 0.0 0.5 3.2 2.3 0.7 0.5 2.5 0.4 1.2 0.4 0.0 0.0 0.6 0.2 0.0 4.7 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 10.0 0.0 1.5 0.0 0.0 0.0 0.0 1.8 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 1.3 0.0 23.5 2.1 0.2 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.2 0.1 0.0 0.0 0.0 0.2 0.0 0.0 1.0 0.4 0.3 0.4 0.2 0.4 0.3 0.3 0.3 0.2 0.7 0.4 0.4 2.5 1.2 0.2 0.5 0.2 0.0 1.3 4.0 4.7 6.2 1.0 4.0 1.5 1.5 13.4 0.0 0.0 3.2 0.0 0.2 0.0 11.5 10.0 0.0 0.0 0.0 97.7 0.0 0.2 0.0 0.8 0.4 1.0 0.0 0.0 82.2 0.2 1.9 1.6 0.0 0.0 0.3 1.6 22.5 0.6 0.0 1.3 0.9 0.0 0.0 1.0 0.4 1.2 31.4 0.0 0.0 0.0 3.9 6.5 3.1 0.0 1.3 0.1 0.5 0.0 0.0 0.3 KCNK9 "K2p9.1, TASK-3, TASK3" ENSG00000169427 "Potassium two pore domain channel subfamily K member 9" Q9NPC2 8 139600838-139703056 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "adrenal gland: 9.4;brain: 15.4" "Cell type enhanced" "Detected in some" 18 "Collecting duct cells: 1.8;Distal tubular cells: 1.7;Exocrine glandular cells: 2.2;Late spermatids: 4.6" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in many" "cerebellum: 15.4" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "PC-3: 6.6;SCLC-21H: 2.9;SH-SY5Y: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA075842 Approved "Plasma membrane" NA NA "Plasma membrane" "HPA075842: " "unprognostic (1.84e-2)" "unprognostic (2.57e-1)" "unprognostic (1.58e-1)" "unprognostic (8.96e-8)" "unprognostic (1.91e-1)" "unprognostic (8.17e-3)" "unprognostic (2.19e-3)" "unprognostic (1.65e-1)" "unprognostic (3.87e-1)" "unprognostic (1.69e-1)" "unprognostic (1.00e-2)" "unprognostic (3.21e-1)" "unprognostic (5.12e-6)" "unprognostic (2.94e-2)" "unprognostic (1.64e-1)" "unprognostic (9.99e-3)" "unprognostic (1.76e-1)" 0.2 9.4 0.5 0.5 1.0 0.1 0.1 15.4 7.7 1.3 0.5 0.0 0.0 0.1 0.3 0.1 0.2 0.3 0.1 0.2 1.6 1.4 0.1 0.1 0.1 0.1 0.7 1.7 0.1 0.1 0.1 1.1 0.2 6.6 0.1 0.2 0.2 0.1 0.1 1.4 0.1 0.1 0.6 0.6 0.1 0.3 0.5 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 6.6 0.0 0.0 0.0 0.0 0.0 2.9 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 1.0 15.4 3.7 1.6 1.4 0.7 1.7 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 1.8 0.0 0.0 1.7 0.2 1.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 KCNMB1 hslo-beta ENSG00000145936 "Potassium calcium-activated channel subfamily M regulatory beta subunit 1" Q16558 5 170374671-170389677 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 55.5" "Cell type enriched" "Detected in many" 6 "Peritubular cells: 333.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "dendritic cells: 7.0;monocytes: 7.1" "Cell line enhanced" "Detected in some" "REH: 13.0;SK-BR-3: 3.2;U-937: 5.4" "Low region specificity" "Detected in some" "Low region specificity" "Detected in single" NA NA "unprognostic (2.06e-2)" "unprognostic (2.70e-4)" "unprognostic (1.69e-2)" "unprognostic (1.27e-1)" "unprognostic (3.37e-2)" "unprognostic (8.88e-2)" "unprognostic (1.61e-2)" "unprognostic (3.46e-1)" "unprognostic (2.28e-1)" "unprognostic (4.68e-2)" "unprognostic (5.37e-1)" "unprognostic (1.00e-1)" "prognostic unfavorable (4.13e-6)" "unprognostic (1.08e-1)" "unprognostic (2.49e-1)" "unprognostic (4.31e-2)" "unprognostic (1.04e-2)" 3.2 1.0 0.6 7.7 0.5 0.7 4.2 0.4 0.6 26.8 34.7 0.8 12.6 2.2 31.3 10.6 29.8 10.9 32.4 2.6 0.6 0.7 1.9 0.4 2.2 1.3 1.1 0.9 8.7 0.5 0.1 0.5 0.9 2.2 29.4 5.0 5.6 5.3 29.3 0.9 1.6 11.4 55.5 1.5 1.1 13.4 8.0 0.6 0.3 1.0 1.5 1.6 43.4 6.4 0.5 7.0 1.4 7.1 0.6 0.3 1.0 0.1 0.2 2.3 0.6 0.2 0.0 0.4 0.3 0.1 0.1 0.1 0.5 0.4 0.2 1.6 0.1 0.6 0.2 0.1 0.1 0.1 0.5 0.1 1.5 0.8 0.3 0.0 0.6 0.4 0.4 0.0 0.2 0.4 0.2 0.2 0.7 0.5 1.1 0.1 1.0 0.0 1.4 0.4 0.1 0.2 13.0 0.1 0.3 0.1 0.4 0.5 0.3 0.1 3.2 0.0 1.1 0.2 1.4 0.8 0.3 0.5 0.5 0.1 0.8 0.3 0.2 0.2 5.4 0.2 1.3 4.3 0.4 0.2 7.1 0.1 0.2 0.3 0.2 7.0 0.5 0.2 0.2 1.4 0.6 6.0 2.6 0.2 1.0 0.6 0.5 0.4 0.5 0.6 0.7 1.1 0.9 2.2 0.6 0.0 7.5 1.3 1.0 1.8 1.5 2.6 2.5 8.1 7.9 1.8 5.9 0.5 0.0 0.1 0.5 2.7 0.0 0.0 0.4 0.6 14.4 1.0 19.6 0.0 7.7 1.6 0.0 1.8 9.1 1.6 35.6 21.4 3.3 29.7 0.0 1.1 0.0 0.0 333.0 0.0 1.8 45.3 59.8 0.7 0.9 1.5 0.5 0.0 0.0 0.5 KCNMB2 ENSG00000197584 "Potassium calcium-activated channel subfamily M regulatory beta subunit 2" Q9Y691 3 178272932-178844429 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "epididymis: 36.8" "Group enriched" "Detected in some" 4 "Ciliated cells: 14.7;Intestinal endocrine cells: 13.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ hTERT+: 6.5;fHDF/TERT166: 2.6;RPMI-8226: 1.8;SCLC-21H: 8.5" CAB022649 Uncertain NA NA "CAB022649: " "unprognostic (9.52e-2)" "unprognostic (1.13e-1)" "unprognostic (6.82e-2)" "unprognostic (2.07e-1)" "unprognostic (2.19e-2)" "unprognostic (1.04e-2)" "unprognostic (2.43e-2)" "unprognostic (6.97e-2)" "unprognostic (6.74e-2)" "unprognostic (2.15e-1)" "unprognostic (3.58e-3)" "unprognostic (3.57e-2)" "unprognostic (1.71e-2)" "unprognostic (2.07e-1)" "unprognostic (1.68e-1)" "unprognostic (6.89e-4)" "unprognostic (7.85e-2)" 0.7 6.3 7.8 0.5 6.2 0.4 1.3 1.8 11.2 2.5 1.9 2.2 4.4 1.0 7.2 36.8 0.9 14.3 0.9 7.4 13.2 4.5 4.1 0.6 1.6 0.4 4.7 4.9 16.3 4.5 0.4 10.2 0.5 6.2 1.1 0.9 0.5 0.6 1.9 0.6 0.7 0.9 3.0 3.2 1.9 3.6 0.6 3.2 0.0 1.1 0.0 0.4 0.6 1.5 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 6.5 0.0 0.0 0.4 0.0 0.0 1.4 2.6 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.1 0.0 0.0 0.7 0.1 0.0 0.0 0.0 1.8 0.0 1.0 8.5 0.0 0.0 0.5 0.0 0.6 1.4 0.0 0.3 0.0 0.1 0.0 0.0 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.8 6.2 1.8 11.2 13.2 4.5 4.7 4.9 6.2 3.2 0.0 0.0 0.0 0.0 0.0 0.4 2.8 0.0 14.7 1.2 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 13.3 2.5 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KCNMB3 "KCNMB2, KCNMBL" ENSG00000171121 "Potassium calcium-activated channel subfamily M regulatory beta subunit 3" Q9NPA1 3 179236691-179267002 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 6 "Cone photoreceptor cells: 13.7;Late spermatids: 10.9" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HEL: 11.2;NB-4: 7.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA015665, HPA019185" Approved Approved Nucleoplasm,Mitochondria NA NA Nucleoplasm Mitochondria "HPA015665: AB_1852142, HPA019185: AB_1852144" "unprognostic (2.50e-1)" "unprognostic (1.32e-1)" "unprognostic (6.76e-5)" "unprognostic (2.65e-2)" "unprognostic (2.22e-2)" "unprognostic (2.08e-1)" "unprognostic (4.59e-3)" "unprognostic (1.14e-1)" "unprognostic (9.15e-3)" "unprognostic (5.09e-2)" "unprognostic (1.87e-2)" "unprognostic (1.95e-5)" "unprognostic (5.93e-10)" "unprognostic (7.22e-2)" "unprognostic (4.72e-1)" "unprognostic (8.69e-2)" "unprognostic (3.49e-2)" 3.0 2.0 0.7 2.9 0.7 1.2 3.3 0.2 0.6 1.8 2.0 1.9 2.0 2.3 0.7 1.0 2.4 1.8 1.0 0.9 2.2 4.0 1.2 2.9 1.1 1.6 5.3 3.7 2.1 6.6 2.9 2.2 2.7 1.4 0.5 0.6 2.2 1.9 1.5 5.9 2.6 4.5 2.4 2.6 1.9 1.5 3.5 0.3 2.3 0.4 3.6 1.0 0.0 3.0 0.7 1.2 0.0 1.4 1.1 1.9 0.8 0.5 1.3 0.6 6.5 2.6 0.1 3.0 0.6 2.7 1.1 0.0 0.2 1.5 3.8 0.4 11.2 2.9 2.5 1.2 0.2 3.7 1.9 0.6 0.9 0.0 1.0 1.1 0.1 0.4 0.1 1.5 1.8 0.1 7.6 0.0 1.2 2.3 3.3 0.0 0.1 1.0 2.1 1.5 0.4 1.0 1.2 0.7 1.1 3.1 6.1 0.7 0.6 1.1 0.3 0.9 1.0 0.4 3.6 0.6 4.3 0.8 2.3 0.4 0.5 1.0 0.3 0.6 3.5 0.6 0.8 0.1 2.1 0.4 0.7 1.9 3.6 0.1 0.3 0.9 0.0 0.0 2.2 0.8 1.8 0.2 2.3 0.6 2.5 1.4 2.3 0.0 13.7 1.0 0.0 4.3 8.0 2.7 1.5 0.0 3.1 1.0 1.2 1.6 2.3 1.5 1.0 0.0 4.7 1.8 1.6 10.9 2.6 0.8 0.0 1.0 1.3 1.9 2.7 0.0 2.8 0.0 5.3 6.5 1.4 1.6 1.4 0.1 1.0 0.0 1.1 0.7 KCNN2 "hSK2, KCa2.2" ENSG00000080709 "Potassium calcium-activated channel subfamily N member 2" Q9H2S1 5 114360945-114496500 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Transport" "Calmodulin-binding, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 25.3;brain: 23.1;liver: 33.2" "Cell type enhanced" "Detected in some" 12 "Cardiomyocytes: 10.8;Hepatocytes: 14.7;Melanocytes: 20.3;Rod photoreceptor cells: 7.2" "Group enriched" "Detected in some" 7 "glioma: 3.5;melanoma: 3.2;prostate cancer: 12.6" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ: 15.0;NTERA-2: 5.7;SK-MEL-30: 10.6;THP-1: 18.7;U-937: 6.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA038221 Uncertain Uncertain "Nucleoplasm,Plasma membrane" NA NA "Nucleoplasm, Plasma membrane" "HPA038221: AB_10673044" "unprognostic (9.22e-3)" "unprognostic (1.90e-1)" "unprognostic (2.04e-1)" "unprognostic (5.65e-2)" "unprognostic (1.43e-1)" "unprognostic (1.40e-1)" "unprognostic (2.94e-1)" "unprognostic (1.42e-1)" "unprognostic (1.11e-2)" "unprognostic (1.56e-1)" "unprognostic (1.09e-1)" "unprognostic (1.15e-1)" "unprognostic (1.66e-1)" "unprognostic (1.23e-2)" "unprognostic (4.61e-1)" "unprognostic (3.16e-1)" "unprognostic (4.25e-1)" 0.8 25.3 12.6 0.8 7.3 0.6 1.1 21.7 15.0 1.7 1.2 9.5 0.0 0.9 3.9 0.9 0.8 1.0 1.0 7.7 23.1 3.6 4.8 33.2 2.5 0.9 4.5 16.9 1.4 3.8 1.0 16.0 0.6 9.1 11.7 1.3 4.2 1.1 5.4 9.9 2.1 0.9 2.8 8.4 1.1 1.1 3.8 6.5 0.0 0.9 0.0 0.8 2.4 1.1 0.3 0.3 0.8 0.3 0.1 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.8 15.0 2.3 0.3 0.1 0.0 0.2 0.0 0.5 0.0 2.0 0.0 2.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 3.3 0.0 0.1 0.0 0.2 0.0 1.2 5.7 0.0 0.0 0.1 0.0 0.7 0.3 0.1 1.8 0.0 0.0 0.2 10.6 0.3 0.2 18.7 0.2 0.0 0.4 1.7 0.0 0.1 0.0 0.1 1.8 6.7 0.5 0.5 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.3 0.3 0.1 0.3 0.8 0.1 0.3 0.3 0.1 0.0 12.6 7.3 21.7 15.0 23.1 3.6 4.5 16.9 9.1 6.5 0.0 0.6 0.0 0.1 0.2 6.8 10.8 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.7 5.2 0.0 0.0 0.8 0.0 0.9 4.5 0.0 14.7 0.0 0.0 0.0 6.2 1.0 0.0 0.0 0.0 20.3 0.0 0.5 0.3 1.4 0.0 0.0 0.5 7.2 0.0 0.5 0.5 3.2 0.3 0.0 0.0 0.4 0.1 KCNN4 "hIKCa1, hKCa4, hSK4, IK, KCa3.1" ENSG00000104783 "Potassium calcium-activated channel subfamily N member 4" O15554 19 43766533-43781257 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Immunity, Ion transport, Transport" "Calmodulin-binding, Ion channel" "Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 45.7;salivary gland: 82.3" "Group enriched" "Detected in many" 6 "Cytotrophoblasts: 196.8;Syncytiotrophoblasts: 638.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CAPAN-2: 27.8;hTERT-RPE1: 24.5;SK-BR-3: 27.5;WM-115: 70.6" "Region enhanced" "Detected in single" "olfactory region: 2.3" "Not detected" "Not detected" "HPA053841, HPA059622" Approved NA NA "HPA053841: AB_2682278, HPA059622: AB_2684085" "unprognostic (1.23e-2)" "unprognostic (3.22e-2)" "unprognostic (4.29e-1)" "unprognostic (3.74e-3)" "prognostic unfavorable (2.68e-4)" "unprognostic (1.98e-2)" "unprognostic (7.33e-2)" "unprognostic (1.42e-2)" "unprognostic (2.48e-3)" "unprognostic (4.12e-2)" "prognostic unfavorable (4.56e-4)" "unprognostic (9.96e-3)" "prognostic unfavorable (1.05e-14)" "unprognostic (3.70e-2)" "unprognostic (2.17e-2)" "unprognostic (7.50e-2)" "prognostic favorable (1.75e-4)" 3.0 0.1 0.5 12.2 2.5 6.5 5.6 0.4 0.5 8.0 5.7 0.7 6.4 2.0 0.9 2.9 2.6 2.6 8.8 0.6 1.4 0.5 0.8 0.3 2.6 5.7 1.7 0.6 1.3 0.3 0.0 0.3 45.7 1.5 11.0 3.8 0.8 82.3 6.8 0.7 10.8 10.0 2.0 1.1 8.4 13.6 0.9 1.0 9.1 0.7 3.6 17.3 10.3 2.4 18.7 14.4 1.9 15.8 0.0 6.9 5.2 5.1 9.6 0.0 0.0 0.0 0.8 13.5 0.2 0.7 0.5 0.1 0.1 27.8 1.5 2.2 0.2 3.2 4.1 0.0 9.8 1.4 9.3 0.0 6.8 12.5 0.2 0.0 0.0 0.1 0.0 1.2 0.6 4.4 24.5 0.0 0.0 1.5 0.8 0.1 5.0 1.5 5.2 0.0 21.9 10.3 4.6 0.1 5.1 8.5 14.4 0.0 0.0 13.8 27.5 8.1 0.6 0.0 5.5 0.3 3.8 19.7 0.1 11.1 0.0 0.3 0.6 13.1 1.2 70.6 1.9 10.2 0.0 0.3 15.8 0.4 18.7 5.1 2.6 14.4 9.4 3.4 3.2 0.5 0.0 8.6 0.4 6.9 5.2 0.5 2.5 0.4 0.5 1.4 0.5 1.7 0.6 1.5 1.0 0.0 3.4 27.2 43.3 2.5 0.1 0.4 7.6 0.0 6.8 1.8 3.9 196.8 0.0 3.0 0.7 2.8 4.2 23.3 3.5 6.8 2.8 66.7 0.0 0.0 43.0 0.0 0.0 0.0 7.5 0.0 0.0 28.3 20.3 0.0 5.9 0.0 37.2 16.9 0.0 0.0 0.3 0.0 1.0 0.0 1.3 1.9 638.3 6.5 43.7 53.5 KCNQ1 "JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1" ENSG00000053918 "Potassium voltage-gated channel subfamily Q member 1" P51787 11 2444684-2849110 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Calmodulin-binding, Ion channel, Potassium channel, Voltage-gated channel" "Atrial fibrillation, Deafness, Diabetes mellitus, Disease mutation, FDA approved drug targets, Long QT syndrome, Short QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 78.2;ductus deferens: 88.1;seminal vesicle: 83.6" "Cell type enhanced" "Detected in many" 6 "Enterocytes: 32.7;Undifferentiated cells: 44.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HMC-1: 19.9;OE19: 24.0;RPMI-8226: 13.4;U-266/70: 7.9;U-937: 7.8" "Not detected" "Not detected" "Not detected" "Not detected" "CAB018656, HPA048553" Enhanced NA NA "CAB018656: AB_2131551, HPA048553: AB_2680438" "unprognostic (6.02e-2)" "unprognostic (2.48e-1)" "unprognostic (6.39e-3)" "unprognostic (4.38e-1)" "unprognostic (1.86e-1)" "unprognostic (1.83e-1)" "unprognostic (3.46e-2)" "unprognostic (7.36e-2)" "unprognostic (8.07e-2)" "unprognostic (8.81e-2)" "unprognostic (1.58e-1)" "unprognostic (5.39e-2)" "unprognostic (2.46e-3)" "prognostic favorable (9.85e-4)" "unprognostic (3.99e-2)" "unprognostic (4.19e-2)" "unprognostic (5.27e-2)" 3.0 78.2 1.0 5.1 1.0 3.4 3.1 0.6 1.2 5.0 13.7 4.1 88.1 14.2 1.9 15.9 1.5 2.1 12.2 10.7 1.5 1.0 13.8 1.0 11.4 5.8 1.2 0.8 1.6 25.6 5.6 2.7 1.8 1.8 7.5 4.6 2.5 9.5 83.6 0.8 1.0 18.4 1.5 1.4 5.5 31.2 3.6 1.5 1.6 36.2 0.9 4.8 5.5 3.6 1.2 5.6 5.3 4.7 0.0 1.7 1.4 0.0 0.1 0.0 3.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 1.4 0.9 3.3 0.0 0.2 0.1 0.4 0.0 0.0 0.2 0.9 0.0 2.4 0.2 0.2 0.0 19.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.4 0.7 24.0 0.1 0.1 0.0 13.4 5.0 1.6 0.4 3.7 0.4 0.0 0.0 0.3 0.1 5.1 0.0 0.0 0.1 0.1 0.0 7.9 0.0 0.0 0.0 7.8 0.0 1.6 4.7 4.7 0.0 2.6 0.1 1.2 0.6 0.1 5.6 0.6 1.7 1.7 5.3 0.0 3.7 1.9 0.5 1.4 1.0 1.0 0.6 1.2 1.5 1.0 1.2 0.8 1.8 1.5 3.0 11.7 6.7 6.7 0.6 0.0 15.9 17.8 2.7 5.7 27.9 0.0 1.0 13.3 16.6 1.1 2.9 32.7 0.0 18.8 1.1 1.0 6.2 19.6 0.2 13.9 0.0 6.3 9.2 24.1 0.6 0.3 10.1 1.7 1.8 21.3 0.6 17.8 17.5 0.0 1.6 0.2 6.5 1.0 0.2 0.1 0.9 1.7 1.3 44.9 14.7 KCNQ2 "BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2" ENSG00000075043 "Potassium voltage-gated channel subfamily Q member 2" O43526 20 63400210-63472677 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 50.8" "Group enriched" "Detected in some" 5 "Early spermatids: 10.8;Horizontal cells: 12.7;Late spermatids: 5.7;Spermatocytes: 6.6;Spermatogonia: 17.0" "Cancer enriched" "Detected in some" 9 "glioma: 8.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 2.2;T-reg: 1.5" "Lineage enriched" "Detected in single" 22 "T-cells: 2.2" "Cell line enhanced" "Detected in some" "AF22: 8.5;AN3-CA: 14.0;NTERA-2: 7.8;SCLC-21H: 27.5;SH-SY5Y: 48.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016642, HPA057112" Enhanced Approved "Endoplasmic reticulum" NA NA "Endoplasmic reticulum" "HPA016642: AB_1855555, HPA057112: AB_2683339" "unprognostic (2.35e-1)" "unprognostic (1.41e-1)" "unprognostic (2.22e-4)" "unprognostic (8.21e-6)" "unprognostic (6.18e-2)" "unprognostic (7.58e-2)" "unprognostic (6.06e-2)" "unprognostic (3.16e-1)" "unprognostic (1.73e-1)" "unprognostic (1.92e-1)" "unprognostic (9.96e-2)" "unprognostic (9.39e-2)" "unprognostic (1.43e-5)" "unprognostic (4.36e-2)" "unprognostic (1.02e-1)" "unprognostic (1.81e-1)" "unprognostic (2.70e-2)" 1.2 10.0 18.7 1.3 21.4 1.2 1.2 24.1 50.8 1.2 1.3 2.4 0.0 1.3 1.2 1.3 1.2 1.7 1.7 1.2 15.4 10.0 1.2 1.2 1.2 1.2 8.4 14.1 1.2 1.9 1.2 9.2 1.2 8.9 2.8 1.2 0.0 1.2 1.2 1.2 1.2 1.3 1.2 2.6 1.2 1.3 6.9 4.2 0.0 1.2 0.0 1.2 1.2 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 8.5 14.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 3.3 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 7.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 27.5 48.4 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.8 0.9 0.0 0.0 0.0 0.0 1.5 0.0 18.7 21.4 24.1 31.2 15.4 10.0 8.4 14.1 8.9 4.2 0.0 0.0 0.0 0.0 0.1 1.5 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.8 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 12.7 0.0 0.0 0.0 5.7 0.6 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.4 0.0 2.1 0.0 0.0 6.6 17.0 0.0 0.0 0.0 0.0 0.0 KCNQ3 "EBN2, Kv7.3" ENSG00000184156 "Potassium voltage-gated channel subfamily Q member 3" O43525 8 132120858-132481019 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 9 "brain: 29.5" "Cell type enhanced" "Detected in some" 11 "Alveolar cells type 2: 9.4;Bipolar cells: 5.7;Cardiomyocytes: 4.5;Exocrine glandular cells: 5.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "hTERT-HME1: 10.1;JURKAT: 5.6;RPMI-8226: 4.1;U-2 OS: 6.6;U-87 MG: 5.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA "unprognostic (2.90e-1)" "unprognostic (1.26e-3)" "unprognostic (1.45e-2)" "unprognostic (3.65e-5)" "unprognostic (2.32e-1)" "unprognostic (4.60e-2)" "unprognostic (5.57e-6)" "unprognostic (5.82e-2)" "unprognostic (7.32e-2)" "unprognostic (6.09e-2)" "unprognostic (7.09e-2)" "unprognostic (3.22e-1)" "unprognostic (2.71e-4)" "unprognostic (1.14e-3)" "unprognostic (3.52e-1)" "unprognostic (7.92e-2)" "unprognostic (2.50e-2)" 1.8 3.3 10.6 1.5 13.1 0.7 1.4 0.9 29.5 1.4 1.0 1.7 0.0 1.0 1.0 0.9 0.8 1.2 1.3 1.8 8.0 7.3 1.8 0.7 2.0 0.9 7.4 11.5 0.8 1.2 1.2 1.4 1.0 6.5 1.4 1.0 0.0 1.0 1.8 0.7 1.3 1.7 1.6 2.1 1.3 0.9 1.0 4.7 0.0 1.2 0.0 1.0 1.1 0.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.4 0.1 0.0 0.0 0.5 1.6 0.0 0.5 1.6 0.0 0.0 0.0 1.5 0.0 1.8 2.3 3.8 0.0 0.0 3.7 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.6 0.0 2.6 10.1 0.1 0.0 5.6 0.0 0.2 1.3 0.0 0.0 0.0 0.7 0.0 0.3 0.0 0.0 4.1 2.4 0.0 1.9 1.7 0.7 0.0 0.0 0.3 0.0 1.4 0.0 0.0 6.6 0.2 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.6 13.1 0.9 13.3 8.0 7.3 7.4 11.5 6.5 4.7 0.0 9.4 0.0 0.0 0.2 5.7 4.5 0.0 1.4 2.3 0.0 0.0 0.0 0.0 2.9 1.5 0.6 0.0 0.0 5.1 0.0 0.2 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.3 0.0 1.2 0.0 1.0 0.0 0.2 2.8 0.0 0.0 0.4 0.4 0.0 1.7 0.0 0.2 0.1 0.0 0.0 0.0 0.0 M6PR "CD-M6PR, CD-MPR" ENSG00000003056 "Mannose-6-phosphate receptor, cation dependent" P20645 12 8940363-8949955 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Hofbauer cells: 214.9;monocytes: 227.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 127.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB034464, HPA040445" Approved NA NA 280000 "CAB034464: AB_2139108, HPA040445: AB_2676989" "unprognostic (2.43e-1)" "unprognostic (1.22e-1)" "unprognostic (1.74e-2)" "unprognostic (1.54e-1)" "unprognostic (3.00e-1)" "unprognostic (1.89e-2)" "prognostic unfavorable (3.89e-4)" "unprognostic (1.76e-1)" "unprognostic (2.84e-1)" "unprognostic (5.82e-3)" "unprognostic (1.44e-2)" "unprognostic (6.82e-2)" "unprognostic (4.53e-3)" "unprognostic (3.79e-2)" "unprognostic (1.01e-1)" "unprognostic (3.64e-1)" "unprognostic (3.98e-1)" 37.9 40.5 24.7 40.7 27.6 34.8 32.3 21.8 39.6 25.6 28.3 26.3 27.9 20.8 37.4 26.2 30.0 29.2 28.0 36.5 23.3 22.8 37.2 50.6 42.8 46.8 27.4 23.0 30.1 40.0 31.3 24.8 34.0 24.2 27.8 35.2 26.1 37.0 29.4 32.3 27.7 36.9 31.7 26.5 56.1 31.6 33.9 25.2 43.1 46.9 24.4 44.8 34.3 27.2 17.6 47.4 75.4 74.6 22.1 30.4 57.5 14.7 23.0 15.4 17.3 27.2 13.1 46.4 19.4 22.6 26.7 29.4 24.5 36.0 25.8 7.1 20.4 58.1 22.3 21.8 19.4 30.9 127.9 12.0 45.0 19.3 18.3 32.3 48.9 85.5 19.7 23.0 28.6 36.3 26.5 14.5 18.9 12.7 17.1 23.1 14.4 17.5 16.3 53.7 26.7 9.8 16.9 33.9 14.2 20.6 37.4 3.5 15.8 21.4 20.4 25.6 57.2 5.1 31.3 14.6 22.1 26.4 26.6 28.5 21.6 37.7 29.4 25.6 29.8 16.2 75.4 40.3 42.9 26.9 64.5 29.7 17.6 30.4 28.0 47.4 14.5 22.5 25.4 5.9 22.1 74.6 28.2 23.9 57.5 24.7 27.6 21.8 39.6 23.3 22.8 27.4 23.0 24.2 25.2 53.6 53.6 73.6 61.1 39.2 43.5 8.7 17.8 60.2 69.4 29.6 21.6 56.3 16.6 78.0 6.0 32.2 18.8 23.3 58.0 58.9 32.0 49.1 127.2 22.7 214.9 52.4 36.8 31.9 110.8 5.2 32.5 120.2 64.1 227.2 29.6 31.8 48.3 24.6 30.1 33.8 31.4 25.8 44.8 102.2 45.3 35.4 44.4 78.7 41.7 55.7 MC2R ACTHR ENSG00000185231 "Melanocortin 2 receptor" Q01718 18 13882044-13915707 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "adrenal gland: 31.7;pituitary gland: 14.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "basophil: 1.3" "Lineage enriched" "Detected in single" 4 "granulocytes: 1.3" "Cell line enhanced" "Detected in some" "HeLa: 1.7;MCF7: 3.6;SuSa: 1.8" "Not detected" "Not detected" "Not detected" "Not detected" HPA079148 Enhanced NA NA "HPA079148: " "unprognostic (2.09e-1)" "unprognostic (3.63e-2)" "unprognostic (1.85e-2)" 0.0 31.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 14.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.1 0.0 0.0 0.3 0.0 0.1 0.1 1.3 0.3 0.1 0.1 0.0 0.2 0.0 0.1 0.3 0.1 0.3 1.1 0.2 0.0 0.1 0.3 0.1 0.2 0.0 0.0 0.4 0.1 0.3 0.1 0.9 0.1 0.0 0.5 0.0 1.7 0.2 0.0 0.2 0.0 0.0 0.9 0.0 0.6 0.2 0.0 0.2 0.1 0.4 0.0 3.6 0.0 0.0 0.6 0.0 0.1 0.2 0.5 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.1 1.8 0.1 0.3 0.0 0.2 0.3 0.5 0.0 0.2 0.2 0.0 0.1 0.4 0.0 1.3 0.1 0.0 0.1 0.3 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.5 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MS4A1 "B1, Bp35, CD20, MS4A2" ENSG00000156738 "Membrane spanning 4-domains A1" P11836 11 60455752-60470760 "CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "B-cell activation" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 77.7;intestine: 46.1;lymphoid tissue: 134.1" "Cell type enriched" "Detected in some" 61 "B-cells: 527.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 105 "memory B-cell: 77.7;naive B-cell: 77.7" "Lineage enriched" "Detected in single" 105 "B-cells: 77.7" "Group enriched" "Detected in some" 25 "Daudi: 122.9;U-698: 61.8" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000015, HPA014341, HPA014391" Enhanced Supported "Plasma membrane" NA NA "Plasma membrane" "CAB000015: AB_2282030, HPA014341: AB_1846265, HPA014391: AB_1846264" "prognostic favorable (4.34e-5)" "unprognostic (4.45e-4)" "unprognostic (1.19e-4)" "unprognostic (2.04e-3)" "unprognostic (1.06e-1)" "unprognostic (5.53e-7)" "unprognostic (2.46e-3)" "unprognostic (1.85e-3)" "unprognostic (3.06e-2)" "unprognostic (2.89e-4)" "unprognostic (6.96e-2)" "unprognostic (2.84e-2)" "unprognostic (3.96e-5)" "unprognostic (2.23e-1)" "unprognostic (8.04e-2)" "unprognostic (1.44e-1)" "unprognostic (1.30e-1)" 1.6 0.3 0.3 79.0 0.3 3.6 0.6 0.3 0.3 0.5 2.0 0.0 0.0 0.2 0.4 0.5 7.0 0.4 1.3 0.7 0.3 0.3 2.0 0.9 2.7 81.2 0.3 0.1 0.3 0.4 0.0 0.4 0.4 0.1 1.1 1.7 0.6 14.5 0.2 0.3 0.3 46.1 0.1 0.4 90.7 2.6 0.6 0.0 15.7 2.5 2.7 134.1 6.4 0.8 77.7 0.0 0.2 0.0 0.7 0.6 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 122.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 61.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 77.7 0.3 0.6 0.0 77.7 0.0 0.2 0.2 0.7 0.0 0.0 0.0 3.5 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.1 0.1 0.0 0.0 6.7 527.8 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.3 0.0 0.1 0.0 0.0 0.0 0.6 1.8 0.0 0.0 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 8.7 0.0 0.0 MS4A2 "APY, FCER1B, IGER, MS4A1" ENSG00000149534 "Membrane spanning 4-domains A2" Q01362 11 60088261-60098466 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "IgE-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 72.0" "Cell type enriched" "Detected in some" 18 "granulocytes: 912.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 720 "basophil: 72.0" "Lineage enriched" "Detected in single" 720 "granulocytes: 72.0" "Cell line enhanced" "Detected in some" "HEL: 7.1;NB-4: 2.6;THP-1: 4.2;U-937: 1.9" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA059967 Enhanced NA NA "HPA059967: AB_2684183" "unprognostic (7.28e-2)" "unprognostic (9.21e-2)" "unprognostic (2.50e-4)" "unprognostic (4.97e-2)" "unprognostic (4.47e-1)" "unprognostic (2.40e-6)" "unprognostic (1.88e-2)" "unprognostic (6.21e-3)" "unprognostic (3.96e-1)" "unprognostic (1.21e-1)" "unprognostic (1.41e-1)" "unprognostic (6.63e-3)" "unprognostic (6.49e-3)" "unprognostic (9.95e-2)" "unprognostic (4.03e-2)" "unprognostic (1.57e-1)" "unprognostic (1.74e-1)" 4.9 0.5 0.4 5.1 0.4 0.2 2.1 0.4 0.4 11.9 4.6 0.1 4.5 4.7 14.3 11.2 5.9 1.1 14.6 2.1 0.4 0.4 1.5 0.9 12.9 0.5 0.4 0.1 1.1 1.2 0.2 0.6 0.6 0.1 17.5 5.6 4.5 3.2 5.4 1.5 4.3 7.4 15.9 0.4 0.6 4.5 2.7 0.2 1.2 0.6 6.7 3.4 5.1 4.1 0.0 0.0 72.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.3 0.2 0.0 0.3 0.0 0.0 0.1 0.3 0.2 0.4 0.1 0.1 0.0 0.0 0.2 0.0 0.1 0.1 0.3 0.0 7.1 0.5 0.2 0.3 0.9 0.4 0.1 0.2 0.0 0.1 0.0 0.1 0.1 0.9 0.3 0.0 0.1 0.0 2.6 0.1 0.0 0.1 0.1 0.0 0.2 0.0 1.0 0.2 0.1 0.1 0.2 0.0 0.0 0.3 4.2 0.0 0.1 0.1 0.3 0.1 0.1 0.0 0.1 0.2 1.9 0.2 72.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.1 0.1 0.2 0.0 51.4 0.0 0.6 0.0 0.4 0.4 0.0 1.4 12.5 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.5 912.4 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 MTNR1A MEL-1A-R ENSG00000168412 "Melatonin receptor 1A" P48039 4 186533655-186555567 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 3.8;intestine: 3.1;kidney: 5.7;testis: 2.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 2.8;EFO-21: 2.0;HEK 293: 2.1;NTERA-2: 1.8;SCLC-21H: 1.6;SH-SY5Y: 3.2" "Low region specificity" "Detected in single" "Not detected" "Not detected" NA NA "unprognostic (7.99e-2)" "unprognostic (2.27e-1)" "unprognostic (2.16e-1)" "unprognostic (3.67e-1)" "unprognostic (2.14e-1)" "unprognostic (9.88e-2)" "unprognostic (9.20e-2)" "unprognostic (8.81e-2)" 0.0 0.0 0.1 1.2 0.1 0.0 0.0 3.8 0.2 0.0 3.1 0.3 0.0 0.0 0.0 0.4 0.6 0.0 0.1 0.1 5.7 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 2.4 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.5 0.0 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.8 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.3 0.5 0.0 2.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.1 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 NPR2 "AMDM, ANPb, ANPRB, GUCY2B, NPRB" ENSG00000159899 "Natriuretic peptide receptor 2" P20594 9 35792154-35809732 "Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "cGMP biosynthesis, Osteogenesis" "Lyase, Receptor" "Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 32.7" "Cell type enhanced" "Detected in many" 5 "Leydig cells: 8.6;Muller glia cells: 8.2;Peritubular cells: 7.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 3.1" "Group enriched" "Detected in many" 6 "dendritic cells: 3.1;T-cells: 2.1" "Cell line enhanced" "Detected in many" "ASC diff: 27.6;ASC TERT1: 20.6;BJ hTERT+: 16.8;HSkMC: 20.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (2.93e-2)" "unprognostic (8.22e-3)" "unprognostic (9.25e-3)" "unprognostic (3.59e-2)" "unprognostic (6.13e-2)" "unprognostic (2.63e-2)" "unprognostic (1.41e-1)" "unprognostic (1.56e-1)" "unprognostic (1.56e-1)" "unprognostic (2.40e-1)" "unprognostic (3.06e-1)" "unprognostic (1.49e-1)" "unprognostic (3.99e-2)" "unprognostic (6.99e-3)" "unprognostic (7.10e-2)" "unprognostic (3.24e-1)" "unprognostic (7.86e-2)" 9.0 4.8 3.8 1.9 6.4 0.0 7.2 32.7 11.2 29.2 7.8 1.8 4.4 1.8 22.6 9.8 5.3 7.6 5.7 7.6 3.7 4.2 3.7 8.4 4.7 2.3 2.5 5.1 8.0 1.3 2.7 7.9 7.1 11.8 8.3 4.0 8.3 3.3 9.5 7.7 6.2 3.7 17.1 3.9 2.6 4.5 5.5 4.0 0.9 3.2 2.4 2.0 6.2 8.9 0.4 3.1 0.0 0.0 0.1 2.1 0.1 0.0 1.6 1.9 0.0 27.6 20.6 1.2 7.7 16.8 6.2 6.7 4.0 2.7 1.1 2.0 15.0 11.6 0.7 2.3 0.2 5.6 1.3 0.7 1.0 1.8 2.0 15.0 0.1 0.0 20.4 1.1 6.9 0.5 6.1 10.1 1.7 0.5 0.1 11.6 0.5 0.3 0.4 2.6 0.8 2.8 1.3 0.1 0.5 1.0 0.8 0.5 0.6 0.2 0.0 0.3 3.1 0.1 0.0 6.5 6.6 5.1 2.1 0.7 0.2 0.3 3.0 8.4 0.3 3.7 0.0 0.0 0.0 1.1 0.0 0.0 0.4 1.2 0.6 0.0 0.0 0.5 0.4 0.0 0.1 0.0 3.1 2.1 0.1 3.8 6.4 32.7 11.2 3.7 4.2 2.5 5.1 11.8 4.0 3.0 4.3 0.0 0.6 1.0 4.0 0.6 0.0 1.4 0.0 0.0 2.0 0.3 0.0 0.4 0.1 2.3 0.1 0.0 0.7 0.1 5.7 1.7 1.1 5.7 0.3 3.2 0.0 2.5 0.3 0.0 8.6 0.0 0.0 0.0 0.9 8.2 0.5 3.1 7.4 0.6 2.1 0.0 1.9 2.8 2.0 1.4 0.2 0.0 1.0 0.3 NR1H4 "FXR, HRR-1, HRR1, RIP14" ENSG00000012504 "Nuclear receptor subfamily 1 group H member 4" Q96RI1 12 100473708-100564413 "Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters" "Immunity, Inflammatory response, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Disease mutation, FDA approved drug targets, Intrahepatic cholestasis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "liver: 109.4" "Cell type enhanced" "Detected in some" 15 "Cholangiocytes: 79.0;Distal tubular cells: 36.5;Hepatocytes: 90.4;Proximal tubular cells: 116.5" "Group enriched" "Detected in some" 11 "liver cancer: 18.7;renal cancer: 12.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 32 "Hep G2: 18.4;HHSteC: 11.1;RPTEC TERT1: 29.7" "Not detected" "Not detected" "Not detected" "Not detected" HPA047699 Approved Nucleoplasm NA NA Nucleoplasm "HPA047699: AB_10965320" "unprognostic (1.78e-1)" "unprognostic (1.81e-1)" "unprognostic (6.68e-2)" "unprognostic (2.49e-1)" "unprognostic (1.60e-1)" "unprognostic (9.39e-2)" "unprognostic (2.01e-1)" "unprognostic (1.88e-2)" "unprognostic (1.16e-1)" "unprognostic (2.43e-1)" "unprognostic (3.77e-3)" 0.1 11.3 0.1 1.4 0.4 0.0 0.2 0.1 0.2 0.2 5.8 0.4 0.1 11.3 0.1 0.4 0.1 0.1 7.0 0.1 0.1 0.0 25.0 109.4 0.6 2.4 0.1 0.1 7.7 2.7 0.0 2.9 0.2 0.3 0.5 0.4 0.6 0.1 0.1 0.1 0.0 19.5 0.3 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.3 0.3 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.4 11.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.1 0.2 0.1 0.0 0.1 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 79.0 0.0 0.0 21.0 0.0 0.0 36.5 6.3 0.2 0.0 25.7 0.0 0.0 0.0 0.0 0.0 0.0 90.4 0.0 0.0 0.0 14.7 1.9 1.3 0.9 0.0 0.0 0.0 0.1 0.0 0.6 2.9 0.0 116.5 0.0 0.0 0.1 0.5 0.7 0.0 0.0 0.0 0.3 0.9 OPRM1 MOR1 ENSG00000112038 "Opioid receptor mu 1" P35372 6 154010496-154246867 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 37.9" "Group enriched" "Detected in some" 33 "Early spermatids: 24.0;Late spermatids: 23.1" "Not detected" "Not detected" "Region enhanced" "Detected in many" "cerebellum: 37.9" "Cell type enhanced" "Detected in single" "neutrophil: 2.1" "Low lineage specificity" "Detected in single" "Cell line enriched" "Detected in single" 24 "SH-SY5Y: 13.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA014509, HPA067435" Enhanced Supported NA NA "HPA014509: AB_1854801, HPA067435: " "unprognostic (7.34e-2)" "unprognostic (6.91e-2)" 0.5 3.4 7.0 0.6 17.5 1.8 0.9 37.9 7.6 0.5 0.6 0.8 0.0 0.6 0.7 1.4 3.7 0.5 1.0 0.5 2.6 2.3 0.5 0.5 0.5 0.9 0.6 9.3 0.8 0.7 0.4 0.6 0.5 5.2 0.7 0.4 0.0 0.6 0.2 0.9 1.8 0.5 0.3 1.9 0.6 1.0 8.0 0.5 0.0 1.0 0.0 0.3 0.5 0.5 0.5 0.2 2.1 0.1 0.1 0.7 0.0 0.1 0.0 0.2 0.4 0.0 0.2 0.2 0.2 0.0 0.1 0.0 0.2 0.4 0.4 0.1 0.0 0.5 0.3 0.3 0.2 0.1 0.3 0.1 0.1 0.4 0.1 0.0 0.3 0.5 0.1 0.5 0.0 0.1 0.0 0.1 0.2 0.1 0.3 0.3 0.2 0.1 0.0 0.1 0.0 0.0 0.2 0.2 0.0 0.1 0.1 0.3 13.1 0.0 0.1 0.3 0.4 0.3 0.1 0.3 0.4 0.1 0.3 0.1 0.4 0.2 0.1 0.3 0.1 0.0 0.2 0.1 0.6 0.6 0.0 0.7 0.2 0.3 0.5 0.1 0.5 0.4 0.1 2.1 0.1 0.0 0.2 0.3 0.0 7.0 17.5 37.9 7.6 2.6 2.3 0.6 9.3 5.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.5 0.0 0.1 OXTR ENSG00000180914 "Oxytocin receptor" P30559 3 8750408-8769628 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "breast: 42.5" "Cell type enriched" "Detected in some" 8 "Ciliated cells: 93.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "neutrophil: 1.6" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.6" "Cell line enhanced" "Detected in some" "BJ: 81.2;BJ hTERT+: 24.9;BJ hTERT+ SV40 Large T+: 23.6;fHDF/TERT166: 81.3;HBF TERT88: 18.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA "unprognostic (1.18e-1)" "unprognostic (7.94e-2)" "unprognostic (4.76e-2)" "unprognostic (1.29e-2)" "unprognostic (2.02e-2)" "unprognostic (2.02e-1)" "unprognostic (1.46e-2)" "unprognostic (2.56e-3)" "unprognostic (2.12e-1)" "unprognostic (3.42e-1)" "unprognostic (2.76e-1)" "unprognostic (3.80e-2)" "unprognostic (4.24e-4)" "unprognostic (8.25e-2)" "unprognostic (4.60e-2)" "unprognostic (2.71e-1)" "unprognostic (1.84e-1)" 0.5 0.4 1.8 0.3 6.5 0.6 42.5 0.9 2.2 0.5 0.3 0.1 0.0 0.3 2.8 0.5 1.1 2.7 1.0 0.6 1.8 4.0 0.6 0.4 1.0 0.4 8.6 0.8 2.8 0.3 0.3 0.3 1.3 3.7 0.9 0.3 1.6 0.4 0.9 0.3 0.4 0.4 0.6 2.5 0.5 0.3 0.5 1.2 0.1 0.4 0.0 0.4 0.4 0.0 0.0 0.2 1.6 0.1 0.1 0.3 1.0 0.2 0.8 0.4 0.1 0.1 0.2 0.1 81.2 24.9 23.6 12.6 0.1 2.1 0.0 0.1 81.3 0.3 0.1 0.3 0.1 18.4 0.7 0.4 0.2 0.3 0.1 0.4 0.1 0.2 0.1 0.1 0.3 0.1 7.1 0.0 0.2 0.0 0.1 13.1 0.0 0.1 0.6 0.5 0.2 3.6 0.1 0.3 4.8 0.9 0.0 0.1 0.1 0.1 0.1 0.0 1.6 0.0 0.1 0.1 1.1 0.3 0.2 0.2 0.1 0.2 0.0 0.1 0.2 0.2 0.5 0.0 0.1 0.2 0.1 0.2 0.0 0.2 0.2 0.2 0.0 0.2 0.3 1.6 0.1 0.0 0.1 0.1 1.0 1.8 6.5 0.9 2.2 1.8 4.0 8.6 0.8 3.7 1.2 8.9 1.4 0.0 0.4 0.3 0.2 1.2 0.0 93.7 11.4 0.0 0.0 0.0 0.0 2.6 0.9 0.0 0.0 0.0 0.0 0.1 0.5 1.7 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.5 0.0 0.2 0.0 0.0 0.0 5.8 1.0 0.0 0.4 0.0 0.0 0.0 0.5 0.7 1.3 0.1 0.0 0.0 0.0 0.1 P2RX4 P2X4 ENSG00000135124 "Purinergic receptor P2X 4" Q99571 12 121209857-121234106 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Cytotrophoblasts: 110.0;Hofbauer cells: 116.1;Syncytiotrophoblasts: 130.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" HPA039494 Enhanced NA NA "HPA039494: AB_10969132" "unprognostic (4.02e-3)" "unprognostic (1.06e-1)" "unprognostic (5.43e-2)" "prognostic favorable (6.30e-10)" "unprognostic (2.98e-2)" "unprognostic (2.52e-1)" "unprognostic (2.06e-3)" "unprognostic (1.68e-1)" "unprognostic (1.21e-1)" "unprognostic (5.42e-2)" "unprognostic (7.71e-2)" "unprognostic (2.18e-1)" "unprognostic (1.81e-2)" "unprognostic (1.13e-1)" "unprognostic (6.06e-2)" "unprognostic (1.42e-2)" "unprognostic (4.76e-3)" 14.1 7.8 4.9 6.5 4.7 4.8 13.8 24.0 8.1 11.3 16.3 8.8 5.5 13.4 6.3 5.5 5.6 8.4 8.6 6.1 3.9 3.4 10.2 13.2 11.6 16.1 6.0 3.5 9.9 22.7 15.7 8.4 25.9 5.8 7.7 13.9 7.0 15.7 9.5 2.3 4.1 17.6 8.4 6.8 11.5 11.2 4.2 5.0 4.2 7.1 2.8 7.1 7.8 5.8 2.7 6.1 17.1 14.2 5.6 6.1 7.2 2.2 6.2 0.1 7.7 4.0 3.7 19.3 2.3 12.4 3.2 5.6 3.6 9.1 1.6 7.0 7.5 20.0 0.9 2.1 1.2 1.5 7.7 4.5 1.0 0.1 3.2 9.7 2.8 16.7 4.6 2.5 3.2 4.2 7.8 11.1 2.5 2.8 5.8 2.4 11.6 1.5 1.9 2.0 11.3 5.0 1.6 11.2 11.9 1.1 3.8 1.9 3.7 5.4 3.2 20.9 2.2 15.6 5.2 0.6 4.5 3.7 0.4 1.3 8.3 9.4 1.5 9.0 3.4 4.3 17.1 13.0 2.1 4.2 14.2 4.2 2.7 6.1 3.4 6.1 1.5 4.5 2.2 0.1 5.6 12.2 1.4 3.9 7.2 4.9 4.7 24.0 8.1 3.9 3.4 6.0 3.5 5.8 5.0 6.0 19.2 9.8 7.8 3.4 11.5 2.7 17.8 9.4 14.8 19.2 2.0 110.0 0.0 52.0 12.4 8.8 73.4 0.0 31.1 62.5 11.8 13.0 12.8 8.5 116.1 14.3 20.6 27.0 43.8 19.4 8.1 37.9 10.1 84.8 75.8 6.3 36.8 55.1 9.2 18.9 7.4 19.4 9.2 5.1 4.9 3.4 130.2 15.2 22.5 8.0 P2RY2 P2U ENSG00000175591 "Purinergic receptor P2Y2" P41231 11 73218298-73236352 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.1;skeletal muscle: 29.5" "Cell type enhanced" "Detected in many" 5 "Cytotrophoblasts: 14.0;Enterocytes: 12.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "eosinophil: 28.1" "Group enriched" "Detected in many" 12 "granulocytes: 28.1;monocytes: 10.4" "Cell line enhanced" "Detected in many" "HaCaT: 16.4;HL-60: 15.5;MCF7: 12.4;NB-4: 12.6;PC-3: 12.9;SK-BR-3: 14.3;THP-1: 36.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" CAB022642 Uncertain Uncertain Cytosol NA NA Cytosol "CAB022642: " "unprognostic (1.24e-1)" "unprognostic (1.13e-1)" "unprognostic (6.36e-2)" "unprognostic (7.97e-3)" "unprognostic (6.50e-4)" "unprognostic (2.04e-2)" "unprognostic (4.66e-3)" "unprognostic (8.93e-2)" "unprognostic (2.87e-1)" "unprognostic (4.17e-2)" "prognostic unfavorable (2.19e-5)" "unprognostic (9.69e-2)" "unprognostic (4.92e-4)" "unprognostic (1.34e-1)" "unprognostic (2.82e-1)" "unprognostic (1.05e-1)" "unprognostic (8.57e-3)" 0.4 2.3 0.9 1.4 1.2 10.8 1.3 0.3 1.1 5.5 3.1 1.1 0.3 2.2 1.3 2.3 20.0 1.2 2.8 11.7 0.6 0.3 0.9 2.6 2.9 1.5 1.2 0.6 1.7 1.7 6.1 1.1 10.3 1.0 1.7 2.4 3.3 4.0 1.6 29.5 3.4 10.8 0.4 0.4 6.6 0.6 0.7 0.6 0.6 20.2 20.6 12.8 2.1 10.9 0.0 1.6 28.1 10.4 0.0 0.0 1.2 3.6 3.4 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 8.4 2.8 0.0 5.6 0.2 0.0 16.4 0.4 7.7 0.0 0.0 0.3 1.2 0.2 1.5 0.0 15.5 0.0 0.0 3.6 1.2 0.2 0.0 0.7 0.0 0.7 0.0 0.0 12.4 0.0 12.6 0.2 3.3 12.9 0.0 0.0 0.5 1.2 8.8 0.0 0.0 0.2 14.3 0.0 0.1 6.6 36.3 5.3 0.0 0.1 0.0 0.0 0.5 0.2 0.0 0.0 2.8 0.0 0.2 3.4 28.1 0.0 10.4 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.1 0.0 6.2 0.0 0.0 1.2 0.9 1.2 0.3 1.1 0.6 0.3 1.2 0.6 1.0 0.6 3.0 0.3 0.0 6.8 3.3 0.5 5.3 7.6 0.0 4.5 0.0 0.0 14.0 1.7 5.0 5.3 0.5 12.9 0.0 5.6 0.5 0.4 1.1 0.0 4.5 2.3 0.0 0.0 0.0 2.7 6.7 0.0 0.9 0.0 0.0 2.9 5.2 11.6 10.5 0.0 0.3 0.2 0.0 0.2 0.0 0.0 6.4 9.2 0.0 2.3 11.1 PTAFR ENSG00000169403 "Platelet activating factor receptor" P25105 1 28147166-28193936 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Chemotaxis "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 98.3" "Group enriched" "Detected in many" 7 "granulocytes: 73.9;Hofbauer cells: 62.8;Kupffer cells: 70.6;Macrophages: 55.7;Pancreatic endocrine cells: 55.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "classical monocyte: 28.2;eosinophil: 98.3;neutrophil: 85.7" "Group enriched" "Detected in many" 5 "granulocytes: 98.3;monocytes: 28.2" "Group enriched" "Detected in some" 4 "HBEC3-KT: 14.7;HMC-1: 53.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA027543 Approved Uncertain "Nucleoplasm,Vesicles,Plasma membrane" NA NA "Nucleoplasm, Vesicles" "Plasma membrane" "HPA027543: AB_10610287" "unprognostic (2.22e-2)" "unprognostic (2.59e-2)" "unprognostic (6.73e-2)" "unprognostic (1.24e-1)" "unprognostic (2.75e-1)" "unprognostic (3.74e-2)" "unprognostic (1.07e-1)" "unprognostic (1.72e-1)" "unprognostic (3.35e-1)" "unprognostic (1.23e-1)" "unprognostic (2.39e-1)" "unprognostic (1.60e-1)" "unprognostic (2.79e-2)" "unprognostic (3.52e-1)" "unprognostic (2.59e-2)" "unprognostic (5.48e-2)" "unprognostic (1.38e-2)" 5.6 2.3 2.4 16.2 1.9 20.3 2.4 0.6 2.0 6.9 3.4 1.6 3.5 1.8 2.8 1.4 16.8 2.8 7.5 3.5 2.1 2.3 6.4 1.8 9.2 6.1 4.1 1.0 1.5 2.7 0.9 0.7 3.5 1.8 2.6 3.4 0.6 3.4 2.6 1.1 2.8 5.0 3.8 5.1 15.4 2.3 2.2 1.1 2.3 1.4 22.2 21.7 5.9 3.6 1.5 13.2 98.3 28.2 0.0 0.1 10.1 7.7 0.1 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.3 0.1 0.1 2.2 0.5 0.0 0.0 0.1 5.3 0.2 14.7 0.3 0.1 0.2 2.9 0.0 0.3 0.0 0.7 53.6 0.0 2.4 0.2 0.1 0.0 0.0 0.0 0.2 0.2 0.0 0.5 0.0 7.2 0.2 0.2 0.1 0.1 0.0 0.0 3.6 0.8 0.1 0.0 0.0 7.3 0.0 0.2 0.1 2.0 0.0 0.1 0.3 0.0 0.0 0.5 0.4 2.1 0.0 0.9 0.2 5.9 28.2 98.3 0.0 8.9 0.1 1.5 0.0 0.0 13.2 0.7 0.0 0.0 85.7 0.0 3.5 0.1 0.1 10.1 2.4 1.9 0.6 2.0 2.1 2.3 4.1 1.0 1.8 1.1 6.0 7.9 4.3 1.5 5.8 1.2 2.0 2.5 6.7 2.3 1.8 2.0 0.5 0.0 8.8 0.0 5.9 0.2 0.0 4.6 0.4 2.2 0.4 73.9 0.8 62.8 0.0 0.0 1.8 70.6 0.0 0.6 55.7 0.0 4.6 0.0 0.2 55.1 0.0 0.0 0.0 0.8 0.0 0.9 2.1 0.5 2.5 1.3 1.0 0.0 8.6 PTGER1 EP1 ENSG00000160951 "Prostaglandin E receptor 1" P34995 19 14472466-14475362 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "kidney: 13.6;lymphoid tissue: 14.2" "Cell type enriched" "Detected in some" 75 "Collecting duct cells: 188.5" "Cancer enhanced" "Detected in many" "ovarian cancer: 4.1" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "intermediate monocyte: 1.5;NK-cell: 2.6" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HEL: 5.4;NB-4: 2.9;PC-3: 7.2;SH-SY5Y: 4.2" "Low region specificity" "Detected in single" "Not detected" "Not detected" NA NA "unprognostic (3.44e-2)" "unprognostic (3.31e-1)" "unprognostic (2.68e-1)" "unprognostic (3.50e-4)" "unprognostic (8.69e-2)" "unprognostic (5.58e-2)" "unprognostic (2.39e-2)" "unprognostic (3.19e-2)" "unprognostic (2.05e-1)" "unprognostic (3.53e-2)" "unprognostic (1.41e-1)" "unprognostic (1.42e-1)" "unprognostic (7.74e-8)" "unprognostic (1.19e-1)" "unprognostic (4.41e-2)" "unprognostic (4.27e-3)" "unprognostic (4.88e-2)" 0.7 1.4 1.1 2.7 1.3 0.2 1.5 0.6 1.2 1.3 1.5 0.1 0.0 1.2 0.4 0.3 1.7 1.0 0.4 3.1 0.4 0.4 13.6 0.5 4.9 6.7 1.8 0.0 1.6 1.8 0.2 1.4 0.3 1.0 0.5 0.3 0.3 0.3 0.4 0.7 0.2 1.9 1.4 0.1 14.2 3.2 0.4 0.6 0.0 0.7 0.0 0.3 0.6 1.3 0.0 0.4 0.0 1.5 2.6 1.1 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.3 1.4 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.3 5.4 0.0 0.3 0.6 0.0 0.1 0.1 0.0 0.2 0.0 0.1 0.0 0.2 0.6 0.0 0.0 0.0 0.0 2.9 0.3 0.0 7.2 0.8 0.0 0.2 0.0 0.1 0.5 4.2 0.1 0.1 0.2 0.0 0.2 0.4 1.3 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 1.5 0.0 0.0 0.0 1.1 0.4 0.0 0.0 0.0 0.0 2.6 0.5 0.0 0.0 0.2 1.1 1.3 0.6 1.2 0.4 0.4 1.8 0.0 1.0 0.6 0.0 0.0 0.0 0.2 0.0 0.4 0.8 2.5 0.0 0.0 188.5 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.8 0.0 0.5 0.3 0.0 0.0 0.6 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.3 1.1 0.0 0.0 0.3 0.0 0.0 0.6 0.2 0.7 0.0 0.0 0.0 0.0 0.2 PTH1R "PTHR, PTHR1" ENSG00000160801 "Parathyroid hormone 1 receptor" Q03431 3 46877746-46903799 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "kidney: 90.4" "Cell type enhanced" "Detected in many" 20 "Distal tubular cells: 81.2;Proximal tubular cells: 259.5;Sertoli cells: 135.8" "Cancer enhanced" "Detected in many" "renal cancer: 18.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 7 "RPTEC TERT1: 51.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA075879 Enhanced NA NA "HPA075879: " "unprognostic (1.26e-1)" "unprognostic (7.09e-2)" "unprognostic (2.24e-5)" "unprognostic (7.46e-2)" "unprognostic (3.46e-1)" "unprognostic (5.02e-2)" "unprognostic (3.84e-3)" "unprognostic (5.47e-2)" "unprognostic (2.18e-1)" "unprognostic (1.13e-2)" "unprognostic (7.51e-2)" "unprognostic (8.44e-2)" "prognostic favorable (6.79e-6)" "unprognostic (4.22e-3)" "unprognostic (1.50e-1)" "unprognostic (1.35e-4)" "unprognostic (6.62e-3)" 8.5 17.9 4.2 1.4 5.9 0.8 5.0 3.7 5.0 6.2 2.3 5.2 1.1 1.5 4.5 2.5 2.3 3.8 2.8 4.3 5.5 3.9 90.4 13.4 4.1 6.9 6.0 5.0 5.4 1.6 1.0 0.9 10.1 4.7 3.2 1.2 3.4 1.5 3.0 4.0 2.6 1.8 4.6 4.1 9.6 1.5 2.2 5.7 0.0 1.2 0.6 1.0 2.8 5.5 0.0 0.0 0.4 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 7.2 0.8 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 7.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.0 2.3 0.0 51.7 0.0 0.0 0.3 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 4.2 5.9 3.7 5.0 5.5 3.9 6.0 5.0 4.7 5.7 0.0 0.0 0.5 0.0 1.1 0.7 2.2 0.0 0.0 0.0 31.4 0.0 0.5 81.2 0.0 8.7 1.5 0.0 0.0 0.5 48.7 10.8 0.0 0.0 0.4 1.8 1.6 0.0 22.1 1.5 22.5 5.5 0.0 0.0 0.0 0.0 3.0 0.2 0.0 2.1 259.5 0.6 135.8 3.1 0.7 1.3 0.6 0.7 0.0 0.0 0.1 RYR1 "CCO, MHS, MHS1, PPP1R137, RYR" ENSG00000196218 "Ryanodine receptor 1" P21817 19 38433699-38587564 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Developmental protein, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "skeletal muscle: 231.0" "Cell type enriched" "Detected in many" 5 "Muller glia cells: 46.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "intermediate monocyte: 3.2;myeloid DC: 5.3;non-classical monocyte: 6.3" "Group enriched" "Detected in many" 7 "dendritic cells: 5.3;monocytes: 6.3" "Cell line enhanced" "Detected in some" "A549: 5.7;HaCaT: 14.0;hTCEpi: 5.7;RH-30: 11.5;SiHa: 22.8;U-2 OS: 9.6" "Low region specificity" "Detected in some" HPA056416 Enhanced Approved "Golgi apparatus,Vesicles,Cytosol" NA NA "Golgi apparatus, Vesicles" Cytosol "HPA056416: AB_2683121" "unprognostic (2.22e-3)" "unprognostic (1.91e-3)" "unprognostic (9.59e-2)" "unprognostic (5.34e-4)" "unprognostic (2.50e-1)" "unprognostic (6.00e-2)" "unprognostic (2.11e-1)" "unprognostic (1.06e-1)" "unprognostic (1.18e-1)" "unprognostic (3.20e-3)" "unprognostic (3.52e-1)" "unprognostic (2.35e-1)" "unprognostic (1.07e-5)" "unprognostic (1.13e-2)" "unprognostic (8.10e-2)" "unprognostic (6.62e-3)" "unprognostic (1.34e-1)" 5.3 0.7 3.0 0.6 1.9 0.4 0.6 2.7 1.7 0.6 0.4 2.7 0.0 0.4 0.4 6.7 3.0 0.6 0.5 0.4 1.8 4.0 0.5 0.4 0.7 0.6 1.5 1.3 0.4 0.4 0.3 0.3 0.6 1.9 0.9 0.4 0.4 2.2 0.6 231.0 2.4 0.5 0.4 1.1 0.6 0.5 1.6 1.9 0.0 1.6 55.1 3.2 0.6 0.5 0.7 5.3 0.1 6.3 0.0 0.6 0.6 0.0 5.7 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 2.0 0.3 0.3 4.8 0.0 0.0 14.0 0.2 0.0 0.0 0.0 0.3 1.0 0.0 0.0 0.0 0.0 0.4 1.3 5.7 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.4 0.7 0.0 0.0 11.5 1.1 0.6 0.0 0.0 1.1 22.8 0.0 0.0 0.4 0.5 4.3 0.0 0.0 9.6 0.2 0.0 0.3 1.0 0.3 0.1 0.0 0.0 0.0 0.6 0.0 0.4 3.2 0.5 0.4 0.3 0.6 5.3 0.7 0.0 0.0 0.1 0.0 6.3 0.0 0.6 0.6 3.0 1.9 2.7 1.7 1.8 4.0 1.5 1.3 1.9 1.9 0.0 0.6 0.0 3.4 10.1 4.1 3.4 0.0 0.0 0.0 0.0 2.0 0.1 5.0 0.1 5.2 0.0 0.0 0.0 0.0 0.2 0.3 0.6 0.0 0.0 7.1 1.6 0.0 0.6 1.9 4.7 2.8 4.5 0.0 0.0 0.0 46.0 0.0 0.0 1.8 0.0 1.5 0.0 0.3 5.5 6.9 4.1 0.2 0.0 0.0 0.1 RYR2 "ARVC2, ARVD2, VTSIP" ENSG00000198626 "Ryanodine receptor 2" Q92736 1 237042205-237833988 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Developmental protein, Ion channel, Ligand-gated ion channel, Receptor" "Cardiomyopathy, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "heart muscle: 106.6" "Cell type enriched" "Detected in many" 30 "Cardiomyocytes: 1960.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HDLM-2: 7.8;HEK 293: 10.7;K-562: 3.3;NB-4: 2.7;NTERA-2: 4.0;U-937: 4.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020028 Approved Uncertain "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Nucleoplasm, Plasma membrane, Cytosol" "HPA020028: AB_1856528" "unprognostic (5.23e-3)" "unprognostic (2.15e-2)" "unprognostic (5.02e-4)" "unprognostic (6.26e-2)" "unprognostic (8.74e-2)" "unprognostic (2.99e-3)" "unprognostic (5.28e-2)" "unprognostic (1.45e-3)" "unprognostic (2.69e-2)" "unprognostic (1.04e-1)" "unprognostic (1.10e-1)" "unprognostic (4.04e-2)" "unprognostic (0.00e+0)" "unprognostic (2.36e-2)" "unprognostic (1.42e-1)" "unprognostic (3.13e-2)" "unprognostic (1.06e-2)" 1.1 0.9 6.2 0.9 18.7 0.5 1.1 14.8 10.5 1.3 1.2 0.0 1.2 0.7 1.1 0.7 1.8 1.0 1.8 106.6 5.7 1.1 0.9 0.9 1.4 0.6 1.0 7.3 2.2 4.2 0.5 2.0 1.1 1.6 2.0 0.8 0.2 0.9 1.4 0.9 1.0 1.0 4.6 1.0 1.0 1.2 1.1 3.0 0.0 2.7 0.0 0.6 1.2 1.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.7 0.3 0.0 0.0 0.3 0.6 0.0 0.0 7.8 10.7 2.1 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 3.3 0.2 0.0 0.0 0.0 2.7 4.0 0.1 0.4 0.0 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 4.9 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 6.2 18.7 14.8 10.5 5.7 1.1 1.0 7.3 1.6 3.0 0.0 0.3 0.0 0.0 0.3 65.2 1960.0 0.0 1.4 2.3 1.8 9.8 0.0 0.0 0.0 15.8 1.5 0.0 0.0 2.5 0.0 2.1 0.0 0.0 0.0 0.1 1.6 3.4 1.3 0.0 10.2 1.1 0.0 8.5 0.0 0.0 1.5 0.3 0.0 0.0 0.0 4.7 0.0 18.6 3.2 0.9 0.0 0.0 0.0 0.0 0.0 S1PR1 "CD363, D1S3362, edg-1, EDG1" ENSG00000170989 "Sphingosine-1-phosphate receptor 1" P21453 1 101236888-101241518 "Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Angiogenesis, Chemotaxis" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 88.9" "Group enriched" "Detected in many" 5 "Endothelial cells: 89.9;Ito cells: 114.2;Muller glia cells: 38.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 19.4;HUVEC TERT2: 54.9;TIME: 30.5;U-251 MG: 37.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010104, HPA075568" Supported Supported Vesicles No NA Vesicles "CAB010104: AB_2238920, HPA075568: AB_2686758" "unprognostic (1.41e-1)" "unprognostic (9.35e-2)" "unprognostic (2.46e-2)" "unprognostic (2.61e-1)" "unprognostic (9.78e-2)" "unprognostic (4.49e-3)" "unprognostic (1.34e-3)" "unprognostic (1.99e-1)" "unprognostic (1.36e-1)" "unprognostic (9.12e-2)" "unprognostic (2.34e-2)" "unprognostic (2.23e-1)" "unprognostic (5.82e-3)" "unprognostic (2.54e-2)" "unprognostic (1.04e-1)" "unprognostic (3.64e-1)" "prognostic unfavorable (8.78e-4)" 72.3 8.4 24.7 16.6 26.2 9.7 46.3 21.6 21.8 13.3 10.5 9.5 2.5 5.7 12.1 5.0 14.7 11.5 17.6 43.5 22.9 15.4 8.9 20.5 35.7 24.5 23.2 14.0 7.9 11.0 13.4 4.7 29.6 21.2 8.9 7.0 9.3 7.5 5.6 21.7 8.2 9.8 19.0 11.0 35.2 8.0 5.8 13.9 4.4 17.0 8.7 15.7 15.2 18.5 27.4 0.2 88.9 0.2 33.4 49.8 30.8 3.6 0.0 3.9 0.0 0.4 9.3 0.0 19.4 3.5 11.8 4.2 0.0 0.1 0.0 4.8 6.7 0.0 0.0 0.5 0.2 7.9 1.3 0.4 1.3 0.1 0.0 1.8 0.0 0.8 12.5 0.0 0.0 0.9 0.5 54.9 1.1 0.0 4.0 3.7 0.0 4.6 0.0 1.0 0.1 1.3 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 30.5 2.0 0.7 0.4 37.6 0.3 0.0 0.2 0.2 0.0 0.1 88.9 0.1 4.9 49.8 0.1 40.2 25.1 45.3 44.1 0.2 27.4 35.7 36.2 1.4 33.4 0.2 0.2 26.8 30.8 24.7 26.2 21.6 16.8 22.9 15.4 23.2 14.0 21.2 13.9 0.0 12.8 17.1 0.1 6.8 0.0 16.9 2.5 0.0 2.3 0.0 0.0 5.5 0.0 0.0 0.0 89.9 0.0 0.0 0.0 0.3 8.4 0.5 7.0 6.0 7.6 0.0 0.0 114.2 6.9 0.0 0.9 1.5 5.0 14.4 0.0 38.0 0.0 0.0 0.0 0.0 1.0 0.0 1.4 0.4 0.7 4.4 2.2 9.2 0.0 0.4 SCN11A "NaN, Nav1.9, SCN12A, SNS-2" ENSG00000168356 "Sodium voltage-gated channel alpha subunit 11" Q9UI33 3 38845769-38950561 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 7.5;placenta: 5.2" "Cell type enhanced" "Detected in some" 8 "Ciliated cells: 4.0;Early spermatids: 5.4;Sertoli cells: 6.5;Spermatocytes: 3.9;Spermatogonia: 6.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 1.8;HDLM-2: 5.0;SCLC-21H: 1.1;SuSa: 1.3" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA036746, HPA036747" Uncertain NA NA "HPA036746: AB_10696785, HPA036747: AB_2675287" "unprognostic (6.11e-2)" "unprognostic (5.16e-1)" "unprognostic (1.66e-1)" "unprognostic (4.75e-2)" "unprognostic (4.21e-2)" "unprognostic (2.34e-2)" "unprognostic (2.79e-2)" "unprognostic (5.66e-2)" "unprognostic (4.44e-2)" "unprognostic (5.21e-2)" "unprognostic (2.30e-4)" "unprognostic (1.91e-2)" "unprognostic (5.43e-2)" "unprognostic (5.02e-2)" "unprognostic (2.95e-1)" "unprognostic (3.12e-2)" "unprognostic (8.30e-4)" 0.9 0.2 0.8 0.5 0.8 0.0 0.6 0.1 0.3 0.0 1.1 0.4 0.0 1.4 0.0 0.1 0.1 0.0 0.4 0.5 0.4 0.3 0.0 0.2 0.4 0.0 0.1 0.0 0.4 5.2 0.1 1.3 0.0 0.0 0.1 0.8 1.0 0.5 0.6 7.5 0.0 2.6 0.1 0.1 3.4 0.1 0.2 0.4 0.9 0.1 0.1 0.2 0.0 0.0 0.0 1.8 0.0 0.1 0.2 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.3 0.1 0.1 5.0 0.4 0.1 0.0 0.1 0.3 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.1 0.3 0.0 0.2 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.5 1.1 0.6 0.0 0.0 0.0 1.3 0.0 0.2 0.3 0.0 0.1 0.0 0.0 0.7 0.1 0.3 0.0 0.0 0.1 0.7 0.1 0.0 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.9 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.8 0.7 0.1 0.8 0.0 4.0 1.2 0.0 0.0 0.2 0.0 0.0 5.4 0.6 0.0 0.0 0.2 0.0 0.6 0.3 0.0 0.2 0.3 0.0 0.0 2.5 0.0 1.0 0.0 0.0 1.7 0.0 0.0 0.7 0.1 0.0 0.0 0.1 0.4 6.5 0.9 3.9 6.0 0.6 0.2 0.0 0.0 0.9 SCN1A "FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI" ENSG00000144285 "Sodium voltage-gated channel alpha subunit 1" P35498 2 165984641-166149214 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 33.9" "Group enriched" "Detected in some" 5 "Alveolar cells type 2: 26.9;Bipolar cells: 33.9" "Cancer enriched" "Detected in single" 8 "glioma: 1.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "ASC TERT1: 11.6;Hep G2: 6.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA078664 Supported "Nucleoplasm,Nuclear bodies,Plasma membrane" NA NA "Nucleoplasm, Plasma membrane" "Nuclear bodies" "HPA078664: AB_2686888" "unprognostic (9.25e-2)" "unprognostic (3.97e-2)" "unprognostic (6.88e-2)" "unprognostic (7.44e-2)" "unprognostic (1.50e-1)" "unprognostic (2.74e-1)" "unprognostic (4.70e-2)" "unprognostic (2.88e-1)" "unprognostic (1.67e-1)" "unprognostic (9.59e-2)" "unprognostic (1.23e-1)" "unprognostic (5.03e-9)" "unprognostic (6.92e-2)" "unprognostic (3.69e-2)" "unprognostic (5.06e-3)" "unprognostic (6.93e-1)" 1.1 1.3 5.2 1.1 13.6 1.0 1.1 10.3 26.6 1.1 1.1 2.3 0.0 1.0 1.1 1.1 1.0 6.8 1.0 1.1 6.9 8.3 1.1 1.1 5.6 1.0 5.7 9.7 1.0 1.0 1.1 2.9 1.2 33.9 1.1 1.1 0.3 1.0 1.0 1.2 1.1 1.1 1.1 3.6 1.1 1.1 1.4 4.2 0.0 1.1 0.0 1.0 1.1 0.1 0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 11.6 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 6.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 5.2 13.6 10.3 26.6 6.9 8.3 5.7 9.7 33.9 4.2 6.0 26.9 0.0 0.0 0.0 33.9 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.7 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 SCN2A "HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2" ENSG00000136531 "Sodium voltage-gated channel alpha subunit 2" Q99250 2 165194993-165392310 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 68.0" "Cell type enhanced" "Detected in some" 17 "Bipolar cells: 48.0;Cone photoreceptor cells: 45.2;Horizontal cells: 14.3" "Cancer enhanced" "Detected in single" "glioma: 1.3" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "naive B-cell: 1.4" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "HSkMC: 3.4;SH-SY5Y: 3.1;U-138 MG: 5.8;U-266/84: 12.0;U-87 MG: 3.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB022567 Enhanced NA NA "CAB022567: " "unprognostic (1.16e-1)" "unprognostic (3.56e-4)" "unprognostic (5.28e-2)" "unprognostic (6.12e-3)" "unprognostic (2.97e-1)" "unprognostic (8.62e-3)" "unprognostic (1.18e-1)" "unprognostic (7.25e-3)" "unprognostic (1.40e-1)" "unprognostic (2.78e-1)" "unprognostic (1.32e-2)" "unprognostic (5.21e-2)" "unprognostic (3.44e-2)" "unprognostic (1.76e-1)" "unprognostic (1.05e-1)" "unprognostic (4.88e-2)" "unprognostic (2.14e-1)" 1.3 3.0 19.1 1.3 36.4 1.1 2.2 68.0 50.3 1.5 1.3 1.1 0.0 1.5 1.9 2.6 1.2 1.3 2.3 1.3 30.3 8.2 4.0 1.4 1.5 1.2 3.8 23.5 1.5 1.3 1.1 8.2 1.3 9.9 1.3 1.3 0.0 1.5 1.8 1.1 1.2 1.5 2.0 3.7 1.3 1.5 1.5 4.1 0.0 1.1 0.0 1.2 1.3 0.5 1.4 0.6 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.2 0.8 0.0 0.0 2.8 0.0 2.7 0.0 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.5 0.1 1.0 0.7 0.0 0.4 0.0 0.4 0.0 0.2 3.4 0.1 0.3 0.0 2.4 0.0 0.0 0.0 0.3 1.5 0.0 0.2 0.0 2.0 0.1 0.3 0.0 0.0 0.0 0.1 0.1 2.9 3.1 0.0 0.0 0.0 1.3 0.0 0.0 0.0 5.8 0.4 0.3 0.0 0.5 12.0 0.0 3.6 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 1.4 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 19.1 36.4 68.0 43.7 30.3 8.2 3.8 23.5 9.9 4.1 0.0 1.7 0.0 0.1 0.2 48.0 0.6 0.0 0.0 0.0 10.4 45.2 0.1 5.0 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.3 0.0 0.0 0.0 1.3 1.1 0.0 0.0 0.0 0.0 3.7 0.5 0.0 5.6 0.0 3.4 0.0 0.4 0.0 0.6 0.1 0.0 0.0 0.0 0.0 SCN2B ENSG00000149575 "Sodium voltage-gated channel beta subunit 2" O60939 11 118161951-118176673 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Brugada syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 37.0;heart muscle: 17.5;skeletal muscle: 9.7" "Group enriched" "Detected in some" 5 "Bipolar cells: 7.9;Cardiomyocytes: 14.0;Horizontal cells: 12.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 2.1" "Lineage enriched" "Detected in single" 6 "granulocytes: 2.1" "Group enriched" "Detected in some" 5 "HBEC3-KT: 1.5;U-2 OS: 2.6;U-2197: 6.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (9.01e-2)" "unprognostic (3.50e-2)" "unprognostic (7.58e-2)" "unprognostic (2.12e-2)" "unprognostic (1.41e-2)" "unprognostic (4.02e-1)" "unprognostic (2.71e-4)" "unprognostic (5.17e-2)" "unprognostic (8.59e-2)" "unprognostic (2.77e-1)" "unprognostic (7.89e-2)" "unprognostic (1.61e-2)" "unprognostic (3.51e-2)" "unprognostic (1.27e-2)" "unprognostic (4.35e-2)" "unprognostic (4.55e-1)" "unprognostic (2.88e-3)" 1.8 3.0 14.7 1.4 31.5 1.0 1.9 31.1 37.0 2.9 2.0 3.1 0.0 1.7 3.2 2.9 3.6 2.9 2.7 17.5 22.5 11.6 1.6 1.0 2.5 1.0 8.7 30.6 2.8 1.1 1.0 0.8 1.0 12.8 2.4 1.9 0.4 1.8 2.7 9.7 1.4 2.5 3.5 13.9 1.1 1.3 1.3 6.9 0.0 1.9 0.7 1.0 1.5 0.6 0.3 0.2 2.1 0.3 0.2 0.2 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.1 0.1 0.1 1.5 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.1 0.2 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.3 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.2 0.0 0.7 0.1 0.0 0.0 0.1 2.6 6.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 2.1 0.3 0.9 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.3 0.2 0.2 1.3 0.2 0.0 0.2 0.1 0.0 14.7 31.5 31.1 37.0 22.5 11.6 8.7 30.6 12.8 6.9 0.0 0.0 0.0 0.5 0.3 7.9 14.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.1 12.7 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.9 0.0 0.0 2.1 0.0 1.4 0.0 1.0 0.0 0.6 0.1 0.0 0.0 0.0 0.2 SCN4A "HYKPP, HYPP, Nav1.4, SkM1" ENSG00000007314 "Sodium voltage-gated channel alpha subunit 4" P35499 17 63938554-63972918 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "skeletal muscle: 53.7" "Cell type enhanced" "Detected in some" 15 "Early spermatids: 3.4;Ito cells: 3.1;Late spermatids: 2.9" "Cancer enhanced" "Detected in some" "thyroid cancer: 2.2" "Cell type enhanced" "Detected in single" "naive B-cell: 1.9" "Lineage enhanced" "Detected in single" "B-cells: 1.9" "Group enriched" "Detected in some" 11 "REH: 10.1;RH-30: 31.7" "Not detected" "Not detected" "Not detected" "Not detected" HPA053992 Approved "Nucleoplasm,Centriolar satellite" NA NA Nucleoplasm "Centriolar satellite" "HPA053992: AB_2797249" "unprognostic (2.47e-1)" "unprognostic (1.74e-1)" "unprognostic (1.57e-2)" "unprognostic (1.78e-3)" "unprognostic (2.80e-2)" "unprognostic (1.63e-2)" "unprognostic (3.87e-4)" "unprognostic (3.84e-3)" "unprognostic (1.61e-1)" "unprognostic (1.36e-1)" "unprognostic (1.59e-3)" "unprognostic (3.15e-2)" "unprognostic (2.70e-2)" "unprognostic (4.38e-3)" "unprognostic (3.46e-1)" "unprognostic (4.15e-1)" "unprognostic (6.45e-2)" 5.9 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.3 0.0 0.1 0.0 0.5 0.0 53.7 0.0 0.0 0.0 0.0 0.1 0.0 0.4 1.6 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.0 0.0 0.0 10.1 31.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.9 0.9 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.2 0.1 0.0 0.0 0.0 0.0 SCN4B LQT10 ENSG00000177098 "Sodium voltage-gated channel beta subunit 4" Q8IWT1 11 118133377-118152888 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Disease mutation, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 36.4;skeletal muscle: 25.6" "Cell type enriched" "Detected in some" 4 "Sertoli cells: 45.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AN3-CA: 3.9;HBEC3-KT: 3.0;NTERA-2: 4.4;SH-SY5Y: 1.7;U-2 OS: 4.0" "Region enriched" "Detected in many" 11 "basal ganglia: 731.2" "Region enhanced" "Detected in many" "basal ganglia: 122.8" HPA017293 Approved NA NA "HPA017293: AB_2184174" "unprognostic (1.98e-1)" "unprognostic (1.13e-1)" "unprognostic (1.13e-1)" "unprognostic (2.43e-1)" "unprognostic (1.45e-1)" "unprognostic (1.07e-1)" "unprognostic (9.82e-3)" "unprognostic (9.17e-3)" "unprognostic (1.20e-2)" "unprognostic (1.23e-2)" "unprognostic (1.03e-2)" "unprognostic (3.27e-2)" "unprognostic (1.07e-1)" "unprognostic (2.07e-2)" "unprognostic (2.18e-3)" "unprognostic (1.53e-1)" "unprognostic (5.31e-4)" 20.5 5.4 1.9 1.2 36.4 0.1 6.1 11.7 21.7 2.4 2.6 2.0 0.5 2.4 3.7 1.8 5.4 5.5 3.2 11.0 3.1 2.9 1.4 0.6 8.7 2.0 5.3 2.1 0.7 5.0 6.4 2.4 1.9 28.7 2.1 2.2 4.3 2.8 2.6 25.6 3.8 4.6 7.0 5.5 0.5 3.0 0.8 8.7 1.5 10.4 9.5 1.1 3.4 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 3.9 0.0 0.0 0.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.6 0.3 3.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 1.1 0.5 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 1.7 0.4 0.0 0.0 1.1 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 36.4 11.7 21.7 3.1 2.9 5.3 2.1 28.7 8.7 0.0 0.0 0.0 0.3 1.1 1.1 2.8 0.0 6.7 1.2 0.0 0.0 0.0 0.0 0.0 1.3 0.7 0.0 0.0 0.0 0.0 1.6 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.3 3.3 2.0 0.8 0.0 0.0 0.0 0.3 0.0 0.0 1.4 0.0 0.3 45.3 10.8 0.0 0.6 1.0 0.0 0.0 0.0 0.1 SCN5A "CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1" ENSG00000183873 "Sodium voltage-gated channel alpha subunit 5" Q14524 3 38548057-38649673 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Calmodulin-binding, Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Brugada syndrome, Cardiomyopathy, Disease mutation, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "heart muscle: 67.3" "Cell type enriched" "Detected in some" 5 "Cardiomyocytes: 66.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "LHCN-M2: 22.0;RH-30: 18.3" "Group enriched" "Detected in some" 5 "amygdala: 3.2;basal ganglia: 10.5;hypothalamus: 7.0" "Low region specificity" "Detected in many" HPA063346 Supported "Nucleoplasm,Nucleoli,Plasma membrane" NA NA "Plasma membrane" "Nucleoplasm, Nucleoli" "HPA063346: " "unprognostic (9.29e-4)" "unprognostic (4.05e-2)" "unprognostic (9.95e-2)" "unprognostic (1.74e-1)" "unprognostic (9.21e-2)" "unprognostic (1.24e-2)" "unprognostic (1.15e-1)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (8.48e-2)" "unprognostic (7.12e-3)" "unprognostic (5.28e-2)" "unprognostic (1.16e-4)" "unprognostic (4.85e-3)" "unprognostic (1.09e-1)" "unprognostic (5.35e-2)" "unprognostic (4.95e-3)" 0.3 0.2 1.3 0.2 0.3 0.4 0.6 0.1 2.3 2.0 0.4 0.0 0.4 0.3 0.9 0.8 0.2 0.4 0.3 67.3 0.5 0.7 0.1 0.1 0.2 0.1 0.1 0.3 0.6 0.2 0.1 0.8 0.3 0.0 1.3 0.2 1.2 0.3 1.6 5.5 0.2 0.3 0.4 0.1 0.2 0.2 0.5 0.0 0.0 0.3 0.1 0.1 0.8 1.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.5 0.1 0.0 0.1 0.8 0.4 0.0 0.1 0.3 2.7 0.0 0.0 0.0 0.9 0.9 2.7 0.0 0.4 0.0 1.2 0.7 0.0 0.1 0.1 0.0 0.1 0.5 0.0 0.5 0.0 1.7 3.6 0.4 0.0 0.0 22.0 1.1 0.0 0.0 2.0 0.0 0.0 0.0 18.3 0.0 0.0 2.4 0.3 2.4 0.0 0.0 0.0 0.7 0.0 0.0 4.4 0.0 4.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.3 0.1 2.3 0.5 0.7 0.1 0.3 0.0 0.0 0.0 0.0 0.0 1.1 0.2 3.1 66.1 0.0 0.0 0.0 0.0 13.7 0.1 0.0 0.1 1.0 0.4 0.0 0.0 0.0 0.2 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.0 0.7 0.0 0.4 0.3 0.9 0.0 0.0 0.0 0.0 1.0 SCN8A "CerIII, CIAT, MED, NaCh6, Nav1.6, PN4" ENSG00000196876 "Sodium voltage-gated channel alpha subunit 8" Q9UQD0 12 51590266-51812864 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 27.6;pituitary gland: 9.7" "Cell type enhanced" "Detected in some" 9 "Bipolar cells: 13.7;Cone photoreceptor cells: 9.8;Intestinal endocrine cells: 10.9;Rod photoreceptor cells: 10.5;Spermatogonia: 10.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "memory CD8 T-cell: 1.0" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "AF22: 12.0;ASC TERT1: 12.7;BJ hTERT+: 11.2;WM-115: 11.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022169, HPA043937, HPA073590" Approved "Vesicles,Plasma membrane,Cell Junctions" NA NA "Plasma membrane" "Vesicles, Cell Junctions" "CAB022169: , HPA043937: , HPA073590: " "unprognostic (2.96e-2)" "unprognostic (8.49e-2)" "unprognostic (6.93e-2)" "unprognostic (3.52e-6)" "unprognostic (8.13e-2)" "unprognostic (1.51e-2)" "unprognostic (1.16e-1)" "unprognostic (7.77e-2)" "unprognostic (5.44e-2)" "unprognostic (1.16e-1)" "unprognostic (4.73e-4)" "unprognostic (1.69e-2)" "unprognostic (1.29e-5)" "unprognostic (4.38e-1)" "unprognostic (1.56e-1)" "unprognostic (2.37e-1)" "unprognostic (4.75e-2)" 1.1 3.0 9.1 1.5 18.1 1.9 1.9 16.7 27.6 1.0 2.0 1.6 0.0 1.1 1.5 2.0 0.9 1.1 2.5 0.9 12.6 4.5 1.9 4.3 1.0 1.3 3.2 13.7 1.8 3.2 1.5 9.7 0.9 14.8 1.8 2.5 0.9 1.7 1.2 1.0 1.1 1.2 1.0 2.2 1.7 2.7 3.8 1.6 0.0 1.7 0.0 1.2 1.0 0.6 0.4 0.2 0.0 0.0 0.0 1.0 0.0 1.4 1.0 12.0 0.1 1.6 12.7 0.2 6.8 11.2 7.9 7.3 2.0 1.4 0.3 1.6 8.9 3.5 0.0 1.9 0.0 9.3 1.2 0.6 0.1 0.1 0.2 0.1 0.2 0.9 1.7 0.0 5.2 1.1 3.1 8.4 2.8 0.1 0.1 4.9 0.8 2.0 0.1 4.1 0.7 3.8 0.0 0.6 0.0 0.0 0.4 4.8 2.0 3.5 1.8 0.2 1.8 0.3 0.1 2.2 7.7 5.1 2.8 4.3 0.1 0.1 0.0 1.5 1.6 11.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.7 1.0 0.0 0.4 0.4 0.2 0.0 0.0 0.0 0.2 0.0 0.0 9.1 18.1 16.7 25.0 12.6 4.5 3.2 13.7 14.8 1.6 0.0 0.0 0.0 0.4 0.0 13.7 1.2 0.0 0.0 0.0 0.0 9.8 0.0 0.0 0.2 0.4 0.4 0.0 0.0 0.5 0.0 0.0 0.2 0.0 3.4 0.0 4.8 10.9 1.3 0.0 0.2 0.0 0.0 0.0 0.0 1.3 5.3 0.5 0.0 0.7 0.5 10.5 0.0 0.3 1.9 10.0 0.0 0.0 0.0 0.6 0.1 SCN9A "ETHA, Nav1.7, NE-NA, NENA, PN1" ENSG00000169432 "Sodium voltage-gated channel alpha subunit 9" Q15858 2 166195185-166376001 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 8 "Exocrine glandular cells: 27.7;Hofbauer cells: 50.6;Intestinal endocrine cells: 31.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 17 "plasmacytoid DC: 18.6" "Lineage enriched" "Detected in single" 24 "dendritic cells: 18.6" "Cell line enhanced" "Detected in many" "BJ: 17.2;BJ hTERT+: 12.8;HHSteC: 14.8;hTERT-RPE1: 12.0" "Region enriched" "Detected in some" 5 "hypothalamus: 10.9" "Low region specificity" "Detected in all" "CAB013679, HPA061843" Uncertain Approved "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA "Plasma membrane, Actin filaments, Focal adhesion sites" "CAB013679: , HPA061843: AB_2684625" "unprognostic (2.10e-1)" "unprognostic (2.83e-1)" "unprognostic (1.13e-1)" "unprognostic (8.98e-5)" "unprognostic (1.47e-3)" "unprognostic (9.43e-3)" "unprognostic (2.28e-2)" "unprognostic (2.24e-1)" "unprognostic (2.23e-1)" "unprognostic (3.64e-1)" "unprognostic (1.45e-1)" "unprognostic (2.27e-1)" "prognostic unfavorable (2.30e-5)" "unprognostic (1.69e-3)" "unprognostic (6.74e-2)" "unprognostic (2.46e-2)" "unprognostic (2.46e-1)" 6.6 4.2 3.8 2.8 9.1 4.2 2.7 0.9 4.4 1.8 10.2 0.5 0.1 1.4 0.9 3.8 2.6 1.2 5.8 2.9 2.8 15.9 4.8 8.3 4.5 3.5 4.1 2.3 2.1 4.8 0.6 11.3 9.2 7.3 2.0 7.0 1.7 1.8 1.9 0.9 1.8 4.2 5.2 2.5 12.4 1.7 16.2 0.4 10.3 1.4 1.9 1.2 3.6 1.8 0.0 18.6 0.7 0.1 0.4 0.0 0.0 0.0 1.9 0.1 0.0 7.4 6.5 0.0 17.2 12.8 4.0 1.3 0.5 0.0 0.0 0.0 2.1 0.2 0.0 4.9 0.6 6.6 0.0 1.6 1.3 1.5 1.4 14.8 0.0 0.0 0.4 0.2 6.8 1.3 12.0 0.8 0.9 4.3 5.0 0.6 0.0 2.6 0.0 1.5 0.0 0.5 0.7 2.5 6.5 1.8 7.2 0.8 7.2 0.0 0.0 0.3 3.8 0.2 0.0 0.0 0.0 1.1 0.1 0.3 0.1 0.0 0.0 2.5 0.0 1.4 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.7 0.4 0.1 18.6 0.0 0.0 3.8 9.1 0.9 4.4 2.8 15.9 4.1 2.3 7.3 0.4 11.9 18.4 0.9 0.2 0.9 0.2 1.6 5.1 4.0 7.9 5.2 0.0 0.2 3.3 14.9 1.7 2.2 11.3 0.0 27.7 0.4 1.2 0.2 3.5 6.0 50.6 0.0 31.7 20.3 1.5 1.9 1.1 4.3 3.3 0.0 14.6 1.3 18.8 8.6 0.0 12.2 0.0 0.0 1.0 0.0 0.4 0.4 0.9 0.0 10.7 0.1 SCNN1A "ENaCalpha, SCNN1" ENSG00000111319 "Sodium channel epithelial 1 alpha subunit" P37088 12 6346843-6377730 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 100.4" "Cell type enhanced" "Detected in many" 9 "Collecting duct cells: 108.2;Mucus-secreting cells: 167.5" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in some" 8 "pons and medulla: 9.4" "Group enriched" "Detected in some" 4 "naive CD4 T-cell: 1.7;neutrophil: 4.4;plasmacytoid DC: 3.0;T-reg: 1.3" "Group enriched" "Detected in many" 5 "dendritic cells: 3.0;granulocytes: 4.4;T-cells: 1.7" "Cell line enhanced" "Detected in some" "CAPAN-2: 71.8;HBEC3-KT: 48.2;hTCEpi: 20.7;RPTEC TERT1: 25.2;RT4: 27.0;SK-BR-3: 23.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA012743 Enhanced NA NA "HPA012743: AB_1856627" "unprognostic (1.68e-1)" "unprognostic (4.16e-2)" "unprognostic (1.62e-1)" "unprognostic (2.19e-1)" "unprognostic (5.16e-2)" "unprognostic (6.77e-3)" "unprognostic (3.09e-2)" "unprognostic (2.62e-2)" "unprognostic (5.13e-2)" "prognostic unfavorable (8.86e-4)" "prognostic unfavorable (2.30e-4)" "unprognostic (5.56e-2)" "prognostic favorable (9.21e-8)" "unprognostic (2.38e-1)" "unprognostic (3.93e-2)" "unprognostic (1.16e-1)" "unprognostic (1.01e-2)" 0.9 3.7 0.4 7.5 0.4 0.0 10.1 0.4 0.9 22.0 20.6 2.2 60.9 5.6 8.1 15.7 47.3 19.3 7.0 0.4 1.1 0.1 100.4 2.2 53.6 0.4 0.5 0.4 5.9 14.2 0.0 10.2 1.6 9.4 15.0 21.5 6.2 53.1 55.5 0.6 14.4 11.8 1.0 0.4 0.4 20.3 2.8 0.4 0.9 74.7 21.1 41.3 10.3 13.8 0.0 3.0 4.4 0.5 0.0 1.7 0.3 5.0 0.9 0.0 0.4 0.0 0.1 4.3 0.0 0.0 0.0 0.0 1.4 71.8 0.0 0.1 0.0 0.0 3.3 0.0 48.2 0.0 0.0 0.0 0.0 4.0 0.7 5.2 0.0 0.0 1.2 20.7 0.0 15.1 0.1 0.0 0.1 0.0 0.0 0.1 0.4 0.0 0.0 4.2 9.1 0.1 0.0 0.0 0.1 25.2 27.0 0.3 0.0 0.5 23.3 0.0 4.3 5.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.3 0.5 0.0 0.0 0.2 0.6 0.5 0.0 1.7 0.3 4.4 0.0 0.1 3.0 1.3 0.3 0.4 0.4 0.4 0.9 1.1 0.1 0.5 0.4 9.4 0.4 68.5 63.0 0.0 21.9 1.6 0.8 0.8 68.8 26.8 47.8 108.2 3.9 1.2 5.0 41.1 0.4 1.4 57.4 0.0 30.8 0.2 2.4 31.3 2.3 2.4 0.3 1.6 26.0 0.6 1.9 0.2 1.7 2.1 0.0 1.8 167.5 0.3 24.0 47.5 1.4 4.2 1.6 0.0 1.0 1.4 2.1 7.8 1.4 1.9 31.6 33.3 SCNN1B ENaCbeta ENSG00000168447 "Sodium channel epithelial 1 beta subunit" P51168 16 23278231-23381299 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 42.4" "Cell type enhanced" "Detected in many" 12 "Alveolar cells type 1: 92.3;Club cells: 66.0;Collecting duct cells: 54.1;Enterocytes: 54.8" "Cancer enhanced" "Detected in many" "urothelial cancer: 26.4" "Region enhanced" "Detected in single" "cerebellum: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "hTCEpi: 19.4;RT4: 10.4;U-266/70: 32.0;U-266/84: 11.1" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA015612 Uncertain NA NA "HPA015612: AB_1856629" "unprognostic (7.45e-2)" "unprognostic (1.76e-3)" "unprognostic (1.39e-1)" "unprognostic (6.74e-3)" "unprognostic (1.74e-2)" "unprognostic (5.11e-3)" "unprognostic (7.74e-2)" "unprognostic (5.49e-3)" "unprognostic (2.60e-1)" "unprognostic (2.40e-1)" "unprognostic (3.68e-1)" "unprognostic (2.84e-1)" "prognostic unfavorable (2.09e-6)" "unprognostic (2.32e-1)" "unprognostic (4.66e-2)" "unprognostic (3.93e-3)" "unprognostic (1.25e-2)" 35.1 0.2 0.1 4.0 0.2 0.0 21.2 1.1 0.1 28.3 27.2 0.0 1.3 1.3 2.9 2.5 42.4 1.3 3.3 0.6 0.0 0.0 13.0 0.0 31.1 1.3 0.0 0.0 2.0 0.8 0.3 1.6 25.2 0.3 5.7 19.7 0.5 29.7 2.4 3.9 13.2 1.7 4.2 0.1 1.9 8.9 1.6 0.0 0.6 16.2 17.8 15.5 5.6 19.6 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.4 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 1.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 4.9 0.0 10.4 0.1 0.0 0.0 0.3 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 32.0 11.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.1 0.2 1.1 0.1 0.0 0.0 0.0 0.0 0.3 0.0 92.3 27.0 2.2 14.0 2.7 0.0 0.8 0.0 10.7 66.0 54.1 0.0 0.7 0.0 0.0 0.0 0.7 54.8 0.0 0.4 0.2 0.2 4.3 8.1 0.0 0.1 0.0 7.5 0.0 0.0 0.0 0.0 0.0 10.1 0.0 7.9 0.0 0.2 9.3 0.0 0.0 0.0 0.0 0.3 0.0 0.2 4.6 1.8 0.0 7.6 17.0 SCNN1D "dNaCh, ENaCdelta" ENSG00000162572 "Sodium channel epithelial 1 delta subunit" P51172 1 1280436-1292029 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 7 "Early spermatids: 9.6" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "U-266/70: 11.4" HPA026884 Enhanced Supported "Plasma membrane,Actin filaments" NA NA "Plasma membrane, Actin filaments" "HPA026884: AB_10601501" "unprognostic (2.08e-2)" "unprognostic (2.08e-1)" "unprognostic (7.39e-4)" "unprognostic (1.06e-2)" "unprognostic (2.74e-1)" "prognostic favorable (1.60e-4)" "unprognostic (1.44e-2)" "unprognostic (1.81e-1)" "unprognostic (2.08e-2)" "unprognostic (1.14e-1)" "prognostic favorable (1.32e-4)" "unprognostic (5.27e-2)" "prognostic unfavorable (6.67e-5)" "unprognostic (3.13e-1)" "unprognostic (4.18e-2)" "unprognostic (2.13e-1)" "unprognostic (7.06e-2)" 3.2 3.8 4.0 1.9 5.1 3.6 1.2 12.8 6.3 1.7 2.0 7.0 3.2 1.1 1.1 3.9 1.5 1.5 4.1 3.3 1.4 3.2 1.5 2.5 3.1 4.6 3.0 0.8 5.9 1.3 2.3 0.2 8.6 2.4 3.9 4.6 5.1 1.0 3.2 3.8 2.4 10.2 1.3 0.7 0.7 1.8 0.5 0.9 0.0 0.2 0.0 0.8 0.2 0.6 5.0 2.0 5.2 1.4 0.8 0.9 3.3 1.0 1.7 1.9 0.9 2.8 3.6 1.8 1.5 2.5 0.8 0.9 0.8 0.3 6.7 3.1 0.4 6.0 1.3 1.4 0.1 3.6 2.3 1.1 2.6 0.0 2.2 0.5 6.5 2.4 8.5 0.4 1.8 1.4 2.4 1.0 0.6 3.7 9.3 0.4 0.8 0.8 0.2 2.7 3.8 1.4 1.5 2.2 0.8 6.6 1.8 1.4 3.2 2.7 5.0 1.1 11.4 0.7 2.9 2.9 6.1 3.6 0.0 0.2 0.0 0.8 0.0 0.0 0.0 0.3 0.0 0.0 0.5 0.3 0.1 0.0 0.0 0.0 0.9 0.0 0.2 3.0 2.9 0.0 0.2 0.7 3.2 4.0 0.0 2.7 2.3 0.0 3.9 0.1 0.0 0.4 9.6 0.0 1.7 0.0 0.4 0.2 1.0 0.1 2.3 2.1 0.3 4.8 1.2 0.6 0.6 3.2 0.9 0.9 0.0 0.0 0.2 2.0 1.2 3.5 1.8 0.6 2.5 0.0 0.9 1.8 2.1 1.4 0.0 0.0 0.6 0.3 SCNN1G "ENaCgamma, SCNEG" ENSG00000166828 "Sodium channel epithelial 1 gamma subunit" P51170 16 23182715-23216883 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 42.9;salivary gland: 26.8" "Cell type enhanced" "Detected in some" 29 "Alveolar cells type 1: 17.9;Club cells: 21.6;Collecting duct cells: 85.5" "Cancer enhanced" "Detected in many" "urothelial cancer: 15.6" "Region enriched" "Detected in some" 6 "cerebellum: 9.7" "Cell type enhanced" "Detected in single" "neutrophil: 1.8" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.8" "Group enriched" "Detected in some" 7 "hTCEpi: 31.4;RT4: 14.2" "Region enriched" "Detected in single" 13 "cerebellum: 2.8" "Low region specificity" "Detected in all" HPA071194 Supported "Nucleoplasm,Plasma membrane" NA NA "Plasma membrane" Nucleoplasm "HPA071194: AB_2686359" "unprognostic (2.90e-1)" "unprognostic (5.21e-3)" "unprognostic (5.79e-2)" "unprognostic (4.31e-2)" "unprognostic (1.92e-3)" "unprognostic (1.71e-3)" "unprognostic (1.97e-1)" "unprognostic (4.85e-2)" "unprognostic (7.84e-3)" "unprognostic (1.90e-1)" "unprognostic (2.57e-2)" "prognostic unfavorable (3.20e-7)" "unprognostic (2.80e-2)" "unprognostic (1.34e-1)" "unprognostic (2.63e-1)" "unprognostic (4.17e-3)" 1.1 0.3 0.6 0.2 0.0 0.4 2.5 9.7 0.4 14.0 5.5 0.0 4.8 0.2 3.2 1.7 10.3 0.5 0.2 0.2 1.5 0.0 42.9 0.2 15.6 0.2 0.0 0.3 0.2 3.8 0.2 6.5 0.7 0.7 10.2 1.1 0.0 26.8 12.8 2.2 6.6 0.2 0.3 0.3 0.2 6.9 0.3 0.0 1.5 25.5 3.3 3.9 1.7 11.3 0.3 0.3 1.8 0.2 0.2 0.3 0.0 0.7 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 31.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.9 0.0 0.0 0.0 0.0 14.2 1.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.2 0.3 0.2 0.1 0.1 0.1 0.1 0.0 0.3 0.2 0.1 1.8 0.2 0.1 0.3 0.1 0.0 0.6 0.0 9.7 0.4 1.5 0.0 0.0 0.3 0.7 0.0 17.9 3.4 0.0 4.0 0.3 0.0 0.8 0.0 2.7 21.6 85.5 0.0 0.1 0.0 1.3 0.0 0.0 0.3 0.0 1.5 0.0 0.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.0 0.0 1.4 SCTR ENSG00000080293 "Secretin receptor" P47872 2 119439843-119525301 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "intestine: 13.5;pancreas: 35.3" "Group enriched" "Detected in some" 7 "Alveolar cells type 2: 64.4;Ductal cells: 72.3;Exocrine glandular cells: 84.2;Pancreatic endocrine cells: 51.5" "Cancer enhanced" "Detected in many" "pancreatic cancer: 15.3" "Cell type enhanced" "Detected in some" "basophil: 3.8" "Lineage enriched" "Detected in single" 7 "granulocytes: 3.8" "Cell line enriched" "Detected in some" 5 "Karpas-707: 8.2" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 12 "midbrain: 1.2;pons and medulla: 1.3;thalamus: 1.5" HPA007269 Uncertain NA NA "HPA007269: AB_1856640" "unprognostic (1.51e-1)" "unprognostic (2.22e-1)" "unprognostic (4.99e-2)" "unprognostic (5.82e-2)" "unprognostic (1.71e-1)" "unprognostic (4.12e-2)" "unprognostic (1.68e-1)" "unprognostic (1.09e-1)" "unprognostic (1.68e-2)" "unprognostic (9.08e-2)" "unprognostic (7.35e-2)" "unprognostic (2.38e-2)" "unprognostic (6.11e-3)" "unprognostic (1.65e-3)" "unprognostic (1.77e-1)" "unprognostic (2.24e-1)" "unprognostic (4.38e-2)" 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 13.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.7 0.2 4.1 0.0 0.0 0.0 35.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 1.9 0.2 0.2 0.0 0.0 0.0 0.5 0.1 3.8 0.3 0.3 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.2 0.1 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.8 0.0 0.5 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 8.2 0.7 0.5 0.1 0.0 0.9 0.3 0.0 0.1 0.0 1.5 0.3 0.5 0.0 0.3 0.0 0.3 0.0 0.3 0.0 1.1 0.0 0.0 0.4 0.6 0.0 0.9 0.3 0.1 0.0 0.0 0.1 3.8 0.3 0.9 0.3 0.2 0.4 0.3 0.3 0.0 0.0 0.5 0.3 0.2 1.2 0.3 0.3 0.1 0.4 0.0 0.0 64.4 0.0 0.2 0.0 0.0 3.1 0.0 0.0 3.4 5.2 0.0 0.0 10.0 72.3 0.4 0.0 0.0 0.0 84.2 0.0 0.0 0.0 2.3 0.0 0.5 4.8 2.4 0.0 0.0 1.1 0.0 0.0 0.0 2.8 0.0 0.2 51.5 0.0 0.0 0.2 1.1 0.0 0.6 0.0 0.2 0.0 0.2 0.0 0.0 0.0 SIGMAR1 "OPRS1, SR-BP1" ENSG00000147955 "Sigma non-opioid intracellular receptor 1" Q99720 9 34634722-34637809 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Lipid transport, Transport" Receptor "Amyotrophic lateral sclerosis, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 89.1" "Cell type enhanced" "Detected in many" 5 "Extravillous trophoblasts: 82.3;Hepatocytes: 84.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013470, HPA018002, HPA024071" Enhanced NA NA "CAB013470: AB_2533521, HPA018002: AB_1854802, HPA024071: AB_1854803" "unprognostic (1.39e-1)" "unprognostic (2.64e-1)" "unprognostic (1.56e-1)" "unprognostic (1.95e-1)" "unprognostic (8.06e-2)" "unprognostic (3.71e-2)" "unprognostic (4.89e-2)" "unprognostic (2.50e-2)" "unprognostic (2.58e-2)" "unprognostic (2.01e-3)" "unprognostic (3.88e-2)" "unprognostic (4.28e-1)" "unprognostic (2.78e-2)" "unprognostic (2.46e-1)" "unprognostic (2.39e-1)" "unprognostic (6.44e-3)" "prognostic unfavorable (3.42e-4)" 15.3 19.7 9.2 9.8 14.5 8.5 13.0 9.4 16.1 17.0 18.2 13.4 13.3 23.0 18.6 13.4 18.6 17.4 17.1 12.1 9.4 12.0 14.2 89.1 9.6 14.5 10.7 10.7 20.1 22.9 15.0 8.3 17.8 14.0 18.9 13.2 15.7 12.0 19.6 7.7 16.8 24.9 15.1 9.2 9.8 14.6 9.4 9.3 9.6 11.8 15.0 15.8 16.4 15.2 14.0 23.8 12.4 19.3 13.1 32.6 20.1 41.1 36.5 12.7 41.4 47.0 32.6 16.4 30.0 20.3 26.5 24.5 22.9 18.0 20.2 17.8 32.5 16.8 25.8 16.2 34.0 5.8 35.1 43.7 19.3 54.4 25.0 30.9 33.1 16.8 32.9 36.4 29.1 36.2 14.0 20.0 26.7 7.2 37.4 28.3 0.2 20.1 48.0 15.9 21.8 47.5 23.5 14.2 56.8 24.1 8.2 14.9 16.8 29.8 21.3 15.7 5.2 25.2 22.6 16.8 22.0 17.6 23.2 4.4 10.4 16.4 0.5 22.8 28.8 45.5 10.5 19.1 12.4 22.2 18.4 24.2 14.0 32.6 26.7 23.8 10.8 27.8 22.6 5.4 13.1 19.3 17.5 29.9 20.1 9.2 14.5 9.4 16.1 9.4 12.0 10.7 10.7 14.0 9.3 3.0 9.9 15.9 14.7 16.4 7.7 7.3 15.3 8.1 6.8 7.0 0.0 35.2 0.0 30.9 0.6 12.4 34.1 23.3 29.3 82.3 26.6 19.8 6.9 84.9 34.7 4.8 9.9 14.7 11.0 1.1 25.3 7.9 18.6 11.8 22.5 12.7 25.2 28.5 24.1 11.0 6.2 19.4 20.6 5.7 10.0 18.7 30.6 11.7 37.5 11.6 SLC12A1 NKCC2 ENSG00000074803 "Solute carrier family 12 member 1" Q13621 15 48178438-48304078 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Symport, Transport" "Bartter syndrome, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 75 "kidney: 143.2" "Cell type enriched" "Detected in some" 5 "Distal tubular cells: 177.4" "Cancer enhanced" "Detected in single" "renal cancer: 1.0" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 9 "basophil: 1.9;neutrophil: 1.5" "Lineage enriched" "Detected in single" 10 "granulocytes: 1.9" "Cell line enriched" "Detected in single" 26 "RPTEC TERT1: 24.3" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA014967, HPA018107" Enhanced Approved Nucleoplasm,Vesicles NA NA Vesicles Nucleoplasm "HPA014967: AB_1854503, HPA018107: AB_1854504" "unprognostic (3.52e-2)" "unprognostic (1.30e-2)" "unprognostic (9.65e-2)" "unprognostic (1.74e-2)" "unprognostic (7.77e-2)" "unprognostic (1.04e-1)" "unprognostic (8.72e-2)" "unprognostic (2.06e-1)" "unprognostic (9.85e-3)" "unprognostic (2.81e-4)" "unprognostic (9.75e-2)" "unprognostic (2.61e-1)" "unprognostic (5.47e-2)" "unprognostic (2.03e-1)" "unprognostic (5.20e-4)" "unprognostic (8.52e-2)" 0.0 0.0 0.3 0.0 1.0 0.0 0.0 1.4 1.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 143.2 0.1 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.1 0.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 1.9 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.3 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 1.5 0.1 0.0 0.1 0.0 0.0 0.3 1.0 1.4 1.5 0.1 0.3 0.3 0.4 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 36.6 0.0 0.0 177.4 0.0 11.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 SLC12A2 "BSC, BSC2, NKCC1, PPP1R141" ENSG00000064651 "Solute carrier family 12 member 2" P55011 5 128083766-128189688 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 50.7;salivary gland: 61.2" "Cell type enhanced" "Detected in many" 8 "Glandular cells: 203.2;Mucus-secreting cells: 402.7;Undifferentiated cells: 269.5" "Cancer enhanced" "Detected in all" "colorectal cancer: 54.3" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 9.8" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "OE19: 55.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020130, HPA063697" Approved Approved "Vesicles,Plasma membrane" NA NA Vesicles "Plasma membrane" "HPA020130: AB_1854502, HPA063697: AB_2685094" "unprognostic (4.61e-2)" "unprognostic (2.63e-1)" "unprognostic (4.20e-3)" "prognostic favorable (8.60e-4)" "unprognostic (3.99e-1)" "unprognostic (5.65e-3)" "unprognostic (1.44e-3)" "unprognostic (1.81e-1)" "unprognostic (3.30e-1)" "unprognostic (2.95e-2)" "unprognostic (7.22e-2)" "unprognostic (1.39e-1)" "prognostic favorable (7.09e-4)" "unprognostic (1.63e-1)" "unprognostic (2.30e-1)" "unprognostic (3.79e-1)" "unprognostic (3.88e-3)" 5.5 11.0 10.8 9.4 24.1 2.7 26.2 11.4 18.1 5.1 28.5 37.2 0.0 24.6 5.7 1.9 3.8 4.1 50.7 4.1 15.5 9.9 4.5 2.9 6.5 3.5 36.1 13.5 5.6 5.3 11.2 5.5 3.3 30.0 14.8 36.3 8.5 61.2 2.1 8.5 23.0 28.8 6.6 27.7 2.9 36.3 5.5 26.7 2.0 5.6 6.8 18.3 4.2 3.6 3.6 9.8 0.5 1.2 3.6 3.0 0.4 4.8 24.1 24.8 9.6 6.2 4.0 5.1 4.5 3.4 3.2 3.4 9.6 7.7 7.2 6.1 3.9 2.9 14.7 4.7 5.2 5.0 7.2 5.9 2.0 4.3 1.4 1.9 2.6 3.6 4.2 1.9 7.2 4.3 2.4 5.3 3.1 3.3 4.9 5.0 5.1 4.6 2.2 2.9 55.9 7.9 2.5 7.0 2.9 3.8 16.5 4.4 2.8 9.1 4.0 3.5 2.8 2.2 1.3 8.8 8.1 5.4 6.1 5.7 4.1 3.7 8.0 4.2 1.5 6.5 0.5 0.7 0.2 1.9 1.2 3.0 2.7 1.8 2.3 0.9 3.6 2.0 2.7 0.3 3.6 0.8 9.8 1.6 0.4 10.8 24.1 11.4 18.1 15.5 9.9 36.1 13.5 30.0 26.7 14.9 37.4 13.4 18.3 20.4 45.1 14.0 99.3 10.7 38.7 31.4 119.8 0.9 1.7 45.3 45.7 23.6 29.9 0.0 41.4 2.1 14.8 203.2 18.4 7.4 3.6 76.3 71.5 6.7 7.3 70.8 79.1 10.2 194.0 0.0 402.7 27.8 49.2 77.2 27.3 9.6 76.9 71.1 24.5 27.0 21.5 26.2 1.1 12.1 269.5 16.9 SLC12A3 NCCT ENSG00000070915 "Solute carrier family 12 member 3" P55017 16 56865207-56915850 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "kidney: 88.6" "Group enriched" "Detected in some" 9 "Collecting duct cells: 3.5;Distal tubular cells: 5.0;monocytes: 7.2" "Cancer enhanced" "Detected in some" "renal cancer: 2.5" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 17 "plasmacytoid DC: 14.6" "Lineage enriched" "Detected in single" 17 "dendritic cells: 14.6" "Group enriched" "Detected in some" 10 "BEWO: 10.2;HAP1: 5.6;HeLa: 11.4;SuSa: 3.9" "Not detected" "Not detected" "Not detected" "Not detected" HPA028748 Enhanced NA NA "HPA028748: AB_10603886" "unprognostic (1.54e-3)" "unprognostic (7.09e-5)" "unprognostic (1.35e-1)" "unprognostic (1.41e-2)" "unprognostic (2.91e-1)" "unprognostic (2.38e-4)" "unprognostic (1.81e-1)" "unprognostic (9.70e-2)" "unprognostic (1.34e-1)" "unprognostic (7.25e-2)" "unprognostic (6.84e-2)" "unprognostic (1.83e-1)" "unprognostic (1.43e-1)" "unprognostic (2.09e-1)" "unprognostic (1.38e-1)" "unprognostic (1.40e-2)" "unprognostic (1.70e-1)" 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 88.6 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 14.6 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 10.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.7 5.6 0.0 0.0 0.0 0.0 0.0 11.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.4 0.0 3.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.0 14.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 3.5 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SLC12A4 KCC1 ENSG00000124067 "Solute carrier family 12 member 4" Q9UP95 16 67943474-67969601 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Syncytiotrophoblasts: 53.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041138 Approved Approved Endosomes NA NA Endosomes "HPA041138: AB_10794544" "unprognostic (5.07e-2)" "unprognostic (6.18e-2)" "unprognostic (1.25e-1)" "unprognostic (2.68e-2)" "unprognostic (9.28e-2)" "unprognostic (1.48e-2)" "unprognostic (4.28e-2)" "unprognostic (3.26e-3)" "unprognostic (9.58e-2)" "unprognostic (1.55e-1)" "unprognostic (2.01e-2)" "unprognostic (1.81e-2)" "prognostic favorable (2.25e-6)" "unprognostic (6.42e-2)" "unprognostic (1.42e-1)" "unprognostic (7.64e-2)" "unprognostic (2.26e-1)" 16.6 18.3 9.2 8.0 8.8 3.1 26.5 7.0 12.7 19.4 16.5 20.1 12.0 5.1 20.7 9.7 11.8 13.8 15.5 24.4 12.2 5.2 10.7 17.1 19.5 6.6 11.4 8.2 14.2 11.9 30.1 8.1 32.6 18.1 17.8 4.3 23.0 10.5 20.7 14.6 16.9 8.6 27.4 10.0 10.2 10.9 17.6 9.8 8.8 21.0 9.1 8.4 16.5 16.6 1.0 2.4 8.3 5.4 2.7 1.6 1.6 5.0 6.8 5.3 10.0 17.6 15.5 28.6 15.6 16.2 13.5 11.8 13.6 8.2 1.8 7.7 21.5 7.5 9.3 2.5 19.3 10.2 1.8 2.0 1.3 8.9 14.9 20.0 0.1 6.4 17.1 12.7 18.1 6.6 15.8 8.3 3.4 4.1 1.5 18.5 0.8 1.9 5.1 4.0 1.5 3.6 2.0 10.0 1.6 7.4 4.4 0.0 3.2 29.7 1.8 2.6 13.8 14.2 2.0 11.2 19.3 13.7 8.5 6.7 9.3 2.3 3.0 11.2 1.4 16.6 8.3 3.9 2.0 1.5 5.4 1.0 0.4 0.9 0.9 2.4 1.0 0.8 0.7 1.4 2.7 3.8 1.1 1.6 1.6 9.2 8.8 7.0 8.6 12.2 5.2 11.4 8.2 18.1 9.8 14.9 7.8 2.2 12.2 9.0 1.0 25.6 2.5 6.7 10.3 14.0 0.0 24.6 0.0 10.9 2.1 14.3 0.0 0.0 7.1 13.5 13.6 12.7 1.1 7.5 6.9 0.0 0.0 14.1 4.6 1.3 18.4 4.4 10.1 16.2 0.0 21.0 12.7 0.0 34.3 3.4 0.8 38.8 27.6 9.7 6.6 4.5 53.1 1.5 0.0 8.6 SLC12A5 "KCC2, KIAA1176" ENSG00000124140 "Solute carrier family 12 member 5" Q9H2X9 20 46021690-46060152 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Symport, Transport" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 64.6" "Group enriched" "Detected in many" 13 "Bipolar cells: 205.2;Cone photoreceptor cells: 361.3;Rod photoreceptor cells: 172.9" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 5.7" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Hep G2: 13.7;NB-4: 28.3;SK-BR-3: 14.3;U-2 OS: 16.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA072058 Enhanced NA NA "HPA072058: AB_2686485" "unprognostic (2.01e-1)" "unprognostic (3.58e-1)" "unprognostic (7.55e-2)" "unprognostic (9.44e-4)" "prognostic unfavorable (5.60e-4)" "unprognostic (2.48e-1)" "unprognostic (5.16e-3)" "unprognostic (3.61e-1)" "unprognostic (2.49e-1)" "unprognostic (6.63e-2)" "unprognostic (3.72e-3)" "unprognostic (5.61e-4)" "unprognostic (8.78e-4)" "unprognostic (3.25e-2)" "unprognostic (9.22e-2)" "unprognostic (1.99e-1)" "unprognostic (2.34e-2)" 1.4 11.2 21.1 2.0 28.8 1.5 1.7 52.1 64.6 2.3 2.1 2.7 0.0 2.2 1.6 2.2 1.3 1.7 1.9 2.1 20.5 19.2 1.4 2.2 2.7 3.1 9.5 32.1 2.0 3.6 1.5 4.8 3.3 15.3 1.5 2.1 4.9 1.9 1.8 1.5 1.5 2.1 1.6 6.3 2.8 3.1 3.4 5.8 0.0 1.3 0.0 2.6 1.2 0.5 1.3 0.2 0.1 1.5 0.7 5.7 1.3 0.0 8.6 3.8 2.8 0.3 0.0 0.8 0.3 0.0 0.0 0.3 1.1 0.0 3.2 13.1 0.2 3.4 0.8 2.5 1.3 0.2 2.0 3.3 2.7 1.6 13.7 1.5 0.0 3.8 0.5 0.0 0.0 0.2 5.9 0.8 3.1 5.1 0.0 0.0 13.0 1.9 28.3 1.4 1.2 4.4 3.2 2.4 0.7 1.3 0.0 4.7 6.7 1.7 14.3 4.1 3.7 5.2 8.1 1.3 1.5 16.3 0.1 0.6 0.0 2.1 4.5 3.5 3.3 0.1 0.0 1.5 0.0 2.6 0.8 1.0 1.0 0.3 0.4 0.2 1.3 5.7 3.2 0.1 0.7 0.2 0.0 3.5 1.3 21.1 28.8 52.1 36.4 20.5 19.2 9.5 32.1 15.3 5.8 0.0 0.0 0.0 0.0 0.5 205.2 0.8 0.0 0.0 0.0 0.0 361.3 1.1 1.7 0.0 1.6 1.6 0.0 0.0 0.2 2.6 0.4 0.4 0.0 0.5 15.2 12.7 19.1 3.7 0.6 3.4 0.0 3.2 5.0 1.0 0.4 12.9 0.5 0.0 0.0 0.2 172.9 0.0 0.4 1.4 2.5 0.5 1.4 0.0 0.4 0.0 SLC18A1 "CGAT, VAT1, VMAT1" ENSG00000036565 "Solute carrier family 18 member A1" P54219 8 20144855-20183206 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 25.4;intestine: 10.8" "Cell type enriched" "Detected in some" 37 "Intestinal endocrine cells: 133.5" "Cancer enhanced" "Detected in some" "colorectal cancer: 0.8" "Region enriched" "Detected in single" 4 "midbrain: 2.0" "Group enriched" "Detected in some" 12 "intermediate monocyte: 2.3;non-classical monocyte: 6.0" "Lineage enriched" "Detected in single" 18 "monocytes: 6.0" "Cell line enriched" "Detected in some" 8 "SH-SY5Y: 39.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA006877, HPA063797" Enhanced NA NA "HPA006877: AB_2667690, HPA063797: AB_2685125" "unprognostic (8.03e-4)" "unprognostic (1.02e-1)" "unprognostic (3.75e-3)" "unprognostic (3.50e-1)" "unprognostic (6.61e-2)" "unprognostic (3.09e-3)" "unprognostic (1.67e-1)" "unprognostic (2.16e-2)" "unprognostic (3.45e-2)" "unprognostic (1.48e-1)" "unprognostic (1.32e-3)" "unprognostic (1.61e-1)" "unprognostic (2.48e-2)" "unprognostic (8.25e-2)" "unprognostic (4.41e-2)" "unprognostic (2.06e-1)" "unprognostic (1.05e-1)" 0.0 25.4 0.2 0.8 0.1 0.0 0.0 0.0 0.2 0.2 8.8 1.3 1.3 1.4 0.4 0.0 0.0 0.0 0.7 0.1 0.1 0.4 0.0 0.0 0.0 0.0 2.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 1.0 2.7 0.0 0.0 2.8 0.0 0.0 10.8 0.0 0.1 0.3 1.1 0.2 0.0 0.2 0.2 0.0 0.1 1.3 0.4 0.0 0.3 0.2 6.0 0.0 0.0 0.3 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 2.2 39.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 6.0 0.0 0.0 0.3 0.2 0.1 0.0 0.2 0.1 0.4 2.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 133.5 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 SLC18A2 "SVAT, SVMT, VMAT2" ENSG00000165646 "Solute carrier family 18 member A2" Q05940 10 117241073-117279430 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "Disease mutation, Dystonia, FDA approved drug targets, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 26.3;brain: 28.3;cervix, uterine: 31.2" "Cell type enriched" "Detected in some" 22 "granulocytes: 603.6" "Low cancer specificity" "Detected in some" "Group enriched" "Detected in many" 10 "hypothalamus: 9.0;midbrain: 28.3;pons and medulla: 26.5" "Cell type enriched" "Detected in some" 13 "basophil: 26.3" "Lineage enriched" "Detected in many" 13 "granulocytes: 26.3" "Cell line enriched" "Detected in some" 20 "HMC-1: 91.2" "Region enhanced" "Detected in many" "midbrain: 75.4" "Group enriched" "Detected in all" 5 "midbrain: 143.8;pons and medulla: 34.7" HPA073224 Enhanced Approved Vesicles,Centrosome NA NA "Vesicles, Centrosome" "HPA073224: AB_2732222" "unprognostic (1.49e-1)" "unprognostic (2.48e-1)" "unprognostic (2.33e-3)" "unprognostic (9.00e-2)" "unprognostic (2.85e-1)" "unprognostic (5.33e-3)" "unprognostic (2.23e-1)" "unprognostic (1.71e-2)" "unprognostic (1.40e-1)" "unprognostic (4.55e-2)" "unprognostic (2.00e-1)" "unprognostic (6.06e-3)" "unprognostic (7.94e-5)" "unprognostic (2.95e-2)" "unprognostic (2.31e-1)" "unprognostic (2.43e-1)" "unprognostic (3.57e-2)" 1.7 13.9 1.7 3.1 2.0 2.0 2.0 1.7 1.6 31.2 2.3 0.5 2.2 1.5 11.2 4.9 3.0 1.1 15.9 1.0 1.9 9.0 1.1 3.3 7.6 1.5 28.3 0.2 9.7 3.7 0.5 1.6 2.1 26.5 10.8 3.4 3.1 1.0 4.0 1.1 5.8 2.5 5.4 2.9 0.5 3.5 1.5 0.3 14.1 0.6 3.4 2.9 3.1 5.4 0.0 2.0 26.3 0.0 0.0 0.3 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 4.6 0.0 0.0 0.0 0.2 91.2 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.1 0.1 0.0 0.1 0.4 0.0 26.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.2 0.0 0.0 2.0 0.0 1.1 1.7 2.0 1.7 1.6 1.9 9.0 28.3 0.2 26.5 0.3 8.9 27.6 0.0 0.0 1.6 0.6 0.2 0.0 1.4 4.5 0.0 3.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 4.4 603.6 0.0 0.7 0.0 8.5 11.6 1.8 0.0 0.6 0.6 1.7 0.0 0.0 0.3 0.1 0.0 4.6 0.0 0.7 0.0 0.2 0.2 0.1 2.4 0.0 0.0 0.0 0.0 SLC1A5 "AAAT, ASCT2, M7V1, RDRC" ENSG00000105281 "Solute carrier family 1 member 5" Q15758 19 46774883-46788594 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Host-virus interaction, Symport, Transport" "Host cell receptor for virus entry, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 5 "Basal glandular cells: 134.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 34.6" "Group enriched" "Detected in many" 4 "dendritic cells: 34.6;monocytes: 22.4" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA035239, HPA035240" Enhanced Enhanced "Plasma membrane" NA NA "Plasma membrane" "HPA035239: AB_10670587, HPA035240: AB_10604092" "unprognostic (8.26e-3)" "unprognostic (6.38e-2)" "unprognostic (7.24e-2)" "unprognostic (7.94e-2)" "unprognostic (2.32e-1)" "unprognostic (1.24e-1)" "prognostic unfavorable (1.66e-8)" "unprognostic (2.08e-1)" "unprognostic (1.06e-2)" "unprognostic (9.82e-2)" "unprognostic (9.40e-3)" "unprognostic (9.57e-3)" "prognostic unfavorable (1.18e-7)" "unprognostic (1.28e-2)" "unprognostic (6.30e-2)" "unprognostic (1.06e-2)" "unprognostic (9.83e-2)" 39.3 5.7 3.4 16.0 5.4 16.2 45.0 0.9 3.0 20.7 15.8 5.0 50.4 4.9 14.3 33.7 33.9 18.1 31.2 10.0 4.5 2.2 23.7 4.1 23.4 17.7 8.2 0.9 33.3 24.6 0.2 9.1 25.8 4.9 35.2 13.8 5.2 99.0 55.7 6.9 18.6 12.1 23.1 5.3 19.8 17.9 21.7 6.1 14.9 6.5 28.4 25.9 48.3 44.9 7.0 34.6 0.9 22.4 6.9 5.6 7.4 23.8 44.1 10.6 16.0 27.7 23.6 25.1 34.1 39.0 25.6 37.2 40.0 27.0 26.2 16.7 84.6 14.7 38.5 30.9 40.5 19.1 17.3 28.0 43.4 16.9 37.5 71.7 30.2 25.6 38.3 101.3 30.0 76.2 8.6 13.6 35.0 45.8 69.4 13.6 40.6 13.8 81.3 18.5 85.5 19.4 15.7 12.0 37.2 14.3 52.2 16.4 12.0 16.8 46.0 36.5 8.6 26.5 39.9 10.1 15.4 24.7 12.0 27.7 43.1 41.6 21.8 29.0 37.7 37.7 0.0 11.5 0.9 5.3 19.9 4.4 7.0 3.1 3.7 17.8 2.5 0.7 2.3 0.3 6.9 22.4 34.6 5.6 7.4 3.4 5.4 0.9 3.0 4.5 2.2 8.2 0.9 4.9 6.1 0.0 15.9 11.9 134.3 51.3 0.1 19.9 20.4 4.0 7.9 0.0 0.0 80.4 3.3 26.8 14.6 17.1 22.0 93.5 55.3 97.4 44.3 44.4 28.8 0.5 33.9 0.0 10.3 26.4 16.8 10.3 17.5 27.3 18.6 10.8 88.4 0.6 35.9 74.6 18.4 23.9 0.8 6.5 22.6 4.4 4.3 24.7 20.4 20.8 50.3 96.8 SLC22A11 OAT4 ENSG00000168065 "Solute carrier family 22 member 11" Q9NSA0 11 64555626-64572875 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 10 "epididymis: 22.2;kidney: 47.6;placenta: 64.7" "Group enriched" "Detected in some" 17 "Cytotrophoblasts: 554.5;Syncytiotrophoblasts: 1271.5" "Group enriched" "Detected in some" 14 "liver cancer: 3.7;renal cancer: 15.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 4.8;CACO-2: 1.1;Hep G2: 3.4;SuSa: 1.9" "Not detected" "Not detected" HPA026076 Enhanced NA NA "HPA026076: AB_1854756" "unprognostic (8.21e-5)" "unprognostic (3.29e-2)" "unprognostic (3.57e-1)" "unprognostic (1.57e-1)" "unprognostic (3.20e-2)" "unprognostic (4.57e-3)" "unprognostic (3.48e-1)" "unprognostic (1.93e-1)" "unprognostic (4.86e-2)" "unprognostic (4.51e-2)" "unprognostic (7.56e-2)" "unprognostic (1.13e-1)" "prognostic favorable (3.68e-5)" "unprognostic (4.62e-2)" "unprognostic (6.52e-2)" "unprognostic (3.50e-2)" "unprognostic (8.24e-3)" 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 4.4 0.0 0.1 22.2 0.1 0.1 0.0 0.1 0.1 0.1 47.6 0.4 0.1 0.0 0.2 0.0 0.1 0.3 0.0 0.1 64.7 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.3 0.1 0.4 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.2 4.8 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.3 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.2 0.0 1.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 554.5 5.0 0.0 1.0 0.0 0.0 0.0 0.3 13.6 0.6 0.0 0.0 0.0 44.6 0.0 0.0 0.0 0.0 1.3 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 54.2 0.0 0.0 0.0 0.0 0.1 0.0 1271.5 0.0 0.0 0.0 SLC22A12 "OAT4L, RST, URAT1" ENSG00000197891 "Solute carrier family 22 member 12" Q96S37 11 64590641-64602353 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 349 "kidney: 70.1" "Cell type enriched" "Detected in some" 18 "Proximal tubular cells: 149.1" "Group enriched" "Detected in some" 207 "liver cancer: 4.0;renal cancer: 16.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Not detected" "Not detected" HPA024575 Enhanced NA NA "HPA024575: AB_1858650" "unprognostic (5.88e-2)" "unprognostic (2.33e-1)" "prognostic favorable (2.63e-4)" "unprognostic (6.19e-2)" "unprognostic (3.91e-2)" 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 70.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.8 0.0 0.0 8.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 149.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SLC22A6 "OAT1, PAHT, ROAT1" ENSG00000197901 "Solute carrier family 22 member 6" Q4U2R8 11 62936385-62984983 "FDA approved drug targets, Predicted membrane proteins, Transporters" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "kidney: 94.2" "Cell type enriched" "Detected in some" 14 "Proximal tubular cells: 213.4" "Cancer enriched" "Detected in single" 102 "renal cancer: 18.8" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA074559, CAB075704" Enhanced NA NA "CAB075704: , HPA074559: AB_2732260" "unprognostic (2.42e-2)" "unprognostic (2.25e-3)" "unprognostic (4.43e-1)" 0.2 0.2 0.8 0.2 1.3 0.2 0.2 0.4 1.4 0.2 0.2 0.7 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.8 1.8 94.2 0.2 0.2 0.2 2.4 0.6 0.2 0.2 0.2 0.1 0.2 4.1 0.2 0.2 9.4 0.2 0.2 0.2 0.2 0.2 0.2 2.4 0.2 0.2 0.2 0.5 0.0 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 1.3 0.4 1.4 0.8 1.8 2.4 0.6 4.1 0.5 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 7.0 0.0 0.0 14.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 213.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SLC22A8 OAT3 ENSG00000149452 "Solute carrier family 22 member 8" Q8TCC7 11 62989154-63015839 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Detoxification, Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 341 "brain: 33.7;kidney: 127.3;retina: 93.5" "Cell type enriched" "Detected in some" 30 "Proximal tubular cells: 197.4" "Cancer enhanced" "Detected in single" "renal cancer: 0.6" "Region enriched" "Detected in some" 25 "pons and medulla: 33.7" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 13 "EFO-21: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044174 Enhanced NA NA "HPA044174: AB_10963058" "unprognostic (5.35e-4)" "unprognostic (4.66e-1)" "unprognostic (6.88e-3)" "unprognostic (1.72e-1)" "unprognostic (2.20e-1)" 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.4 1.0 0.1 0.1 3.8 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.7 0.1 127.3 0.1 0.1 0.1 0.1 1.3 0.1 0.1 0.1 0.2 0.1 33.7 0.1 0.1 93.5 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.4 1.0 0.7 0.1 0.1 1.3 33.7 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.8 0.0 0.0 0.0 5.2 0.0 0.0 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 197.4 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SLC25A4 "ANT1, PEO2, PEO3, T1" ENSG00000151729 "Solute carrier family 25 member 4" P12235 4 185143241-185150382 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Host-virus interaction, Transport" "Cardiomyopathy, Disease mutation, FDA approved drug targets, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 5 "heart muscle: 163.7;skeletal muscle: 92.5;tongue: 62.4" "Cell type enriched" "Detected in many" 5 "Cardiomyocytes: 4236.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "B-cells: 3.5;dendritic cells: 3.0;T-cells: 4.1" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046835, HPA071684" Approved Supported Mitochondria NA NA Mitochondria "HPA046835: AB_2679831, HPA071684: AB_2686431" "unprognostic (4.19e-2)" "unprognostic (1.06e-2)" "unprognostic (3.11e-1)" "unprognostic (8.85e-2)" "unprognostic (1.37e-1)" "unprognostic (2.90e-3)" "unprognostic (8.25e-2)" "unprognostic (1.26e-2)" "unprognostic (7.87e-2)" "unprognostic (1.60e-1)" "prognostic favorable (3.41e-4)" "unprognostic (2.05e-1)" "prognostic favorable (0.00e+0)" "unprognostic (1.98e-1)" "unprognostic (1.05e-1)" "unprognostic (1.73e-1)" "unprognostic (8.28e-3)" 3.0 4.2 6.9 2.0 10.8 1.4 3.1 19.4 14.4 2.6 6.6 3.7 2.9 2.8 3.0 3.4 6.7 3.7 3.5 163.7 7.4 7.3 8.3 4.3 3.0 2.0 6.3 6.1 3.6 3.0 4.6 4.6 2.2 12.8 6.2 3.4 7.9 4.4 8.5 92.5 2.3 4.1 5.5 4.5 2.1 5.3 3.1 2.3 0.0 4.6 62.4 3.4 4.4 2.1 3.5 3.0 0.4 0.0 0.7 4.1 1.5 0.7 3.3 2.7 5.5 3.0 0.3 5.0 2.7 0.9 3.3 3.3 7.1 1.8 2.4 2.0 3.3 2.6 2.6 10.4 2.9 2.2 4.0 8.9 1.6 4.9 8.3 6.1 1.4 1.6 2.2 7.1 5.1 1.4 7.8 2.4 4.2 3.8 1.9 2.0 5.1 1.6 3.2 4.4 2.3 7.1 2.6 1.4 3.3 7.5 5.1 8.8 6.7 3.2 1.4 12.6 5.1 2.6 1.2 1.8 0.2 1.5 1.7 3.5 7.9 3.6 3.1 2.4 0.3 3.0 0.0 0.0 0.0 4.1 0.0 3.1 3.5 1.4 3.5 0.1 2.2 1.2 3.0 0.4 0.7 0.0 3.0 1.2 1.5 6.9 10.8 19.4 14.1 7.4 7.3 6.3 6.1 12.8 2.3 80.4 55.4 33.5 125.8 39.2 174.4 4236.1 140.1 112.4 42.1 68.0 98.2 59.7 837.3 68.4 15.8 25.9 41.2 0.0 65.1 47.9 24.6 55.0 11.5 83.9 50.1 151.0 51.6 24.5 7.6 7.7 43.1 7.9 180.5 15.4 35.7 473.2 51.1 24.6 106.1 140.9 178.4 103.5 194.8 24.0 35.3 15.8 33.9 10.7 48.8 46.9 SLC25A5 "2F1, ANT2, T2, T3" ENSG00000005022 "Solute carrier family 25 member 5" P05141 X 119468400-119471319 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Chromosome partition, Host-virus interaction, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Distal tubular cells: 2147.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046835, HPA071684" Approved Supported Mitochondria NA NA 7800000 Mitochondria "HPA046835: AB_2679831, HPA071684: AB_2686431" "unprognostic (1.25e-2)" "prognostic favorable (7.35e-4)" "prognostic favorable (7.47e-4)" "unprognostic (1.48e-1)" "unprognostic (4.58e-2)" "unprognostic (1.45e-2)" "unprognostic (2.73e-2)" "unprognostic (1.36e-1)" "unprognostic (6.52e-2)" "unprognostic (2.47e-1)" "unprognostic (1.60e-1)" "unprognostic (2.17e-1)" "prognostic favorable (8.06e-6)" "unprognostic (1.41e-1)" "unprognostic (2.65e-1)" "unprognostic (4.36e-2)" "unprognostic (3.03e-1)" 26.0 28.9 26.8 32.2 29.5 36.5 36.6 21.8 39.0 23.0 74.1 16.3 26.0 120.7 22.5 18.3 64.1 17.5 39.5 31.4 22.5 18.8 80.7 71.0 38.3 53.8 27.2 23.8 18.1 128.2 22.5 14.6 30.7 24.2 18.9 84.9 20.1 58.3 21.5 16.6 42.1 157.5 33.6 20.5 34.3 68.2 16.8 17.1 87.0 31.1 59.9 47.0 30.8 33.8 51.6 97.8 18.5 113.2 33.4 48.0 84.9 82.0 78.9 30.9 53.1 19.8 29.2 57.4 30.7 33.5 64.8 58.0 65.5 52.1 104.2 41.3 29.4 46.8 57.8 75.8 64.1 59.2 27.5 73.1 35.1 47.7 46.6 25.1 95.3 58.0 31.7 72.1 66.7 42.6 24.7 67.2 53.7 28.1 43.2 35.3 182.7 84.3 96.8 65.0 112.7 127.2 46.3 39.1 80.8 49.3 66.0 37.4 35.4 52.7 80.3 62.1 32.9 33.1 48.3 27.9 30.7 44.4 68.3 110.0 50.7 62.9 83.4 33.9 97.5 49.5 10.1 68.1 18.5 20.7 113.2 23.9 51.6 30.1 26.9 97.8 39.7 30.1 28.3 11.3 33.4 84.9 53.9 48.0 84.9 26.8 29.5 21.8 39.0 22.5 18.8 27.2 23.8 24.2 17.1 151.8 244.7 335.6 401.9 724.7 105.3 125.5 328.6 187.4 221.8 177.9 56.9 945.1 2147.0 467.3 2.7 209.6 1628.0 163.5 919.2 321.7 246.2 228.4 191.3 343.1 785.8 25.4 385.2 119.1 477.4 13.9 134.6 447.5 519.6 300.2 755.1 85.2 524.3 956.2 104.0 1138.1 131.4 129.4 460.4 8.9 116.7 839.4 1329.0 292.0 958.7 657.9 SLC25A6 "ANT3, ANT3Y, MGC17525" ENSG00000169100 "Solute carrier family 25 member 6" P12236 X 1386152-1392724 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Apoptosis, Host-virus interaction, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 85.7" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "HPA046835, HPA071684" Approved Supported Mitochondria NA NA 7200000 Mitochondria "HPA046835: AB_2679831, HPA071684: AB_2686431" "unprognostic (1.13e-1)" "unprognostic (1.65e-2)" "unprognostic (4.79e-2)" "unprognostic (1.45e-1)" "unprognostic (2.14e-1)" "unprognostic (1.41e-1)" "unprognostic (1.01e-3)" "unprognostic (1.34e-1)" "unprognostic (8.07e-2)" "unprognostic (1.48e-1)" "unprognostic (1.37e-3)" "unprognostic (2.51e-1)" "unprognostic (3.96e-2)" "unprognostic (2.73e-1)" "unprognostic (1.69e-1)" "unprognostic (2.85e-1)" "unprognostic (4.57e-3)" 18.5 19.7 12.1 12.2 14.0 23.7 14.4 8.2 12.2 9.8 16.5 28.9 14.3 4.8 16.4 10.4 7.0 9.4 10.3 8.2 18.4 5.4 11.1 14.4 9.4 25.6 38.7 10.1 14.0 8.6 12.4 8.8 45.0 12.5 6.1 14.9 23.3 7.7 5.8 15.4 19.2 2.4 16.3 9.5 14.2 11.2 62.2 85.7 3.7 69.0 30.1 43.6 71.2 22.2 48.7 34.6 35.3 24.0 46.8 37.5 34.1 32.7 25.2 25.1 64.4 27.2 82.8 27.6 22.4 38.0 14.5 23.2 40.7 7.9 20.7 73.8 45.2 33.4 73.5 56.3 32.5 55.2 77.2 75.0 19.7 29.0 32.7 37.3 26.1 31.5 19.5 24.6 47.4 60.1 62.3 43.9 8.8 65.7 30.4 28.6 64.2 30.7 56.0 56.6 88.9 23.1 70.1 97.0 21.0 38.9 67.0 42.7 25.7 14.4 50.2 34.0 50.6 8.1 55.8 3.8 31.4 13.9 2.4 58.1 3.7 29.4 69.0 43.6 62.2 40.4 34.8 85.7 47.5 38.1 37.2 3.0 30.1 67.9 41.0 38.7 71.2 137.0 195.3 871.5 1042.4 1022.6 282.9 87.0 257.4 128.5 280.9 300.1 92.3 1322.2 1405.9 633.0 8.9 418.0 863.0 303.7 1275.3 963.9 807.0 855.9 337.0 132.8 1090.5 228.8 892.0 411.9 1235.3 26.5 618.4 976.3 715.3 1354.4 1107.0 100.8 835.0 866.6 344.4 1021.3 199.6 336.3 860.1 13.3 52.8 1155.2 1458.6 553.5 1380.0 1328.6 SLC52A2 "D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2" ENSG00000185803 "Solute carrier family 52 member 2" Q9HAB3 8 144354135-144361286 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport "Host cell receptor for virus entry, Receptor" "Deafness, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "PC-3: 51.0" "Low region specificity" "Detected in all" HPA063036 Approved NA NA "HPA063036: AB_2684928" "unprognostic (7.80e-3)" "prognostic unfavorable (7.55e-4)" "unprognostic (2.15e-1)" "unprognostic (2.94e-1)" "unprognostic (3.09e-2)" "unprognostic (3.94e-2)" "prognostic unfavorable (2.04e-6)" "unprognostic (7.74e-3)" "unprognostic (9.20e-2)" "unprognostic (2.24e-2)" "unprognostic (4.85e-2)" "unprognostic (3.99e-2)" "prognostic unfavorable (1.23e-4)" "unprognostic (3.12e-2)" "unprognostic (1.73e-1)" "unprognostic (1.51e-1)" "unprognostic (1.07e-1)" 16.0 12.8 7.3 13.2 8.8 9.9 23.7 19.2 10.5 10.9 18.1 7.5 19.3 19.6 10.7 19.9 14.6 7.4 16.3 8.0 7.7 9.0 14.7 12.4 10.7 10.7 13.0 5.9 10.6 22.4 7.9 10.9 19.5 9.5 10.8 9.3 7.2 21.3 14.1 7.0 12.6 17.8 8.5 7.9 15.2 16.8 17.0 7.4 11.5 12.4 11.6 14.6 8.6 13.1 7.7 9.0 9.2 7.4 5.7 6.3 1.9 12.8 18.5 2.6 6.9 4.9 3.7 13.4 9.9 7.0 9.0 7.2 14.7 15.5 6.1 16.3 7.1 6.6 15.3 4.4 7.6 1.9 7.5 10.5 10.6 10.6 13.3 16.0 3.9 9.1 5.1 9.2 8.2 6.8 4.4 5.2 5.8 14.5 7.8 4.7 37.4 6.0 10.3 5.6 16.0 51.0 11.2 3.1 13.8 7.3 9.5 8.2 9.8 12.2 12.7 11.4 2.5 10.0 5.1 7.4 7.4 16.8 18.4 14.2 3.9 5.4 4.6 12.2 9.7 8.5 1.2 4.2 9.2 5.9 6.1 3.7 4.2 4.7 6.3 5.2 7.7 4.6 3.1 1.4 5.7 7.4 9.0 5.7 1.9 7.3 8.8 19.2 10.5 7.7 9.0 13.0 5.9 9.5 7.4 6.0 5.4 19.3 19.4 27.7 10.9 2.5 12.7 4.0 14.8 12.2 2.0 74.0 0.0 60.6 2.5 20.6 60.0 0.0 58.0 74.5 27.7 31.3 10.3 4.0 47.5 11.1 16.7 17.8 14.8 4.2 11.8 20.9 28.7 55.1 32.0 13.5 64.4 42.1 18.7 12.9 8.9 19.4 26.4 31.7 39.6 31.6 43.9 20.8 38.1 32.6 SLC5A2 SGLT2 ENSG00000140675 "Solute carrier family 5 member 2" P31639 16 31483002-31490860 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Sugar transport, Symport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 17 "kidney: 33.7" "Group enriched" "Detected in some" 11 "Early spermatids: 46.9;Late spermatids: 103.8;Proximal tubular cells: 139.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 1.6" "Group enriched" "Detected in many" 16 "NK-cells: 1.4;T-cells: 1.6" "Cell line enhanced" "Detected in some" "BEWO: 1.2;EFO-21: 2.0;Hep G2: 2.6;NB-4: 1.3;U-2 OS: 1.2;U-266/84: 1.8;U-937: 1.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA041603 Enhanced NA NA "HPA041603: AB_10960540" "unprognostic (1.61e-1)" "unprognostic (2.95e-1)" "unprognostic (2.84e-1)" "unprognostic (3.00e-2)" "unprognostic (8.04e-2)" "unprognostic (8.23e-3)" "unprognostic (1.49e-1)" "unprognostic (2.25e-3)" "unprognostic (2.57e-1)" "unprognostic (1.12e-2)" "unprognostic (6.43e-2)" "unprognostic (2.47e-1)" "unprognostic (1.42e-3)" "unprognostic (5.88e-2)" "unprognostic (2.14e-1)" "unprognostic (4.18e-2)" "unprognostic (3.22e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 1.6 0.6 0.1 0.4 0.0 0.9 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 2.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.5 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.0 0.3 1.2 0.1 0.0 0.0 1.8 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 1.6 0.5 0.0 0.0 0.5 0.1 0.0 1.4 0.0 0.0 1.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.2 0.0 0.3 0.0 1.4 0.0 8.7 0.0 0.2 6.6 0.7 46.9 0.0 0.3 0.0 0.4 0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 103.8 2.0 0.4 0.0 0.0 0.2 0.0 0.7 0.0 1.4 139.8 0.0 0.0 0.0 3.2 0.9 0.3 0.1 0.0 0.6 0.0 SLC6A1 "GABATHG, GABATR, GAT1" ENSG00000157103 "Solute carrier family 6 member 1" P30531 3 10992186-11039249 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "brain: 56.2;liver: 75.6" "Cell type enhanced" "Detected in some" 16 "Cholangiocytes: 17.8;Hepatocytes: 24.5;Muller glia cells: 41.9;Sertoli cells: 12.9" "Group enriched" "Detected in some" 16 "glioma: 16.1;liver cancer: 24.4" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HeLa: 4.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013341, CAB022293" Enhanced Uncertain Mitochondria No NA Mitochondria "CAB022293: , HPA013341: AB_1849509" "unprognostic (1.66e-3)" "unprognostic (1.30e-3)" "unprognostic (4.12e-3)" "unprognostic (1.70e-1)" "unprognostic (2.53e-1)" "unprognostic (2.53e-1)" "prognostic favorable (3.20e-4)" "unprognostic (1.05e-1)" "unprognostic (4.27e-2)" "unprognostic (8.26e-2)" "unprognostic (2.90e-1)" "unprognostic (2.69e-1)" "prognostic unfavorable (5.05e-6)" "unprognostic (7.32e-3)" "unprognostic (2.36e-1)" "unprognostic (1.35e-1)" "unprognostic (5.34e-2)" 1.8 2.1 32.2 1.6 31.0 3.0 1.8 15.1 56.2 2.0 1.7 25.4 0.0 1.7 1.9 3.9 4.3 2.4 2.3 3.3 22.2 16.6 2.1 75.6 2.5 1.7 22.7 25.3 2.4 1.4 9.3 1.0 2.0 17.0 2.1 1.8 1.7 1.6 5.0 3.3 1.7 1.7 1.8 13.7 1.9 1.7 4.4 14.3 0.5 1.9 0.0 1.7 1.9 0.9 1.0 0.8 1.2 0.3 0.2 0.8 0.2 0.8 0.6 1.9 1.3 1.5 0.4 1.1 0.7 0.2 0.8 1.1 1.5 1.0 1.6 0.3 0.4 1.8 1.3 2.3 0.9 0.7 0.2 1.8 1.3 4.6 2.8 0.7 2.2 2.3 1.1 0.2 0.2 1.3 0.5 0.3 1.7 1.1 3.7 0.2 1.1 0.7 1.8 0.8 1.2 1.4 1.2 0.2 0.1 0.6 1.8 0.8 0.3 1.0 0.7 0.2 1.1 1.0 1.0 0.3 0.8 0.5 0.7 0.7 1.1 0.3 1.2 0.9 1.7 0.4 0.3 0.3 1.1 0.5 0.1 0.8 0.9 0.6 0.5 0.3 1.0 0.3 0.5 1.2 0.2 0.3 0.8 0.3 0.2 32.2 31.0 15.1 41.5 22.2 16.6 22.7 25.3 17.0 14.3 0.0 0.3 0.0 0.0 0.2 1.8 1.4 17.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 1.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 2.3 24.5 0.0 0.0 0.0 0.0 1.0 0.2 5.2 0.0 0.0 0.0 0.0 41.9 0.0 0.0 9.6 0.1 3.3 12.9 2.1 5.0 0.0 0.0 0.0 0.0 0.0 0.0 SLC6A2 "NAT1, NET, NET1, SLC6A5" ENSG00000103546 "Solute carrier family 6 member 2" P23975 16 55655604-55706192 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 20.4;placenta: 41.8" "Group enriched" "Detected in some" 5 "Early spermatids: 3.2;Extravillous trophoblasts: 6.9;Late spermatids: 3.7;Spermatocytes: 10.4;Syncytiotrophoblasts: 4.7" "Cancer enhanced" "Detected in some" "liver cancer: 1.9" "Region enriched" "Detected in single" 27 "pons and medulla: 9.7" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 30 "SH-SY5Y: 107.1" "Region enriched" "Detected in some" 4 "pons and medulla: 8.2" "Region enriched" "Detected in single" 32 "pons and medulla: 23.1" "HPA004057, HPA076311, CAB078195" Enhanced Supported Approved Mitochondria,Cytosol NA NA Cytosol Mitochondria "CAB078195: AB_2665806, HPA004057: AB_1080012, HPA076311: AB_2732307" "unprognostic (9.58e-3)" "unprognostic (5.48e-2)" "unprognostic (1.26e-4)" "unprognostic (4.07e-1)" "unprognostic (4.16e-1)" "unprognostic (8.38e-2)" "unprognostic (2.97e-2)" "unprognostic (3.29e-1)" "unprognostic (2.31e-1)" "unprognostic (3.27e-1)" "unprognostic (2.12e-2)" "unprognostic (2.95e-2)" "unprognostic (1.72e-1)" "unprognostic (6.02e-2)" "unprognostic (8.48e-2)" "unprognostic (1.43e-2)" 2.4 20.4 0.3 0.1 0.1 0.0 1.8 0.1 0.3 3.2 0.3 0.3 0.1 0.0 4.5 7.2 0.8 0.4 0.4 0.1 0.1 0.0 0.4 1.0 0.5 0.1 0.1 0.1 0.2 0.1 0.0 0.1 41.8 9.7 0.5 0.1 0.1 1.6 1.7 0.1 11.4 0.4 1.0 0.2 0.1 0.2 8.3 0.2 0.1 0.2 0.9 0.5 0.5 1.7 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.8 107.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.1 0.3 0.1 0.0 0.1 0.1 9.7 0.2 0.0 0.0 0.0 0.1 1.3 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 3.2 0.0 0.0 0.0 0.0 6.9 0.4 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.4 0.1 0.4 4.7 0.0 0.0 0.0 SLC6A3 "DAT, DAT1" ENSG00000142319 "Solute carrier family 6 member 3" Q01959 5 1392790-1445430 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, Dystonia, FDA approved drug targets, Neurodegeneration, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "brain: 48.4" "Cell type enriched" "Detected in single" 5 "Alveolar cells type 2: 2.9" "Cancer enriched" "Detected in some" 18 "renal cancer: 25.7" "Region enriched" "Detected in some" 47 "midbrain: 48.4" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "NTERA-2: 1.2;RPMI-8226: 2.1;SCLC-21H: 3.8" "Group enriched" "Detected in some" 8 "midbrain: 96.4;thalamus: 31.8" "Region enriched" "Detected in single" 138 "midbrain: 362.2" "HPA012763, HPA013602, CAB016249, CAB078172" Enhanced Supported Approved Vesicles NA NA Vesicles "CAB016249: AB_627402, CAB078172: AB_2665810, HPA012763: AB_2732405, HPA013602: AB_1847484" "unprognostic (2.25e-4)" "unprognostic (2.22e-1)" "unprognostic (8.45e-2)" "unprognostic (5.24e-2)" "unprognostic (7.75e-2)" "unprognostic (1.41e-2)" "unprognostic (4.64e-5)" "unprognostic (9.31e-2)" "unprognostic (7.89e-2)" "unprognostic (4.81e-2)" "unprognostic (1.30e-1)" "unprognostic (2.12e-2)" "prognostic unfavorable (3.40e-7)" "unprognostic (6.98e-2)" "unprognostic (1.64e-1)" "unprognostic (2.22e-2)" "unprognostic (4.74e-2)" 0.2 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.3 0.7 0.0 0.0 0.0 0.3 1.1 0.8 0.1 0.8 0.6 0.1 0.0 0.6 0.3 0.0 3.4 0.0 48.4 0.0 1.5 0.0 0.0 0.0 0.1 1.0 0.7 0.0 1.7 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.1 0.0 0.8 0.0 2.4 2.2 0.0 0.3 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.2 0.0 0.0 0.0 0.0 2.1 0.0 0.1 3.8 0.0 0.0 0.1 0.0 0.4 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.3 0.0 0.6 48.4 0.0 1.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 SLC6A4 "5-HTT, HTT, OCD1, SERT1" ENSG00000108576 "Solute carrier family 6 member 4" P31645 17 30194319-30236002 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 25.0;lung: 50.5" "Group enriched" "Detected in some" 6 "Cytotrophoblasts: 90.5;Syncytiotrophoblasts: 89.0" "Cancer enhanced" "Detected in some" "breast cancer: 2.3" "Region enriched" "Detected in single" 36 "pons and medulla: 11.2" "Cell type enhanced" "Detected in single" "neutrophil: 1.0" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "BEWO: 2.9;CACO-2: 5.5;Hep G2: 14.7" "Region enriched" "Detected in some" 5 "midbrain: 69.9" "Low region specificity" "Detected in all" "HPA054723, HPA071354, HPA074728" Supported Supported Supported "Golgi apparatus,Vesicles" NA NA "Golgi apparatus, Vesicles" "HPA054723: , HPA071354: , HPA074728: AB_2686708" "unprognostic (7.45e-2)" "unprognostic (7.13e-2)" "unprognostic (2.26e-1)" "unprognostic (3.72e-4)" "unprognostic (2.07e-1)" "unprognostic (8.42e-3)" "unprognostic (2.73e-2)" "unprognostic (3.39e-2)" "unprognostic (3.37e-3)" "unprognostic (1.17e-3)" "unprognostic (2.70e-3)" "unprognostic (1.16e-1)" "unprognostic (8.78e-2)" "unprognostic (4.98e-2)" "unprognostic (1.76e-1)" "unprognostic (4.05e-2)" "unprognostic (7.18e-2)" 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.3 0.2 0.2 0.1 0.1 6.3 0.1 0.3 1.6 0.9 0.1 0.7 0.1 0.1 0.3 0.1 50.5 0.1 0.1 0.1 0.1 0.6 0.0 0.1 11.3 11.2 0.1 0.0 0.2 0.7 0.1 0.1 0.4 25.0 0.4 0.1 0.1 0.5 0.3 0.1 0.1 0.2 0.1 0.3 0.1 0.3 0.0 0.1 1.0 0.2 0.4 0.3 2.3 0.0 0.0 0.0 0.1 0.0 0.0 2.9 0.0 0.0 0.0 0.0 5.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 14.7 1.5 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.4 0.1 0.1 0.0 1.0 0.0 0.7 0.8 0.0 0.0 0.1 0.2 0.2 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.3 0.1 0.1 0.3 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.2 0.1 1.0 0.4 0.2 0.1 0.0 2.3 0.1 0.1 0.2 0.3 0.1 0.1 0.1 0.1 11.2 0.1 14.9 5.3 0.0 0.4 0.1 0.2 0.8 0.0 1.4 3.4 1.8 0.0 90.5 0.0 0.0 2.3 0.5 1.0 0.0 0.0 7.0 1.6 0.3 2.3 0.0 8.4 0.0 0.0 2.5 0.6 1.0 0.3 0.4 0.0 0.0 0.0 0.5 0.5 0.0 0.4 0.3 0.9 0.0 1.4 0.0 0.4 0.3 89.0 0.0 0.0 0.3 SLC6A8 "CRTR, CT1" ENSG00000130821 "Solute carrier family 6 member 8" P48029 X 153688099-153696593 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Bipolar cells: 127.1;Enterocytes: 208.5;Horizontal cells: 112.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 4 "neutrophil: 2.6" "Lineage enriched" "Detected in single" 4 "granulocytes: 2.6" "Cell line enhanced" "Detected in many" "AN3-CA: 42.8;SK-BR-3: 44.4" NA NA "unprognostic (5.80e-2)" "unprognostic (1.24e-1)" "unprognostic (2.39e-2)" "unprognostic (9.98e-2)" "unprognostic (1.47e-1)" "unprognostic (7.16e-2)" "unprognostic (1.59e-2)" "unprognostic (1.59e-2)" "unprognostic (2.08e-1)" "unprognostic (2.10e-1)" "unprognostic (1.21e-1)" "unprognostic (1.43e-1)" "prognostic unfavorable (1.53e-4)" "unprognostic (1.41e-1)" "unprognostic (1.06e-1)" "prognostic unfavorable (7.39e-4)" "unprognostic (2.87e-1)" 17.6 19.5 26.3 5.8 39.0 19.3 7.3 23.9 31.9 6.1 26.8 36.6 7.6 32.4 11.2 9.1 20.0 10.6 20.2 53.1 29.3 16.1 27.3 1.9 3.1 1.9 55.6 22.0 5.1 8.3 17.0 7.2 22.6 25.8 12.8 20.2 20.9 31.8 24.9 76.4 28.0 48.3 13.5 28.2 5.1 11.0 16.7 38.9 4.6 2.8 11.0 5.0 40.4 10.1 0.5 0.0 2.6 0.2 0.0 0.0 0.1 40.6 1.7 12.5 42.8 4.0 2.8 2.9 6.1 10.1 7.9 9.8 5.2 0.5 0.0 4.7 7.3 9.3 15.1 25.0 21.0 4.9 0.7 23.8 0.1 14.1 15.5 13.9 0.3 2.8 5.9 4.5 7.9 28.7 15.0 3.9 0.2 9.9 0.6 4.4 2.4 0.2 0.9 12.8 8.1 17.9 1.9 1.4 0.5 8.6 7.9 16.1 18.0 8.9 44.4 28.8 3.0 8.6 6.2 3.9 13.1 20.9 16.8 18.0 1.5 0.7 0.4 29.3 1.2 13.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.1 26.3 39.0 23.9 30.4 29.3 16.1 55.6 22.0 25.8 38.9 0.0 3.4 2.7 10.6 20.6 127.1 89.0 25.5 8.1 0.0 5.2 104.1 11.0 3.3 3.6 0.6 5.6 208.5 23.3 18.9 27.8 11.2 21.2 4.6 0.8 4.3 112.8 24.9 4.9 1.3 2.2 8.3 1.6 23.6 5.4 32.8 17.4 55.3 41.8 7.8 49.9 48.6 32.3 15.3 2.9 2.8 13.7 76.0 0.0 15.7 17.6 SLC7A11 xCT ENSG00000151012 "Solute carrier family 7 member 11" Q9UPY5 4 138164097-138242349 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 27.2" "Cell type enhanced" "Detected in many" 13 "Glandular cells: 37.7;monocytes: 90.2;Muller glia cells: 48.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 8 "plasmacytoid DC: 3.8" "Lineage enriched" "Detected in single" 8 "dendritic cells: 3.8" "Cell line enhanced" "Detected in many" "hTCEpi: 28.6;TIME: 31.4;WM-115: 46.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA064215 Approved Vesicles NA NA Vesicles "HPA064215: AB_2685213" "unprognostic (3.55e-3)" "unprognostic (4.64e-3)" "unprognostic (2.43e-2)" "unprognostic (7.18e-3)" "unprognostic (2.59e-1)" "unprognostic (8.80e-3)" "unprognostic (2.07e-8)" "unprognostic (1.98e-2)" "unprognostic (1.09e-2)" "prognostic favorable (1.77e-4)" "unprognostic (1.90e-2)" "unprognostic (4.07e-2)" "unprognostic (2.22e-8)" "unprognostic (3.81e-2)" "unprognostic (3.76e-2)" "unprognostic (2.29e-2)" "unprognostic (1.54e-2)" 1.1 0.9 16.3 4.7 15.8 2.2 1.5 8.2 26.0 2.4 2.0 17.9 0.0 1.5 1.3 13.4 3.3 8.9 3.8 2.5 17.4 6.9 0.9 0.9 2.3 1.5 12.6 16.8 1.7 5.4 1.0 1.2 2.1 17.2 2.0 2.8 0.3 1.6 1.0 0.8 1.9 1.4 1.0 27.2 1.4 9.2 2.2 14.0 0.0 8.9 6.0 2.2 4.0 0.8 0.1 3.8 0.4 0.0 0.1 0.0 0.0 1.6 13.8 6.2 4.8 1.3 1.7 1.7 7.6 5.3 1.7 4.0 1.5 5.8 3.1 10.0 26.5 9.4 2.2 3.3 6.5 7.4 5.9 0.7 2.2 13.1 3.4 20.6 5.8 2.1 4.1 28.6 4.9 22.1 2.6 21.6 3.2 3.0 8.2 9.1 1.2 0.8 0.5 1.2 8.1 3.9 0.9 2.0 3.6 1.0 6.6 2.5 0.5 3.3 0.9 11.7 1.4 1.5 12.4 31.4 2.3 6.5 3.4 6.0 6.9 3.1 3.2 3.9 3.2 46.1 0.3 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.0 3.8 0.0 0.0 16.3 15.8 8.2 15.9 17.4 6.9 12.6 16.8 17.2 14.0 0.0 5.9 3.7 7.0 4.0 4.0 3.6 2.5 1.4 3.4 0.0 2.0 2.2 0.0 3.6 2.1 1.6 1.1 0.0 21.4 0.5 1.0 37.7 4.6 0.4 0.5 1.6 25.9 3.7 0.0 0.4 2.3 9.0 5.0 90.2 5.4 48.4 27.4 1.1 2.1 0.0 1.9 0.0 1.0 0.7 0.7 2.8 0.9 0.0 1.3 11.1 SLC7A3 "ATRC3, CAT-3, FLJ14541" ENSG00000165349 "Solute carrier family 7 member 3" Q8WY07 X 70925582-70931125 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 45.5" "Group enriched" "Detected in some" 6 "Early spermatids: 5.3;Late spermatids: 1.9" "Cancer enriched" "Detected in some" 12 "testis cancer: 43.0" "Region enhanced" "Detected in many" "hypothalamus: 6.7" "Cell type enriched" "Detected in single" 16 "naive CD8 T-cell: 1.5" "Lineage enriched" "Detected in single" 16 "T-cells: 1.5" "Group enriched" "Detected in some" 4 "HAP1: 20.7;NTERA-2: 42.6;SuSa: 53.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA "unprognostic (1.42e-4)" "unprognostic (4.30e-4)" "unprognostic (3.59e-3)" "unprognostic (1.81e-2)" "unprognostic (6.45e-2)" "unprognostic (1.45e-2)" "unprognostic (3.66e-1)" "unprognostic (9.18e-3)" "unprognostic (1.89e-1)" "unprognostic (7.99e-5)" "unprognostic (1.31e-2)" "unprognostic (5.42e-4)" "unprognostic (3.57e-2)" 0.1 0.0 1.0 0.1 1.0 1.3 1.4 0.1 2.1 2.0 0.1 1.1 0.8 0.1 9.1 6.2 0.7 2.7 0.1 0.0 1.2 6.7 0.2 0.0 0.1 0.5 0.5 0.5 1.7 0.0 0.0 0.6 0.0 1.2 10.4 0.0 0.5 0.2 9.4 0.0 0.0 0.3 4.6 0.2 0.1 5.6 2.4 0.4 45.5 0.0 0.2 0.5 4.0 1.4 0.0 0.0 0.0 0.0 0.0 1.5 0.3 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.1 0.0 0.0 0.0 20.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.1 0.0 42.6 0.0 0.0 8.9 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 53.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.3 1.0 1.0 0.1 2.1 1.2 6.7 0.5 0.5 1.2 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.6 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 SLC7A7 "LPI, y+LAT-1" ENSG00000155465 "Solute carrier family 7 member 7" Q9UM01 14 22773222-22829820 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 63.8;intestine: 93.5;kidney: 67.3" "Cell type enhanced" "Detected in many" 13 "Hofbauer cells: 200.4;Kupffer cells: 312.3;Macrophages: 142.1;Proximal tubular cells: 254.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "intermediate monocyte: 59.5;non-classical monocyte: 63.8" "Lineage enriched" "Detected in many" 4 "monocytes: 63.8" "Cell line enhanced" "Detected in some" "BEWO: 44.5;CACO-2: 72.0;EFO-21: 15.6;OE19: 63.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA036227 Enhanced NA NA "HPA036227: AB_10696653" "unprognostic (1.34e-1)" "unprognostic (7.65e-2)" "unprognostic (4.25e-2)" "unprognostic (2.52e-1)" "unprognostic (6.12e-2)" "unprognostic (3.69e-2)" "unprognostic (7.84e-3)" "unprognostic (1.47e-1)" "unprognostic (2.88e-2)" "unprognostic (1.73e-2)" "unprognostic (2.60e-3)" "unprognostic (7.15e-2)" "prognostic unfavorable (6.28e-6)" "unprognostic (2.68e-3)" "unprognostic (1.86e-2)" "unprognostic (2.61e-1)" "unprognostic (1.12e-1)" 10.4 2.8 1.9 8.3 3.1 3.6 3.2 0.7 2.7 2.6 48.0 4.1 0.2 24.1 2.7 2.3 2.1 4.6 7.6 3.0 2.2 1.6 67.3 6.5 15.3 20.5 3.7 1.0 2.6 2.7 26.3 1.0 6.5 3.2 2.7 3.4 2.1 3.3 0.9 1.6 1.8 93.5 3.5 4.5 32.4 3.0 13.4 2.7 2.1 2.8 0.8 5.7 4.1 3.6 3.0 14.6 5.4 63.8 0.0 0.1 17.8 0.0 2.4 0.2 0.1 0.4 0.8 44.5 0.5 3.6 0.1 0.3 72.0 7.3 3.5 15.6 0.3 0.2 2.7 0.0 0.0 0.1 0.1 0.0 0.2 0.0 0.7 2.1 0.3 0.3 1.6 0.2 0.2 0.1 0.3 5.5 0.2 0.0 2.8 0.5 0.1 0.0 0.3 0.7 63.3 0.0 0.6 7.8 2.1 0.1 0.2 0.0 0.1 0.1 0.1 0.5 2.1 0.1 1.7 0.3 0.1 0.3 0.1 0.1 0.6 0.1 1.8 0.2 0.1 0.0 0.0 41.2 0.1 0.0 59.5 0.0 3.0 0.0 0.0 14.6 2.3 0.1 0.0 5.4 0.0 63.8 0.5 0.1 17.8 1.9 3.1 0.7 2.7 2.2 1.6 3.7 1.0 3.2 2.7 11.9 10.3 23.7 0.1 0.9 0.0 0.8 58.6 9.4 4.5 3.5 0.0 1.0 10.0 6.7 40.8 4.5 8.6 0.0 5.8 4.5 4.8 0.2 1.1 1.3 200.4 0.0 1.2 22.1 312.3 7.5 3.4 142.1 5.0 34.3 0.4 0.5 7.3 0.0 0.0 254.4 1.2 6.5 2.8 12.2 1.7 0.4 1.5 5.0 0.3 0.0 SLC8A1 NCX1 ENSG00000183023 "Solute carrier family 8 member A1" P32418 2 40097270-40611053 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Antiport, Calcium transport, Ion transport, Sodium transport, Transport" Calmodulin-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 67.7" "Cell type enriched" "Detected in many" 11 "Cardiomyocytes: 601.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 4 "neutrophil: 25.2" "Lineage enriched" "Detected in many" 4 "granulocytes: 25.2" "Cell line enhanced" "Detected in many" "BJ: 15.4;fHDF/TERT166: 37.3;hTERT-HME1: 10.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022694, HPA070007" Uncertain Supported "Nucleoplasm,Plasma membrane" "Intracellular and membrane" NA NA "Nucleoplasm, Plasma membrane" "CAB022694: , HPA070007: AB_2686227" "unprognostic (2.46e-1)" "unprognostic (1.33e-2)" "unprognostic (1.42e-2)" "unprognostic (7.57e-6)" "unprognostic (1.56e-1)" "unprognostic (3.94e-1)" "unprognostic (2.28e-2)" "unprognostic (4.60e-2)" "unprognostic (1.31e-1)" "unprognostic (7.71e-2)" "unprognostic (1.21e-2)" "unprognostic (1.07e-1)" "unprognostic (3.66e-2)" "unprognostic (7.04e-3)" "unprognostic (3.93e-2)" "unprognostic (5.46e-2)" "unprognostic (6.77e-2)" 3.9 2.9 7.7 4.4 14.3 1.4 2.0 3.5 15.3 5.5 7.3 1.8 7.1 3.3 12.2 3.9 4.0 3.9 5.3 67.7 7.7 6.6 11.0 2.2 3.7 2.5 5.2 8.2 2.1 1.5 1.1 1.9 6.8 7.6 12.2 3.4 1.0 1.5 17.2 1.5 2.1 3.6 20.5 2.8 4.4 2.5 1.4 2.5 0.1 1.6 0.0 1.3 9.8 2.8 0.0 2.4 25.2 6.0 0.0 0.0 0.5 1.5 1.2 1.1 0.1 1.7 3.6 0.0 15.4 6.0 5.1 3.3 0.0 2.5 0.0 1.2 37.3 5.5 0.6 0.3 2.5 5.3 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.2 2.0 0.0 5.9 10.9 2.3 0.4 0.0 0.0 0.2 6.5 0.0 0.4 0.0 0.8 0.1 2.1 4.1 8.1 0.0 1.8 0.2 1.7 0.3 0.0 0.0 0.0 5.6 0.0 0.3 5.2 4.8 0.1 0.0 1.6 0.8 0.0 0.0 0.8 0.9 0.7 0.0 4.9 0.0 0.0 5.1 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 25.2 0.0 6.0 0.1 0.0 0.5 7.7 14.3 3.5 15.3 7.7 6.6 5.2 8.2 7.6 2.5 3.0 3.2 2.9 0.0 1.1 50.8 601.5 2.5 0.0 1.2 33.2 3.9 0.4 0.0 0.0 0.8 3.3 0.0 0.0 0.0 1.4 4.8 0.1 0.0 0.0 28.3 0.0 0.0 20.3 56.6 0.7 0.0 46.7 1.7 1.0 0.6 35.9 0.1 0.0 7.8 0.1 6.9 12.9 19.6 0.2 0.4 2.8 0.9 0.0 0.0 0.0 SLCO2B1 "OATP-B, OATP2B1, SLC21A9" ENSG00000137491 "Solute carrier organic anion transporter family member 2B1" O94956 11 75100563-75206549 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 98.1" "Group enriched" "Detected in many" 5 "Hepatocytes: 171.3;Hofbauer cells: 103.0;Kupffer cells: 116.2;Macrophages: 55.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CACO-2: 36.0;GAMG: 8.9;Hep G2: 8.1;HMC-1: 10.9;OE19: 43.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020659 Uncertain NA NA "HPA020659: AB_1857219" "unprognostic (8.25e-2)" "unprognostic (5.30e-2)" "unprognostic (2.02e-2)" "unprognostic (3.57e-1)" "unprognostic (3.40e-1)" "unprognostic (1.03e-1)" "unprognostic (1.58e-2)" "unprognostic (1.09e-1)" "unprognostic (2.61e-1)" "unprognostic (2.00e-3)" "unprognostic (1.99e-1)" "unprognostic (2.09e-1)" "unprognostic (9.75e-3)" "unprognostic (2.54e-2)" "unprognostic (4.57e-3)" "unprognostic (1.04e-1)" "unprognostic (3.87e-2)" 21.4 15.2 15.0 13.4 23.1 1.4 7.8 4.8 15.8 8.6 12.9 22.8 0.8 18.0 5.8 7.7 8.8 8.3 12.3 7.1 15.6 11.9 9.6 98.1 24.9 21.4 23.9 7.4 4.9 9.6 3.7 4.0 18.3 17.7 4.9 10.4 9.1 6.3 4.7 2.6 3.0 21.2 10.9 24.1 23.6 6.5 4.4 21.3 4.0 6.8 3.6 11.8 12.5 4.8 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.3 1.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 36.0 0.0 0.0 0.0 0.0 8.9 0.0 0.0 0.0 0.0 0.4 0.0 5.9 0.3 8.1 0.0 0.4 10.9 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.1 3.6 0.0 0.0 0.0 0.0 0.0 43.2 0.0 0.0 1.0 3.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.6 0.6 0.0 0.6 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.0 23.1 4.8 15.8 15.6 11.9 23.9 7.4 17.7 21.3 0.0 12.8 1.5 0.0 1.6 1.6 2.0 20.4 1.4 3.4 0.0 0.0 0.6 1.7 0.0 2.4 12.9 20.2 0.0 0.2 2.1 1.8 0.0 23.0 171.3 103.0 0.0 0.0 3.1 116.2 1.1 10.0 55.1 0.0 3.6 4.4 0.3 0.1 14.0 9.9 7.0 0.2 0.0 0.3 0.5 0.2 0.4 2.1 0.7 9.3 0.0 SMO "FZD11, SMOH" ENSG00000128602 "Smoothened, frizzled class receptor" Q99835 7 129188872-129213545 "Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 8 "Collecting duct cells: 10.4;Leydig cells: 19.2;Muller glia cells: 15.1;Peritubular cells: 20.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AF22: 20.3;AN3-CA: 37.6;NTERA-2: 28.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB011446 Approved NA NA "CAB011446: " "unprognostic (2.48e-2)" "unprognostic (2.69e-2)" "unprognostic (7.09e-2)" "unprognostic (1.10e-1)" "unprognostic (8.16e-2)" "unprognostic (2.02e-1)" "unprognostic (3.63e-1)" "unprognostic (5.89e-2)" "unprognostic (5.38e-3)" "unprognostic (1.59e-1)" "unprognostic (1.17e-2)" "unprognostic (8.74e-3)" "unprognostic (1.62e-1)" "unprognostic (5.15e-3)" "unprognostic (2.09e-1)" "unprognostic (2.25e-1)" "unprognostic (2.61e-2)" 4.0 4.1 4.2 3.8 4.8 0.5 7.4 5.3 4.6 18.2 5.8 5.1 9.2 2.5 20.9 18.7 10.3 11.4 10.0 5.2 8.4 3.7 10.6 13.7 2.4 2.0 4.3 4.5 23.0 7.1 14.4 13.5 2.6 9.0 18.4 2.2 17.2 9.4 12.8 3.5 16.6 3.5 9.8 7.0 2.0 4.2 7.9 3.4 5.3 9.2 6.8 4.6 6.3 17.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.6 8.0 20.3 37.6 0.5 0.1 6.4 2.2 2.9 4.5 2.6 6.1 0.1 0.0 6.2 4.5 10.2 12.4 12.2 0.7 1.7 0.0 9.9 3.9 0.0 9.8 2.5 0.1 0.0 7.4 5.0 1.4 0.0 9.0 2.6 11.2 0.6 0.0 1.4 0.0 10.3 0.0 28.8 0.0 2.3 15.0 8.7 0.0 2.3 0.0 0.6 13.6 0.0 0.0 5.3 8.1 4.9 2.6 0.0 0.3 6.5 7.8 4.3 0.4 0.0 0.0 0.0 0.0 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 4.8 5.3 4.6 8.4 3.7 4.3 4.5 9.0 3.4 0.0 0.0 0.0 2.3 1.6 0.6 1.2 2.5 0.0 4.5 10.4 0.0 0.3 1.7 3.2 0.3 0.4 0.0 0.0 1.0 0.3 4.4 2.8 0.0 5.1 3.3 0.0 0.0 1.3 1.3 0.9 19.2 0.4 0.0 1.0 0.0 15.1 1.9 0.0 20.5 3.7 0.3 6.5 2.1 0.0 0.4 2.5 0.5 0.0 0.0 0.4 SNAP25 "bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25" ENSG00000132639 "Synaptosome associated protein 25" P60880 20 10218830-10307418 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters" "Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 22 "brain: 356.9" "Cell type enhanced" "Detected in many" 23 "Bipolar cells: 497.2;Cone photoreceptor cells: 100.1;Rod photoreceptor cells: 186.3" "Group enriched" "Detected in many" 6 "glioma: 28.9;pancreatic cancer: 6.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.6" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in many" 4 "Karpas-707: 11.0;SCLC-21H: 36.6;SH-SY5Y: 21.8;U-87 MG: 26.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000360, HPA001830, HPA071013" Enhanced Supported Approved "Vesicles,Plasma membrane" NA NA "Plasma membrane" Vesicles "CAB000360: AB_2286342, HPA001830: AB_1080039, HPA071013: " "unprognostic (1.64e-3)" "unprognostic (7.26e-3)" "unprognostic (4.36e-2)" "unprognostic (2.49e-7)" "unprognostic (6.86e-3)" "unprognostic (5.87e-3)" "unprognostic (1.15e-2)" "unprognostic (9.94e-2)" "unprognostic (3.13e-1)" "unprognostic (5.82e-3)" "unprognostic (4.80e-3)" "unprognostic (8.06e-2)" "unprognostic (1.09e-1)" "unprognostic (6.18e-3)" "unprognostic (2.48e-1)" "unprognostic (6.28e-3)" "unprognostic (1.02e-2)" 2.2 16.4 81.0 3.3 60.0 2.1 3.4 202.9 356.9 2.2 2.8 3.4 3.7 3.2 4.6 6.4 2.2 4.0 2.8 2.4 86.5 37.1 2.5 2.3 2.6 2.2 46.7 65.2 3.7 4.1 2.1 5.5 2.3 97.7 3.1 2.8 4.0 2.2 11.9 2.1 2.2 3.3 4.7 13.9 2.1 4.3 3.2 7.4 0.0 2.3 0.0 2.2 2.6 0.1 0.0 1.6 0.7 0.0 0.0 0.6 0.3 0.0 2.1 1.8 0.0 0.2 0.0 0.0 0.9 0.0 2.2 0.6 0.0 0.0 0.0 2.0 0.0 1.6 0.4 0.2 0.0 4.5 0.2 0.1 0.0 3.0 0.3 1.6 0.0 0.2 2.1 0.0 1.8 0.0 5.0 0.0 1.3 0.0 11.0 0.7 0.0 0.0 0.0 0.4 1.3 0.0 0.0 0.0 0.0 0.4 0.0 36.6 21.8 0.3 0.0 0.0 1.1 0.0 2.9 0.0 2.3 3.1 0.0 1.0 0.0 5.6 0.0 26.3 0.0 2.1 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.6 0.6 0.3 81.0 60.0 202.9 163.5 86.5 37.1 46.7 65.2 97.7 7.4 0.0 0.0 0.0 1.7 0.7 497.2 0.4 7.6 0.0 0.0 0.0 100.1 0.0 0.0 0.1 16.5 0.6 0.0 0.0 0.0 0.1 1.0 0.5 0.0 0.0 0.1 62.0 41.6 0.0 0.0 56.7 15.8 0.2 1.7 0.0 0.0 42.9 1.6 0.2 64.7 1.4 186.3 0.0 1.0 0.9 0.3 0.6 0.0 0.0 0.0 0.0 SRC "ASV, c-src, SRC1" ENSG00000197122 "SRC proto-oncogene, non-receptor tyrosine kinase" P12931 20 37344685-37406050 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell adhesion, Cell cycle, Host-virus interaction, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 5.3;non-classical monocyte: 4.4" "Group enriched" "Detected in many" 6 "dendritic cells: 3.0;monocytes: 5.3" "Cell line enhanced" "Detected in many" "A549: 35.9;HBEC3-KT: 33.4;RT4: 34.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004023, HPA030875" Approved Supported "Nucleoplasm,Plasma membrane,Cell Junctions,Cytosol" NA NA 20000000 "Plasma membrane, Cell Junctions" "Nucleoplasm, Cytosol" "CAB004023: AB_2106059, HPA030875: AB_2673640" "unprognostic (5.58e-2)" "unprognostic (9.83e-2)" "unprognostic (3.56e-1)" "unprognostic (4.54e-3)" "unprognostic (1.52e-1)" "unprognostic (1.54e-2)" "prognostic unfavorable (4.90e-5)" "unprognostic (3.89e-2)" "unprognostic (7.04e-2)" "unprognostic (8.13e-2)" "unprognostic (1.54e-2)" "prognostic unfavorable (1.63e-4)" "prognostic unfavorable (1.22e-4)" "unprognostic (2.33e-2)" "unprognostic (4.72e-2)" "unprognostic (3.65e-2)" "prognostic favorable (5.22e-5)" 6.9 17.5 12.8 11.1 12.0 5.4 9.9 6.4 16.0 16.0 16.4 3.5 15.1 29.5 20.3 9.7 16.2 14.2 42.1 5.8 11.3 6.6 13.4 2.9 10.4 7.0 3.3 9.9 15.8 19.1 6.6 11.3 6.3 5.1 19.9 13.1 13.1 7.5 22.5 3.4 7.7 28.1 27.2 3.6 12.2 29.8 27.3 4.8 4.0 6.6 10.5 10.4 26.4 20.0 0.3 3.0 0.1 5.3 0.6 0.1 1.6 7.7 35.9 8.3 7.4 3.1 5.0 17.2 7.2 6.2 8.8 5.6 13.5 7.0 0.2 4.5 13.0 10.0 14.2 4.9 33.4 3.4 0.0 4.5 2.0 1.3 20.9 7.5 0.1 3.1 5.3 11.4 5.7 7.7 9.8 8.0 4.6 0.2 0.0 1.4 5.3 1.9 0.2 3.9 21.5 32.6 8.4 2.2 0.2 3.7 34.4 7.7 27.9 8.1 11.4 8.9 6.6 10.2 2.8 11.6 10.5 7.1 3.8 6.4 0.1 0.2 0.1 7.4 0.0 7.8 0.0 2.6 0.0 0.0 5.3 0.0 0.3 0.0 0.1 1.1 0.3 0.0 0.0 0.1 0.6 4.4 3.0 0.1 1.6 12.8 12.0 6.4 16.0 11.3 6.6 3.3 9.9 5.1 4.8 3.0 1.7 4.4 10.8 7.2 5.4 1.6 15.3 1.4 0.0 12.2 2.0 1.6 1.7 9.7 1.3 1.4 30.0 0.0 16.2 7.0 8.2 11.2 0.0 0.9 5.8 3.2 16.1 1.3 6.9 1.5 10.0 12.1 1.7 7.2 25.9 4.1 29.0 18.1 16.3 9.5 4.7 12.9 6.4 0.2 0.7 8.0 1.9 0.0 14.9 27.7 TLR4 "ARMD10, CD284, hToll, TLR-4" ENSG00000136869 "Toll like receptor 4" O00206 9 117704175-117724730 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Immunity, Inflammatory response, Innate immunity" "Hydrolase, Receptor" "Age-related macular degeneration, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 15 "Hofbauer cells: 31.7;Ito cells: 59.5;Kupffer cells: 88.0;Macrophages: 33.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 30.1" "Group enriched" "Detected in many" 30 "dendritic cells: 7.5;granulocytes: 30.1;monocytes: 21.4" "Cell line enhanced" "Detected in many" "Karpas-707: 29.6;TIME: 21.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB004025, HPA049174" Approved Supported "Golgi apparatus,Plasma membrane" "Intracellular and membrane" NA NA "Plasma membrane" "Golgi apparatus" "CAB004025: , HPA049174: AB_2680662" "unprognostic (1.60e-1)" "unprognostic (8.34e-2)" "unprognostic (7.22e-2)" "prognostic favorable (6.29e-4)" "unprognostic (3.39e-1)" "unprognostic (7.48e-2)" "unprognostic (8.68e-2)" "unprognostic (1.80e-1)" "unprognostic (3.38e-1)" "unprognostic (5.18e-2)" "unprognostic (8.00e-2)" "unprognostic (9.42e-2)" "unprognostic (4.08e-2)" "unprognostic (8.63e-2)" "prognostic unfavorable (3.79e-4)" "unprognostic (1.09e-2)" "unprognostic (1.96e-2)" 29.2 12.1 15.5 23.5 12.5 17.8 21.9 9.4 10.3 6.9 6.8 10.6 3.0 4.4 5.8 7.7 5.0 6.8 10.6 10.9 19.9 7.5 9.0 16.5 16.0 30.9 12.4 11.4 6.7 3.0 2.9 3.8 22.8 10.5 5.7 7.4 7.2 9.0 3.6 7.4 5.2 6.6 10.4 11.1 41.4 4.5 2.4 13.0 1.1 8.3 5.6 7.5 12.1 16.1 0.6 7.5 30.1 21.4 0.0 0.0 6.9 0.0 0.0 12.7 0.0 5.9 12.0 0.1 5.0 8.8 1.3 0.7 0.0 1.2 1.7 0.2 13.0 3.9 0.0 0.0 1.1 1.9 0.0 0.0 2.7 2.7 0.1 4.4 9.1 0.0 7.4 0.0 2.8 0.3 11.4 15.5 0.0 0.0 29.6 15.4 0.0 0.0 1.8 1.5 1.2 0.6 0.0 14.3 9.3 0.5 14.8 0.0 0.0 3.2 0.0 0.5 1.2 0.0 5.0 21.4 0.7 9.6 0.0 2.4 0.0 0.0 0.0 0.4 9.6 7.6 17.6 21.4 7.2 0.0 19.6 0.0 0.6 0.0 0.0 7.5 0.2 0.0 0.0 30.1 0.0 20.2 0.3 0.0 6.9 15.5 12.5 9.4 10.3 19.9 7.5 12.4 11.4 10.5 13.0 0.0 5.3 1.5 0.1 0.7 0.2 2.5 5.1 2.7 4.5 0.0 0.0 0.2 0.0 0.0 0.0 19.7 0.3 0.0 0.2 0.2 1.9 0.2 15.1 1.8 31.7 0.0 0.0 59.5 88.0 0.0 0.0 33.1 1.7 0.0 0.6 13.8 0.3 1.7 0.0 0.4 0.8 6.5 0.9 0.0 0.2 0.0 0.7 0.0 0.1 2.2 TRHR ENSG00000174417 "Thyrotropin releasing hormone receptor" P34981 8 109086621-109119584 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Congenital hypothyroidism, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 1.0;pituitary gland: 3.3;thyroid gland: 1.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "PC-3: 1.6;SH-SY5Y: 1.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA055162 Approved NA NA "HPA055162: AB_2732592" "unprognostic (1.92e-2)" "unprognostic (8.58e-2)" "unprognostic (1.17e-1)" 0.0 0.0 0.1 0.4 0.1 0.0 0.0 0.0 1.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.3 0.2 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.0 0.1 0.0 0.0 1.6 0.0 0.4 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.2 0.3 0.2 0.3 0.6 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 TRPA1 ANKTM1 ENSG00000104321 "Transient receptor potential cation channel subfamily A member 1" O75762 8 72019917-72075617 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sensory transduction, Transport" "Ion channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 20.8;urinary bladder: 20.1;vagina: 12.1" "Group enriched" "Detected in some" 10 "Early spermatids: 6.4;Mucus-secreting cells: 5.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 2.6" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in some" 5 "HHSteC: 24.5" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" NA NA "unprognostic (2.14e-2)" "unprognostic (2.50e-2)" "prognostic favorable (6.57e-4)" "unprognostic (1.28e-2)" "unprognostic (2.34e-1)" "unprognostic (1.95e-1)" "unprognostic (1.37e-2)" "unprognostic (8.11e-3)" "unprognostic (4.22e-2)" "unprognostic (2.47e-1)" "unprognostic (2.78e-3)" "unprognostic (1.49e-1)" "unprognostic (2.16e-4)" "unprognostic (2.37e-1)" "unprognostic (9.67e-2)" "unprognostic (1.57e-1)" "unprognostic (2.90e-1)" 0.3 0.2 0.2 9.1 0.2 0.0 0.2 0.2 0.4 0.4 16.8 0.3 0.0 4.8 0.2 0.3 2.2 0.2 5.7 0.3 0.2 0.2 0.2 0.2 0.3 0.8 0.3 0.0 0.4 0.2 0.0 0.2 0.3 0.1 4.7 7.5 0.0 0.2 0.0 0.2 0.2 20.8 3.8 0.2 0.4 7.9 0.4 0.0 0.6 0.2 0.3 1.4 20.1 12.1 0.5 0.6 0.1 1.1 0.3 2.6 0.2 0.0 2.5 0.7 0.0 0.0 0.1 0.0 0.3 2.3 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 1.8 0.4 1.4 0.1 0.0 0.5 0.0 24.5 0.0 0.2 1.6 0.0 1.1 0.2 5.1 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.1 0.5 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.1 0.4 0.0 2.4 0.2 0.0 0.3 0.0 0.1 3.8 1.1 0.0 0.3 0.3 0.0 1.8 0.0 1.7 0.0 0.0 0.0 0.3 0.0 1.1 0.5 0.5 2.6 0.0 0.5 0.0 0.4 0.1 0.3 1.1 0.6 1.0 0.2 0.2 0.2 0.2 0.4 0.2 0.2 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 TRPV1 VR1 ENSG00000196689 "Transient receptor potential cation channel subfamily V member 1" Q8NER1 17 3565444-3609411 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 11.7" "Cell type enhanced" "Detected in many" 12 "Cone photoreceptor cells: 15.7;Rod photoreceptor cells: 25.1" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HaCaT: 13.2" "Not detected" "Not detected" "Low region specificity" "Detected in single" NA NA "unprognostic (3.96e-2)" "unprognostic (1.63e-1)" "unprognostic (1.18e-1)" "unprognostic (1.33e-2)" "unprognostic (6.83e-2)" "unprognostic (3.21e-4)" "unprognostic (9.90e-2)" "unprognostic (2.95e-1)" "unprognostic (2.03e-1)" "unprognostic (2.56e-2)" "unprognostic (3.43e-3)" "unprognostic (6.17e-3)" "unprognostic (6.97e-4)" "unprognostic (4.25e-1)" "unprognostic (4.78e-1)" "unprognostic (3.81e-2)" "unprognostic (5.12e-3)" 1.4 1.2 3.5 0.7 2.9 0.3 1.7 2.7 2.1 2.1 1.4 6.5 2.3 1.5 0.8 2.8 1.1 1.9 3.2 3.6 2.5 11.7 0.7 1.3 4.7 5.1 2.5 1.0 2.0 1.2 1.5 1.7 2.1 1.0 2.8 4.7 5.1 0.9 2.3 1.2 2.2 1.2 1.3 0.8 1.2 1.1 1.1 1.4 1.5 0.8 0.5 2.2 0.3 3.0 5.6 4.5 5.0 4.9 4.7 4.1 1.7 2.4 2.6 2.4 1.4 1.7 1.2 2.3 1.8 1.8 13.2 2.8 0.9 1.9 7.3 6.7 0.7 2.9 5.6 2.2 0.4 5.7 5.6 3.0 3.8 1.5 2.5 0.5 2.9 0.3 2.2 1.5 3.8 2.1 1.0 3.0 0.6 2.7 6.2 2.9 0.9 2.2 2.7 1.9 4.2 2.3 4.4 2.2 3.5 8.3 2.3 1.7 1.1 2.7 4.5 2.2 1.9 1.3 0.5 1.9 2.4 2.4 0.9 0.8 1.5 0.7 0.2 0.9 0.4 0.6 0.2 0.1 1.1 0.8 2.2 1.5 0.5 0.3 1.4 0.2 0.3 0.0 1.6 0.0 0.4 0.0 8.6 0.2 2.5 4.0 2.3 5.2 15.7 1.0 0.0 0.4 1.8 0.0 2.6 0.0 0.6 0.3 0.4 0.6 0.0 6.4 0.7 6.4 1.2 2.5 0.6 0.2 4.4 1.2 0.0 0.0 1.5 2.8 0.4 0.0 3.5 1.4 25.1 0.0 0.1 0.7 0.7 0.0 0.7 0.0 2.2 0.3 UGCG GCS ENSG00000148154 "UDP-glucose ceramide glucosyltransferase" Q16739 9 111896766-111935369 "Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Lipid biosynthesis, Lipid metabolism, Sphingolipid metabolism" "Glycosyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 9 "Urothelial cells: 446.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 19 "plasmacytoid DC: 39.7" "Lineage enriched" "Detected in many" 19 "dendritic cells: 39.7" "Cell line enhanced" "Detected in all" "LHCN-M2: 50.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA024124 Approved NA NA "HPA024124: AB_1858595" "unprognostic (1.22e-2)" "prognostic favorable (6.62e-4)" "unprognostic (5.39e-2)" "prognostic favorable (4.44e-5)" "unprognostic (1.53e-2)" "unprognostic (9.70e-2)" "unprognostic (3.20e-2)" "unprognostic (2.04e-1)" "unprognostic (3.40e-1)" "unprognostic (1.31e-1)" "unprognostic (1.95e-2)" "unprognostic (3.22e-1)" "unprognostic (9.84e-3)" "unprognostic (2.24e-2)" "unprognostic (4.92e-2)" "unprognostic (1.99e-1)" "unprognostic (3.77e-2)" 33.7 37.7 5.9 21.4 7.8 55.2 20.5 9.5 11.2 14.6 19.6 5.0 3.3 13.3 10.6 8.6 34.0 11.1 24.5 17.5 8.6 9.0 23.8 18.4 28.1 35.4 7.1 5.8 15.9 11.4 3.5 11.9 15.3 6.8 12.4 10.5 11.9 10.8 5.4 14.0 21.7 25.5 12.4 12.9 33.1 26.1 11.7 6.2 17.9 8.5 16.9 27.7 34.2 25.9 2.0 39.7 0.4 0.3 0.5 1.2 0.5 23.1 2.4 4.0 2.7 8.8 10.6 2.1 14.5 15.3 17.0 23.1 4.9 17.8 5.5 11.5 9.6 37.3 11.9 4.7 6.3 18.3 2.2 2.7 2.2 3.7 2.4 6.3 2.4 3.6 10.5 4.9 16.2 23.4 39.5 5.2 2.7 12.1 10.7 50.2 3.9 2.6 2.7 4.6 7.8 2.6 3.0 28.9 1.7 39.1 8.8 1.9 3.1 6.4 5.4 15.9 25.1 29.2 2.5 24.4 7.8 4.0 21.9 10.3 2.0 7.3 2.5 9.7 1.5 10.6 0.0 0.1 0.0 0.4 0.2 0.7 1.6 0.8 0.6 0.6 2.0 0.7 0.7 0.4 0.5 0.3 39.7 1.2 0.5 5.9 7.8 9.5 11.2 8.6 9.0 7.1 5.8 6.8 6.2 38.7 48.5 29.9 123.9 67.2 26.0 9.2 30.6 115.1 113.7 27.9 58.9 5.7 14.9 98.3 14.5 72.6 52.6 0.0 43.7 10.2 46.0 156.5 10.4 15.5 19.6 17.5 17.7 92.7 30.2 3.6 45.5 30.8 55.6 69.5 41.5 7.8 67.4 21.0 36.0 56.0 14.2 12.9 60.8 1.6 1.5 106.9 2.9 26.6 12.8 446.9 VAMP1 "SYB1, VAMP-1" ENSG00000139190 "Vesicle associated membrane protein 1" P23763 12 6462237-6470987 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 38.7;brain: 85.2" "Cell type enhanced" "Detected in many" 6 "Bipolar cells: 16.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enriched" "Detected in many" 6 "U-698: 67.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002779, CAB016119, CAB079000" Approved Supported NA NA "CAB002779: , CAB016119: AB_628309, CAB079000: " "unprognostic (2.33e-1)" "unprognostic (6.72e-3)" "prognostic unfavorable (6.37e-5)" "unprognostic (8.09e-3)" "unprognostic (2.17e-1)" "unprognostic (1.14e-3)" "prognostic unfavorable (6.97e-4)" "unprognostic (1.22e-2)" "unprognostic (6.33e-2)" "unprognostic (1.05e-1)" "unprognostic (1.40e-3)" "unprognostic (3.48e-2)" "prognostic unfavorable (1.04e-11)" "unprognostic (1.47e-2)" "unprognostic (5.99e-2)" "unprognostic (1.62e-1)" "unprognostic (3.65e-2)" 3.4 6.8 10.2 13.7 12.8 38.7 4.2 9.8 53.1 5.7 8.0 11.1 1.6 4.7 8.7 5.4 3.9 5.1 5.2 4.0 14.1 25.4 3.2 4.3 5.3 24.3 33.5 10.0 3.8 2.4 1.1 3.1 2.4 85.2 8.6 8.8 4.8 6.3 7.6 4.0 4.2 7.9 7.7 31.3 12.4 5.4 3.7 8.3 3.7 7.9 0.8 23.0 5.0 4.7 5.5 2.5 13.4 1.0 2.1 7.0 2.5 0.9 3.5 1.9 2.6 5.7 6.6 2.2 1.8 3.5 1.9 5.5 1.1 3.2 9.9 0.4 4.4 1.9 3.0 2.3 1.0 2.8 7.8 5.5 1.5 10.4 1.2 2.7 3.8 3.8 4.8 0.4 2.5 1.4 6.5 1.7 4.4 0.5 2.9 4.3 1.0 5.0 4.4 9.4 0.4 1.5 5.5 3.1 1.8 1.2 1.3 0.4 0.8 3.8 2.0 1.4 10.8 0.6 1.5 2.1 0.9 3.0 2.0 1.2 2.6 1.0 67.8 3.6 8.0 0.7 6.9 1.0 13.4 6.7 0.4 5.3 5.5 5.5 6.2 1.1 1.3 5.8 4.8 5.5 2.1 0.5 2.5 7.0 2.5 10.2 12.8 9.8 53.1 14.1 25.4 33.5 10.0 85.2 8.3 6.0 1.3 8.2 2.7 1.0 16.3 1.4 2.5 4.0 2.3 0.0 5.9 0.3 1.7 0.2 0.3 2.2 1.7 0.0 0.4 0.7 2.6 2.4 10.4 3.2 1.4 1.6 4.6 2.5 1.8 0.4 3.4 2.4 0.0 4.6 1.2 6.1 0.5 0.9 4.6 0.3 6.8 6.5 3.6 2.3 2.6 0.6 0.1 9.2 1.5 0.8 VAMP2 "SYB2, VAMP-2" ENSG00000220205 "Vesicle associated membrane protein 2" P63027 17 8159149-8163546 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 168.0" "Cell type enhanced" "Detected in all" 7 "Bipolar cells: 1189.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" CAB078785 Supported NA NA "CAB078785: " "unprognostic (8.25e-2)" "unprognostic (4.41e-2)" "unprognostic (1.58e-2)" "prognostic favorable (1.08e-4)" "unprognostic (2.81e-2)" "unprognostic (1.15e-1)" "unprognostic (1.43e-2)" "unprognostic (7.28e-2)" "unprognostic (5.15e-2)" "unprognostic (1.55e-1)" "prognostic favorable (3.83e-6)" "unprognostic (8.27e-2)" "prognostic favorable (9.76e-8)" "unprognostic (1.21e-2)" "unprognostic (7.00e-2)" "unprognostic (1.54e-1)" "unprognostic (1.08e-1)" 22.0 38.3 65.1 16.2 111.7 57.4 20.2 72.2 168.0 20.1 16.3 51.6 11.6 15.7 27.4 24.1 11.6 26.8 14.4 22.1 61.7 56.5 23.5 11.4 21.0 23.1 52.7 71.1 48.4 22.6 52.2 40.6 15.4 88.4 25.1 19.3 37.5 19.5 27.0 33.6 25.0 17.9 25.2 30.7 27.2 17.4 15.1 35.1 9.2 22.0 8.8 22.8 11.7 16.0 25.1 15.4 37.8 8.8 25.1 33.4 9.3 13.8 10.4 25.8 13.8 22.7 17.8 11.6 13.0 16.5 13.3 18.3 4.1 9.5 15.8 9.3 20.8 12.5 16.9 16.9 14.0 15.4 18.3 18.5 11.0 26.7 5.6 20.4 7.3 17.1 19.6 21.1 15.3 23.0 27.5 12.9 27.7 8.5 18.4 22.5 7.3 19.1 10.1 5.9 9.3 7.7 24.4 11.8 12.4 17.2 9.3 12.0 19.2 10.2 5.7 12.7 11.8 13.0 9.5 19.7 8.1 11.2 14.8 12.0 20.3 11.5 11.4 20.6 12.8 18.3 13.7 7.4 24.5 28.4 6.9 24.4 25.1 28.2 30.0 5.7 22.1 33.4 30.8 37.8 25.1 8.8 15.4 20.1 9.3 65.1 111.7 72.2 168.0 61.7 56.5 52.7 71.1 88.4 35.1 38.7 21.2 219.6 147.9 101.1 1189.4 24.3 147.7 17.4 34.2 219.8 233.7 157.6 334.9 66.7 5.4 128.8 97.5 23.3 73.0 75.1 142.8 110.4 150.8 68.4 95.0 440.2 310.2 154.7 94.0 5.9 242.4 101.2 183.9 129.8 134.5 437.1 85.1 111.2 202.6 152.5 445.5 291.1 199.4 106.5 119.6 131.7 267.6 252.2 82.9 115.3 VDR "NR1I1, PPP1R163" ENSG00000111424 "Vitamin D receptor" P11473 12 47841537-47943048 "Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 57.1;parathyroid gland: 45.8" "Cell type enhanced" "Detected in many" 10 "Enterocytes: 101.9;Paneth cells: 43.0;Undifferentiated cells: 54.4" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 6 "classical monocyte: 3.7;eosinophil: 2.1;intermediate monocyte: 7.0;myeloid DC: 5.7;neutrophil: 7.5;non-classical monocyte: 6.9" "Group enriched" "Detected in many" 8 "dendritic cells: 5.7;granulocytes: 7.5;monocytes: 7.0" "Cell line enhanced" "Detected in many" "HBEC3-KT: 23.0;HDLM-2: 32.4;U-937: 31.8" "Region enhanced" "Detected in single" "olfactory region: 2.5" "Not detected" "Not detected" "CAB004617, HPA047740, HPA072102" Supported "Nucleoplasm,Intermediate filaments,Cytosol" NA NA Nucleoplasm "Intermediate filaments, Cytosol" "CAB004617: AB_628040, HPA047740: AB_2680142, HPA072102: " "unprognostic (1.11e-2)" "unprognostic (5.49e-2)" "unprognostic (1.01e-1)" "unprognostic (7.59e-3)" "unprognostic (3.33e-3)" "unprognostic (2.74e-2)" "unprognostic (4.78e-2)" "unprognostic (1.69e-1)" "unprognostic (1.40e-1)" "unprognostic (1.62e-1)" "unprognostic (5.53e-3)" "unprognostic (6.72e-2)" "prognostic favorable (4.89e-6)" "unprognostic (1.46e-1)" "unprognostic (8.76e-2)" "unprognostic (3.28e-1)" "unprognostic (3.82e-2)" 3.0 9.2 0.2 10.0 0.3 2.5 7.8 0.3 0.6 3.5 40.9 0.4 4.1 21.2 1.2 7.7 10.2 1.1 10.7 1.5 0.5 0.3 13.0 0.6 8.3 3.8 0.5 0.1 1.3 6.5 45.8 11.7 4.4 0.6 2.1 12.6 0.4 4.9 2.8 5.3 15.2 57.1 1.2 1.5 3.1 2.6 1.5 0.2 2.0 1.9 9.4 8.2 4.0 5.2 0.7 5.7 7.5 7.0 0.2 0.8 1.2 5.5 0.9 0.0 0.0 4.8 7.0 0.1 6.8 3.5 5.8 5.0 4.0 4.7 1.4 7.4 4.6 4.1 10.4 0.2 23.0 2.7 32.4 1.7 2.4 1.3 0.3 3.5 4.9 7.8 9.4 10.8 6.4 10.5 9.2 0.4 0.5 0.7 1.5 2.6 3.7 0.1 2.4 0.0 13.8 7.5 0.1 0.0 3.5 5.2 5.5 2.6 0.1 5.8 16.7 2.1 0.0 18.8 2.7 0.4 11.1 2.9 3.2 3.8 0.9 0.0 1.2 3.4 31.8 2.8 0.2 3.7 2.1 0.0 7.0 0.1 0.7 0.3 0.0 5.7 0.1 0.1 0.0 7.5 0.2 6.9 0.6 0.8 1.2 0.2 0.3 0.3 0.6 0.5 0.3 0.5 0.1 0.6 0.2 11.9 15.3 1.9 8.2 32.1 0.4 1.2 0.0 9.4 11.4 7.0 0.0 0.1 6.6 3.7 0.1 0.8 101.9 0.0 9.4 0.1 7.8 3.9 6.9 0.4 3.6 0.0 20.8 0.0 6.6 0.0 0.0 18.7 8.5 6.4 30.0 0.2 14.7 43.0 0.4 17.5 0.2 0.0 2.8 0.7 0.3 35.5 0.2 3.2 54.4 8.4